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Major depressive disorder is marked by high rates of relapse and recurrence. Research 
has suggested that formerly depressed individuals exhibit dysphoric mood or dysfunctional 
beliefs that are similar to currently depressed individuals while in a dysphoric, but not euthymic, 
mood and these changes prospectively predict relapse and recurrence over time. While there is 
still disagreement as to whether dysfunctional thinking or dysphoric mood characterizes remitted 
depression, these changes appear to be mood state dependent, or undetectable until activated by 
sadness. These findings have led to the hypothesis that cardiovascular functioning may also be 
mood state dependent in remitted depression; however, this has not yet been adequately assessed. 
The few studies (Bylsma et al., 2015; Rottenberg et al., 2005b; Yaroslavsky et al., 2013, 2014) 
that have investigated cardiovascular reactivity in response to sadness in formerly depressed 
individuals have methodological issues. No studies have examined a wide range of 
cardiovascular measures to assess cardiovascular reactivity to and recovery from a sad mood in 
an exclusively formerly depressed sample. 
The proposed study aimed to characterize cognitive, mood, and cardiovascular reactivity 




never depressed individuals. Participants (N = 132) included formerly depressed and healthy 
control individuals. Following screening, participants completed self-report measures of 
depressive and anxiety symptoms and a structured clinical interview. Eligible participants were 
randomly assigned to an experimental paradigm condition. During the experimental paradigm, 
participants were connected to psychophysiological equipment, participated in a sad or neutral 
music and autobiographical recall mood induction, and completed self-report measures of 
dysfunctional thoughts and dysphoric mood pre- and post-mood induction. Results suggested 
that mood, rather than cognitive, reactivity in response to a transient sad mood is present in 
formerly depressed individuals. Additionally, results suggested that reduced heart period 
recovery, rather than reactivity, following the induction of a transient sad mood is present in 
formerly depressed individuals. Results indicated that formerly depressed individuals exhibit 
increased sadness and impaired heart period recovery in response to a transient sad mood, which 
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Negative Emotional Scale 
PEP Pre-ejection period 
PHQ-9 Patient Health Questionnaire – 9  
PNS Parasympathetic nervous system 
PRE Pre-mood induction 
PRIME-MD Primary Care Evaluation of Mental Disorders 
POST Post-mood induction 








RD Remitted depressed 
RDoC Research domain criteria 
REBT Rational emotive behavior therapy 
RM Repeated measures 
RMSSD Root Mean Square Successive Difference 
RSA Respiratory sinus arrhythmia 
SA Sinoatrial 
SADSL Schedule for Affective Disorders and Schizophrenia – Lifetime Version 
SCID-I Structured Clinical Interview for DSM-IV 
SCID-IV-RV Structured Clinical Interview for DSM-IV-TR – Research Version 
SDNN Standard Deviation of the Normal-to-Normal 
SNS Sympathetic nervous system 
STAI-I  State-Trait Anxiety Inventory – I  
STAI-II State-Trait Anxiety Inventory – II 
STAI-I & II State-Trait Anxiety Inventory – I & II 
SV Stroke volume 
TAU Treatment as usual 
TPR Total peripheral resistance 
TP-HRV Total power HRV 
TSST Trier Social Stress Task 
ULF-HRV Ultra-low frequency HRV 
VAS Visual Analogue Scale 
VC Vasoconstriction 
VLF-HRV Very low frequency HRV 
ZRES Residualized change scores 
2 Average obtained during a two-minute interval 






 Major Depressive Disorder (MDD), characterized by prolonged depressed mood and/or 
lack of interest or pleasure, is a serious and debilitating mental illness. Prevalence and incidence 
rates obtained from large scale epidemiological studies have indicated that MDD is a commonly 
occurring disorder. Various psychosocial factors that have been associated with MDD include 
gender, age, race, ethnicity, national origin, and socioeconomic status. The course of MDD is 
marked by high rates of relapse and recurrence. Consequently, it is often considered a chronic 
disorder that typically recurs over time. While psychological and medical comorbidities 
commonly co-occur with MDD, the disorder itself is independently associated with elevated 
levels of functional impairment, disability, and death. The direct and indirect problems 
associated with MDD pose a significant health and economic burden for the individuals suffering 
with the disorder and society. 
Diagnostic Criteria 
According to the Diagnostic and Statistical Manual – Fifth Edition (DSM-5; American 
Psychological Association (APAA), 2013), MDD is characterized by persistent depressed mood 
and/or diminished interest or pleasure in previously enjoyed activities. These symptoms can be 
based on the subjective experience reported by the individual or objective presentation observed 
by others. In addition to these cardinal symptoms, an individual must endorse four or more of the 
following disturbances in appetite, weight, sleep, psychomotor activity, energy level, self-
conceptualization, cognitive ability, and suicidality. There is significant heterogeneity in 
symptom presentation, such as increases or decreases in appetite, weight, sleep, and psychomotor 




adequate rest, negative self-concept (e.g., worthlessness or inappropriate guilt), and impaired 
cognitive abilities (e.g., difficulty thinking or making decisions). In addition, a spectrum of 
suicidal thoughts and behaviors can occur, including recurrent thoughts of death or dying and 
suicidal ideations, plans, or attempts. A clinical diagnosis of depression requires that symptoms 
are present most of the day, nearly every day for two weeks or longer and result in marked 
impairment at school, work, or home or in social situations. In addition, these symptoms must be 
attributable to depression and cannot be better explained by a medical condition, substance use, 
or other psychiatric condition. 
 Recovery from a major depressive episode is classified as partial or full remission 
(APAA, 2013). MDD in partial remission is defined as the absence of depressive symptoms for 
less than two months or the presence of depressive symptoms that cause marked impairment but 
do not meet the diagnostic threshold. MDD in full remission is defined as either the absence of 
any depressive symptoms for at least two months or the presence of one or two depressive 
symptoms that are mild in severity. 
The diagnostic criteria for MDD allows for significant heterogeneity of symptoms. 
Researchers have criticized the architects of the DSM-5 for its reliance on a symptom-based, 
categorical approach, limited use of biological correlates, and inclusion of contradictory 
symptomology within a single diagnosis (e.g., increase or decrease in appetite; Casey et al., 
2013). While the DSM-5 provides researchers and clinicians with the nomenclature necessary for 
communication, the field is currently exploring alternative classification systems such as the 





 MDD is one of the most commonly occurring mental disorders (National Institute of 
Mental Health (NIMH), 2017). The occurrence of MDD within the general population has been 
assessed by large epidemiological studies using two different measurement methods: prevalence 
and incidence.  
Prevalence 
Prevalence is defined as the proportion of the population who have a condition during a 
specific period of time. The majority of studies report point prevalence rates obtained within a 
12-month period or within an individual’s lifetime. Several large-scale epidemiological studies 
using the DSM – Fourth Edition (DSM-IV; APAA, 2000) diagnostic criteria have obtained a 
range of prevalence rates of MDD depending on the sample and methodology used.  
Eaton, Kalaydjian, Scharfstein, Mezuk, and Ding (2007) reported the lowest 12-month 
prevalence rate of 2.70% among two cohorts using the Diagnostic Interview Schedule (DIS). 
Hasin, Goodwin, Stinson, and Grant (2005) found a 12-month prevalence rate of 5.30% and a 
lifetime prevalence rate of 13.20% using the Alcohol Use Disorder and Associated Disabilities 
Interview Schedule – DSM-IV Version (AUDADIS-IV). The majority of studies have used the 
Composite International Diagnostic Interview (CIDI) to diagnose depression, which have 
obtained higher prevalence rates of MDD. Kessler and colleagues (2003) attained a 12-month 
prevalence rate of 6.60% and a lifetime prevalence rate of 16.20%. Similarly, Kessler and 
colleagues (2005) found a lifetime prevalence rate of 16.60%. González, Tarraf, Whitfield, and 
Vega (2010) obtained a 12-month prevalence rate of 8.10% and a lifetime prevalence rate of 
18.60%. Finally, Kessler and colleagues (2010) reported the highest 12-month prevalence rate of 




that the prevalence rate for MDD ranges between 2.70% and 8.30% during a 12-month period 
and 13.20% to 19.20% across an individual’s lifespan. 
Incidence 
Incidence is defined as the number of new cases of a condition within a certain time 
period. The majority of studies report person-time incidence rates, which is defined as the 
number of new cases that occur within the amount of time that the sample of participants were at 
risk for developing the disease of interest. While prevalence rates are more commonly reported 
in the literature, they are influenced by the chronicity of a disorder (Palsson, Östling, & Skoog, 
2001). MDD is characterized as a chronic disorder in a subset of individuals (Monroe, Anderson, 
& Harkness, in press; Richards, 2011); therefore, it is important to also assess the incidence rate 
for MDD. Several large-scale epidemiological studies using the DSM-IV diagnostic criteria have 
obtained a range of incidence rates of MDD depending on the measurement formula and 
methodology used. 
Eaton and colleagues (2007) reported the lowest incidence rate of 1.90 per 1,000 person 
years using the DIS. Murphy, Laird, Monson, Sobol, and Leighton (2000) found similar 
incidence rates for two cohorts using the DePression and AnXiety (DPAX) interview. Incidence 
rates ranged from 4.50 per 1,000 person years for the cohort recruited from 1950 to 1970 to 3.70 
per 1,000 person years for the cohort recruited from 1970 to 1992. Grant and colleagues (2009) 
obtained the highest incidence rate of 1.51 per 100 person years, which is equal to 15.10 per 
1,000 person years, using the AUDADIS-IV. Together, these epidemiological studies suggest 







One of the strongest predictors for the occurrence of MDD is gender. Epidemiological 
studies conducted in the United States have consistently shown that women report increased 
prevalence and incidence rates of MDD. Kessler and colleagues (2003) reported that the 
prevalence rate of MDD was elevated in women during a 12-month period (OR = 1.40, CI = 
1.10, 1.80, p < .05) and over the course of their lifetime (OR = 1.70, CI = 1.50, 2.00, p < .05) 
using the CIDI. Hasin and colleagues (2005) replicated these results using the AUDADIS-IV, 
showing that the prevalence rate of MDD was two times higher in women over the course of 
their lifetime (OR = 2.00, CI = 1.80, 2.40). Eaton and colleagues (2007) obtained even more 
staggering results with the DIS, finding that the prevalence rate of MDD was over three times 
higher in women during a 12-month period (OR = 3.80, CI = 2.60, 5.60). In addition, the authors 
reported that the incidence rate of MDD was over two times higher in women during a 12-month 
period (OR = 2.60, CI = 1.50, 4.10). Similarly, Grant and colleagues (2009) found that women 
reported an elevated incidence rate of MDD (OR = 1.00) compared to men (OR = .50, CI = .37, 
.76) on the AUDADIS-IV.  
These results have been replicated by epidemiological studies conducted in countries 
around the world, suggesting that increased rates of depression in women occurs cross-culturally. 
Kuehner (2003) completed a systematic review of epidemiological studies that assessed the 
prevalence of depression worldwide using various structured clinical interviews. Results 
indicated that the prevalence rates for depressive disorders were significantly higher in women 
compared to men, with a sex ratio of 1.70:1.00 for current prevalence and 2.10:1.00 for lifetime 
prevalence. These results held true for studies conducted outside of the United States, which 




studies have been conducted to specifically assess gender differences in depression. Seedat and 
colleagues (2009) obtained lifetime rates of MDD for individuals residing in 15 countries using 
the CIDI. Results revealed that the lifetime prevalence rate for MDD was significantly higher in 
women compared to men (OR = 1.90, CI = 1.80, 2.00). Together, these studies suggest that the 
prevalence and incidence of MDD is generally two times higher in women compared to men 
(Nolen-Hoeksema, 2001). 
Several factors have been proposed to explain the elevated rates of MDD observed in 
women. First, it is possible that differences in depression are an artifact of diagnostic or 
methodological problems. Diagnostic issues include differences in the endorsement or 
experience of depressive symptoms among men and women. Research has shown that women 
are more likely to endorse more depressive symptoms than men, even though the two sexes 
experience similar levels of impairment (Piccinelli & Wilkinson, 2000). In addition, it has been 
suggested that there may be symptomatic differences between the sexes; women may be more 
likely to experience stereotypical depressive symptoms like sadness and men may be more likely 
to experience atypical depressive symptoms like irritability. Consequently, the diagnostic criteria 
for MDD has been criticized as overemphasizing the depressive symptoms that are typically 
experienced by females (Kuehner, 2003). Methodological issues include failure to account for 
differences in the course of the disorder or treatment seeking behaviors among men and women. 
Some research has suggested that females may be more likely to experience a singular depressive 
episode, which would account for difference in point prevalence rates but not lifetime prevalence 
rates (Piccinelli & Wilkinson, 2000). In addition, research has documented the differences in 
treatment seeking behaviors across the sexes, which may explain why women are more likely to 




likely than men to seek medical and psychological treatment (Piccinelli & Wilkinson, 2000) 
while studies conducted in community and primary care settings have estimated that the 
prevalence of MDD is roughly equal across the sexes (Kuehner, 2003). The literature has 
identified some diagnostic or methodological issues that may account for the gender difference 
in depression. 
Second, biological factors specific to women have been associated with increased 
vulnerability to developing depression. While differences in the heritability of depression have 
not be identified, genetic differences may make women more vulnerable to developing 
internalizing disorders (Kuehner, 2003). Sex hormones, such as estrogen, may directly or 
indirectly impact mood. Research has shown that changes in sex hormones are associated with 
changes in mood during puberty, postpartum, and premenstrual periods (Grigoriadis & 
Robinson, 2007; Kuehner, 2003). In addition, sex hormones influence the activity of regulatory 
mechanisms in the brain including neurotransmitters and components of the endocrine system 
such as the hypothalamic-pituitary-adrenal (HPA) and hypothalamic-pituitary-thyroid axes 
(Grigoriadis & Robinson, 2007; Kuehner, 2003).  
Third, it has been proposed that psychosocial factors specific to women increase 
vulnerability to depression. Women possess less social status and power in society compared to 
men, which increases the likelihood for experiencing stressful life events such as sexual abuse 
and assault, trauma, and victimization (Grigoriadis & Robinson, 2007; Nolen-Hoeksema, 2001). 
In addition, society has subscribed certain social roles and expectations to women, which can 
lead to significant emotional distress due to personal, educational, professional, and financial 





Fourth, it has been proposed that psychological factors commonly observed in women 
may increase their vulnerability to depression. Differences in coping style appear to exist among 
men and women. Females tend to cope with stress using maladaptive strategies such as 
rumination, or internally dwelling on problems, while males tend to use more adaptive and active 
strategies such as distraction. Research has shown that rumination negatively impacts mood and 
problem solving strategies and plays a significant role in the development of depression (Nolen-
Hoeksema, 2001). Additionally, some sex differences in self-perception have been identified. 
Women tend to report lower self-esteem, self-confidence, and perceived control compared to 
men, which may contribute to feelings of hopelessness and helplessness that are associated with 
depression (Grigoriadis & Robinson, 2007; Kuehner, 2003; Piccinelli & Wilkinson, 2000).  
Finally, the presence of previous mental health problems in women during adolescence 
have been associated with increased vulnerability to depression across the lifespan. Research has 
shown that women are at an increased risk for developing anxiety and depression earlier in life 
compared to men (Piccinelli & Wilkinson, 2000). Early exposure to anxiety or depression is 
thought to make women more vulnerable to experiencing multiple depressive episodes over the 
course of their lifetime. This theory is based on the findings that the course of depression is 
typically chronic and anxiety increases risk for the occurrence of depressive episode in the future 
(Kuehner, 2003).  
Age 
As reviewed by Haigh, Bogucki, Sigmon, and Blazer (2018a), it has long been assumed 
that older age is related to an increased occurrence of MDD. This commonly held belief is likely 
due to the challenges typically associated with aging (e.g., changes in interpersonal relationships 




result in significant emotional distress. However, the literature has consistently indicated that 
older adults are significantly less likely to experience MDD compared to their younger 
counterparts. 
Large scale epidemiological and community-based studies have shown that younger 
adults report higher prevalence and incidence rates of MDD compared to older adults. Kessler 
and colleagues (2003) compared the prevalence of MDD across age groups using the CIDI. 
Participants 60 years or older reported significantly lower point (OR = 1.00, χ2 = 42.3, p < .05) 
and lifetime (OR = 1.00, χ2 = 53.5, p < .05) prevalence rates of MDD compared to younger 
participants. 12-month prevalence rates were significantly higher for participants age 18 to 29 
(OR = 3.00, CI = 2.00, 4.40, p < .05) and 30 to 44 (OR = 1.80, CI = 1.10, 2.90, p < .05) while 
lifetime prevalence rates were significantly higher for participants age 18 to 29 (OR = 1.70, CI = 
1.40, 2.20, p < .05), 30 to 44 (OR = 2.20, CI = 1.80, 2.80, p < .05), and 45 to 59 (OR = 2.00, CI = 
1.60, 2.60, p < .05).  
Kessler and colleagues (2005) replicated this result using the same structured interview, 
finding a statistically significant difference for the lifetime prevalence rate of MDD in 
participants age 18 to 29 (15.40%), 30 to 44 (19.80%), 45 to 59 (18.80%), and 60 or older 
(10.60%; χ2 = 49.90, p < .05). Eaton and colleagues (2007) compared incidence rates of MDD 
among middle age and older adults using the DIS. Younger participants age 30 to 44 (3.20%) 
and 45 to 64 (1.90%) reported elevated incidence rates of MDD compared to participants 65 
years or older (0.00%). Grant and colleagues (2009) examined differences in the incidence of 
MDD across a wider age range with the AUDADIS-IV. Compared to participants 55 years or 
older (OR = 1.00), incidence rates for MDD were significantly higher in participants age 20 to 29 




Kessler and colleagues (2010) specifically assessed age-related differences in MDD using 
the CIDI. Results indicated that there was a statistically significant difference in the prevalence 
of MDD assessed across age groups. For the 30-day prevalence rate, participants in the 18 to 34 
and 35 to 49-year age groups (3.70%) reported the highest rates while participants in the over 65 
years age group reported the lowest rates (1.00%; χ2 = 46.9, p < .05). For the 12-month 
prevalence rate, participants in the 18 to 34-year age group (10.40%) reported the higher rates 
while participants in the over 65 years age group reported the lowest rates (2.60%, χ2 = 103.50, p 
< .05). For the lifetime prevalence rate, participants in the 35 to 49-year age group (22.70%) 
reported the higher rates while participants in the over 65 years age group reported the lowest 
rates (9.80%, χ2 = 70.40, p < .05). Together, these studies suggest that younger adults are at the 
highest risk for experiencing MDD. While the rates of MDD reported by middle age adults are 
typically lower than young adults, they are still elevated compared to elderly population.  
Multiple factors have been proposed to explain why the rate of MDD differs across the 
lifespan. First, it is possible that recruitment and methodological issues account for the low rates 
of depression reported by older adults. Recruitment issues include premature death, failure to 
account for the elderly population that resides in assisted living or nursing home facilities, and 
diminished interest in participating in research. Methodological issues include recall bias and 
failure to endorse the presence of mental illness due to stigma and social desirability. However, 
there is limited evidence supporting these recruitment and methodological issues, which suggests 
that MDD does occur at different rates across the lifespan (as reviewed by Kessler et al., 2010). 
Second, psychological factors specific to older adults may be protective against depression later 
in life. Research has indicated that older adults report an increase in positive affect and well-




regulation abilities or a normalization of adverse events that occur during this phase of life (as 
reviewed by Haigh et al., 2018a). Therefore, it is possible that older adults are better able to cope 
with stressful life events, which are a causal risk factor for depression (Kendler, Karkowski, & 
Prescott, 1999), than their younger counterparts. 
Race, Ethnicity, and National Origin 
Race, ethnicity, and national origin impact the occurrence of MDD. Large scale 
epidemiological and community-based studies have identified some differences in the prevalence 
rates among racial and ethnic groups. Kessler and colleagues (2003) found that African 
American individuals reported the lowest lifetime prevalence rate of MDD (OR = .60, CI = .50, 
.80, p < .05) on the CIDI compared to individuals who identified as Hispanic, Caucasian, or 
other (OR = 1.00-1.20, CI = .80, 1.50). No significant differences in 12-month prevalence rates 
were identified between groups. Hasin and colleagues (2005) found that compared to Caucasian 
participants, Native American participants reported significantly higher lifetime prevalence rate 
of MDD (OR = 1.50, CI = 1.10, 2.10) while African American, Asian or Pacific Islander, and 
Hispanic participants reported a significantly lower lifetime prevalence rate of MDD (OR = .60-
.70, CI = .40, .90) on the AUDADIS-IV. Williams and colleagues (2007) found that Caucasian 
participants reporting significantly higher lifetime prevalence rates of MDD (17.90%, p < .001) 
on the CIDI compared to African American (10.40%) and Caribbean Black (12.90%) 
participants. Similar to Kessler and colleagues (2003), no significant differences in 12-month 
prevalence rates reported on the CIDI were identified between groups. 
Other studies have used the CIDI to examine the impact of other race-related variables, 
such as membership to a particular ethnic group and country of national origin. Alegría and 




in the United States. Findings suggested that there were some group differences; participants of 
Mexican descent were significant less likely to experience any depressive disorder during their 
lifetime (OR = .57-.69, CI = .34, .99, p < .05) compared to Puerto Rican participants. However, 
this relationship was not found for 12-month prevalence rates. Alegría and colleagues (2008) 
investigated differences in prevalence rates among Latino and non-Latino individuals living in 
the United States. Findings indicated that non-Latino Caucasian participants had significantly 
higher lifetime prevalence rates for MDD (22.10%, p < .001) compared to all Latino participants 
(15.20%). Lifetime prevalence rates did not significantly differ among Latino subgroups (p = 
.65). Immigration status also had an impact on both groups, with participants born in the United 
States reporting significantly higher lifetime prevalence rates for both Latino (p < .001) and non-
Latino (p < .008) groups. González and colleagues (2010) reported differences in prevalence 
rates for MDD based on ethnic group and immigration status. Results indicated that ethnic 
groups reported differences in both 12-month (χ2 = 33.70, p < .001) and lifetime (χ2 = 4.60, p < 
.001) prevalence rates for MDD, with Puerto Rican participants reporting the highest rates and 
Filipino, Vietnamese, and Chinese participants reporting the lowest rates. In addition, 
participants who were born in the United States reported higher 12-month (χ2 = 28.20, p < .001) 
and lifetime (χ2 = 87.30, p < .001) prevalence rates of MDD compared to foreign born 
participants. 
Together, these studies suggest that Caucasian individuals are significantly more likely to 
experience MDD over the course of their lifetime than individuals from diverse racial or ethnic 
backgrounds, with the exception of Native American individuals. In addition, it appears that 
individuals born in the United States are at higher risk for developing MDD than foreign born 




Several factors have been proposed to explain the elevated rates of MDD observed in 
Caucasian individuals. First, it is possible that the low rates of depression in racial and ethnic 
minorities is attributable to cultural bias. The diagnostic system (i.e., DSM) used to assess the 
presence of mental disorders has been criticized for failing to adequately represent minority 
groups, which is likely to impact the assessment and diagnosis of mental illness (as reviewed by 
Kress, Eriksen, Rayle, & Ford, 2005). In addition, the clinicians who implement the diagnostic 
system may be culturally biased. Multicultural competence is a requirement of ethical practice; 
clinicians must assess a client’s cultural identify to obtain an accurate formulation of a client’s 
psychological, emotional, and behavioral functioning (as reviewed by Kress et al., 2005). 
However, it is possible that clinicians who have inadequate cultural training may exhibit a bias 
when assessing and diagnosing mental illness in culturally diverse clients. Second, the low rates 
of depression in racial and ethnic minorities may be due to cultural differences in the experience 
of depression, which has an impact on symptom reporting, treatment seeking behavior, and the 
therapeutic relationship (Kleinman, 2004). Finally, some race-related variables (e.g., ethnicity, 
national origin, acculturation status, etc.) are often overlooked by large epidemiology or 
community-based studies (Alegría et al., 2008; Williams et al., 2007). Additional research on the 
influence of these cultural factors on depression is warranted. 
Socioeconomic Status 
Socioeconomic status is defined as a combination of educational achievement and 
income level. Research has identified an association between socioeconomic status and 
depression. Cross-sectional studies have generally shown that individuals of low socioeconomic 
status report elevated levels of depressive symptoms compared to individuals of middle or high 




generally shown that low socioeconomic status prospectively predicts an increased risk for the 
development of MDD over time (as reviewed by Everson, Maty, Lynch, & Kaplan, 2002; Gallo 
& Matthews, 2003; Muntaner, Eaton, Miech, & O’Campo, 2004). Of note, some longitudinal 
studies that have used a specific epidemiological sample (i.e., Epidemiologic Catchment Area 
Study) or dichotomous variables to classify socioeconomic status have failed to find this 
association, suggesting that these null findings could be due to methodological differences across 
studies (see Gallo & Matthews, 2003 for review of discrepant results). Together, these results 
suggest that compared to individuals of higher socioeconomic status, individuals of lower 
socioeconomic status are generally at higher risk for experiencing depressive symptoms and a 
clinically-significant depressive episode over the course of their lifetime. 
Building on this body of work, Lorant and colleagues (2003) conducted a meta-analysis 
of 51 articles to quantify the relationship between socioeconomic status and depression. 
Depression was assessed via self-report or structured clinical interviews, such that the final 
sample was comprised of individuals with clinical and non-clinical depression. Results indicated 
that the individuals of lower socioeconomic status reported higher prevalence (OR = 1.81, CI = 
1.57, 2.10, p < .001) and incidence (OR = 1.24, CI = 1.04, 1.48, p < .004) rates of MDD 
compared to individuals of higher socioeconomic status. In addition, individuals of lower 
socioeconomic status were significantly more likely to experience persistent MDD (OR = 2.06, 
CI = 1.39, 3.05, p < .001). A dose dependent relationship between socioeconomic factors and 
depression appeared to exist. Increases in education and income were associated with decreases 
in the likelihood of depression, which suggests that there is a linear relationship between these 
variables. Of note, some of the studies utilized self-report measures to assess depressive 




samples. Overall, this body of research indicates that individuals of lower socioeconomic status 
are at higher risk for experiencing depressive symptoms and depression compared to individuals 
of higher socioeconomic status.   
Multiple factors have been proposed to explain the elevated rates of MDD observed in 
individuals of lower socioeconomic status. First, it has been suggested that individuals of lower 
socioeconomic status are exposed to more stressful life events or have less resources to combat 
stressful life events. More specifically, these individuals may exhibit more maladaptive coping 
strategies and diminished perception of personal abilities, mastery, and control in response to 
stressful life events (Lorant et al., 2003). Second, it has been proposed that individuals of lower 
socioeconomic status experience significantly more strain due to larger societal factors. For 
example, these individuals are treated more negatively due to societal views and values 
associated with economic standing and public policy (Lorant et al., 2003). Therefore, it is 
possible that individual or societal factors or an interaction between these factors contribute to 
the relationship between socioeconomic status and depression. 
Comorbidity 
Psychological Comorbidity 
MDD is marked by elevated rates of psychological comorbidities. Multiple large-scale 
epidemiological studies have calculated rates of disorders comorbid with MDD. Kessler and 
colleagues (2003) found that MDD was associated with elevated rates of comorbid psychological 
conditions on the CIDI. The majority of participants (64.00%) who endorsed experiencing MDD 
over the past 12 months also endorsed the presence of a comorbid psychological disorder, which 
included an anxiety (57.50%), impulse control (16.60%), or substance use (8.50%) disorder. An 




course of their lifetime also endorsed the presence of a comorbid psychological disorder, which 
included an anxiety (59.20%), impulse control (30.00%), or substance use (24.00%) disorder. 
The onset of MDD was generally proceeded by another psychological disorder, with MDD 
occurring first in a relatively small portion of participants (12.60% for 12-month prevalence, 
12.30% for lifetime prevalence). Kessler and colleagues (2010) replicated these results using the 
same diagnostic measure. Anxiety (64.20%) and other mood (37.20%) disorders were the most 
common comorbid conditions while impulse control (14.70%) and substance use (10.70%) 
disorders were less likely, but still frequently reported within the sample. Results indicated that 
the majority of participants (75.80%) endorsed the presence of at least one comorbid 
psychological condition, with participants reporting one (25.60%), two (17.60%), or three or 
more (32.60%) comorbidities. 
Hasin and colleagues (2005) examined a more expansive list of comorbid psychological 
conditions using the AUDADIS-IV. Participants who endorsed MDD during the past 12 months 
reported elevated rates of personality disorders (37.90%), anxiety disorders (36.10%), and 
nicotine dependence (26.00%). Of note, these participants reported relatively low rates of alcohol 
(14.10%) and drug (4.60%) use disorders. A different pattern of comorbidity emerged for 
participants who endorsed MDD at some point during their lifetime, including elevated rates of 
anxiety disorders (41.40%), alcohol use disorders (40.30%), personality disorders (30.80%), 
nicotine dependence (30.00%), and drug use disorders (17.20%). The authors concluded that 
individuals who endorse MDD over a 12-month period or their lifetime are highly likely to also 
endorse the presence of a comorbid condition during the same time span. 
The literature has clearly shown that MDD is associated with elevated rates of 




comorbid conditions. Personality, mood, impulse control, and substance use disorders also 
commonly co-occur with MDD. 
Medical Comorbidity 
MDD has been associated with an elevated risk for chronic medical conditions, such as 
asthma, arthritis, cardiovascular disorder (CVD), cancer, and diabetes (as reviewed by Chapman, 
Perry, & Strine, 2005). Epidemiological studies have provided additional evidence for the 
association between depression and medical conditions. Kessler and colleagues (2010) found that 
individuals who endorsed MDD on the CIDI over a 12-month period were highly likely to also 
endorse the presence of a comorbid medical condition during the same time span. Various types 
of musculoskeletal (48.20%), respiratory (43.50%), pain (41.30%), and cardiovascular (24.20%) 
disorders were commonly reported by individuals who have recently suffered from depression. 
Results indicated that the majority of participants (79.80%) endorsed the presence of at least one 
medical comorbidity, with participants reporting one (22.30%), two (21.10%), or three or more 
(36.40%) comorbidities. 
These results have been replicated by large scale studies conducted around the world. 
Moussavi and colleagues (2007) assessed the association between MDD and medical conditions 
in a culturally diverse sample. Participants from 60 countries were assessed for the presence of 
chronic medical conditions based on reports of MDD using the CIDI. Prevalence rates for 
chronic medical conditions were relatively low, with rates ranging as high as 4.50% for angina 
and as low as 2.00% for diabetes. There was a strong association between depression and chronic 
medical conditions; participants with diabetes (9.30%), arthritis (10.70%), angina (15.00%), and 
asthma (15.00%) also reported experiencing comorbid depression. The rates of depression were 




was significantly different from healthy participants free from such conditions (3.20%, p < .001). 
In addition, participants with chronic medical conditions and comorbid depression reported 
significantly lower health scores than non-depressant participants with one or more chronic 
medical conditions (p < .0001). Together, these results suggest that depression commonly co-
occurs with comorbid medical conditions and has an additive negative impact on physical health. 
The literature has indicated that depression is also associated with elevated rates of 
mortality. Depressed individuals are significantly more likely to die by suicide than the general 
population. Research has consistently shown that suicidal thoughts and behaviors are 
significantly more common in depressed individuals. Depressed individuals are about 20 times 
more likely to attempt and commit suicide compared to individuals who have never been 
depressed (as reviewed by Lépine & Briley, 2011). In addition, the presence of certain comorbid 
medical conditions in depressed individuals has been associated with an increased risk of death. 
More specifically, research has shown that individuals with CVD and comorbid depression or 
depressive symptoms are significantly more likely to die from cardiovascular-related causes than 
their non-depressed counterparts (as reviewed by Lépine & Briley, 2011). These results indicate 
that depression has a significant and negative impact on an individual’s life trajectory. 
As outlined by Katon (2003), there are several potential reasons for the relationship 
between depression and medical conditions. First, it is possible that depression is a risk factor for 
certain medical conditions. Depression is associated with negative health behaviors (e.g., 
inactivity and obesity) that may contribute to the development of medical conditions. 
Longitudinal studies that have found that depression prospectively predicts the risk for some 
medical conditions, such as diabetes and CVD, have provided some support for this hypothesis. 




medical condition. This experience can result in functional impairment, reduced quality of life, 
and feelings of helplessness, hopelessness, and stress, potentially leading to the development of 
depression. Third, depression may be the result of a medication prescribed to treat the medical 
condition. Depression is a known side effect for certain medications. However, depression has 
also been reported as a nonspecific side effect that is not due to the pharmacological mechanism 
of action (Barsky, Saintfort, Rogers, & Borus, 2002). Finally, it is possible that the medical 
condition causes physiological changes that leads to the development of depression. The 
potential mechanisms of change may be directly or indirectly related to the medical condition; 
direct effects include changes to the brain structure or function while indirect effects include 
changes in physiological systems (e.g., inflammation and cytokines) that has down-stream 
effects on the brain. 
Individual and Societal Impact 
Individual Impact 
MDD is associated with significant cost to the individual and society. Individuals with 
MDD struggle with maladaptive thoughts, feelings, and behaviors that negatively impact 
multiple aspects of their lives. In addition, these individuals experience elevated functional 
impairment and reduced quality of life that make it more difficult to function within the 
confounds of society. Functional impairment is defined as diminished ability to perform 
everyday tasks. Backenstrass and colleagues (2006) assessed the impact of depression on 
different areas of functioning. Participants who reported minimal depressive symptoms (n = 56) 
or depressive symptoms consistent with major (n = 28) or minor (n = 38) depression on the 
Patient Health Questionnaire – 9 (PHQ-9) were compared to healthy control participants (n = 




experiencing significantly more days of minor impairment and missing daily activities or work 
due to illness compared to participants with subclinical depressive symptoms or healthy control 
participants (p < .001), suggesting that functional impairment is significantly worse in 
individuals with clinically significant symptoms. These results indicate that depression has a 
significant and negative impact on an individual’s ability to function within everyday activities 
across multiple settings. 
Quality of life is defined as diminished well-being due to disability in different aspects of 
functioning, including physical and emotional health, professional and economic standing, 
interpersonal relationships, and life satisfaction. Rapaport, Clary, Fayyad, and Endicott (2005) 
assessed differences in quality of life using a large sample of participants with MDD (n = 242) 
recruited from 11 multisite trials. Quality of life was assessed using the Quality of Life 
Enjoyment and Satisfaction Questionnaire. Results indicated that participants with MDD 
endorsed lower quality of life ratings for all categories compared to healthy control participants 
from the community (n = 67). The majority of participants with MDD (63.00%) reported 
clinically severe impairments in quality of life relative to healthy control participants (1.70%). 
Impairments were even more pronounced in chronic or double depression (i.e., MDD and 
dysthymia), with 85.00% of participants reporting clinically severe impairments in quality of 
life. These results indicate that depression has a significant and negative impact on an 
individual’s ability to engage in positive and pleasurable activities. 
Societal Impact 
Overall, the literature suggests that depression has a negative impact on an individual’s 
functional ability and quality of life. These impairments result in a significant burden that makes 




depression is associated with increased disability rates and decreased workplace productivity 
(Lépine & Briley, 2011). Over the past several decades, the burden of depression has steadily 
risen. As outlined by Whitaker (2015), the disability rate rose from one in every 468 Americans 
in 1955 to one in every 184 Americans in 1987. This trend has continued to grow exponentially, 
with the disability rate reaching one in every 70 Americans in 2013. This finding does not appear 
to be confined to the United States, with other Western countries reporting similar increases in 
disability rates. According to Mathers, Fat, and Boerma (2008), MDD is currently the leading 
cause of disability and second leading cause of disease burden around the world. The negative 
impact of MDD is projected to significantly increase relative to other disorders over the next 
decade. Predictions have indicated that MDD will become the leading cause of disease burden by 
the year 2030. These projections have significant implications for an individual’s ability to 
function within the confounds of society. 
The complications directly and indirectly associated with MDD are extremely costly to 
society. The economic burden associated with MDD has risen in recent years. According to 
Greenberg, Fournier, Sisitsky, Pike, and Kessler (2015), the estimated cost of MDD has 
increased from $173.50 billion in 2005 to $210.50 billion in 2010. The rise in estimated cost was 
attributable to increases direct (i.e., medical and pharmaceutical treatment expenses) and indirect 
(i.e., suicide, work, and comorbidity related expenses) costs associated with depression or 
comorbid psychological and medical conditions. The literature has clearly shown that MDD 
represents a significant burden on individuals suffering from the disorder and society at-large. 
Course 
The course of MDD is characterized by different stages that occur within different phases 




definitions for the stages of depression that occur within the phases of treatment have been 
proposed. The goal of the acute phase of treatment is to generate a treatment response, which is 
defined as a reduction in the severity of depressive symptoms (e.g., typically a 50.00% reduction 
compared to baseline). Over time, depressive symptoms begin to remit. The transition from the 
acute phase to the continuation phase of depression is marked by remission, which is defined as 
the absence of depressive symptoms for a period of time (e.g., typically two months) when an 
individual is considered to be generally well. Remission can be categorized as partial, unstable, 
or stable. Partial and unstable remission are characterized by the consistent (i.e., partial) or 
inconsistent (i.e., unstable) presence of some residual depressive symptom. During the 
continuation phase, depressive symptoms may increase to clinically significant levels. This 
phenomenon is characterized as relapse, which is defined as the reemergence of a depressive 
episode while an episode of depression is in remission. Alternatively, the transition from the 
continuation phase to the maintenance phase of depression is marked by recovery, which is 
defined as defined as the end of a depressive episode after a period of time (e.g., typically six to 
12 months) when an individual is considered to no longer be depressed. During the maintenance 
phase, depressive symptoms may increase to clinically significant levels. This phenomenon is 
characterized as recurrence, which is defined as the experience of a new depressive episode after 
recovery from an episode. While these phases of depression are typically conceptualized within 








Figure 1. Diagram of the Stages of Depression from Bockting et al. (2015) 
 
The literature has consistently shown that MDD is marked by high rates of relapse and 
recurrence. Hardeveld, Spijker, De Graaf, Nolen, and Beekman (2010) conducted a systematic 
review of nine naturalistic studies that assessed the recurrence in MDD using a structured 
diagnostic interview. Prevalence rates for recurrence ranged from 21.00% to 40.00% within the 
first year, 42.00% to 75.00% within a five-year span, 67.00% within a 10-year span, and 35.00% 
to 85.00% within a 15-year span, indicating that recurrence is a commonly occurring 
phenomenon. These results have been replicated by multiple studies conducted over the past 
decade.  
Poutanen and colleagues (2007) assessed the trajectory of depression in a sample of 
Finnish outpatients. Participants recruited from primary (n = 62) and psychiatric (n = 84) care 
settings were diagnosed with mild or severe depression using the Present State Examination 
interview. Depression status was re-assessed at a seven-year follow-up using the CIDI – Short 
Form. Results indicated that participants with mild and severe depression recruited from both 
settings showed elevated rates of depression during the follow-up period. Depression was present 
in 42.40% of participants with severe MDD and 48.30% of participants with mild MDD 




with severe MDD and 68.50% of participants with mild MDD recruited from psychiatric care 
settings. While this study provides important information about the chronicity of depression 
across different healthcare settings, it does not decipher between relapse and recurrence rates. 
Hardeveld, Spijker, De Graaf, Nolen, and Beekman (2013) assessed the recurrence of 
MDD in the Netherlands Mental Health Survey and Incidence Study (NEMESIS), a large 
community-based study of Dutch adults. Participants with a history of depression (n = 687) 
retrospectively reported the timing of their last depressive episode on the CIDI. Participants were 
longitudinally followed and depressive status was assessed after one and three years. The use of 
retrospective and longitudinal assessments enabled the calculation of cumulative recurrence 
rates, which spanned 20 years time. Results indicated that 19.70% of participants experienced a 
recurrent episode of depression during the follow-up period. Cumulative recurrence rates ranged 
from 2.50% at one year, 4.50% at two years, 13.20% at five years, 23.20% at 10 years, and 
42.00% at 20 years, suggesting that the probability of recurrence of MDD increased as more time 
passed. 
ten Doesschate, Bockting, Koeter, and Schene (2010) extended these findings by 
assessing the relapse and recurrence of MDD following treatment. Participants with a history of 
depression (n = 172) participated in a clinical trial of cognitive therapy (CT) or treatment as 
usual (TAU) for depression. Participants were assessed for depression at baseline and three, 12, 
24, 36, and 66 months posttreatment using the Structured Clinical Interview for DSM-IV (SCID-
I). Results indicated that across treatment conditions, the majority of participants (79.00%) 
experienced a relapse or recurrence of MDD over the 5.50-year follow-up period. While the 
authors did not specifically distinguish between relapse and recurrence, the results suggest that 




Johansson, Lundh, and Bjärehed (2013) replicated these results in a sample of Swedish 
outpatients who had successfully completed treatment. Participants with a history of depression 
(n = 51) who were in remission from MDD after exposure to psychotherapy or pharmacotherapy 
were recruited. Depression status was assessed at baseline and 12-month follow-up using the 
SCID-I. Results indicated that the majority of participants (61.00%) experienced a re-emergence 
of depression during the 12-month follow-up period, with no significant differences across 
groups based on the type of treatment modality. Recurrence (77.00%) was more common among 
these participants than relapse (23.00%), indicating that typically participants recovered from 
MDD posttreatment before experiencing a new depressive episode.  
Together, these studies indicate that individuals with MDD experience high rates of 
relapse and recurrence. There is significant variability for the estimated occurrence of relapse 
and recurrence, with rates ranging from 2.50% to 85.00% over a period of one to 20 years. The 
majority of research has combined the terms relapse and recurrence, making it difficult to 












SAD MOOD REACTIVITY AND VULNERABILITY TO DEPRESSION 
Research clearly suggests that MDD is marked by high rates of relapse and recurrence 
and is typically viewed as a chronic mental illness (Richards, 2011). Most recent research 
estimates that half of individuals who experience a major depressive episode will experience a 
recurrence during their lifetime, with a subset of those individuals experiencing a relapsing-
remitting trajectory marked by multiple episodes of depression (Monroe et al., in press).  
Vulnerability Factors 
Vulnerability to depressive relapse and recurrence likely reflects a complex interaction of 
biological, psychological, and environmental factors. Burcusa and Iacono (2007) completed a 
review of the literature to identify vulnerability factors for relapse and recurrence, which can be 
classified in different categories. Demographic vulnerability factors include female gender, lower 
socioeconomic status, and single relationship status. Clinical vulnerability factors include a 
higher number of previous depressive episodes, higher severity of first depressive episode, and 
the presence of comorbid pathology, especially other mood disorders. Familial vulnerability 
factors include a family history of psychopathology, especially depression or other mood 
disorders. Psychological vulnerability factors include negative cognitions and high levels of 
neuroticism. Psychosocial vulnerability factors include poor social support and exposure to 
stressful life events during childhood and adulthood. Recent studies on the prevalence of relapse 
and recurrence of depression have identified many of the same vulnerability factors, providing 
additional evidence for their predictive validity (Harveveld et al., 2010, 2013; Johansson et al., 




Unfortunately, the majority of vulnerability factors that have been identified are not 
amenable to modification (e.g. female gender, multiple depressive episodes, stressful life events, 
etc.), which makes it difficult for medical and mental healthcare providers to prevent or intervene 
during the depressogenic cycle. Additional research is needed to identify and target malleable 
vulnerability factors that are related to increased risk for future episodes of depression. Two 
potentially malleable vulnerability factors that have been identified in the literature include 
cognitive and mood reactivity in response to a sad mood. The following section will review the 




Cognitive theories of depression propose that dysfunctional patterns of thinking represent 
a cognitive vulnerability that contributes to the etiology, maintenance, and reoccurrence of 
depression (Beck, 1967; Lau, Segal, & Williams, 2004; Scher, Ingram, & Segal, 2005). Indeed, a 
large body of empirical evidence has shown that currently, but not formerly, depressed 
individuals endorse elevated rates of dysfunctional thoughts (as reviewed by Teasdale, 1999). 
Interestingly, formerly depressed individuals remain at increased risk for depressive relapse or 
recurrence, despite no longer exhibiting cognitive vulnerability to depression while in a euthymic 
mood state. Several theoretical models have been proposed to account for differences in 
cognitive patterns observed between currently and formerly depressed individuals. In particular, 
the differential activation hypothesis and mood state dependent hypothesis have extended the 
cognitive model of depression originally proposed by Beck (1967) and suggest that maladaptive 




The differential activation hypothesis. The differential activation hypothesis by 
Teasdale (1988) suggests that depression results in a myriad of cognitive changes that continue 
to persist after recovery from depression. Maladaptive cognitive patterns, including 
dysfunctional thinking and biased information processing, are activated by dysphoric mood. 
Over time, these cognitive patterns become associated with depressed mood and are 
hypothesized to maintain depressive symptoms in individuals with current MDD. According to 
this hypothesis, dysphoric mood can reactivate biased information processing and related 
cognitive patterns (e.g., dysfunctional beliefs) among individuals who have recovered from 
depression. In other words, whether dysfunctional thinking is activated among a formerly 
depressed individual depends on their current mood state. Formerly depressed individuals who 
are currently euthymic have low levels of dysfunctional thinking that resembles never depressed 
individuals. In contrast, formerly depressed individuals in a dysphoric mood state experience an 
increase in dysfunctional thinking similar to currently depressed individuals. The resurgence of 
maladaptive cognitive patterns during a dysphoric mood for formerly depressed individuals is 
hypothesized to increase the likelihood that an otherwise transient negative mood will develop 
into a depressive episode. Overall, this hypothesis proposes a cyclical relationship in which 
depressed mood leads to the activation of biased informational processing and dysfunctional 
thinking patterns that serve to maintain or initiate a depressed mood or depressive episode. 
The differential activation hypothesis by Teasdale (1988) argues that maladaptive 
cognitive patterns are activated by dysphoric mood and perpetuate depressed mood. According 
to this theory, the maladaptive cognitive patterns associated with depression include a wide range 
of cognitive processes (e.g., biased attention, memory, and dysfunctional thinking patterns; as 




similar theory, the mood state dependent hypothesis by Miranda and Persons (1988), focuses on 
a narrower range of maladaptive cognitive processes (i.e., dysfunctional beliefs only).  
The mood state dependent hypothesis. The mood state dependent hypothesis by 
Miranda and Persons (1988) attempts to account for the differential patterns of dysfunctional 
thinking observed in currently and formerly depressed individuals. Previous research has shown 
that currently, but not formerly, depressed individuals endorse elevated levels of dysfunctional 
thinking. It was hypothesized that dysfunctional thinking is mood state dependent in formerly 
depressed individuals. Specifically, cognitive vulnerability in an individual with a history of 
depression is not explicitly present during a euthymic mood state but is evident when an 
individual is in a dysphoric mood state. According to this hypothesis, formerly depressed 
individuals exhibit cognitive reactivity, or a significant increase in dysfunctional thinking after 
exposure to a dysphoric mood. It is theorized that individuals with remitted MDD maintain latent 
cognitive vulnerabilities that are activated by a sad mood. Once activated, these patterns of 
dysfunctional thoughts are thought to increase risk for a subsequent depressive episode in 
individuals who have a history of depression.  
The depression literature has examined the tenants of the differential activation and mood 
state dependent hypotheses. In the following sections, the experimental methodology used to 
investigate these theoretical models as well as the empirical evidence for these theoretical 
models is reviewed. 
Mood Induction Procedures 
Mood induction procedures induce a specific, transient mood state within an 
experimental setting, which enables researchers to investigate the cognitive, affective, and 




states that are characteristic of psychopathology. Martin (1990) systematically reviewed the 
range of mood induction procedures that have been used in experimental psychology. While 14 
different types of mood induction procedures have been empirically validated in the literature, 
this review will focus on music plus autobiographical recall procedure, which is most commonly 
used approach within the depression literature. During a music plus autobiographical recall mood 
induction, individuals listen to a piece of emotionally-valenced music and are instructed to recall 
an emotionally-valenced autobiographical memory to induce a particular mood. Research on 
negative affect would typically ask participants to think about a specific time in their life when 
they experienced sadness (i.e., autobiographical recall mood induction) while listening to a sad 
piece of non-lyrical music played at a slower rate (i.e., music mood induction).  
Martin (1990) acknowledged that while there is not a universally accepted procedure for 
inducing transient mood states, the depression literature has identified the music plus 
autobiographical recall mood induction as an effective method for inducing a sad mood state. 
The sad music plus autobiographical recall mood induction has been compared to multiple self-
report, behavioral, and performance-based measures. Overall, the sad music plus 
autobiographical recall mood induction has been shown to instate a transient despondent mood 
that is equivalent to an intermediate level of clinical depression in more than 75.00% of 
participants. In addition, the sad music plus autobiographical recall mood induction has been 
shown to induce a mood state that most closely resembles the cognitive, somatic, and emotional 
aspects of depression without the presence of residual anxiety. Of note, the transient mood state 
only persists for a few minutes, which indicates that these mood induction procedures are not 




procedure has been empirically validated as a reliable and valid method for eliciting a sad mood 
within an experimental setting.  
Empirical Evidence 
Theoretical models have suggested that increases in maladaptive cognitive patterns in 
response to sadness contribute to the recurrence and maintenance of depression. Studies have 
assessed the presence of cognitive reactivity and its potential role as a predictor of relapse and 
recurrence. Cognitive reactivity is defined as the change in underlying negative cognitions in 
response to a sad mood induction. Cognitive reactivity is typically measured using the 
Dysfunctional Attitudes Scale (DAS), which is used to compare the change in dysfunctional 
beliefs assessed pre- and post-mood induction.  
The differential activation and mood state dependent hypotheses have been investigated 
by a large body of literature. Studies have employed a variety of empirically-validated sad mood 
induction procedures to examine cognitive reactivity in participants with remitted MDD as these 
experimental procedures have been shown to transiently create the cognitive, somatic, and 
emotional experiences of depression in euthymic individuals. The majority of studies have used a 
combination of music and autobiographical recall to create a mild, transient sad mood (Fresco, 
Heimberg, Abramowtiz, & Bertram, 2006; Gemar, Segal, Sagrati, & Kennedy, 2001; Jarrett et 
al., 2012; Kuyken et al., 2010; Lau, Haigh, Christensen, Segal, & Taube-Schiff, 2012; Pfeiffer, 
Brockmeyer, Zimmermann, & Backenstrass, 2015; Segal, Gemar, & Williams, 1999; Segal et al., 
2006; Van der Does, 2002, 2005). Though, some studies have used other empirically-supported 
techniques such as a combination of sad-valence music and self-statements (e.g., “I’m 
discouraged and unhappy about myself”; Dykman, 1997), a sad-valence film (i.e., clip of a son 




Miranda, Gross, Persons, & Hahn, 1998), or a naturally occurring negative mood state (Miranda, 
Persons, & Byers, 1990; Roberts & Kassel, 1996).  
In general, cross-sectional studies have shown that participants with remitted MDD report 
a significantly greater increase in dysfunctional attitudes following a negative mood state or after 
exposure to a sad mood induction compared to healthy control participants (Gemar et al., 2001; 
Lau et al., 2012; Miranda et al., 1990, 1998; Roberts & Kassel, 1996; Van der Does, 2002). 
However, some studies failed to find this association, with formerly depressed and never 
depressed participants reporting similar levels of dysfunctional attitudes following a negative 
mood state or after exposure to a sad mood induction (Brosse et al., 1999; Dykman, 1999; Fresco 
et al., 2006; Pfeiffer et al., 2015; Van der Does, 2005). Together, these results provide mixed 
evidence for the hypothesis that individuals with remitted MDD exhibit significantly more 
dysfunctional attitudes while in a dysphoric mood than their never depressed counterparts. 
 Longitudinal studies have investigated cognitive reactivity as a risk factor for relapse and 
recurrence of MDD. Segal and colleagues (1999) examined differences in cognitive reactivity 
between participants with remitted MDD who were successfully treated with cognitive-
behavioral therapy (CBT; n = 25) or antidepressant medications (n = 29). At baseline, 
participants completed a sad mood music and autobiographical recall mood induction. One to 
five years later, participants were assessed for recurrence using the SCID-I. Results indicated 
that at baseline, formerly depressed participants treated with antidepressant medications reported 
a significantly greater increase in dysfunctional attitudes post-mood induction compared to those 
treated with CBT (R2 = .09, p < .05). In addition, formerly depressed participants who reported 
an increase in cognitive reactivity post-mood induction were significantly more likely to 




reactivity may be a risk factor for subsequent relapse and proposed that CBT may be an 
efficacious treatment method for decreasing an individual’s dysfunctional attitudes. 
 In a follow up study, Segal and colleagues (2006) sought to replicate the finding that the 
type of treatment for depression has an impact on subsequent cognitive reactivity. Participants 
with current MDD were recruited and randomly assigned to a treatment condition, including 
CBT (n = 88) or antidepressant medication (n = 56). After successful achieving remission from 
MDD, participants completed a sad mood music and autobiographical recall induction. 18-
months later, participants were assessed for recurrence using the Longitudinal Interval Follow-
Up Evaluation interview and Hamilton Depression Rating Scale (HDRS). Results indicated that 
formerly depressed participants who reported a significantly greater increase in dysfunctional 
attitudes following the mood induction were at greater risk for experiencing a relapse during the 
follow-up period (χ12 = 7.12, p < .05). Contrary to the Segal and colleagues (1999) findings, there 
was no significant difference in cognitive reactivity between treatment groups (χ12 = .256, p > 
.05), casting doubt on the hypothesis that CBT leads to a change in underlying dysfunctional 
beliefs. However, this study does provide additional support for the finding that the presence of 
cognitive reactivity predicts the recurrence of another depressive episode in participants with 
remitted MDD. 
 Kuyken and colleagues (2010) aimed to extend previous findings to a different type of 
psychotherapy: mindfulness-based cognitive therapy (MBCT). Participants in partial or full 
remission from recurrent MDD (i.e., three or more lifetime episodes of depression) were 
recruited and randomly assigned to a treatment condition, including MBCT plus discontinuation 
of antidepressant medication (n = 43) or maintenance of antidepressant medication (n = 37). 




autobiographical recall induction. Fifteen months later, participants were assessed for recurrence 
using the SCID-I and depressive symptoms using the HDRS. Results indicated that formerly 
depressed participants who received MBCT reported a significantly greater increase in 
dysfunctional attitudes following the mood induction compared to formerly depressed 
participants who received antidepressant medication (d = .47, p < .05). While formerly depressed 
participants treated with antidepressant medications who reported increases in dysfunctional 
attitudes following the mood induction were at greater risk for elevated depressive symptoms 
and relapse during the follow-up period, this relationship was not found for participants who 
received MBCT (χ12 = .01, p = .91). This study provides additional support for the finding that 
the presence of cognitive reactivity predicts relapse in participants with remitted MDD and 
proposed that MCBT may be protect against future episodes of depression. 
 Jarrett and colleagues (2012) investigated the impact of cognitive reactivity on relapse 
and recurrence in formerly depressed participants who were at high risk for experiencing another 
depressive episode. Participants with recurrent MDD and elevated depressive symptomology (n 
= 523) who previously responded to CT were recruited and randomly assigned to an 8-month 
continuation treatment condition, including CT, antidepressant medication, or placebo. Before 
beginning continuation treatment, participants completed a sad mood music and autobiographical 
recall mood induction. Participants were assessed for relapse using the SCID-I and HRSD eight, 
20, and 32-months after the start of continuation treatment. Contrary to previous research, there 
was no significant increase in dysfunctional attitudes following the mood induction (p = .76). 
While these results are not in line with the differential activation or mood state dependent 
hypotheses, are in line with previous research that has shown that participants who have received 




(Segal et al., 1999). Additional analyses identified a relationship between unprimed 
dysfunctional attitudes and relapse of depression over time; formerly depressed participants in all 
conditions who endorsed higher dysfunctional attitudes pre-mood induction were at a greater risk 
for relapse at 20 (χ2 = 3.93, p < .05) and 32 (χ2 = 4.49, p < .05) months, regardless of 
posttreatment depressive symptom severity. Overall, this study suggests that the presence of 
dysfunctional attitudes during a euthymic, rather than dysphoric, mood state has negative 
implications for sustained remission in MDD. 
 The literature has found some support for the differential activation and mood state 
dependent hypotheses. Cross-sectional studies have generally suggested that individuals who 
have recovered from depression exhibit cognitive reactivity in response to a negative mood state 
or sad mood induction compared to individuals without a history of depression. In addition, 
longitudinal studies have shown that formerly depressed individuals who exhibit cognitive 
reactivity while euthymic or dysphoric have higher rates of relapse and recurrence over time. 
However, there are inconsistencies in this literature base. As a result, researchers have examined 
other forms of reactivity that may explain elevated rates of relapse and recurrence. In the 
following section, research examining mood reactivity in response to sadness will be reviewed. 
Mood Reactivity 
Theoretical Models 
Some etiological theories of depression have focused on the experience of negative 
emotions, proposing that depressed individuals exhibit abnormal patterns of mood reactivity, or a 
significant change in mood state after exposure to a dysphoric mood. The cardinal symptoms of 
depression include sad, low mood and loss of interest or pleasure in activities that were 




of positive mood as well as high levels of negative mood (Rottenberg, Gross, & Gotlib, 2005b). 
Indeed, research has indicated that individuals with current MDD report fewer positive emotions 
and exhibit fewer positive responses to pleasurable stimuli. While depressed individuals have 
conventionally been thought to express more negative emotions, the empirical evidence is mixed. 
Some research has shown that individuals with current MDD exhibit greater responsivity to 
negative stimuli while other studies have found the opposite (Rottenberg, Gross, & Gotlib, 
2005b). Theoretical models that have been proposed to explain these empirical findings include 
the positive attenuation, the negative potentiation, and the emotion context insensitivity 
hypotheses. 
The positive attenuation hypothesis. The positive attenuation hypothesis proposes that 
currently depressed individuals exhibit a blunted emotional response to positively-valenced 
emotional stimuli. This hypothesis is primarily based on clinical observations of depression; the 
disorder is associated with symptoms related to reduced emotional (e.g., loss of interest), 
behavioral (e.g., psychomotor retardation), and physiological (e.g., reduced appetite, weight, and 
energy level) engagement that is adaptive and life sustaining (Rottenberg et al., 2005b). The 
literature has generally provided empirical support for the positive attenuation hypothesis. A 
meta-analysis by Bylsma, Morris, and Rottenberg (2007) found that positive emotional reactivity 
was lower for self-report (p < .0001, d = -.70) and behavioral (p < .001, d = -.45) measures in 
depressed participants compared to healthy control participants. Fewer studies have examined 
positive emotional reactivity using physiological methodology, resulting in similar results across 
depressed and never depressed participants (p = .29, d = -.15).  
The negative potentiation hypothesis. The negative potentiation hypothesis proposes 




valenced emotional stimuli. This hypothesis is also based on clinical observations of depression; 
the disorder is associated with symptoms related to negative mood states (e.g., depressed mood) 
and is often characterized by negative-valence behavioral reactions (e.g., crying and withdrawal; 
Rottenberg et al., 2005b). It has been theorized that negative mood states result in a cascade of 
cognitive changes that perpetuate depressogenic responsivity. As previously reviewed, the 
cognitive model of depression states that negative mood activates maladaptive cognitive patterns 
that lead to biased informational processing, dysfunctional thinking, and depressogenic behaviors 
(Beck, 1967). The cyclical relationship between depressogenic thoughts, feelings, and behaviors 
is hypothesized to initiate and maintain depression. The findings for the negative potentiation 
hypothesis have been inconsistent. For example, studies have found that currently depressed 
individual exhibit increased or decreased physiological reactivity to negatively-valenced stimuli 
(as reviewed by Rottenberg et al., 2005b). In addition, meta-analysis by Bylsma and colleagues 
(2007) found that negative emotional reactivity was lower for self-report (p < .0001, d = -.36) 
and physiological (p < .05, d = -.22) measures in depressed participants compared to healthy 
control participants. Results were less clear for negative emotional reactivity assessed by 
behavioral measures, resulting in non-significant differences between depressed and never 
depressed participants (p = .54, d = -.05). In general, the literature refutes the negative 
potentiation hypothesis and suggest that depressed individuals tend to exhibit blunted, rather than 
exaggerated, reactivity to negatively-valenced emotional stimuli. 
The emotion context insensitivity hypothesis. The emotional context insensitivity 
hypothesis by Rottenberg and Gotlib (2004) builds upon the empirical findings related to the 
positive attenuation and negative potentiation hypotheses in proposing that depressed individuals 




stimuli. The theory provides an evolutionary explanation to the emotional, behavioral, and 
physiological reactions observed in depressed individuals. It is theorized that depressed 
individuals disengage from positive and negative stimuli in their environment to protect 
themselves from potential danger. As a result, depressed individuals exhibit blunted emotional, 
behavioral, and physiological reactions in response to both positive and negative stimuli that are 
normative and idiographic in nature. This pattern of responsivity is not appropriate in relation to 
the environmental demands and results in a less adaptive response that is theorized to perpetuate 
depressive symptoms or lead to recurrence of depression.  
While it was initially hypothesized that this pattern of responsivity would be observed in 
individuals with a history of depression, early empirical evidence (i.e., Rottenberg et al., 2005b) 
suggested that emotional, behavioral, and physiological reactivity is mood state dependent in 
formerly depressed individuals. Therefore, individuals who have a history of depression will 
exhibit blunted responsivity while in a dysphoric mood, but not during a euthymic mood. This 
pattern of responsivity is hypothesized to serve as a risk factor for experiencing a subsequent 
depressive episode. The depression literature assessing reactivity to sad mood induction 
procedures has primarily examined the emotion context insensitivity hypothesis. In the following 
section, empirical evidence supporting and refuting this theoretical model will be reviewed. 
Mood Induction Procedures 
Studies have typically obtained multiple measures of mood to assess how emotions 
changes in response to mood induction procedures. Within the cognitive reactivity literature, 
changes in mood have been employed as a manipulation check to ensure that the sad mood 
induction was in fact inducing a transient, dysphoric mood in participants. The aforementioned 




in self-reported sad mood on the Visual Analogue Scale (VAS). Of the studies that examined 
group differences among formerly depressed and never depressed participants, none found 
significant variations in the degree of sadness endorsed by the two groups after exposure to the 
sad mood induction procedures (Brosse et al., 1999; Dykman, 1997; Fresco et al., 2006; Gemar 
et al., 2001; Lau et al., 2012; Miranda & Persons, 1988; Miranda et al., 1998; Segal et al., 2006; 
Solomon et al., 1998; Van der Does, 2002, 2005). These findings suggest that formerly 
depressed and healthy control participants show similar levels of mood reactivity in response to a 
sad mood induction. 
Empirical Evidence 
Given that some studies have failed to show cognitive reactivity to sadness in individuals 
with remitted depression, researchers examined other potential predictors of relapse and 
recurrence. Recent findings suggest that there may be a difference in mood reactivity among 
participants with remitted MDD. Mood reactivity is defined as the change in mood state in 
response to a sad mood induction. Mood reactivity is typically measured using the VAS, which 
compares an individual’s mood state (i.e., happy, sad, depressed, etc.) pre- and post-mood 
induction 
Before formally proposing the emotion context insensitivity hypothesis, Rottenberg, 
Kasch, Gross, and Gotlib (2002) investigated mood reactivity in currently depressed individuals. 
Depression was assessed using the SCID-I. Participants included individuals with current MDD 
(n = 72) and healthy control participants without a history of Axis I disorders (n = 33). 
Experimental procedures included a neutral film, two negative (i.e., sad and fear) films presented 
in a counterbalanced order and separated by an arithmetic task, and an amusing film. Self-report 




Results indicated that participants with current MDD reported more sadness in response to the 
neutral (R2 = 25.11, p < .001) and amusing (R2 = 8.25, p < .01) films, but not the sad (R2 = 1.19, p 
> .10) or fear (R2 = 2.05, p > .10) films, compared to healthy control participants. In addition, 
participants with current MDD reported less amusement (R2 = 4.91, p < .05) in response to the 
amusing film, but group differences were not statistically significant (p > .05). This study 
provided empirical evidence for the successive theory that currently depressed individuals 
exhibit inappropriate and insensitive mood reactivity to emotionally-valenced stimuli. 
Rottenberg, Gross, and Gotlib (2005b) sought to extend these results to formerly 
depressed individuals. Depression was assessed using the SCID-I. Participants were individuals 
with current MDD (n = 19), remitted MDD (n = 22), and healthy control participants without a 
history of Axis I disorders (n = 26). Experimental tasks included normative and idiographic sad, 
happy, and neutral valenced films and imagery tasks (i.e., participants were instructed to create a 
visual picture in their mind of the previously watched film) presented in a counterbalanced order. 
Each film and imagery task were preceded by a one-minute resting baseline and followed by a 
one-minute filler task to reduce carry over effects. Results indicated that participants with current 
MDD reported similar levels of sadness (p > .10) and less happiness (p < .001) across all stimuli 
compared to the two other groups, suggesting that these participants did not respond to the 
emotional valence of the stimuli appropriately. Participants with current MDD who reported 
higher levels of sadness and lower levels of happiness in response to idiographic stimuli were 
more likely to have been depressed for a longer period of time. Participants with remitted MDD 
reported emotional (i.e., happy, amused, sad, and anxious) responses that were similar to healthy 
control participants (p < .001), indicating that both groups reported appropriate emotional 




context insensitivity hypothesis is mood state dependent, much like the previously reviewed 
cognitive vulnerabilities. 
The literature has used sad mood induction procedures to investigate the applicability of 
the emotion context insensitivity hypothesis to formerly depressed individuals. Lethbridge and 
Allen (2008) examined if cognitive or mood reactivity predicted recurrence in participants with 
remitted MDD (n = 52). Depression was assessed with the SCID-I. At baseline, participants 
completed a sad mood music and autobiographical recall mood induction. Cognitive reactivity 
was assessed using the DAS while mood reactivity was assessed using the VAS. One year later, 
participants were assessed for recurrence using the SCID-I and reported stressful life events 
using the Stressful Life Events Questionnaire. In line with the cognitive reactivity literature, 
results showed that participants with remitted MDD reported significant decreases in happiness (t 
= 3.66-7.90, p < .01) and increases in sadness (t = -6.34--4.60, p < .01) on the VAS as well as 
significant increases in dysfunctional thinking (t = -43.83, p < .01) on the DAS post-mood 
induction. Mood reactivity on the happy scale of the VAS (i.e., decrease in happiness in response 
to the sad mood induction) and self-reported life stress was predictive of relapse. Formerly 
depressed participants who reported less decrease in happiness on the VAS or more life stress 
was significantly more likely to relapse at one-year follow-up. Mood reactivity on the depressed 
scale of the VAS (i.e., increase in depression in response to the sad mood induction) and 
cognitive reactivity on the DAS were both not predictive of relapse.  
While these results suggest that blunted mood reactivity, rather than cognitive reactivity, 
in response to sadness predicts the recurrence of a new depressive episode in formerly depressed 
individuals, these findings are limited by methodological issues. First, the literature consistently 




MDD reported less increase of negative mood on the depressed scale of the VAS than the sad 
scale of the VAS. These participants have experienced what a depressive episode is like, so they 
may be less likely to endorse a mood state of “depressed” when encountered with a transient, sad 
mood. Second, studies (i.e., van Rijsbergen et al., 2013) have hypothesized that it may be 
necessary to assess cognitive reactivity at multiple time points to examine its impact of MDD 
relapse and recurrence. This study conducted the sad mood music and autobiographical recall 
mood induction at a single time point, rather than at baseline and follow-up. Therefore, results 
from this study may have differed based on the methodological procedures that were employed.  
van Rijsbergen and colleagues (2013) examined whether changes in cognitive or mood 
reactivity predicted relapse in participants with remitted MDD after treatment. Participants with 
remitted MDD were recruited and randomly assigned to a relapse prevention condition, 
including preventive CBT and TAU (n = 84) or TAU alone (n = 88). Participants completed the 
sad music and autobiographical recall mood induction at baseline and posttreatment. Cognitive 
reactivity was assessed using the DAS while mood reactivity was assessed using the VAS. 
Participants were assessed for relapse using the SCID-I at three, 12, 24, 36, and 66 months 
follow-up. Results showed that participants in all conditions who endorsed higher DAS scores 
before the mood induction were at a greater risk for relapse (χ2 = 12.29, p < .001), indicating that 
unprimed dysfunctional attitudes predicted relapse 5.50 years later. However, pre (χ2 = 1.14, p = 
.29) and posttreatment (χ2 = 2.10, p = .15) cognitive reactivity was not predictive of relapse. 
While this finding is contradictory to some of the literature (i.e., Kuyken et al., 2010; Segal et al., 
1999, 2006), it is in line with the results obtained by Jarrett and colleagues (2012).  
van Rijsbergen and colleagues (2013) also found that participants in all conditions who 




reactivity predicted relapse 5.50 years later. Of note, this relationship was only found for mood 
reactivity assessed posttreatment (χ2 = 8.29, p = .004), but not pretreatment (χ2 = .06, p = .81). 
Given that previous research has suggested that CBT reduces dysfunctional beliefs (Kuyken et 
al., 2012; Segal et al., 1999), exploratory analyses were conducted to see if there was a change in 
cognitive and mood reactivity before and after participation in the CBT relapse prevention 
condition. Results revealed that an increase in cognitive (χ2 = 6.77, p = .01) and mood (χ2 = 6.85, 
p = .01) reactivity posttreatment was predictive of relapse over the 5.50-year follow-up period. 
This perplexing finding lead the authors to suggest that cognitive reactivity may need to be 
assessed at multiple time points over the course of treatment in order to detect its true effect of 
relapse. Overall, these results suggest that mood reactivity predicts relapse over time but does not 
discount the role of cognitive reactivity in relapse prediction. 
 A growing body of research has supported the emotion context insensitivity hypothesis, 
indicating that currently depressed individuals exhibit blunted emotional, behavioral, and 
physiological reactivity in response to both negatively and positively-valenced stimuli (Bylsma 
et al., 2007; Rottenberg & Hindash, 2015). However, the applicability of the emotion context 
insensitivity hypothesis to formerly depressed individuals is less clear. A very limited literature 
base has suggested that blunted (i.e., Lethbridge & Allen, 2008) or exaggerated (i.e., van 
Rijsbergen et al., 2013) mood reactivity is predictive of another depressive episode. While these 
findings are important, they have not completely discounted the role that cognitive reactivity 
may play. In addition, cross-sectional research has not found differences in mood reactivity 
among formerly depressed and never depressed participants (Brosse et al., 1999; Dykman, 1997; 
Fresco et al., 2006; Gemar et al., 2001; Lau et al., 2012; Miranda & Persons, 1988; Miranda et 




may not be measured properly by single session studies. Additional research is needed to 
examine whether formerly depressed individuals exhibit cognitive or mood reactivity in response 
to sadness and whether either form of reactivity contributes to relapse and recurrence of MDD. 
Multiple mechanisms have been proposed to account for vulnerability to depressive 
relapse. While some risk factors are trait dependent (e.g., age of onset, severity of the first 
episode, number of symptoms, etc.; Burcusa & Iacono, 2007), theoretical models and empirical 
evidence has suggested that some risk factors may be state dependent. Cross-sectional research 
has shown that individuals with remitted MDD endorsed more dysfunctional thoughts (Gemar et 
al., 2001; Lau et al., 2012; Miranda et al., 1990, 1998; Roberts & Kassel, 1996) in response to a 
sad mood induction. Longitudinal research has suggested that individuals with remitted MDD 
who report elevated cognitive (Kuyken et al., 2010; Segal et al., 1999, 2006) or blunted (i.e., 
Lethbridge & Allen, 2008) or exaggerated (i.e., van Rijsbergen et al., 2013) mood reactivity in 
response to sadness are more likely to experience another depressive episode over time. While 
there is currently disagreement in the literature about whether cognitive or mood reactivity are 
markers of vulnerability for relapse in remitted MDD, there is clear support for the notion that 
such vulnerabilities are mood state dependent in remitted depression.  
One way to advance our understanding of the relationship between reactivity to negative 
affect and vulnerability to depression is to move beyond self-report and examine cardiovascular 
reactivity in response to sadness. The next section will provide an overview of the physiological 
systems and psychophysiological markers related to cardiovascular functioning. Several 
theoretical models, and empirical evidence related to cardiovascular functioning, and negative 







 The human body is composed of numerous systems that regulate bodily functions, 
maintain homeostasis, and enable an individual to respond to environmental stimuli. Multiple 
systems and organs play a role in the regulation of the cardiovascular system. The components 
that are most relevant to the cardiovascular system includes the nervous system and the heart. 
The Nervous System 
As outlined by Porges (1992), the nervous system is the executory structure responsible 
for communicating information from the brain and spinal cord via the central nervous system to 
the rest of the body via the peripheral nervous system. The peripheral nervous system is further 
branched into the somatic nervous system and the autonomic nervous system (ANS). The ANS is 
made up of two distinct systems: the sympathetic nervous system (SNS) and the parasympathetic 
nervous system (PNS). The SNS is responsible for preparing and mobilizing the body to react to 
external stimuli presented within the environment, commonly referred to as the fight or flight 
response. The PNS is responsible for demobilizing the body and returning it to baseline 
functioning, also known as the relaxation and restoration response. The SNS and the PNS enable 
the coordination of bodily reactions in response to internal and external stimuli through 
contradictory, but complementary functions. The PNS is mainly responsible for maintaining 
homeostasis, or dynamic regulation of the internal organs to preserve or restore equilibrium, 
while the SNS is mainly responsible for reacting to stress, or an interruption in homeostasis.  
While both branches of the ANS play an important role in cardiovascular functioning, 
psychological research primarily focuses on the activity of the PNS. Focus on the PNS is due to 




(i.e., heart rate (HR); Grossman & Taylor, 2007) or are thought to reflect parasympathetic 
control (i.e., respiratory sinus arrhythmia (RSA); Allen, Chambers, & Towers, 2007).  
The Heart 
The heart is a muscular organ located within the chest cavity that pumps blood 
throughout the body. The ANS is fundamental to cardiovascular functioning. The heart is 
connected to the ANS via the vagus nerve, one of the 12 cranial nerves that branch out from the 
brain to the body. The vagus nerve innervates the sinoatrial (SA) node and is responsible for 
determining the rate at which the heart beats; the SNS accelerates the heart while the PNS 
decelerates the heart (Porges, 1992).  
The major structural components of the heart (Figure 2) include the chambers, valves, 
and nodes. As detailed by Katz (2010), the heart consists of four chambers, the left atrium, right 
atrium, left ventricle, and right ventricle, and two classes of valves, the atrioventricular (AV) 
valves and semilunar valves. The AV valves, including the tricuspid valve on the right side of the 
heart and the bicuspid valve on the left side of the heart, separate the atria from the ventricles. 
The semilunar valves, including the pulmonary valve on the right side of the heart and the aortic 
valve on the left side of the heart, separate the ventricles from the pulmonary artery or aorta. The 
heart contains two clusters of cells that control electrical impulses in the heart, the SA and the 
AV nodes. The SA node, located in the right atrium of the heart, is innervated by the vagus nerve 
and generates the electrical impulses that cause the contraction of the atrial muscles. The AV 
node, located in the center of the heart between the atria and ventricles, receives the electrical 
impulses from the SA node then regulates and transports the electrical impulses to the ventricles, 




of pumps on the left and right side that work in concert with one another. Similar processes occur 
within each side of the heart during the cardiac cycle. 
Figure 2. Diagram of the Heart (n.d.) 
 
The Cardiovascular System 
The cardiovascular system is a complex structure that consists of the heart and 
vasculature that extends throughout the entire body. The cardiovascular system regulates the 
circulation of blood within the body, which follows a sequence of steps outlined by Berntson, 
Quigley, and Lozano (2007). Deoxygenated blood travels through veins from the organs and 
extremities to the heart. Deoxygenated blood enters the right atrium via the superior and inferior 
vena cava, passing through the tricuspid valve into the right ventricle. Deoxygenated blood then 
passes through the pulmonary valve into the pulmonary artery, which is connected to the lungs. 
Blood is circulated through capillaries in the lungs, enabling the absorption of oxygen and 
release of carbon dioxide. Oxygenated blood enters the left atrium via the lungs and pulmonary 
vein, passing through the mitral valve into the left ventricle. Oxygenated blood then passes 




and extremities. Oxygenated blood is transported throughout the entire body via the vasculature 
and circulated through the capillaries in the trunk and extremities, enabling the release of oxygen 
and absorption of carbon dioxide. This sequence of steps occurs continuously, enabling the 
circulation of blood throughout the body. 
The Cardiac Cycle 
The cardiac cycle (Figure 3) represents the mechanical and electrical activity of the 
cardiovascular system that occurs during a single heartbeat. The cardiac cycle, as outlined by 
Berntson and colleagues (2007), includes two distinct phases: systole and diastole. Systole 
represents the contraction of the heart while diastole represents the relaxation of the heart. 
During the diastole phase, the heart is relaxed and the AV valves are open. The atria and 
ventricles fill with blood, resulting in an increase in the volume of blood in the ventricles. 
Depolarization of the SA node occurs in the right atrium and passes through the atrial muscle, 
which is represented on an electrocardiogram (ECG) as the P wave. Depolarization of the SA 
node causes the atrial muscles to contract. Pressure in the atria and ventricles increases, which 
causes the remainder of blood to flow into the ventricles. Depolarization of the AV node occurs 
in the center of the heart near the tricuspid valve and causes the ventricle muscles to contract, 
which leads to the closure of the AV valves. Together, this is represented on an ECG as the QRS 
complex. This marks the end of the diastole phase and the beginning of the systole phase. During 
the systole phase, pressure in the ventricles increases. The increase in ventricular pressure 
compared to pulmonary and aortic pressure leads to the opening of the semilunar valves. Blood 
is ejected through the pulmonary artery and aorta and the semilunar valves close. Pressure in the 
ventricles decreases, resulting in the repolarization of the ventricles, which is represented on an 




cardiac cycle. This sequence of steps occurs continually in the heart so that blood can be pumped 
throughout the body. 
Figure 3. Diagram of the Cardiac Cycle from Berntson et al. (2007) 
 
Cardiovascular Markers 
 There are multiple cardiovascular markers that can be used to measure cardiovascular 
functioning. The cardiovascular measures of interest relevant for this overview include HR, heart 
period (HP), heart rate variability (HRV), RSA, cardiac output (CO), and pre-ejection period 
(PEP), which are obtained through ECG or a combination of ECG and impedance cardiography 
(ICG) as described below.  
ECG 
ECG (Figure 4) is a noninvasive technique for measuring the electrical activity of the 
heart. ECG is obtained through the application of noninvasive electrode sensors placed on the 




certain electrical events that occur during the cardiac cycle (e.g., atrial and ventricular 
depolarization or ventricular repolarization). The ECG waveform is a visual representation of the 
electrical activity occurring in the heart, including the P wave, QRS complex, and T wave. The P 
wave represents atrial depolarization. The QRS complex represents ventricular depolarization. 
The T wave represents ventricular repolarization. In addition, the ECG waveform provides 
information on the speed of HR as well as the speed, magnitude, and direction of electrical 
events (Katz, 2010). 
Figure 4. ECG Waveform from Liang, Zhang, Tan, & Li (2014) 
 
HP and HR. HP is defined as the amount of time between heart beats measured in 
millisecond. For this investigation, HP will be used instead of HR, which is defined as the 
number of beats produced by the heart per minute. While HP and HR are reciprocal 
measurements of cardiovascular functioning, they are not linearly related and can generate 
discrepant results when there are significant differences across participants or changes within 




cardiovascular functioning are thought to be attributed to autonomic effects or differ significantly 
due to experimental tasks or group membership (Berntson et al., 2007).  
ECG is used to assess HP, which is calculated by determining the interbeat interval (IBI) 
between successive R spikes on the ECG in milliseconds. Research has suggested that higher HP 
during experimental procedures that require attention indicates that an individual is attending to 
the stimuli that are presented in the environment. HP has been used in the literature as an index 
of arousal, task involvement, and mental load and effort (Jorna, 1992).  
ICG 
Similar to ECG, ICG (Figure 5) is a noninvasive technique for measuring the electrical 
activity of the heart. ICG can be obtained through the application of noninvasive electrode 
sensors placed on the chest and back. ICG measures changes in blood flow and vascular 
contraction throughout the chest cavity via resistance to electrical signal. ICG must be used in 
concert with ECG, as the ECG waveforms are used as a reference for the timing of the cardiac 
cycle (Berntson et al., 2007). The ICG waveform is a visual representation of electrical and 
mechanical events that occur in the heart, including the B, C, X, Y, and O points. The B point 
represents the opening of the aortic valve while the X point represents the closing of the aortic 
valve. The C point marks the peak of blood flow through the aorta. The Y point signifies the 
closing of the pulmonary valve. The O point indicates the closing of the mitral valve. In addition, 
the ICG waveform provides information on the speed of mechanical events that occur in the 
heart, volume of blood pumped through the heart, and amount of resistance exerted on the blood 






Figure 5. ICG Waveform from Critchley (2013) 
 
HRV. HRV is defined as the beat-to-beat variability in HR and can be assessed using a 
combination of ECG and ICG. HRV can be determined via the time domain method, which 
calculates the IBI between successive R spikes on the ECG based on time. Standard Deviation of 
the Normal-to-Normal (SDNN) examines the IBI across a specific period (e.g., 24 hours), which 
provides a more comprehensive representation of variability with HRV (Carney et al., 2000). 
Root Mean Square Successive Difference (RMSSD) examines the IBI during a short time span, 
which provides a better representation of short-term changes in HRV (Carney et al., 2000). HRV 
can also be assessed via the frequency domain method, which calculates the IBI between 
successive R spikes on the ECG within certain frequencies. High frequency HRV (HF-HRV) 
examines the IBI within the high frequency band (.15-.40 Hertz), which takes respiration into 
account and approximates the amount of control the PNS exerts over the heart (Berntson et al., 




inhalation and decelerates during exhalation. Consequently, HF-HRV represents vagal 
modulation, rather than vagal tone (Shaffer & Ginsberg, 2017). Low frequency HRV (LF-HRV) 
examines the IBI within the low frequency band (.05-.15 Hertz), which is thought to be impacted 
by both sympathetic and parasympathetic rhythms (Berntson et al., 1997, 2007).  
Several less commonly used measures of HRV measures rely on the frequency domain 
method. For example, the LF/HF ratio is thought to approximate the degree of sympovagal 
balance (Vaccarino et al., 2008), but a significant body of evidence contradicts this hypothesis 
(Billman, 2013). Total power HRV (TP-HRV) assesses the IBI within the entire frequency band 
(< .40 Hertz), very low frequency HRV (VLF-HRV) assesses the IBI within a lower frequency 
band than LF-HRV (.0033-.039 Hertz), and ultra-low frequency HRV (ULF-HRV) assesses the 
IBI within the lowest frequency band (< .003 Hertz; Berntson et al., 1997; Vaccarino et al., 
2008). While these measures are thought to be representative of both sympathetic and 
parasympathetic rhythms, they are not well characterized due to their limited use (Berntson et al., 
1997, 2007).  
RSA. RSA is defined as the beat-to-beat variability in HR during the respiration cycle. A 
combination of ECG and ICG can be used to assess RSA, which is calculated using the 
frequency domain method. The frequency domain method converts HP from time-domain to 
frequency-domain then calculates the IBI between successive R spikes on the ECG within the 
high frequency band (.15-.40 Hertz; Allen et al., 2007). Research has suggested that higher RSA 
is generally desirable as it indicates that an individual can flexibly respond to environmental 
stimuli (Berntson et al., 2007).  
RSA sampled within the high frequency band is theorized to reflect the influence of the 




respiration (Berntson et al., 1997, 2007). Greater parasympathetic input is thought to result in 
more acceleration of cardiac activity during respiration and more deceleration of cardiac activity 
after expiration, resulting in variable intervals between the heartbeats. Consequently, RSA has 
been used in the literature as an index of cardiac vagal control, which approximates the amount 
of control the PNS exerts over the heart (Grossman & Taylor, 2007). RSA is equivalent to the 
cardiac measure of high-frequency heart rate variability (HF-HRV) and the two terms are often 
used interchangeably in the literature (Allen et al., 2007).  
CO. CO is defined as the volume of blood pumped by the heart per minute. CO is not 
only influenced by the rate at which the heart beats, but changes in the contractility, preload, and 
afterload of the cardiovascular muscles (Vincent, 2008). A combination of ECG and ICG are 
used to assess CO, which is calculated by multiplying HR and stroke volume (SV; CO = HR X 
SV), or volume of blood pumped through each ventricle per minute. Changes in CO is primarily 
controlled by HR as SV remains consistent across time. CO has been used in the literature to 
represent the efficiency of the heart. Research has suggested that higher CO indicates that the 
heart is functioning in an efficient manner (Berntson et al, 2007).  
PEP. PEP is defined as the amount of contractile force produced by the heart. CO is 
influenced by changes in the contractility of the cardiovascular muscles (van Lien, Schutte, 
Meijer, & de Geus, 2013). PEP is calculated by determining the amount of time between the Q 
wave on an ECG, which represents the beginning of ventricular depolarization, and B on an ICG, 
which represents the opening of the aortic valve and beginning of ejection.  
PEP is hypothesized to reflect the influence of the SNS on the heart (Berntson et al., 
2007; van Lien et al., 2013). Research has suggested that higher PEP during experimental 




and is associated with negative physiological responses (e.g., increase in cortisol and 
Hypothalamic-Pituitary-Adrenal (HPA) axis activation; as reviewed by Uchino, Smith, Holt-
Lunstad, Campo, & Reblin, 2007). Consequently, PEP has been used in the literature as an index 
of sympathetic cardiac control, which approximates the amount of control the SNS exerts over 
the heart (Berntson et al., 2007). 
In summary, the ANS is made up of two distinct systems that serve contradictory, but 
complementary, purposes: the SNS and the PNS. The SNS, or fight or flight response, is 
responsible for preparing and mobilizing the body to react to external stimuli presented within 
the environment. The PNS, or relaxation and restoration response, is responsible for 
demobilizing the body and returning it to baseline functioning. The heart is connected to the 
ANS via the vagus nerve, which connect the brain and the body. Consequently, the ANS is 
fundamental to and influential on cardiovascular functioning. 
There are multiple cardiovascular markers that can be used to quantify cardiovascular 
functioning. The cardiovascular measures that were assessed in this investigation include HP, 
RSA, CO, and RSA, which are obtained through ECG or a combination of ECG and ICG. Each 
cardiovascular marker has been used as an index of physiological functioning. Higher HP during 
experimental tasks that involve attention is believed to be adaptive, as it is thought to represent 
arousal, task involvement, and mental load and effort. Higher RSA is hypothesized to be 
adaptive and has been used index of cardiac vagal control, which approximates the amount of 
control the PNS exerts over the heart. Higher CO is thought to be adaptive, as it has been used to 
represent the efficiency of the heart. Finally, lower PEP during experimental tasks that induce 
stress is hypothesized to be adaptive and has been used index of cardiac vagal control, which 





 Several theoretical models have been proposed to account for individual differences in 
cardiovascular functioning. Generally, these theories characterize patterns of cardiovascular 
functioning as adaptive or maladaptive. Relevant theoretical models include the polyvagal 
theory, biopsychosocial model of challenge and threat, and hawk-dove model. 
The polyvagal theory. The polyvagal theory by Porges (1995) focuses on the impact of 
the ANS on physiological, psychological, and behavioral processes. The ANS contains two 
opposing systems: the sympathetic-adrenal system and the vagus system. The sympathetic-
adrenal system mobilizes the body through the activation of SNS activity. The vagus system is 
further branched into two subsystems: the ventral vagal complex and the dorsal vagal complex. 
The ventral vagal complex contains myelinated vagal pathways that demobilizes the body 
through the inhibition of SNS activity, which is referred to as the vagal brake. The vagal brake 
activates the vagus nerve to reduce HR and blood pressure (BP), which produces a calming, 
restorative response that is adaptive (Porges, 2007). The dorsal vagal complex contains 
unmyelinated vagal pathways that immobilize the body through the inhibition of SA node, which 
is referred to as the dorsal vagal surge. The dorsal vagal surge also activates the vagus nerve to 
reduce HR and BP but is significantly more suppressing as it results in a shutdown physical and 
behavioral responsivity (Porges, 2001). 
The polyvagal theory provides an evolutionary explanation to explicate the dynamic 
relationship between physiological, psychological, and behavioral processes. Each physiological 
state is characterized by a pattern of physical, psychological, and behavioral reactivity. More 
specifically, the sympathetic-adrenal system results in active avoidance, which include 




adrenal system is characterized by vagal withdrawal, or reduced RSA during an attention-
demanding task compared to RSA at rest (Porges, 2007). The ventral vagal complex results in 
social engagement, which includes facial expressions, vocalizations, eye contact, head 
orientation, and other communicative behaviors. In addition, the ventral vagal complex is 
characterized by vagal augmentation, or increased RSA during an attention-demanding task 
compared to RSA at rest (Porges, 2007). The dorsal vagal complex results in behavioral 
immobilization, which includes passive avoidance, dissociation, and collapse. Of note, a valid 
cardiovascular index does not yet exist for the dorsal vagal complex as the system has less 
impact on the rate at which the heart pumps (Chapleau & Sabharwal, 2015). The polyvagal 
theory proposes that the underlying neurobiological structures are responsible for determining 
physiological, psychological, and behavioral response. 
The polyvagal theory has been applied to the study of depression. Depression is a 
disorder characterized by maladaptive patterns of social, emotional, and behavioral responding. 
More specifically, research has shown that participants with current MDD exhibit deficits in 
social engagement (e.g., withdrawal from and impairment in social relationships) as well as 
emotional (e.g., flat affect) and behavioral (e.g., reduced startle response) inflexibility 
(Rottenberg, 2007b). Research has also identified some cardiovascular differences in depressed 
individuals that are in line with the polyvagal theory. Participants with current (Rottenberg, 
Wilhelm, Gross, & Gotlib, 2003) MDD show blunted RSA reactivity when crying in response to 
a sad film. In addition, depressed participants who exhibit this maladaptive pattern of 
cardiovascular reactivity report lower rates of recovery over time (Rottenberg, Salomon, Gross, 
& Gotlib, 2005a; Panaite et al., 2016). Empirical investigations of the polyvagal theory have 




inducing, or attention-demanding tasks show maladaptive patterns of social, emotional, and 
behavioral responding (e.g., DiPietro, Porges, & Uhly, 1992; Huffman et al., 1998; Porges, 
Doussard-Roosevelt, Portales, & Greenspan, 1996; Stifter & Corey, 2001; Stifter & Fox, 1990). 
Together, these studies suggest that the polyvagal theory can inform our understanding of 
cardiovascular reactivity in response to sadness in depressed populations. 
The biopsychosocial model of challenge and threat. The biopsychosocial model of 
challenge and threat by Blascovich and Tomaka (1996) proposes a physiological basis for 
psychological states experienced in response to stressors. The model is typically examined 
within a goal-relevant situation, which can include motivated performance situations that require 
attention and cognition or passive situations that are attention demanding, but not cognitively 
draining. The goal-relevant situation leads to physiological and emotional responses, which are 
influenced by a combination of biological, physiological, cognitive, and interpersonal factors. 
The perception of goal-relevant situations is impacted by two components of cognitive appraisal: 
primary and secondary appraisal. Primary appraisal is defined as the amount of demands 
required by situation while secondary appraisal is defined as the amount of personal resources 
one has within a situation. Primary and secondary appraisals influence how an individual 
perceives a goal-relevant situation. When an individual perceives that he or she has the personal 
resources necessary to surmount the situational demands, the situation is viewed as a challenge. 
Conversely, when an individual perceives that he or she does not have the personal resources to 
meet the situational demands, the situation is viewed as a threat.  
As outlined by Mendes, Major, McCoy, and Blascovich (2008), challenge and threat 
responses are theorized to result in differential patterns of performance and emotional and 




which is associated with approach toward the task. Emotional reactions associated with 
challenge include positively-valenced emotions such as confidence and pride as well as 
externalized negatively-valenced emotions such as anger. The pattern of cardiovascular 
reactivity associated with challenge includes increased HR, CO, and vasoconstriction (VC) and 
decreased total peripheral resistance (TPR). Contrariwise, threat is associated with a decrease in 
performance on goal-relevant tasks, which is associated with avoidance of, vigilance towards, or 
feelings of defeat related to the task. Emotional reactions associated with threat include 
internalized negatively-valenced emotions such as shame and anxiety. The pattern of 
cardiovascular reactivity associated with threat includes increased HR, VC, and TPR and no 
change in CO. The biopsychosocial model of challenge and threat proposes that the perception of 
a situation influences physiological, psychological, and behavioral responsivity. 
 The biopsychosocial model of challenge and threat has been examined in relation to 
depression. Research has shown that participants with current MDD exhibit lower HR, HRV, 
RSA, and CO (Bylsma, Salomon, Taylor-Cliff, Morris, & Rottenberg, 2014; Salomon, Clift, 
Karlsdóttir, & Rottenberg, 2009; Salomon, Bylsma, White, Panaite, & Rottenberg, 2013) when 
exposed to stressors. While these findings are not in line with the patterns of cardiovascular 
reactivity hypothesized by the biopsychosocial model of challenge and threat, they do suggest an 
atypical pattern of cardiovascular reactivity in response to stress among currently depressed 
individuals.  
The biopsychosocial model of challenge and threat has been explored in depressed 
populations within the context of stress, but not sadness. It is possible that individuals with 




individuals may perceive that they have low personal resources in both types of high-demands 
situations. 
The hawk-dove model. The hawk-dove model by Smith (1982) provides an evolutionary 
account of behavioral and physiological differences in response to stress. The model focuses on 
the concepts of allostasis, or the process of attaining homeostasis through the regulation of 
internal processes in response to external stressors, and allostatic load, or the impact of allostatic 
regulation on the body. The model proposes two architypes that represent an individual’s typical 
response to allostasis: “hawks” and “doves” (Korte, Koolhaas, Wingfield, & McEwen, 2005). 
Individuals who are categorized as hawks exhibit aggressive, intrepid behavior. Their typical 
behavioral response is to either react or run away, which results in limited behavioral flexibility. 
Conversely, individuals who are categorized as doves exhibit non-aggressive, vigilant behavior. 
Their typical behavioral response is to freeze or hide, which results in high levels of behavioral 
flexibility. The behavioral patterns across groups are hypothesized to reflect differences in 
underlying physiology (Korte et al., 2005). More specifically, hawks show elevated sympathetic 
reactivity and reduced parasympathetic reactivity while doves show elevated parasympathetic 
reactivity and reduced sympathetic reactivity. These differences in autonomic reactivity are 
thought to result in varied cardiovascular responsivity, with hawks exhibiting increased 
sympathetic activity as indexed by lower HRV and doves exhibited increased parasympathetic 
activity as indexed by higher HRV (Korte et al., 2005). 
The hawk-dove model has been extended to the study of depression. As reviewed by 
Korte and colleagues (2005), allostatic load appears to have distinct effects on individuals 
categorized as “hawks” or “doves.” Hawks have been found to have higher rates of coronary 




sympathetic activity. Dominance of the sympathetic activity also impacts the immune system; 
reduced activity of the HPA axis leads to a hyper-immune state characterized by excessive 
inflammation and autoimmune responsivity. This physiological pathway is thought to contribute 
to the higher rates of atypical depression in hawks, which is characterized by increased appetite, 
weight gain, sleep, and social withdrawal. Doves more commonly show bradyarrhythmia, or an 
abnormal heart rhythm, due to dominance of parasympathetic activity. In addition, doves have 
been found to have higher rates of hypertension and atherosclerosis because of a cascade of 
physiological events; increased levels of cortisol lead to an increase in fat deposits, which results 
in elevated sympathetic activity. Neural differences in doves are thought to increase activity of 
the HPA axis and sympathetic system, contributing to the higher rates of melancholic depression, 
which is characterized by decreased appetite, weight, and sleep and increased feelings of 
helplessness, worthlessness, anxiety, and arousal. The hawk-dove model proposes that 
differences in physiological reactions may account for the presence of certain subtypes of 
depression observed in research and clinical settings. 
Multiple theoretical models have been proposed to provide a link between behavioral, 
psychological, and physiological responding. These theoretical models have been extended to the 
study of depression, providing a theoretical explanation for the maladaptive patterns of 
cardiovascular responding that have been observed in depressed populations. Together, these 
theoretical and empirical works suggest that cardiovascular functioning is related to depression 
and can advance our understanding risk of relapse and recurrence. The following section will 





Cardiovascular Functioning in Depression 
Current Major Depressive Disorder 
The association between MDD and CVD is likely bidirectional, with depression 
contributing to the development of CVD and CVD related to increased risk of MDD (Lippi, 
Montagnana, Favaloro, & Franchini, 2009). A large body of work indicates that depressive 
symptoms and disorders are associated with an increased risk for CVD (see Haigh, Bogucki, 
Dearborn, Robbins, & Elias, 2018b for a review). Systematic reviews and meta-analysis have 
concluded that depressive symptoms or a clinical diagnosis of depression predict the 
development of coronary heart disease (Gan et al., 2014; Nicholson, Kuper, & Hemingway, 
2006; Ruglies, 2002; Wulsin & Singal, 2003; Van der Kooy et al., 2007), myocardial infarction, 
stroke, and other forms of CVD (Van der Kooy et al., 2007). While evidence from these meta-
analyses and systematic reviews are striking, there are significant 
methodological flaws (e.g., failure to exclude for CVD at baseline, publication bias, impartial 
adjustments, possibility of reverse causality; Nicholson et al., 2006) that temper the 
interpretations that can be made about the impact that depression has on the development of 
CVD.  
Research suggests that cardiovascular events and CVD are associated with increased 
depressive symptomology and diagnosis. Cross-sectional studies have shown that a large 
proportion of individuals with CVD report elevated rates of depressive symptoms (11.00-
50.00%) or meet the diagnostic criteria for MDD (26.00%; Brown, Barton, & Lambert, 2009). 
Longitudinal studies have shown that individuals with CVD who have comorbid depression 
report poorer adherence to medical interventions, reduced quality of life, and increased 




While the literature has established that a relationship exists between depression and 
CVD, the nature of this relationship remains unclear. Cardiovascular functioning has been 
explored as a potential mechanism of action due to its association with physical and 
psychological functioning (Rottenberg, 2007b). With respect to depression, various naturalistic 
and experimental paradigms have been used to assess how different psychological states impact 
cardiovascular functioning. The following section will review the literature base that examines 
cardiovascular functioning at rest and in response to stress and sadness in individuals who are 
currently depressed. 
Cardiovascular functioning at rest. Cardiovascular functioning at rest is an important 
indicator of cardiovascular health. Cardiovascular functioning has been assessed through balance 
of the ANS (Thayer & Lane, 2009). Autonomic balance is evident when equipoise exists 
between the SNS and the PNS while autonomic imbalance is present when the SNS is overactive 
and the PSN is underactive. Previous research has found that autonomic imbalance, as indexed 
by higher HR, lower HRV and RSA, and slower HR recovery, is associated with increased risk 
of functional impairment, morbidity, and mortality (Phillips, Ginty, & Hughes, 2013; Thayer & 
Lane, 2009). 
A large body of literature has investigated cardiovascular functioning in adults with 
current MDD at rest, which has employed a variety of activities (e.g., lay down, sit quietly, sleep, 
engage in daily activities, or complete a breathing task). Rottenberg (2007b) conducted a meta-
analysis of 13 articles that compared RSA at rest in clinically depressed and healthy control 
participants. Results found lower resting RSA in currently depressed participants with (p < .001, 
d = .28) and without (p < .001, d = .33) a history of CVD compared to healthy control 




with and without cardiovascular problems, the presence of CVD may be a confound and 
therefore should be controlled or excluded for when examining the relationship between 
depression and cardiovascular health (Kemp et al., 2010).  
Building on the work of Rottenberg (2007b), Kemp and colleagues (2010) conducted a 
similar meta-analysis of 18 articles that compared multiple measures of HRV at rest in clinically 
depressed and healthy control participants. Importantly, none of the participants included in these 
analyses had a history of CVD. Results indicated that participants with current MDD showed 
lower resting time frequency HRV (p = .01, d = -.29), long-term HRV (p = .03, d = -.46), and 
HF-HRV (p = .03, d = -.21) and higher LF/HF ratio (p = .01, d = 066) compared to healthy 
control participants. In addition, current depressive symptom severity was negatively associated 
with HRV (p < .001, d = -.13), suggesting that more severe depressive symptoms were 
associated with lower resting HRV. Together, these meta-analyses provide evidence for the 
small, but significant association between depression and lower resting RSA and HRV measures. 
This area of inquiry is important as cardiovascular abnormalities have been previously shown to 
contribute to the relationship between depression and CVD (as reviewed by Rottenberg, 2007b). 
Recent studies published after the aforementioned meta-analyses have found similar 
results in currently depressed participants without a history of CVD. Kikuchi and colleagues 
(2009) showed that participants with current MDD showed lower LF-HRV, but not HF-HRV, 
while laying down after a 20-minute resting period compared to participants with panic disorder 
(t = 2.54, p = .02) and healthy control participants (t = 2.47, p = .02). It was hypothesized that 
cardiovascular differences reflect lower baroreflex sensitivity, implicated in the regulation of BP. 
Kemp, Quintana, Felmingham, Matthews, and Jelinek (2012) found that compared to healthy 




measures (R2 = 2.99, η2p = .19, p = .001). Specifically, participants with current MDD showed 
lower LF/HF ratio (R2 = 7.71, p = .01, d = .42) and HF-HRV (R2 = 7.71, p = .01, d = -.46) while 
seated compared to healthy control participants. In addition, subgroup differences were found for 
the current MDD group based on the presence of comorbid anxiety; participants with comorbid 
generalized anxiety disorder had significantly higher LF/HF (p = .03, d = .94) and lower HF-
HRV (p = .01, d = .85) compared to participants without any comorbidities.  
Chang and colleagues (2012) found that participants with current MDD showed 
significantly lower HRV variance, LF-HRV, HF-HRV (p’s < .001), and LF/HF ratio (p = .061) 
while laying down after a 20-minute resting period compared to healthy control participants. In 
addition, subgroup differences existed in the current MDD group based on the presence of 
suicidal ideation. Participants with MDD and suicidal ideations had significantly lower HRV 
variance (p = .04) and HF-HRV (p = .01) compared to MDD participants without suicidal 
ideation. While all studies identified some differences in HRV among currently depressed 
participants, the specific cardiovascular abnormalities differed. This could be due to differences 
in samples (i.e., subsamples with comorbidities) or recording procedures (i.e., laying versus 
sitting, use of a pre-recording resting period). Overall, these studies provide additional support 
for the association between depression and poorer resting cardiovascular functioning and suggest 
that psychiatric comorbidity and suicidality may negatively impact cardiovascular functioning 
further.  
In summary, depression appears to be associated with poorer cardiovascular functioning 
at rest compared to healthy control participants. More specifically, individuals with current MDD 
generally show lower resting RSA and HRV. This line of research is important as it is possible 




CVD. To more fully understand the relationship between depression and cardiovascular 
functioning, research has explored cardiovascular reactivity to emotionally-inducing stimuli (i.e., 
stress and sadness). The following section will review research on cardiovascular reactivity to 
stress among individuals who are currently depressed.  
Cardiovascular reactivity in response to stress. Research suggests that the link 
between depression and CVD might be attributed to excessive cardiovascular reactivity in 
response to stress. Kibler and Ma (2004) conducted a meta-analysis to examine the strength of 
the relationship between depressive symptoms and cardiovascular reactivity to experimental 
stressors (e.g., mental arithmetic, Stroop, startle, cold pressor, mirror tracing, anger recall, verbal 
challenge, and caregiving story). Eleven empirical studies that primarily focused on the impact 
of stress on HR and BP were statistically examined. Results indicated that there was a moderate 
relationship between depressive symptoms and HR reactivity to stress (d = .37) and a weaker 
relationship between depressive symptoms and systolic (d = .13) and diastolic (d = .17) BP 
reactivity to stress. In addition, the effect size for HR and diastolic BP were significantly larger 
in samples that included participants with CVD compared to samples with participants free from 
cardiovascular problems (p’s < .05). Of note, most studies utilized self-report measures to assess 
depressive symptoms rather than diagnostic measures, which limits the generalizability of results 
to clinical samples. While this study does not inform the directionality of the relationship 
between depression and CVD, the results suggest that depressive symptoms are related to 
cardiovascular reactivity in response to stress. 
Additional research has been conducted on cardiovascular reactivity in response to 
experimental stress inductions in current MDD. Studies have employed a variety of empirically-




al., 2011; Rottenberg et al., 2007a; Salomon et al., 2009), cognitively (e.g., mental arithmetic and 
N-back tasks; Ehrenthal et al., 2010; Liang, Lee, Chen, & Chang, 2015; Nugent et al., 2011), 
emotionally (e.g., anger recall task; Ehrenthal et al., 2010), or socially (e.g., speech task; Panaite 
et al., 2016; Rottenberg et al., 2007a; Salomon et al., 2009) stressful in nature. Importantly all 
studies excluded for the presence of CVD. In general, studies showed that participants with 
current MDD exhibited lower cardiovascular reactivity as measured by HR, HRV, RSA, and CO 
in response to most stress induction tasks compared to healthy control participants (i.e., 
Ehrenthal et al., 2010; Liang et al., 2015; Nugent et al. 2011; Rottenberg et al., 2007a; Salomon 
et al., 2009; with the exception of Panaite et al., 2016). In addition, one study showed that 
participants with current MDD exhibited less HR recovery following the speech and mirror 
tracing tasks relative to healthy control participants (p’s < .05; Salomon et al., 2009). Together, 
these results suggest that individuals with current MDD exhibit a less adaptive pattern of 
cardiovascular reactivity when faced with stress.  
There is a growing body of evidence to suggest that depression is associated with 
maladaptive cardiovascular reactivity in response to stress. More specifically, individuals with 
current MDD generally show lower HR, HRV, RSA, and CO when exposed to stressful 
experimental tasks. Given that MDD is characterized by depressed mood, negative affect, and 
apathy, research has explored cardiovascular reactivity in response to sadness. In the following 
section, research examining cardiovascular reactivity in response to sadness in individuals who 
are currently depressed will be reviewed. 
Cardiovascular reactivity in response to sadness. Research has investigated if the link 
between depression and CVD may be attributed to maladaptive cardiovascular reactivity in 




sadness has a significant impact of the cardiovascular functioning of individuals who are already 
experiencing a low, depressogenic mood.  
Some studies have found differences in cardiovascular reactivity in response to sad-
valenced stimuli among currently depressed participants. Rottenberg and colleagues (2003) 
examined cardiovascular reactivity in response to a sad film. Contrary to the studies on 
cardiovascular functioning at rest, no differences in RSA existed between women with current 
MDD and healthy control women at baseline. While RSA significantly increased for healthy 
control women who cried in response to the sad film (R2 = 12.65, p < .005, ε = .739), there was 
no change in RSA among women with current MDD who cried (R2 = 2.64, p > .05, ε = .967).  
Jin, Steding, and Webb (2015) also found that there were no differences in HR and RSA 
between currently depressed and healthy control participants during baseline. While watching 
sad and amusing films, HR decreased significantly more in healthy control participants 
compared to participants with current MDD (p < .05, η2p = .83). This pattern of responding was 
not observed for RSA, suggesting that depressed individuals showed blunted cardiovascular 
reactivity for some, but not all, cardiovascular markers. Together, these studies suggest that 
cardiovascular functioning does not differ between depressed and non-depressed individuals at 
rest; however, differences emerge when exposed to sad stimuli. 
Rottenberg and colleagues (2005a) showed that RSA reactivity in response to the sad 
mood induction predicted recovery from MDD. Specifically, currently depressed participants 
who exhibited vagal withdrawal (i.e., decrease in RSA from baseline) to the sad film had 
significantly higher rates of remission at 6-months follow-up (p < .05). Of note, this relationship 
was not found for the fear and amusing films. This study provides preliminary support for the 




other negatively-valenced stimuli (i.e., fear). Panaite and colleagues (2016) replicated the work 
of Rottenberg and colleagues (2005a). Currently depressed participants who exhibited reduced 
vagal withdrawal in response to a sad film had significantly higher depressive symptoms at 30-
weeks follow-up (b = 5.18, p = .002). This relationship was not found for fear or amusing films 
(p’s > .05). Together, these studies suggest that individuals with current MDD who exhibit 
blunted reactivity in response to sad-valenced stimuli are more likely to report elevated 
depressive symptoms and less likely to experience remission of depression over time. 
In contrast, other studies have failed to find differences in cardiovascular reactivity in 
response to a sad mood induction among currently depressed participants. Rottenberg and 
colleagues (2005b) compared participants with current and remitted MDD to those without a 
history of Axis I disorders. The three groups did not show differences in HR in response to 
happy, neutral, and sad films that were previously experimentally validated or idiographic in 
nature (p’s > .10). Of note, participants with current and remitted MDD exhibited a non-
statistically significant increase in HR during all the experimental tasks. Tsai, Pole, Levenson, 
and Muñoz (2003) compared Latino women with current MDD to those without a history of 
Axis I disorders. Results indicated that current MDD and healthy control participants who 
watched sad and amusing films did not differ in terms of cardiac IBI (p > .05).  
While methodological procedures were generally consistent across studies, Tsai and 
colleagues (2003) did use a different diagnostic assessment and sad mood induction procedure. 
The samples recruited and cardiovascular measures assessed also differed across studies, with 
some studies examining a restricted range of participants (e.g., Tsai et al. (2003) only included 
Latino participants) and cardiovascular markers (e.g., Rottenberg et al. (2005b) only examined 




et al., 2003, 2005a, 2005b; Tsai et al., 2003), which could potentially confound and cause 
discrepancies in the cardiovascular results. These methodological problems could have 
contributed to the differences observed across studies. 
There is some evidence to suggest that depression is associated with maladaptive 
cardiovascular reactivity in response to sadness. Specifically, individuals with current MDD 
generally show blunted HR and RSA reactivity when exposed to sad mood induction procedures. 
However, results have not been consistent across the literature, with some studies failing to 
replicate these patterns of cardiovascular reactivity and showing an opposite trend of 
cardiovascular reactivity (i.e., Rottenberg et al., 2005b; Tsai et al., 2003).  
Remitted Major Depressive Disorder 
As previously detailed, MDD is characterized by high rates of relapse and recurrence. 
The chronic nature of the disorder suggests that a large proportion of individuals with a history 
of depression will experience another depressive episode over the course of their lifetime. 
Therefore, research is needed to identify risk factors for relapse and recurrence in euthymic 
individuals with a history of depression. Two prominent classes of risk factors include cognitive 
and mood vulnerabilities. The literature has suggested that cognitive and mood vulnerabilities 
that are present in currently depressed individuals remain latent in formerly depressed 
individuals until they are activated by dysphoric mood.  
This body of evidence proposes that the differential activation and mood state dependent 
hypotheses may extend to other areas, such as cardiovascular functioning. It is plausible that the 
maladaptive patterns of cardiovascular reactivity observed in currently depressed individuals 
may also be mood state dependent. It would follow that individuals with a history of depression 




stress and sadness, but not while they were euthymic. To test this hypothesis, research has 
examined cardiovascular functioning at rest as well as cardiovascular reactivity in response to 
stress and sadness in adults and adolescents with remitted MDD; however, cardiovascular 
functioning among individuals with a history of depression has not been investigated to the same 
extent as current depression. The available research that examines cardiovascular functioning in 
adults and adolescents with remitted MDD is reviewed below.  
Cardiovascular functioning at rest. Some studies have investigated cardiovascular 
functioning in adults with remitted MDD at rest or during the completion of daily life activities. 
Chang and colleagues (2013) examined HRV at rest among formerly depressed participants with 
or without a history of suicide ideation. Participants were free from CVD and other medical 
conditions (e.g., diabetes, hypertension, etc.) that could impact the recording of physiological 
responses. Depression was diagnosed using the Modified Schedule for Affective Disorders and 
Schizophrenia – Lifetime Version (SADSL) and the HDRS. Participants with remitted MDD 
were classified as having (n = 237) or not having (n = 233) a history of suicidal ideation during a 
past depressive episode. In addition to exploring cardiovascular differences based on a history of 
suicidality, participants with remitted MDD were compared to healthy controls (n = 462) without 
a history of MDD or suicidal ideation. HRV was assessed for five minutes while participants 
relaxed following a 20-minute baseline period. Results showed that participants with remitted 
MDD who endorsed a history of suicidal ideations have significantly lower HRV variance (p = 
.001), HF-HRV (p = .01), and LF-HRV (p = .004) than participants with remitted MDD without 
a history of suicidality and healthy control participants. No differences were identified between 




.05). Overall, these findings suggest that some differences in cardiovascular functioning exist at 
rest in participants with remitted MDD, but only among those with a history of suicidal ideation. 
Vaccarino and colleagues (2008) evaluated HRV among a sample of twins with current 
or remitted MDD. Participants were free from CVD when initially evaluated in 1990; however, 
only coronary heart disease, myocardial infarction, and angina pectoris was assessed at the time 
of the current investigation. The DIS was originally used to diagnose current and past MDD. A 
total of 288 twins contributed psychophysiological data, which included participants with current 
(n = 7) and remitted (n = 61) MDD that were collapsed into a single group. History of MDD was 
re-confirmed by the SCID-I. HRV was recorded over the course of 24-hours and timing of daily 
life activities were matched across participants. While TP-HRV, ULF-HRV, VLF-HRV, and LF-
HRV was significantly lower (p’s < .05) in twins with current or remitted MDD, this relationship 
did not hold when additional variables (e.g., lifestyle factors, comorbid medical, and psychiatric 
conditions) were entered into the model. Several methodological flaws (e.g., poor screening for 
CVD and combined sample of current and remitted MDD participants), temper the finding that 
history of depression is not associated with lower HRV while at rest and during activities of daily 
living. 
As reviewed, there does not appear to be significant differences in cardiovascular 
functioning at rest among individuals with remitted MDD. These findings are in line with the 
differential activation and mood state dependent hypotheses, which suggests that vulnerability to 
depression (e.g. maladaptive patterns of cardiovascular functioning) is only observable when 
formerly depressed individuals are faced with an emotional challenge. Therefore, it is possible 
that maladaptive patterns of cardiovascular reactivity observed in currently depressed 




section, research examining cardiovascular functioning in response to stress in remitted MDD 
will be reviewed. 
Cardiovascular reactivity in response to stress. A portion of the literature has 
investigated cardiovascular functioning in adults with remitted MDD in response to experimental 
stress inductions. Ahrens and colleagues (2008) examined HRV in adults with remitted MDD 
during stressful and cognitively challenging tasks. All participants were free from major 
ventricular or supraventricular arrhythmias and current medical conditions were endorsed as 
stable; however, the presence of CVD was not comprehensively assessed, which could 
potentially confound the cardiovascular results. Participants were women with remitted MDD (n 
= 22) and healthy women without a history of affective disorders (n = 20). Experimental tasks 
included completion of several stressful (i.e., speech and mental arithmetic) and cognitively 
demanding (i.e., computer concentration) tasks. HR and HRV was collected continuously during 
the experimental procedures. Three average HR measurements were computed during baseline, 
completion of tasks, and recovery. Five average HRV measurements were computed during 
baseline while supine and standing and during the speech, mental arithmetic, and computer 
concentration tasks. Results did not reveal any significant differences in HR and HRV between 
participants with remitted MDD and healthy control participants across the experimental 
paradigm (p’s > .05). The authors theorized that the results might be due to the nature of the 
stressful tasks, stating that more demanding tasks may elicit differences in cardiovascular 
functioning across groups. 
Salomon and colleagues (2013) used different methodological procedures to examine 
cardiovascular reactivity in response to stress in adults with remitted MDD. Participants were 




abuse, etc.) or medications (e.g., antipsychotics, beta blockers, etc.) that could impact the 
recording of physiological responses. Depression was assessed using the SCID-I. The sample 
was comprised of participants with current MDD (n = 50) or remitted MDD (n = 25) and healthy 
control participants without a history of Axis I disorders (n = 45). Participants watched a neutral 
video during the baseline period, completed an active (i.e., speech preparation and delivery under 
observation) and passive (i.e., forehead cold pressor task) stressful task in counterbalanced order, 
and watched a video during the recovery period. HR, PEP, and CO were collected continuously 
during the experimental procedures. Six average measurements were computed for each 
cardiovascular measure during baseline, the speech preparation, delivery, and recovery, and the 
cold pressor task and recovery.  
Results did not reveal any significant differences in cardiovascular reactivity among 
currently or formerly depressed or healthy control groups during baseline (p’s > .05) and the 
forehead cold pressor task (p’s > .29). Salomon and colleagues (2013) speculated that the null 
findings might be because participants with current MDD only show reduced reactivity when 
confronted with an active task (e.g., speech) that they perceive as insurmountable, which is in 
line with the biopsychosocial model of challenge and threat. Differential patterns of 
cardiovascular reactivity were observed during components of the speech task. During the 
speech preparation, participants with current MDD showed significantly lower HR (R2 = 3.74, p 
< .01, η2p = .10) and PEP (R
2 = 4.32, p < .05, η2p = .08) reactivity compared to participants with 
remitted MDD and healthy control participants. During the speech delivery, participants with 
current MDD showed significantly lower HR (R2 = 8.14, p < .001, η2p = .14), CO (R
2 = 4.68, p < 
.05, η2p = .08), and PEP (R
2 = 9.33, p < .001, η2p = .16) reactivity compared to participants with 




significantly differ from healthy control participants on any cardiovascular measure during the 
speech preparation delivery, and recovery (p’s > .05). Overall, these findings provide preliminary 
support for the notion that individuals with current MDD, but not remitted MDD, show a blunted 
cardiovascular response to active stressful tasks.  
In a follow up study, Bylsma and colleagues (2014) sought to replicate the finding that 
adults with current but not remitted MDD exhibit blunted cardiovascular reactivity to active, 
stress inducing tasks. All participants were free from CVD and other medical conditions or 
medications that could impact the recording of physiological responses. The sample was 
comprised of participants with current MDD (n = 51) or remitted MDD (n = 25) and healthy 
controls without a history of Axis I disorders (n = 45). Experimental tasks included a baseline 
video, paced breathing baseline, an active (i.e., speech preparation and delivery under 
observation) and passive (i.e., forehead cold pressor task) stressful task in counterbalanced order, 
and recovery video. RSA was collected continuously during the experimental procedures. Eight 
average measurements were computed for RSA during baseline, the paced breathing task, the 
speech instructions, preparation, delivery, and recovery, and the cold pressor task and recovery.  
Results revealed that cardiovascular measures did not significantly differ between groups 
during baseline and the forehead cold pressor task (p’s > .05). However, Bylsma and colleagues 
(2014) did observe differential patterns of cardiovascular reactivity during the speech task. 
During the speech preparation, delivery, and recovery, participants with current MDD showed 
significantly lower RSA (p < .05) compared to participants with remitted MDD and healthy 
control participants. However, this relationship was no longer significant when adjustments were 




colleagues (2013), findings suggested that individuals with current MDD, but not remitted MDD, 
exhibit a blunted cardiovascular response to active stressful tasks. 
Wilson and colleagues (2016) examined cardiovascular reactivity in response to stress 
among adults with a history of MDD with or without a prior suicide attempt. All participants 
were free from CVD and other autonomic disorders (e.g., diabetes, Parkinson’s disease, etc.) that 
could impact the recording of physiological responses. Participants were assessed for depression 
using the SCID-I and history of suicide using the Columbia University Suicide History Form and 
the Lethality Scale. Participants included women with remitted MDD with (n = 13) or without (n 
= 22) a previous suicide attempt. Experimental procedures included a resting baseline and the 
Trier Social Stress Task (TSST), a widely-used laboratory-based paradigm used to induce 
moderate levels of social stress. HF-HRV was collected continuously during the experimental 
procedures and averaged within each experimental phase. Results showed that HF-HRV did not 
significantly differ between groups during baseline (p = .09). However, participants with a 
history of suicide attempts showed significantly lower HF-HRV during the TSST (t = 5.4, p = 
.03) compared to participants without a history of suicide attempts. Findings echo previous 
studies on the impact of stress on cardiovascular functioning, suggesting that individuals with 
remitted MDD who have attempted suicide exhibit blunted cardiovascular reactivity in response 
to stressful tasks that are active. 
While Wilson and colleagues (2016) found that adults with a history of depression show 
lower HF-HRV in response to stress, this study focused on a subset of the remitted depressed 
individuals (i.e., those with a history of suicide behavior) that is not representative or the entire 
population. Instead, the majority of the literature has shown that adults with remitted MDD do 




(i.e., Ahrens et al., 2008; Salomon et al., 2013; Bylsma et al., 2014). It is possible that the 
differential activation and mood state dependent hypotheses only apply to emotions that are 
relevant to depression and that the maladaptive patterns of cardiovascular reactivity observed in 
currently depressed participants will be present in formerly depressed participants who become 
sad. In the following section, research examining cardiovascular reactivity in response to sadness 
in a mixed sample of currently and formerly depressed participants will be reviewed. 
Cardiovascular reactivity in response to sadness. Cardiovascular reactivity in response 
to a sad mood induction is separately reviewed below for research using a mixed adult and 
adolescent sample of current and remitted MDD participants as well as an adult sample of 
remitted MDD participants. 
Cardiovascular reactivity in response to sadness in a mixed adult sample of current 
and remitted depression. A set of studies have examined cardiovascular reactivity in response to 
a sad mood induction in a mixed sample of adults with current and remitted MDD (Table 1). 
Yaroslavsky, Rottenberg, and Kovacs (2013) examined if RSA measured at rest and in response 
to a sad mood could predict current depressive symptoms and history of depression. Participants 
were adults with a history of MDD during adolescence (n = 113; 37.00% currently experiencing 
a depressive episode) and healthy control participants without a history of Axis I disorders (n = 
93). Depressive symptoms were assessed using the BDI and Follow-Up Depression Scale, a 
clinician-rated scale for depressive symptom severity. Experimental tasks included a resting 
baseline and film-based mood inductions for joy, fear, sadness, anger, and disgust that were 





Yaroslavsky and colleagues (2013) found that the combination of resting RSA and RSA 
reactivity, but not resting RSA and RSA reactivity alone, predicted current depressive symptoms 
and previous depression status. Participants who showed high resting RSA and RSA withdrawal 
(i.e., decrease in cardiac vagal control) in response to the sad mood induction were more likely to 
report lower depressive symptoms and less likely to have a history of depression (p’s < .05). In 
contrast, the interaction between resting RSA and RSA augmentation (i.e., increase in cardiac 
vagal control) in response to the sad mood induction was not significant (p = .97). 
Study 1 by Yaroslavsky, Rottenberg, and Kovacs (2014) investigated whether RSA 
measured at rest and in response to a sad mood could predict depressive history in a sample of 
women with juvenile-onset depression. Participants were adult women with a history of MDD 
during adolescence (n = 27; 48.00% currently experiencing a depressive episode) and healthy 
women without a history of Axis I disorders (n = 43). Experimental tasks included a resting 
baseline and film mood inductions for joy and sadness. RSA was collected continuously during 
the experimental procedures. The focus of this study was solely on RSA during rest and RSA in 
response to the sad mood induction; average RSA resting measurements were computed via 
resting baseline while average RSA reactivity was computed during the sad mood induction.  
In Study 1, Yaroslavsky and colleagues (2014) found that participants who showed an 
abnormal pattern of RSA responding (i.e., high resting RSA and RSA augmentation or low 
resting RSA and RSA withdrawal) were more likely to endorse a history (p < .05) or current 
episode (p < .001) of depression. In addition, participants who showed a normal pattern of RSA 
responding (i.e., high resting RSA and RSA withdrawal or low resting RSA and RSA 
augmentation) were less likely to endorse a history or current episode of depression. These 




cardiovascular reactivity during a sad mood can be used to characterize the presence of current 
or past depression. 
The aforementioned studies (Yaroslavsky et al., 2013, 2014 Study 1) showed that the 
interaction between RSA at rest and RSA reactivity was a significant predictor of depressive 
history and symptoms in participants with current and remitted MDD. However, there are 
significant methodological problems that limit the generalizability and validity of these findings. 
First, a portion of the participants endorsed currently experiencing a depressive episode during 
data collection, which resulted in a mixed sample consisting of both current and remitted MDD. 
It is possible that the findings are only applicable to the currently depressed participants as 
research has been shown that current MDD impacts cardiovascular functioning during a sad 
mood induction (e.g., Jin et al., 2015; Rottenberg et al., 2003; Rottenberg et al., 2005a; Panaite et 
al., 2016). Second, participants were not assessed for the presence of CVD. Previous research 
has indicated that CVD may be a confound and therefore should be controlled or excluded for 
when examining the relationship between depression and cardiovascular health (Kemp et al., 
2010). Finally, the studies utilized the same sample of participants who experienced a depressive 
episode during adolescence. Of note, differences have been found between adolescent and adult 
depression (Kaufman, Martin, King, & Charney, 2001). Consequently, the results may not 
generalize to adult-onset depression. While the interaction between RSA at rest and RSA 
reactivity is an intriguing line of inquiry, additional methodologically sound research is needed 
to investigate if this pattern of cardiovascular reactivity truly characterizes remitted depression in 
adults. 
Cardiovascular reactivity in response to sadness in a mixed adolescent sample of 




to a sad mood induction in a mixed sample of adolescents with current and remitted MDD (Table 
1). Study 2 by Yaroslavsky and colleagues (2014) investigated if RSA measured at rest and in 
response to a sad mood could predict depressive history and symptoms in adolescents. 
Participants and another informant completed the Interview Schedule for Children and 
Adolescents: Diagnostic Version (ISCA-D), a semi-structured interview used to diagnose 
depression and the Children’s Depression Inventory – Second Edition (CDI-2), a self-report form 
to assess depressive symptoms. Participants included 147 Hungarian proband-sibling pairs in 
which one sibling had a history of MDD during childhood (n = 132) and the other sibling also 
had a history of MDD during childhood (n = 36) or no history of MDD (n = 111). Of note, the 
authors did not provide detailed information about the sample and refer to previous studies for 
more information. These studies focus on currently depressed adolescents (e.g., Baji et al., 2009; 
Kiss et al., 2007; Tamás et al., 2007), suggesting that the sample of interest is not made up of 
purely formerly depressed participants. Experimental tasks included a paced breathing task and 
film-based sad mood induction. RSA was collected continuously during the experimental 
procedures. Average RSA resting measurements were computed during the paced breathing task 
while average RSA reactivity was computed by taking the difference between RSA during the 
paced breathing task and the sad mood induction.  
In Study 2, Yaroslavsky and colleagues (2014) showed that an abnormal pattern of RSA 
at rest and in response to the sad mood induction (i.e., high resting RSA and RSA augmentation 
or low resting RSA and RSA withdrawal) were present in proband-sibling pairs where both 
children experienced depression (OR = 6.46, CI = 1.15, 36.47, p < .05), but not in proband-
sibling pairs where only the proband experienced depression. These results, which replicate the 




an abnormal pattern of RSA responding in depressed adolescents that corresponded with the 
abnormal pattern of RSA responding previously observed in adults. 
Bylsma and colleagues (2015) examined cardiovascular responsivity to sadness and stress 
in adolescents with remitted MDD. Participants and another informant completed the ISCA-D to 
diagnose depression and the CDI-2 to assess depressive symptoms. Participants included 
adolescents with a history of MDD during childhood (n = 216; 14.80% currently experiencing a 
depressive episode) and healthy control participants without a history of Axis I disorders (n = 
161). Experimental tasks included a neutral and sad film mood induction, unsolvable puzzle, 
handgrip task, and forehead cold pressor task followed by resting periods. RSA, PEP, cardiac 
autonomic balance (CAB), and cardiac autonomic regulation (CAR) was collected continuously 
during the experimental procedures. CAB was calculated by subtracting RSA and PEP and is an 
index of the balance between SNS and PNS activation while CAR was calculated by adding 
RSA and PEP and is an index of activation of both the SNS and the PNS. Average RSA, PEP, 
CAB, and CAR resting measurements were computed during the resting periods while average 
RSA, PEP, CAB, and CAR reactivity was computed for each experimental task.  
Bylsma and colleagues (2015) did not find differences in cardiovascular responding 
between groups at baseline (p’s > .10); however, some group differences did emerge during the 
experimental paradigm. Participants with a history of MDD exhibited a greater increase in CAB 
during the unsolvable puzzle (p = .17) and handgrip tasks (p = .14), which is indicative of greater 
SNS and PNS activation. Conversely, healthy control participants exhibited a greater decrease in 
PEP (p = .001) and increase in CAR during the handgrip task (p = .03), which is indicative of 
greater SNS responding and less SNS and PNS activation. Interestingly, no differences were 




this finding to the potency of the experimental task, the sad film clip (i.e., The Champ) has been 
empirically validated and widely used in the literature. Although these findings suggest that CAB 
increases in remitted depressed participants in response to stress but not sadness, it is possible 
that these results were due to the use of a mixed samples made up of participants with current 
and remitted MDD.  
The aforementioned studies (Bylsma et al., 2015 Yaroslavsky et al., 2014 Study 2) 
showed that adolescents with current and remitted MDD exhibit an abnormal pattern of 
cardiovascular reactivity (i.e., interaction between RSA at rest and RSA reactivity, CAB, and 
CAR) in response to a sad mood compared to healthy control participants. However, these results 
must be evaluated in light of their significant methodological flaws. First, the studies used a 
mixed sample of current and remitted MDD participants, which could limit the generalizability 
of these findings to currently depressed rather than formerly depressed participants. Second, the 
medical screening procedures employed by these studies were insufficient. While participants 
were assessed for major medical disorders, they were not specifically evaluated for CVD. 
Previous research has suggested that the presence of CVD may be a confound and therefore 
should be controlled or excluded for when examining the relationship between depression and 
cardiovascular health (Kemp et al., 2010). Additional methodologically sound research is needed 
to investigate if an abnormal pattern of cardiovascular reactivity in response to sadness is 
consistently observed in adolescents with remitted depression. It should also be noted that 
differences have been found between adolescent and adult depression (Kaufman et al., 2001). 
Consequently, results from these studies may not generalize to adult samples.  
Cardiovascular reactivity in response to sadness in an adult sample of remitted 




MDD in response to an experimentally-induced sad mood (Table 1). Rottenberg and colleagues 
(2005b) examined HR reactivity in response to a sad mood in adults with remitted MDD. 
Participants were free from medical conditions (e.g., head injury, substance abuse, etc.) that 
could impact the recording of physiological responses; however, CVD was not assessed, which 
could potentially confound the cardiovascular results. Depression was assessed using the SCID-I 
and included individuals with current MDD (n = 19) or remitted MDD (n = 22) and healthy 
controls without a history of Axis I disorders (n = 26). During the experimental paradigm, 
participants were instructed to watch sad, happy, and neutral valenced films presented in a 
counterbalanced order then imagine the scene in their mind. Each film and imagery task were 
preceded by a one-minute resting baseline and followed by a one-minute filler task to reduce 
carry over effects. HR was collected continuously during the experimental procedures and 
average measurements were computed. Results revealed that HR did not significantly differ 
across group, emotional valence, or stimulus type (p > .10). These findings provide preliminary 
support that cardiovascular reactivity does not differ based on depression status in the face of 
various emotional experiences.  
The current literature examining cardiovascular reactivity in response to sadness for 
formerly depressed individuals is extremely limited. Rottenberg and colleagues (2005b) did not 
identify a significant difference in HR reactivity in response to sadness between participants with 
remitted MDD to healthy control participants. It is possible that a single cardiovascular marker is 
insufficient to characterize the pattern of cardiovascular reactivity in response to a sad mood 
induction. As explained by the theoretical models, a cascade of complex physiological processes 
is implicated in cardiovascular functioning. As such, it may be necessary to examine multiple 




order to truly characterize how individuals with remitted MDD react to a sad mood induction. 




Table 1. Previous Research on Cardiovascular Reactivity to Sadness in Current and Remitted Depression by Sample
CD in Adult Samples 











CD = 49 
RD = 24 
HC = 45 
SCID-I Sad, fear, and 
happy films 
RSA Yes • ↓ RSA withdrawal during sad film 
predicted ↑ MDD symptoms at follow-up 
in CD 
• No other predictive results for other films 
Jin et al. 
(2015) 
CD = 25 
HC = 25 
SCID-I Sad and 
amusing 
films 
HR, RSA  Yes • ↓ HR decrease during sad and amusing 
films in CD than HC 
• No other group differences during 
baseline or other films 
Rottenberg 
et al. (2003) 
CD = 25♀ 
HC = 31♀ 
SCID-I Sad and 
neutral films 
RSA  No • ↑ RSA after sad film in HC who cried 
during sad film 
• No ΔRSA after sad film in CD who cried 




CD = 55 SCID-I Sad, fear, 
and amusing 
films 
RSA  No • RSA withdrawal to sad film predicted 
recovery from MDD at follow-up 
• No other predictive results for other films 
Tsai et al. 
(2003) 
CD = 12♀ 






Cardiac IBI No • No group differences in cardiac IBI 
during baseline or films 
Combined CD/RD in Adult Samples 










et al. (2013) 
CD/RD = 113 
HC = 93 
SCID-I Sad, anger, 
disgust, fear, 
and joy films 
RSA No • Typical resting RSA X ΔRSA during sad 
film predicted HC status 
• No other results for sad or other films 
       




 Note. CD = current major depressive disorder; CD/RD = mixed sample of current and remitted major depressive disorder; RD = 
remitted major depressive disorder; HC = healthy control; SCID-I = Structured Clinical Interview for the DSM-IV; PRIME-MD = 
Primary Care Evaluation of Mental Disorders; ISCA-D = Interview Schedule for Children and Adolescents: Diagnostic Version; HR = 
heart rate; HRV = heart rate variability; RSA = respiratory sinus arrhythmia; IBI = interbeat interval; CAB = cardiac autonomic 
balance; CAR = cardiac autonomic regulation; ↓ = decrease; ↑ = increase; Δ = change; ♀ = women only. 
 
Table 1 Continued      
Yaroslavsky 
et al. (2014) 
Study 1 
CD/RD = 27♀ 
HC = 43♀ 
SCID-I Sad and joy 
films 
RSA No • Atypical resting RSA X ΔRSA during sad 
film predicted CD/RD status 
• Typical resting RSA X ΔRSA during sad 
film not predictive of CD/RD status 
• No other predictive results for other film 
Combined CD/RD in Adolescent Samples 










et al. (2014) 
Study 2 
Proband: 
CD/RD = 132 
Siblings: 
CD/RD = 36 
HC = 111 
ISCA-D Sad film RSA No • Atypical resting RSA X ΔRSA during sad 
film observed in CD/RD proband/sibling 
pairs  




CD/RD = 216 
HC = 161 




No • No group differences in RSA, PEP, CAB, 
or CAR during baseline or films 
RD in Adult Samples 











CD = 19 
RD = 22 
HC = 26 




HR No • No group differences in HR during 





OVERVIEW AND STATEMENT PURPOSE 
MDD is a serious, debilitating, and commonly occurring mental illness characterized by 
pronounced negative mood and/or lack of interest or pleasure (APAA, 2013; Kessler et al., 2003). 
MDD is associated with negative psychological, medical, and economic outcomes. Research has 
found that individuals with MDD report high rates of morbidity, mortality, and functional 
impairment, which results in increased disability and decreased workplace productivity (Lépine 
& Briley, 2011). Consequently, MDD is currently the leading cause of disability and second 
leading cause of disease burden around the world (Mathers et al., 2008). The direct and indirect 
expenses associated with MDD are estimated to cost the United States $210.50 billion yearly 
(Greenberg et al., 2015). Clearly, MDD is associated with significant burden at the individual 
and societal level. 
While research has typically focused on the acute aspect of depression, MDD is typically 
understood as a chronic illness due to high rates of relapse and recurrence (Richards, 2011). 
Results of a seminal study conducted by the NIMH found that within a 15-year period, up to 
50.00% of individuals with MDD will experience a relapse, or reemergence of a depressive 
episode before MDD has remitted, and up to 85.00% will experience a recurrence, or experience 
of a new depressive episode after MDD has remitted (Mueller et al., 1999). This finding has been 
replicated throughout the literature over the past decade. Research has shown that the rate of 
relapse or recurrence in individuals with a history of MDD ranges from 2.50% to 77.00% over 
periods of time ranging from one to 20 years (Hardeveld et al., 2010, 2013; Johansson et al., 
2015; Nöbbelin, Bogren, Mattisson, & Brådvik, 2018; Poutanen et al., 2007; ten Doesschate et 




Vulnerability to depressive relapse and recurrence is likely multiply determined and due 
to a complex interaction of biological, psychological, and environmental factors (Burcusa & 
Iacono, 2007). Researchers have identified various clinical, demographic, familial, 
psychological, and psychosocial factors that may make an individual more susceptible to 
experiencing another depressive episode (Burcusa & Iacono, 2007; Harveveld et al., 2010, 2013; 
Johansson et al., 2015; ten Doesschate et al., 2010). The majority of these vulnerability factors 
are stable, unchangeable traits. More research is needed to identify malleable vulnerability 
factors that can be specifically targeted during treatment or following treatment for relapse 
prevention to reduce the occurrence of future episodes of depression. 
Cognitive theories of depression have theorized that dysfunctional thinking patterns 
contribute to the occurrence, maintenance, and reoccurrence of depression. Research has 
indicated that currently depressed individuals endorse higher rates of dysfunctional thoughts; 
however, individuals who have recovered from depression report patterns of thoughts that are 
similar to never depressed individuals (as reviewed by Teasdale, 1999). These findings suggest 
that cognitive vulnerability to depression (i.e. dysfunctional thoughts) are no longer present after 
recovery from depression, despite the fact that individuals with a history of depression remain at 
high risk for relapse or recurrence. Research aimed to account for these discrepant findings has 
focused on individual differences in how one responds to a transient, sad mood. Specifically, 
research has sought to understand how individuals with a history of MDD respond to the 
experience of sadness in between depressive episodes.  
The differential activation hypothesis by Teasdale (1988) and mood state dependent 
hypothesis by Miranda and Persons (1988) similarly hypothesized that cognitive vulnerabilities 




mood. In accordance with these theories, researchers have hypothesized that individuals who 
have recovered from depression exhibit maladaptive cognitions and affective states during a 
dysphoric mood, but not a euthymic mood. Empirical evidence has generally supported these 
theories, and found that compared to healthy control participants, those with remitted MDD 
report significant increases in dysfunctional beliefs (i.e., cognitive reactivity; Kuyken et al., 
2010; Segal et al., 1999, 2006) or dysphoric mood (i.e., mood reactivity; Lethbridge & Allen, 
2008; van Rijsbergen et al., 2013) in response to an experimentally-induced sad mood and 
prospectively predict relapse of depression over time. While there is still disagreement in the 
literature whether dysfunctional thinking patterns or dysphoric mood states characterize remitted 
MDD, cognitive and mood reactivity in response to sadness have been proposed as two potential 
pathways of vulnerability to relapse and recurrence for formerly depressed individuals. 
Examination of cardiovascular functioning in response to negative affect may advance 
our understanding of the relationship between reactivity to sad mood and vulnerability to 
depressive relapse and recurrence. A large body of research has highlighted the important role of 
cardiovascular functioning in MDD. Depression and depressive symptoms are associated with an 
increased risk of CVD (Gan et al., 2014; Nicholson et al., 2006; Ruglies, 2002; Wulsin & Singal, 
2003; Van der Kooy et al., 2007) and cardiovascular events. Similarly, CVD is associated with 
increased rates of depression and depressive symptoms (Brown et al., 2009). This relationship 
has led researchers to examine cardiovascular differences that can explain the susceptibility to 
CVD in this population. Maladaptive patterns of cardiovascular functioning have been identified 
in currently depressed individuals. Compared to non-depressed counterparts, individuals with 
current MDD show lower RSA and HRV while at rest (Chang et al., 2012; Kemp et al., 2010, 




stress (Ehrenthal et al., 2010; Liang et al., 2015; Nugent et al. 2011; Rottenberg et al., 2007a; 
Salomon et al., 2009), and blunted HR and RSA in response to sadness (Jin et al., 2015; Panaite 
et al., 2016; Rottenberg et al., 2003, 2005a). Research on cardiovascular reactivity in response to 
sadness is mixed, with some studies failing to replicate these patterns of cardiovascular reactivity 
and showing an opposite trend of cardiovascular reactivity (i.e., Rottenberg et al., 2005b; Tsai et 
al., 2003). 
In general, the cardiovascular abnormalities that have been identified in currently 
depressed individuals do not appear to be present in formerly depressed individuals. Formerly 
depressed and healthy control participants do not differ in cardiovascular functioning at rest 
(HRV; Chang et al., 2013; Vaccarino et al., 2008) or cardiovascular reactivity in response to 
stress (HR, HRV, RSA, CO, and PEP; Ahrens et al., 2008; Bylsma et al., 2014; Salomon et al., 
2013). Thus far, it appears that the cardiovascular functioning of remitted depressed participants 
generally resembles that of healthy control participants. These findings led researchers to 
hypothesize that cardiovascular abnormalities may be mood-state dependent much like the 
cognitive and mood vulnerabilities that have been identified in remitted depression.  
Cardiovascular reactivity is operationalized as the change in an individual’s 
cardiovascular functioning in response to a sad mood induction. The literature on cardiovascular 
reactivity in response to sadness among formerly depressed individuals is limited to one study 
that recruited a sample of adults with remitted depression. Rottenberg and colleagues (2005b) 
failed to find cardiovascular differences among individuals with a history of depression; there 
were no significant differences in HR reactivity in response to a sad mood induction when 
comparing remitted depressed and healthy control participants. While other researchers have 




methodological flaws. Bylsma and colleagues (2015) did not identify any significant differences 
in RSA and PEP reactivity in response to a sad mood induction when comparing remitted 
depressed and healthy control adolescents. Conversely, Yaroslavsky and colleagues (2013, 2014 
Study 2) found that a combined group of currently and formerly depressed adults and adolescents 
exhibited an abnormal pattern of RSA responding (i.e., high resting RSA and RSA augmentation 
or low resting RSA and RSA withdrawal during sad mood induction) compared to healthy 
control participants.  
 While some of these abovementioned studies point to differences in cardiovascular 
reactivity among formerly depressed individuals, there are significant concerns about the quality 
and generalizability of these studies due to multiple methodological issues. First, most of the 
literature has relied upon a mixed sample of participants who were currently or formerly 
depressed (Bylsma et al., 2015; Yaroslavsky et al., 2013, 2014 Studies 1 and 2; with the 
exception of Rottenberg et al., 2005b). The cardiovascular differences that were identified in 
these studies may be attributable to the inclusion of currently depressed participants or the 
presence of subclinical depressive symptom rather than remitted depression. As a result, only 
one study (i.e., Rottenberg et al., 2005b) has truly investigated cardiovascular reactivity in 
response to sadness in remitted depression.  
Second, none of the abovementioned studies explicitly assessed for the presence of CVD 
(Bylsma et al., 2015; Rottenberg et al., 2005b; Yaroslavsky et al., 2013, 2014 Studies 1 and 2). 
Previous research has indicated that the presence of CVD may be a confound and therefore 
should be controlled for or be an exclusion criterion when examining the relationship between 
depression and cardiovascular health (Kemp et al., 2010). Therefore, it is possible that these 




Additionally, it is possible that failure to find significant differences between groups is due to 
differences in cardiovascular status rather than psychological variables. 
Third, most of the literature has examined a very limited range of cardiovascular measures 
(i.e., HR or RSA only; Rottenberg et al., 2005b; Yaroslavsky et al., 2013, 2014 Studies 1 and 2; 
with the exception of Bylsma et al., 2015). The use of a singular cardiovascular measure may be 
insufficient to characterize the complex pattern of cardiovascular reactivity, as different 
measures are thought to index different components of the regulatory systems (e.g., SNS versus 
PNS) that influence cardiovascular functioning. It may be necessary to examine multiple 
measures of cardiovascular reactivity that are thought to index various aspects of the ANS to 
truly characterize how individuals with remitted MDD react to a sad mood induction. Indeed, 
several theoretical models (i.e., the biopsychosocial model of challenge and threat by Blascovich 
and Tomaka (1996) and hawk-dove model by Smith (1982)), propose a complex pattern of 
cardiovascular or physiological reactivity in response to stress. Consequently, analyses must be 
conducted for those cardiovascular markers (e.g., CO and PEP) that have not been examined 
among individuals with remitted depression.  
Fourth, none of the relevant studies investigated cardiovascular recovery (Bylsma et al., 
2015; Rottenberg et al., 2005b; Yaroslavsky et al., 2013, 2014 Studies 1 and 2). Cardiovascular 
recovery is operationalized as the amount of time that it takes for an individual’s cardiovascular 
functioning to return to baseline levels following a sad mood induction. Cardiovascular recovery 
provides an estimate of how long the physiological changes attributable to an emotionally-
valenced stimulus persist after the stimulus has been removed. It has been suggested that the 
study of cardiovascular recovery has significant clinical utility. More specifically, cardiovascular 




physiological dysfunction and disease (Linden, Earle, Gerin, & Christenfeld, 1997; Haynes, 
Gannon, Orimoto, O’Brien, & Brandt, 1991). Cardiovascular recovery following the induction of 
a transient mood state may be especially important as research has shown that individuals take a 
longer amount of time to habituate to emotional distress compared to stress (Linden et al., 1997). 
Given the hypothesis that the relationship between depression and CVD is due to long-standing 
cardiovascular abnormalities, it is necessary to investigate the role of cardiovascular recovery as 
a potential dormant mechanism of vulnerability to MDD that is activated by a dysphoric mood. 
Fifth, a large portion of the literature has failed to compare cardiovascular reactivity in 
response to both sad and neutral mood inductions (Yaroslavsky et al., 2013, 2014 Studies 1 and 
2; with the exceptions of Bylsma et al., 2015 and Rottenberg et al., 2005b). The differential 
activation hypothesis by Teasdale (1988) and mood state dependent hypothesis by Miranda and 
Persons (1988) theorize that formerly depressed individuals only exhibit vulnerabilities to 
depression when in a dysphoric mood. Based on these hypotheses, it is expected that formerly 
depressed participants would react in a maladaptive manner to the sad mood induction but not 
the neutral mood induction. Therefore, the comparison of reactivity to sad and neutral mood 
inductions is necessary to empirically test these hypotheses. 
Finally, a large portion of this literature has been conducted in formerly depressed 
adolescents (Bylsma et al., 2015; Yaroslavsky et al., 2014 Study 2; with the exceptions of 
Rottenberg et al., 2005b and Yaroslavsky et al., 2013, 2014 Study 1). Differences in adolescent 
and adult depression have been identified. For example, depressed children and adolescents do 
not show elevated basal cortisol levels, abnormal cortisol and prolactin secretion, and reduced 




correlates of depression may differ in the two age groups. As a result, these cardiovascular 
findings may not generalize to adult-onset depression.  
The proposed study aimed to examine the cognitive, mood, and cardiovascular correlates 
in response to dysphoric mood among adults with a history of depression. The primary goal of 
this study was to characterize cardiovascular reactivity to and recovery from a sad mood in 
individuals with a history of MDD. To help clarify prior inconsistent results, the secondary goal 
of this study was to examine cognitive and mood reactivity in individuals with a history of 
MDD. This study will advance our understanding of potentially malleable vulnerability factors 
associated with a history of depression. 
This study overcame several methodological weaknesses associated with prior work. 
First, while most of the literature has focused on a single cardiovascular measure, the current 
study examined multiple cardiovascular measures to better characterize the pattern of 
cardiovascular functioning in remitted depression. Second, the current study compared 
cardiovascular reactivity to and recovery from sad and neutral mood induction. Prior work has 
primarily focused on cardiovascular reactivity rather than recovery; however, it is possible that 
cardiovascular recovery may increase vulnerability to depression as well as contribute to 
cardiovascular abnormalities. Third, the current study recruited a sample of participants who 
have fully recovered from depression and are free from CVD and other related medical illnesses. 
Accordingly, results would not be attributable to current depression, residual depressive 
symptoms, or medical comorbidities.  
Research Hypotheses 
This study examined cognitive, mood, and cardiovascular reactivity and cardiovascular 




review of the applicable theoretical models and existing literature, the following hypotheses were 
proposed: 
H1 Formerly depressed participants exposed to the sad mood induction would report  
significantly higher levels of cognitive reactivity on the DAS post-mood induction than 
formerly depressed participants exposed to the neutral mood induction and healthy 
control participants exposed to the sad and neutral mood inductions. 
H2 Formerly depressed and healthy control participants exposed to the sad mood induction  
would report significantly higher levels of mood reactivity on the VAS post-mood 
induction than formerly depressed and healthy control participants exposed to the neutral 
mood inductions. 
H3 Formerly depressed participants exposed to the sad mood induction would exhibit a  
maladaptive pattern of cardiovascular reactivity (i.e., decreased HP, RSA, and CO and 
increased PEP) during the mood induction compared to formerly depressed participants 
exposed to the neutral mood induction and healthy control participants exposed to the sad 
and neutral mood inductions.  
H4 Formerly depressed participants exposed to the sad mood induction would exhibit  
reduced cardiovascular recovery (i.e., decreased HP, RSA, and CO and increased PEP 
compared to baseline) during the recovery film compared to formerly depressed 
participants exposed to the neutral mood induction and healthy control participants 







METHODS AND PROCEDURES 
 The following methods and procedures were employed. The University of Maine 
Institutional Review Board (IRB) for the Protection of Human Subjects approved this study 
(reference number: 2015-09-04, Investigating the Role of Attention and Elaboration in Relapse 
to Depression), which is a large, ongoing study conducted by the Maine Mood Disorders Lab 
(MMDL). 
Participant Recruitment 
 Participants included 132 individuals between the ages of 18 to 60 years who were 
currently undergraduate students enrolled at the University of Maine or individuals residing in 
the surrounding community. Participants completed online and in-person screening procedures to 
determine eligibility for the study. Participants that met inclusion and exclusion criteria were 
invited to participate in the experimental paradigm. Power analysis using G*Power 3.1.9.2 (Faul, 
Erdfelder, Lang, & Buchner, 2007), a statistical power calculation software, indicated that a 
sample of 128 participants would result in an 80.00% chance of detecting a medium effect 
between two groups (i.e., formerly depressed and healthy control participants) exposed to two 
versions of the experimental paradigm (i.e., sad or neutral mood induction).  
Undergraduate Participant Pool Recruitment 
Participants included undergraduate students recruited from the University of Maine 
Department of Psychology undergraduate participant pool. Recruitment was conducted through 
announcements posted on the Sona Systems (2017), a participant management software. 




screening self-report measures (Appendix C) in Qualtrics (2017), an electronic data capturing 
system, to determine eligibility for participating in session 1.  
Participants recruited through the undergraduate pool were compensated for their 
participation with research participation credits. Participants were awarded up to two research 
participation credits for completing session 1 and one research participation credit for completing 
session 2. Participants who did not complete all study procedures received a prorated rate of 
research participation credits that reflected the amount of time that they spent in the laboratory 
(Appendix F). If participants recruited through the undergraduate pool already earned sufficient 
research participation credit, they were offered monetary compensation for their participation. 
Participants were paid $30 for completing session 1 and $15 for completing session 2. 
Participants who did not complete all study procedures received a prorated rate of payment that 
reflected the amount of time that they spent in the laboratory. 
Community Recruitment 
Participants also included individuals recruited from the community surrounding the 
University of Maine. Participants were recruited as part of a larger, ongoing study conducted by 
the MMDL. Recruitment was conducted through electronic flyers (Appendix A) posted on online 
announcement boards (i.e., University of Maine Announcements listserv, which was accessible 
to faculty, staff, and students at the university), online classified advertisement and social media 
websites (i.e., Craigslist and Facebook), and printed flyers placed in public areas within the 
surrounding community (i.e., local business and restaurants). Individuals recruited from the 
surrounding community completed electronic screening self-report measures (Appendix C) in 




Individuals recruited from the surrounding community were paid for their participation. 
Participants were paid $30 for completing session 1 and $15 for completing session 2. 
Participants who did not complete all study procedures received a prorated rate of payment that 
reflected the amount of time that they spent in the laboratory (Appendix G). 
Experimenters 
 The primary author, Olivia E. Bogucki, served as the primary experimenter for this study. 
Study staff included clinical psychology graduate students and undergraduate research assistants 
who have completed the Collaborative Institutional Training Initiative (CITI) online training 
required by the IRB at the University of Maine. Clinical psychology graduate students scored 
self-report measures during screening, completed diagnostic clinical interviews during session 1, 
and determined eligibility during screening and session 1. Undergraduate research assistants 
aided in participant recruitment (e.g., posted advertisements and flyers and contacted 
participants), obtained informed consent and administered self-report measures during session 1 
and 2, attached physiological sensors and monitored physiological recordings during session 2, 
and conducted self-report and psychophysiological data cleaning. Undergraduate research 
assistants were trained and supervised by clinical psychology graduate students. Clinical 
psychology graduate students were supervised by the MMDL Director and Principal 
Investigator, Emily A. P. Haigh, Ph.D. 
Screening 
Screening (Table 2) to determine eligibility for study session 1 participation was 
completed remotely. Advertisements (Appendix A) and the Sona Systems (2017) directed 
participants to complete an online survey hosted through Qualtrics (2017). Participants were 




clearly stated that the purpose of this survey was to determine eligibility for the study. In 
addition, the informed consent document highlighted that participation in the study was 
voluntary and information obtained during the study would remain confidential. More 
specifically, participants were informed that data would be stored via a secure server, 
identification numbers would be assigned to de-identify their responses, and the subject key 
matching participant names and identification numbers would be encrypted and saved on an 
alternate computer. Despite these precautions, participants were made aware of potential risks 
associated with the study (e.g., loss of privacy and potential for emotional discomfort) as well as 
potential benefits (e.g., assistance in helping to better understand the study variables). 
After electronically providing informed consent, participants were asked to provide their 
contact and demographic information and complete self-report measures (Appendix C). Self-
report measures were presented in a standardized order and assessed current and past depressive 
(i.e., Beck Depression Inventory – Second Edition (BDI-II) and Patient Health Questionnaire – 9 
(PHQ-9)) and current anxiety (i.e., Beck Anxiety Inventory (BAI)) symptom severity as well as 
language and visual abilities, learning disabilities, and current and past health conditions (i.e., 
General Health Screening (GHS)). Self-report measures were used to determine eligibility for 
participation in session 1.  
Following the completion of the self-report measures, participants received a referral list 
(Appendix D). This referral list was presented as an information source, not something that must 
be followed. Finally, participants were alerted that they would be contacted via email if they 
were eligible to participate in the study. 
Self-Report Measures 




BDI-II. The BDI-II (Beck, Steer, & Brown, 1996a; Appendix C) was used to evaluate the 
severity of current depressive symptoms. The BDI-II is a 21-item self-report measure that 
assesses cognitive, affective, somatic, and vegetative symptoms of depression. Respondents rate 
the severity of depressive symptoms experienced over the past two weeks on a scale from 0 to 3, 
with 0 indicating the symptom is not present and 3 indicating that the symptom is present and 
severe. Total scores range from 0 to 63, with higher scores indicating greater levels of depressive 
symptom severity.  
Research on the reliability of the BDI-II indicates excellent internal consistency (α = .91-
.94; Arnau, Meagher, Norris, & Bramson, 2001; Beck, Steer, Ball, & Ranieri, 1996b; Dozois, 
Dobson, & Ahnberg, 1998; Osman et al., 1997a; Steer, Ball, Ranieri, & Beck, 1997) and 
adequate test-retest reliability (Beck et al., 1996a). Research on the validity of the BDI-II 
indicates adequate construct validity; convergent validity was evidenced by strong to moderate 
correlations with other measures of depression and perceived mental health (Beck et al., 1996a; 
Arnau et al., 2001; Dozois et al., 1998; Steer et al., 1997) while discriminant validity was 
evidenced by low correlations with measures of social desirability (Osman et al., 1997a).  
PHQ-9. The PHQ-9 (Kroenke, Spitzer, & Williams, 2001; Appendix C) was used to 
evaluate the severity of past depressive symptoms. The PHQ-9 is a 9-item self-report measure 
that assesses cognitive, affective, and vegetative symptoms of depression. Respondents rate the 
severity of the worst depressive symptoms experienced over the course of their lifetime during 
any two-week period on a scale from 0 to 3, with 0 indicating the symptom is not or rarely 
present and 3 indicating that the symptom is present nearly every day. Total scores range from 0 




Research on the reliability of the PHQ-9 indicates good internal consistency (α = .86-.89) 
and adequate test-retest reliability (Kroenke et al., 2001). Research on the validity of PHQ-9 
indicates adequate convergent validity with other measures of depression and psychological 
distress (Martin, Rief, Klaiberg, & Braehler, 2006).  
GHS. The GHS (Appendix C) was created by the MMDL to identify potential 
confounding variables that other researchers have excluded for when examining 
psychophysiological reactivity and recovery in remitted MDD (e.g., Bylsma et al., 2014; Chang 
et al., 2013; Salomon et al., 2013; Wilson et al., 2016). The GHS is a 9-item self-report measure 
that assesses language and visual abilities and learning disabilities that could significantly impair 
an individual’s ability to understand the experimental paradigm as well as a range of current and 
past health conditions that could impact the recording of physiological responses. Respondents 
indicate the presence or absence of such conditions by selecting Yes or No to each question. In 
addition, respondents are provided a free response textbox to report more detailed information.  
BAI. The BAI (Beck & Steer, 1990; Appendix C) was used to evaluate the severity of 
current anxiety symptoms. The BAI is a 21-item self-report measure that assesses cognitive, 
affective, and somatic symptoms of anxiety. Respondents rate the severity of anxiety symptoms 
experienced over the past two weeks on a scale from 0 to 3, with 0 indicating the symptom is not 
present and 3 indicating that the symptom is present and severe. Total scores range from 0 to 63, 
with higher scores indicating greater levels of anxiety symptom severity.  
Research on the reliability of the BAI indicates excellent internal consistency (α = .90-
.92; Beck, Epstein, Brown, & Steer, 1988; Fydrich, Dowdall, & Chambless, 1992; Osman, 
Barrios, Aukes, Osman, & Markway, 1993; Osman, Kopper, Barrios, Osman, & Wade, 1997b; 




1992). Research on the validity of the BAI indicates adequate construct validity; convergent 
validity was evidenced by moderate correlations with other measures of anxiety while 
discriminant validity was evidenced by low to moderate correlations with measures of depression 
(Beck et al., 1988; Fydrich et al., 1992; Osman et al., 1997b; Steer & Ranieri, 1993).  
Eligibility Criteria 
The screening phase included general eligibility criteria that was created for all 
participants and specific eligibility criteria that was created for formerly depressed and healthy 
control participants. Participants who met general and specific eligibility criteria during 
screening were sent an email (Appendix E) that included information on how to schedule session 
1 using the Sona Systems (2017). 
All participants. Participants were required to have been between 18 and 60 years of 
age. The GHS was used to assess for a multitude of different physical and psychological 
conditions. To ensure that participants were able to follow instructions associated with the 
experimental paradigm, participants were deemed ineligible for the study if they did not speak 
and read English fluently, were color blind, or had been diagnosed with a learning disability that 
interferes with their ability to read or process visual information. To diminish the likelihood of 
physical conditions known to impact the recording of physiological responses, participants were 
deemed ineligible for the study if they had experienced head trauma resulting in a loss of 
consciousness for over one hour, stroke, hemorrhage, brain tumors, medication-dependent 
diabetes, cardiovascular disease, heart disease, hypertension, or medical conditions specific to 
the central nervous system (i.e., epilepsy, transient ischemic attack, multiple sclerosis, 




disease). Finally, participants were deemed ineligible for the study if they had undergone brain or 
neural surgery or brain radiation treatment. 
In addition to the GHS, eligibility for healthy control participants was assessed using the 
BDI-II, PHQ-9, and BAI. The BDI-II was used to assess current depressive symptoms during the 
past two weeks while the PHQ-9 was used to assess previous depressive symptoms across the 
lifespan. The BAI was used to assess current anxiety symptoms during the past two weeks. 
Formerly depressed participants. Formerly depressed participants were included in 
session 1 if they obtained a score of less than 9 on the BDI-II, which is indicative of minimal 
current depressive symptoms, and a score equal to or greater than 10 on the PHQ-9, which is 
indicative of moderate to severe past depressive symptoms. Formerly depressed participants 
were included in session 1 regardless of BAI scores as the presence of comorbid anxiety 
disorders was permissible. 
Healthy control participants. Healthy control participants were included in session 1 if 
they obtained a score equal to or less than 8 on the BDI-II and PHQ-9, which is indicative of 
minimal current and past depressive symptoms. Healthy control participants were ineligible for 
session 1 if they obtained a score greater than 6 on the BAI. This exclusion criterion was 
determined based on research examining the optimal cut score for various anxiety disorder 
diagnoses (Leyfer, Ruberg, & Woodruff-Borden, 2006) and was intended to reduce the 
likelihood that potential healthy control participants would ultimately be excluded after session 1 
due to the presence of any major DSM-IV diagnosis. 
Session 1 
Session 1 (Table 2) took place in the MMDL space located in the Innovative Media, 




Participants were greeted by an undergraduate research assistant trained in the standardized study 
procedures. The undergraduate research assistant introduced the study with the following 
statement: “The purpose of the research is to learn about the emotional and physiological 
responses related to sad mood.” The undergraduate research assistant reviewed the informed 
consent document (Appendix H) with the participant, highlighting that participation in the study 
was voluntary and information obtained during the study would remain confidential. More 
specifically, participants were informed that data would be stored via a secure server, 
identification numbers would be assigned to de-identify their responses, and the subject key 
matching participant names and identification numbers would be encrypted and saved on an 
alternate computer. Despite these precautions, participants were made aware of potential risks 
associated with the study (e.g., loss of privacy and potential for emotional discomfort) as well as 
potential benefits (e.g., assistance in helping to better understand the study variables). After the 
undergraduate research assistant checked for comprehension and answered any questions, 
informed consent was obtained from the participant.  
Participants were asked to provide demographic information and complete self-report 
measures (Appendix I) in Qualtrics (2017) on an electronic tablet. Self-report measures were 
presented in a randomized order and assessed current depressive (i.e., BDI-II) and anxiety (i.e., 
State-Trait Anxiety Inventory – I & II (STAI-I & II)) symptoms. Self-report measures were used 
as potential covariates. Following the completion of the self-report measures, clinical psychology 
graduate students obtained the Treatment History self-report measure to identify past and current 
therapeutic and psychopharmacological interventions. Current and past CBT and antidepressant 
medication use were used as potential covariates. Clinical psychology graduate students then 




had been adapted in accordance with the DSM-5 with participants to further determine eligibility 
for participation in session 2. The clinical psychology graduate students recorded diagnoses that 
the participant endorsed on paper, which were later transferred to a de-identified electronic 
spreadsheet.  
If a participant endorsed current suicidal ideation or intent, the clinical psychology 
graduate student completed a suicide risk assessment (Appendix J) and consulted with a licensed 
clinical psychologist affiliated with the University of Maine. If hospitalization was deemed 
necessary, the clinical psychology graduate student encouraged the participant to voluntarily go 
to the emergency department for an evaluation. The clinical psychology graduate student 
accompanied the individual to the hospital by following the participant in their own vehicle. If 
the participant declined to self-admit themselves to the emergency department and there was 
imminent risk to the participants’ safety, the clinical psychology graduate student called law 
enforcement to escort the participant to the emergency department. 
Following the completion of the SCID-IV-RV, participants received a referral list to the 
community counseling services as a potential resource (Appendix D). This referral list, which 
was presented as an information source, and not something that must be followed, was presented 
by a clinical psychology graduate student with the following statement: “This referral list is 
provided for your information. If/when you would like counseling for distressing issues, these are 
some of the available options in this area. The list includes a variety of resources, some of which 
are low cost while others vary based on an hourly rate.”  
The clinical psychology graduate student obtained height, weight, and waist and hip 
circumference measurements. Height and weight measurements were used to calculate body 




their participation during session 1. Participants were compensated for their participation of 
approximately two hours; participants recruited through the undergraduate participant pool were 
awarded up to two research participation credits depending on the amount of time spent in the 
laboratory while participants recruited from the surrounding community were awarded $30 
payment.  
Finally, clinical psychology graduate students determined eligibility for session 2 based 
on the eligibility criteria. Eligible participants were invited to participate in session 2 with the 
following statement: “Based on this interview it appears that you qualify to complete an 
additional portion of this study that takes approximately one to two hours. This session will be 
worth one to two credits. If you are interested, we’d request you avoid wearing a dress, overalls, 
or a turtleneck shirt due to the physiological recordings we will be taking.” Clinical psychology 
graduate students enrolled interested participants in session 2 using the Sona Systems (2017). 
Ineligible participants were alerted that they are not eligible for the remainder of the study with 
the following statement: “We are recruiting individuals who answer interview questions in a 
very specific way, and according to your responses you do not qualify for session 2 at this time. 
Thank you for your participation and we will be updating your Sona account with credits from 
this session within the following month.”  
Self-Report Measures 
The following self-report measures were collected at session 1. 
BDI-II. The BDI-II (Beck, Steer, & Brown, 1996a; Appendix C) was used to evaluate the 
severity of current depressive symptoms at baseline.  
STAI-I & II. The STAI-I & II (Spielberger, Gorsuch, Lushene, Vagg, & Jacobs, 1983; 




contains two 20-item self-report measures that assesses cognitive, affective, and somatic 
symptoms of both state and trait anxiety. Respondents rate the severity of anxiety symptoms 
experienced at the moment for the state version and in general for the trait version from 1 to 4, 
with 1 indicating the symptom is almost never present and 4 indicating that the symptom is 
almost always present. Total scores for each version range from 20 to 80, with higher scores 
indicating greater levels of state or trait anxiety symptom severity.  
Research on the reliability of the STAI-I & II indicates good to excellent internal 
consistency (α = .86-.95; Balsamo et al., 2016; Spielberger et al., 1993) and adequate test-retest 
reliability (Spielberger et al., 1993). Research on the validity of the STAI-I & II indicates 
adequate construct validity; convergent validity was evidenced by increased scores on the state 
form during stressful situations while discriminant validity was evidenced by decreased scores 
on the state form during relaxing situations (Spielberger, Gorsuch, & Luschene, 1970; 
Spielberger, 1983, 1989). In addition, adequate concurrent validity with other measures of 
similar affective states for the trait form has been found (Spielberger et al., 1970; Spielberger, 
1989).  
Interview Measures 
The following interview measures were collected at session 1. 
Treatment history. The Treatment History (Appendix C) self-report measure was 
created by the MMDL to identify current and past therapeutic and psychopharmacological 
interventions that other researchers have excluded for when examining cognitive, mood, and 
psychophysiological reactivity and recovery in remitted MDD (e.g., Lethbridge & Allen, 2008; 
Yaroslavsky et al., 2014 Studies 1 and 2). The Treatment History self-report measure is an 8-




medication use for emotional or behavioral problems. Respondents are asked to indicate the 
presence or absence of such conditions by answering Yes or No to each question. In addition, 
respondents are asked report more detailed information about the types of therapy received (e.g., 
CBT) and medication prescribed (e.g., antidepressants).  
SCID-IV-RV. The SCID-IV-RV (First, Gibbon, Spitzer, & Williams, 1995) was 
administered by clinical psychology graduate students trained in administration and scoring by 
the MMDL Director, Emily A. P. Haigh, Ph.D. The Director was available for supervision and 
consultation when necessary. The SCID-IV-RV is a semi-structured clinical interview that 
assesses current and past major DSM-IV clinical diagnoses based on the diagnostic criteria 
outlined in the Diagnostic and Statistical Manual of Mental Disorders – Fourth Edition – Text 
Revision (DSM-IV-TR). The SCID-IV-RV had been adapted by the MMDL to be in accordance 
with the DSM-5 diagnostic criteria. Clinical interviews were audio-recorded to conduct fidelity 
checks and estimate inter-rater reliability.   
Eligibility Criteria 
Session 1 includes specific eligibility criteria for formerly depressed and healthy control 
participants. Individuals who met specific eligibility criteria during session 1 were scheduled for 
session 2. 
Formerly depressed participants. Formerly depressed participants were included in the 
remainder of the study if they met diagnostic criteria for a past episode of MDD according to 
DSM-5 criteria (APAA, 2013). Participants were excluded from the remainder of the study if 
they met diagnostic criteria for current MDD within the past month, current substance abuse 
within the past 6 months, current or past substance dependence, bipolar disorder, psychotic 




Healthy control participants. Healthy control participants were included in the 
remainder of the study if they were free from any current or past psychological disorder. Healthy 
control participants were excluded from the remainder of the study if they met diagnostic criteria 
for any current or past major DSM-5 diagnosis including mood, psychotic, substance use, 
anxiety, or eating disorders. 
Session 2 
Session 2 (Table 2) took place in the MMDL space located in Corbett Hall on the 
University of Maine campus. Participants were greeted by an undergraduate research assistant 
trained in the standardized study procedures. The undergraduate research assistant provided an 
overview of the study procedures with the following statement: “Thank you for returning for 
session 2 of this study. We are interested in investigating the physiological effects of different 
mood states, so today we will measure your physiological responses to a video and some audio 
clips. There will also be some additional questionnaires for you to complete.” As part of the 
informed consent procedure, the undergraduate research assistant reminded the participant that 
their participation was entirely voluntary and that they could discontinue at any time without 
penalty (Appendix K). After the undergraduate research assistant checked for comprehension 
and answered any questions, informed consent was obtained from the participant. 
Once in the physiological laboratory, participants answered questions about skin 
sensitivity and allergies to electrode gel, medical tape, or Band-Aids. Participants were asked to 
remove their jewelry and place it with other personal belongings (e.g., cell phones). Next, 
participants were asked to wash their hands with glycerin-rich soap and prompted to use the 
restroom, if necessary. Noninvasive electrode sensors were placed by a female undergraduate 




participants were briefed on electrode sensor placement and verbally alerted. While attaching 
electrode sensors, the experimenter engaged the participants in conversation to help them feel 
comfortable. Areas where electrode sensors were placed were cleaned with an abrasive alcohol 
swab.  
During electrode sensor placement, another undergraduate research assistant referred to 
as the monitor examined the associated waveforms in Biolab 3.1, a physiological acquisition 
software created by MindWare Technologies Ltd. (2009), to ensure that electrode sensors were 
accurately placed. After the electrodes were correctly placed, the experimenter asked the 
participant to sit in a comfortable chair in front of a computer screen with uncrossed legs for the 
remainder of the study. The monitor selected the correct paradigm based on a predetermined 
randomization table. The participant completed the experimental paradigm including; baseline 
video, self-report measures, sad or neutral mood induction, self-report measures, recovery video, 
and self-report measures while physiological responding was continuously recorded.  
After completion of the experimental paradigm, the experimenter assisted the participant 
in the removal of electrode sensors. The experimenter reviewed a debriefing form (Appendix M) 
with the participant and answered any questions about the study. After all study procedures were 
completed, participants were thanked for their participation during session 2. Participants were 
compensated for their participation of approximately one hour; participants recruited through the 
undergraduate participant pool were awarded one research participation credit while participants 
recruited from the surrounding community were awarded $15 payment. 
Experimental Paradigm 
The experimental paradigm was presented using Experimenter’s Prime (E-Prime; 




the creation and presentation of experimental paradigms as well as the collection and 
investigation of experimental data. 
Baseline video. Participants completed a baseline period intended to allow physiological 
responses to normalize following electrode placement. Participants were prompted by 
instructions on the computer screen to put on over-ear headphones, sit still, and quietly watch a 
10-minute neutrally valenced travel video about Alaska’s Denali National Park (Kolbeinsson, 
2016). The video consisted of plants, animals, weather, and geographical scenes set to 
instrumental music with minimal dialogue.  
Self-report measures. Following the baseline period, participants were prompted by 
instructions on the computer screen to complete the first set of self-report measures (Appendix 
L) in Qualtrics (2017) on an electronic tablet. Self-report measures were presented in a 
randomized order and assessed depression-related thoughts (i.e., Dysfunctional Attitudes Scale – 
Short Form I (DAS-SF I)) and feelings (i.e., VAS and Positive and Negative Affect Schedule – 
Expanded Form (PANAS-X)).  
Mood induction. Following the first set of self-report measures, participants were 
prompted by instructions on the computer screen to complete the sad or neutral mood induction. 
Prior to the sad mood induction, participants completed a 40-word sad (e.g., doomed, crying, 
hurt, etc.) or neutral (e.g., note, dial, zoom, etc.) emotional Stroop task that was part of a larger, 
ongoing study conducted by the MMDL. Words appeared individually on the computer screen, 
printed in red, green, yellow, or blue and participants were instructed to select the matching color 
key on the keyboard (i.e., f for red, g for green, h for yellow, and j for blue). Before each word is 




participants focus their attention. Participants were collapsed into two groups based on mood 
induction condition (i.e., sad or neutral). 
 Sad mood induction. The sad mood induction methodology used a combination of music 
and autobiographical recall to create a mild, transient sad mood. This method has been 
empirically validated by previous research (e.g., Martin, 1990; Segal et al., 1999, 2006). 
Participants listened to a digitally re-mastered, half-speed, non-lyrical 7:38-minute piece of 
classical music entitled “Russia under the Mongolian Yoke” by Prokofiev. Simultaneously, 
participants were prompted to recall a time in their lives when they felt sad with the following 
statement: “During this task, you will listen to a 7-minute piece of classical music on the 
computer. Please listen to the music and think about a specific time or situation when you felt 
depressed and/or low. If you find that your mind wanders, please go back to thinking about the 
specific time or situation when you felt depressed and/or low.” This text remained on the 
computer screen for the entire neutral mood induction.  
Neutral mood induction. The neutral mood induction methodology used a combination 
of music and autobiographical recall to serve as a control condition. This mood induction method 
has been empirically validated by previous research, which showed that it does not result in a 
significant change in mood (e.g., Green, Sedikides, Saltzberg, Wood, & Forzano, 2003; Wood, 
Saltzberg, & Goldsamt, 1990). Participants listened to a digitally re-mastered, half-speed, non-
lyrical 7:38-minute selection of classical music (i.e., Waltzes No. 11 in G flat, Op. 70, No. 1 and 
No. 12 in F minor, and Op. 70, No. 2 by Chopin). Simultaneously, participants were prompted to 
recall an uneventful day in their life that was neither especially happy nor sad with the following 
statement: “During this task, you will listen to a 7-minute piece of classical music on the 




For example, this could be a typical day at school or work when everything followed your typical 
routine. If you find that your mind wanders, please go back to thinking about the specific but 
unemotional day.” This text remained on the computer screen for the entire neutral mood 
induction. 
Self-report measures. Following the mood induction, participants were prompted by 
instructions on the computer screen to complete a second set of self-report measures (Appendix 
L) in Qualtrics (2017) on an electronic tablet. Self-report measures were presented in a 
randomized order and assessed depression-related thoughts (i.e., Dysfunctional Attitudes Scale – 
Short Form II (DAS-SF II)) and feelings (i.e., VAS, PANAS-X). 
Recovery video. Following the second set of self-report measures, participants 
completed a recovery period intended to evaluate the amount of time that it took for 
physiological responses to return to baseline levels. Participants were instructed on the computer 
screen to sit quietly while watching a different 10-minute neutral travel video about Alaska’s 
Last Frontier. The video consisted of plants, animals, weather, and geographical scenes set to 
instrumental music with minimal dialogue. This recovery procedure was selected to increase 
similarity to the baseline procedure. In addition, this recovery procedure, which was passive yet 
attentionally demanding, was selected in lieu of a silent recovery to reduce the potential impact 
of cognitive processes (e.g., rumination) on recovery and minimize feelings of sadness before 
participants leave the laboratory (Linden et al., 1997).  
Self-Report Measures 
The following self-report measures were collected at session 2. 
DAS-SF I & II. The DAS-SF I & II (Beevers, Strong, Meyer, & Pilkonis, 2007; 




and B (DAS; Weissman & Beck, 1978), was used to evaluate changes in dysfunctional beliefs 
about oneself before and after the mood induction. The DAS-SF I & II are each 9-item self-
report measures that assess an individual’s beliefs about his or her self. Respondents rate their 
beliefs experienced most of the time on a scale of 1 to 4, with 1 indicating that they totally agree 
with the statement and 4 indicating that they totally disagree with the statement. Total scores 
range from 9 to 36, with lower scores indicating greater levels of the dysfunctional beliefs. Two 
versions of the DAS-SF have been created to reduce test-retest effects. Qualtrics (2017) does not 
allow the randomization of self-report measures across a multi-block experimental paradigm, so 
the DAS-SF I & II were presented in a fixed order; the DAS-SF I was always be presented 
before the mood induction while the DAS-SF II was always be presented after the mood 
induction. 
Research on the reliability of the DAS-SF I & II indicates good internal consistency (ɑ = 
.83-.94) and adequate test-retest reliability (Beevers et al., 2007). Research on the validity of 
DAS-SF I & II indicates adequate convergent validity as evidenced by moderate correlations 
with other measures of dysfunctional attitudes and adequate predictive validity as evidenced by 
significant prediction of posttreatment depressive symptom severity scores by pretreatment DAS 
I & II scores (Beevers et al., 2007). In addition, Beevers and colleagues (2007) found that there 
were no significant differences in residualized change scores for the DAS-A, DAS I, and DAS II 
(p’s = .79-.93, d’s = .00-.01) and the residualized change scores for the DAS-A, DAS I, and DAS 
II were very strongly correlated (r’s = .84-.91), suggesting that the long and short forms of the 
DAS perform similarly. 
VAS. The VAS (Appendix L) was used to evaluate subjective changes in mood before 




100, with 0 indicating lower levels of sadness and 100 indicating higher levels of sadness. Total 
scores range from 0 to 100, with higher scores indicating greater levels of sadness. Participants 
were presented with a 100-millimeter line on an electronic tablet anchored by “not at all” at 0 
and “extremely” at 100. 
The VAS has been empirically validated by previous research. Studies have shown that 
the VAS is sensitive to change in emotion and stress states when standardized measures cannot 
be obtained due to time or experimental constraints (Cella & Perry, 1986). Change in sadness 
served as a manipulation check for sad and neutral mood inductions to ensure that they produced 
their intended moods. Research on the reliability of the VAS indicates adequate test-retest 
reliability (Cella & Perry, 1986; Folstein & Luria, 1973). Research on the validity of VAS 
indicates adequate concurrent validity with other measures of similar affective states (Cella & 
Perry, 1986; Folstein & Luria, 1973; Little & McPhail, 1973; Davies, Burrows, & Poynton, 
1975). 
PANAS-X. The PANAS-X (Watson & Clark, 1994; Appendix L), an expanded version 
of the original Positive and Negative Affect Schedule (PANAS; Watson et al., 1988), was used 
to evaluate changes in mood before and after the mood induction. The PANAS-X is a 60-item 
self-report measure that assess affect, including two general dimension scales (i.e., negative 
(PANAS-X N) and positive affect (PANAS-X P)), four basic negative emotional scales (i.e., fear 
(PANAS-X F), guilt (PANAS-X G), hostility (PANAS-X H), and sadness (PANAS-X S)), three 
basic positive emotional scales (i.e., joviality, self-assurance, and attentiveness), and four other 
affective states (i.e., shyness, fatigue, serenity, and surprise). Respondents rate the extent to 
which they are experiencing 60 affective adjectives on a Likert scale from 1 to 5, with 1 




they have experienced the experienced the affective state extremely. Total scores for the general 
dimension scales are calculated by summing the 10 affective adjectives that comprise each scale 
and range from 10 to 50, with higher scores indicating greater levels of the respective affect. 
Total scores for specific affective state scales are calculated by summing the five (i.e., sadness) 
or six (i.e., fear, guilt, and hostility) affective adjectives that comprise each scale and range from 
5 to 25 (i.e., sadness) or 6 to 30 (i.e., fear, guilt, and hostility), with higher scores indicating 
greater levels of the respective affect. Given this investigation’s focus on negative emotionality, 
the negative and positive affect general dimension scales and basic negative emotional scales 
(i.e., fear, guilt, hostility, and sadness) were used. 
Research on the reliability of the PANAS-X indicates excellent to good internal 
consistency (ɑ = .83-.90) for the general dimension scales and excellent to acceptable internal 
consistency (ɑ = .76-.93) for the specific affective state scales as well as adequate test-retest 
reliability (Watson & Clark, 1994). Research on the validity of PANAS-X indicates adequate 
construct validity; convergent validity was evidenced by strong correlations with other measures 
of similar affective states while discriminant validity was evidenced by moderate correlations 
with other measures of dissimilar affective states (Watson & Clark, 1994; Watson & Clark, 
1997). 
Cardiovascular Measures 
Physiological responding was recorded throughout the entire experimental paradigm. The 
physiological recordings of interest were cardiovascular measures derived from ECG and ICG. 
In addition, as part of a larger ongoing study, two electrode sensors filled with isotonic electrode 





ECG. Five Galvanic Skin Conductance (GSC) electrode sensors were filled with 
electrode gel and placed on the participants’ chest to measure the electrical activity of the heart 
and collect data that was used to calculate HP and RSA. MindWare Technologies Ltd. (2009) 
hardware and Biolab 3.1 analysis software set to collect ECG data falling within -5 and 5 volts 
with a sampling rate of 1,000 hertz were utilized in conjunction with the five GSC electrode 
sensors located on the participants’ right collarbone, bottom left rib, bottom right rib, jugular 
notch, and sternum (Figure 6).  
ICG. Two GSC electrode sensors were filled with electrode gel and placed on the 
participants’ chest and back to measure the electrical activity of the heart and collect data that 
was used to calculate RSA, CO, and PEP. MindWare Technologies Ltd. (2009) hardware and 
Biolab 3.1 analysis software set to collect ICG data falling at a sampling rate of 1,000 Hertz and 
calibrated at .10 volts per one-ohm change for Z0 and 1.00 volts per ohms per second for dZ/dt 
were utilized in conjunction with the two GSC electrode sensors located on the participants’ mid-
back and upper-back parallel within 1.50 inches of the jugular notch and sternum sensors (Figure 
6).  
Figure 6. Sensor Placement from MindWare Technologies Ltd. (2009) 
 
Note. Session 2 electrode placement for physiological data collection. Brown, white, and black 
circles represent GSC electrodes for ECG. Red circles represent GSC electrodes for ICG. Green 




Table 2. Study Procedure Chart 




Contact and demographic information 
GHS: language and visual abilities, current and past health conditions 
BDI-II: current depressive symptoms 
PHQ-9: past depressive symptoms 




Demographic information: age, sex, race, ethnicity, marital status, and education level 
BDI-II: current depressive symptoms 
STAI-I & II: current anxiety symptoms 
Physical measure BMI 
Interview 
Treatment History: current and past CBT and antidepressant use 
SCID-IV-RV: psychiatric diagnoses 
Session 2 
Baseline ECG and ICG recording while viewing 10-minute clip of Alaska Denali Park Video 
Self-report 
measures 
DAS-SF I: dysfunctional beliefs at baseline (i.e., baseline cognitions) 
VAS: dysphoric mood at baseline (i.e., baseline mood) 
PANAS-X: dysphoric mood at baseline (i.e., baseline mood) 
Mood induction 
ECG and ICG recording while listening to 7:38-minute piece of sad/neutral music and recalling 
sad/neutral autobiographical memory 
Self-report 
measures 
DAS-SF II: dysfunctional beliefs post-mood induction (i.e., cognitive reactivity to mood induction) 
VAS: dysphoric mood post-mood induction (i.e., mood reactivity to mood induction) 
PANAS-X: dysphoric mood post-mood induction (i.e., mood reactivity to mood induction) 
Recovery ECG and ICG recording while viewing 10-minute clip of Alaska Wilderness Video 
Debriefing  Provide and review debriefing form  
Note. GHS = General Health Screen; BDI-II = Beck Depression Inventory – Second Edition; PHQ-9 = Patient Health Questionnaire – 
9; BAI = Beck Anxiety Inventory; STAI-I & II = State-Trait Anxiety Inventory – I & II; BMI = body mass index; SCID-IV-RV = 
Structured Clinical Interview for DSM-IV-TR – Research Version; ECG = electrocardiogram; ICG = impedance cardiography; DAS I 
= Dysfunctional Attitudes Scale – Short Form I; DAS II = Dysfunctional Attitudes Scale – Short Form II; VAS = Visual Analogue 





ANALYSES AND HYPOTHESIZED RESULTS 
All analyses were conducted using IBM SPSS Statistics Version 25.0 (IBM Corporation, 
2017). 
Preliminary Analyses 
Data Cleaning and Calculation 
The following procedures were used to clean demographic, self-report, cognitive, mood, 
and cardiovascular data and calculate change scores for cognitive, mood, and cardiovascular data 
before analyses were conducted. All data were manually inspected for potential univariate 
outliers, defined as z-scores exceeding ± 3.00 (Daszykowski, Kaczmarek, Heyden, & Walczak, 
2007). Winsorizing, a data transformation procedure that retains outliers by adjusting extreme 
values to the next most non-outlier extreme value, was utilized if necessary. Winsorization is an 
alternative to deleting outliers that reduces the skew of the distribution while preserving the 
general pattern of variability (Field, 2009). Outlier data were winsorized to address extreme 
values at the group by condition level. Outliers for cognitive, mood, and cardiovascular data was 
addressed differently depending on the type of analyses conducted. For analyses conducted using 
difference scores, outliers for pre- and post-mood induction data were not winsorized as 
participants’ data points were dependent upon one another and would impact the validity of the 
difference scores. For analyses conducted using residualized change scores or repeated measures, 
outliers for pre- and post-mood induction data were winsorized as participants’ data points were 
aggregated and therefore, would not impact the validity of the residualized change scores and 





Of note, this study drew from two distinct literature bases (i.e., cognitive and mood 
literature and cardiovascular literature) that use different techniques to calculate change scores. 
Over the years, there has been a fierce debate in the literature about the use of change scores (see 
Cronbach & Furby, 1970 for the argument against the use of change scores and Zimmerman & 
Williams, 1982a, 1982b for rebuttals). Today, the literature has generally come to the consensus 
that the difference score and residualized change score methods for calculating change scores are 
reliable and valid methods for assessing reactivity (Castro-Schilo & Grimm, 2018; Dimitrov & 
Rumrill, 2003; Linden et al., 1997; Llabre et al., 1991). To represent the conventions of each 
literature base, two different data calculation techniques for change scores were used: difference 
scores, which are typically used in the cardiovascular literature, and residualized change scores, 
which are typically used in the cognitive and mood literature. 
Demographic information. Demographic information collected during session 2 (i.e., 
age, sex, race, ethnicity, marital status, education level, current and past CBT and antidepressant 
use, and BMI) were manually inspected for potential univariate outliers. 
Self-report measures. Self-report measures collected during session 2 (i.e., BDI-II, 
STAI-I & II) were manually inspected for potential univariate outliers.  
Cognitive measures. Cognitive measures collected during session 2 (i.e., DAS-SF I & II) 
were manually inspected for potential univariate outliers.  
Difference scores for cognitive reactivity were calculated for the DAS by subtracting 
post-mood induction scores and pre-mood induction scores (i.e., DASPOST – DASPRE). These 
values were used in the subsequent analyses to represent cognitive (i.e., DASDS) reactivity to the 
mood induction procedures. Previous research has shown difference scores are reliable measures 




equal variance and equal reliability (Dimitrov & Rumrill, 2003), which was not hypothesized for 
this study. 
Simple linear regression for cognitive reactivity were used to create residualized change 
scores for the pre- and post-mood induction DAS. These values were used in the subsequent 
analyses to represent cognitive (i.e., ZRESDAS) reactivity to the mood induction procedures. This 
technique has been used in studies investigating similar hypotheses and employing similar 
methodological procedures in an effort to make variability of pre-mood induction DAS scores 
independent from variability of post-mood induction DAS scores (Segal et al., 2006; Van 
Rijsbergen et al., 2013). Previous research has shown that while residualized change scores are 
reliable measures of self-reported reactivity and results in less error than difference scores when 
pre-test score variance is greater than posttest score variance (Dimitrov & Rumrill, 2003), which 
could have been the pattern of responding observed during this study. Of note, the use of 
residualized change scores can lead to an overly conservative test for self-reported reactivity 
(Dimitrov & Rumrill, 2003). 
Mood measures. Mood measures collected during session 2 (i.e., VAS, and PANAS-X 
N, P, F, G, H, and S) were manually inspected for potential univariate outliers.  
Difference scores for mood reactivity were calculated for the VAS and PANAS-X N, P, 
F, G, H, and S by subtracting post-mood induction scores and pre-mood induction scores (i.e., 
VASPOST –VASPRE, PANAS-X NPOST –PANAS-X NPRE, PANAS-X PPOST –PANAS-X PPRE, 
PANAS-X FPOST –PANAS-X FPRE, PANAS-X GPOST –PANAS-X GPRE, PANAS-X HPOST –
PANAS-X HPRE, and PANAS-X SPOST –PANAS-X SPRE). These values were used in the 
subsequent analyses to represent mood (i.e., VASDS) reactivity to the mood induction 




check for the mood induction procedures to ensure that a sad mood was induced (i.e., VASDS) 
and to assess if emotions other than sadness were induced (i.e., PANAS-X NDS, PANAS-X PDS, 
PANAS-X FDS, PANAS-X GDS, PANAS-X HDS, and PANAS-X SDS). Previous research has 
shown difference scores are reliable measures of self-reported reactivity with the exception of 
cases in which pretest and post test scores have equal variance and equal reliability (Dimitrov & 
Rumrill, 2003), which was not hypothesized for this study. 
Simple linear regression for cognitive and mood reactivity were used to create 
residualized change scores for the pre- and post-mood induction VAS and PANAS-X N, P, F, G, 
H, and S. These values were used in the subsequent analyses to represent mood (i.e., ZRESVAS) 
reactivity to the mood induction procedures. In addition, these values were used in the 
subsequent analyses as a manipulation check for the mood induction procedures to ensure that a 
sad mood was induced (i.e., ZRESVAS) and to assess if emotions other than sadness were induced 
(i.e., ZRESPANAS-X N, ZRESPANAS-X P, ZRESPANAS-X F, ZRESPANAS-X G, ZRESPANAS-X 
H, and ZRESPANAS-X S). This technique has been used in studies investigating similar 
hypotheses and employing similar methodological procedures in an effort to make variability of 
pre-mood induction VAS scores independent from variability of post-mood induction VAS 
scores (Segal et al., 2006; Van Rijsbergen et al., 2013). Previous research has shown that while 
residualized change scores are reliable measures of self-reported reactivity and results in less 
error than difference scores when pre-test score variance is greater than posttest score variance 
(Dimitrov & Rumrill, 2003), which could have been the pattern of responding observed during 
this study. Of note, the use of residualized change scores can lead to an overly conservative test 




Cardiovascular measures. Multiple cardiovascular measures were used in this 
investigation including HP, RSA, CO, and PEP. Cardiovascular measures were calculated from 
ECG and ICG data. ECG and ICG data were collected with Mindware hardware and Biolab 3.1 
(MindWare Technologies Ltd., 2009) acquisition software. ECG data fell within -5 and 5 volts 
with a sampling rate of 1,000 Hertz. The following calculation methods were used to compute 
ECG measures: entire for calculation method and Z0 for respiration signal to use. ICG data was 
sampled at a rate of 1,000 Hertz. Z0 was calibrated at .10 volts per one-ohm change while dZ/dt 
was calibrated at 1.00 volts per ohms per second. The following calculation methods were used 
to compute ICG measures: minimum value K to R interval for the ECG Q point (K = 35), the 
Framingham method for LVET windowing (LVET minimum = 300, LVET maximum = 600), 
the percentage of dZ/dt time + C (percent dZ/dt peak = 55.00%, C = 4; Lozano et al., 2008) for 
the ICG B point, the kubieck formula for SV, and measured for dZ/dt source. ECG and ICG data 
were ensemble averaged using 60 second epochs.  
Specialized Biolab software modules (MindWare Technologies Ltd., 2009) were utilized 
to clean and calculate HP, RSA, CO, and PEP data. All data was visually screened and manually 
cleaned for artifacts before calculations are computed. HP and RSA were derived using 
Mindware’s HRV Analysis 3.1.4 module. HP was calculated using the time series method to 
determine the IBI between successive R spikes on the ECG in milliseconds. RSA was calculated 
using the frequency domain method to determine the IBI between successive R spikes on the 
ECG within the high frequency band derived from a Fast Fourier Transform, which fell within 
.15 and .40 Hertz. In addition, the Z0 measure obtained via ICG was used to account for the 
impact of respiration rate on RSA. CO and PEP was derived using Mindware’s Impedance 




determining the time in milliseconds between the B point of dZ/dt from ICG and the Q point 
from ECG. Cardiovascular functioning at baseline, cardiovascular reactivity in response to the 
mood induction, and cardiovascular recovery were calculated by taking an average of the last 
two and five minutes of HP, RSA, CO, and PEP data for baseline (i.e., HPBL2/BL5, RSABL2/BL5, 
COBL2/BL5, and PEPBL2/BL5) and recovery (i.e., HPRC2/RC5, RSARC2/RC5, CORC2/RC5, and PEPRC2/RC5) 
and the first two and five minutes of HP, RSA, CO, and PEP data for the mood induction (i.e., 
HPMI2/MI5, RSAMI2/MI5, COMI2/MI5, and PEPMI2/MI5). Cardiovascular data collected during session 2 
were manually inspected for potential univariate outliers. 
Difference scores for cardiovascular reactivity were calculated for each cardiovascular 
measure by subtracting the average obtained during the first two and five minutes of the mood 
induction from the average obtained during the last two and five minutes of baseline (i.e., 
HPMI2/MI5 – HPBL2/BL5, RSAMI2/MI5 – RSABL2/BL5, COMI2/MI5 – COBL2/BL5, and PEPMI2/MI5 – 
PEPBL2/BL5). These values were used in the subsequent analyses to represent cardiovascular 
reactivity (i.e., HPDS2RA/DS5RA, RSADS2RA/DS5RA, CODS2RA/DS5RA, and PEPDS2RA/DS5RA) to the mood 
induction procedures. In addition, difference scores for cardiovascular recovery were calculated 
for each cardiovascular measure by subtracting the average obtained during the last two and five 
minutes of recovery from the average obtained during the last two and five minutes of baseline 
(i.e., HPRC2/RC5 – HPBL2/BL5, RSARC2/RC5 – RSABL2/BL5, CORC2/RC5 – COBL2/BL5, and PEPRC2/RC5 – 
PEPBL2/BL5). These values were used in the subsequent analyses to represent cardiovascular 
recovery (i.e., HPDS2RA/DS5RC, RSADS2RA/DS5RC, CODS2RA/DS5RC, and PEPDS2RA/DS5RC) from the 
mood induction procedures. This technique has been used in studies investigating similar 
hypotheses and employing similar methodological procedures to examine cardiovascular 




shown that differences scores are reliable measures of psychophysiological reactivity across 
multiple experimental sessions with the exception of cases in which pretest and post test scores 
have equal variance and equal reliability (as reviewed by Llabre, Spitzer, Saab, Ironson, & 
Schneiderman, 1991), which was not hypothesized for this study. 
Simple linear regression for cardiovascular reactivity was used to create residualized 
change scores. These values were used in the subsequent analyses to represent cardiovascular 
reactivity (i.e., ZRES2/RES5HPRA, ZRES2/RES5RSARA, ZRES2/RES5CORA, and ZRES2/RES5PEPRA) to the 
mood induction procedures. In addition, simple linear regression for cardiovascular recovery was 
used to create residualized change scores. These values were used in the subsequent analyses to 
represent cardiovascular recovery (i.e., ZRES2/RES5HPRC, ZRES2/RES5RSARC, ZRES2/RES5CORC, and 
ZRES2/RES5PEPRC) from the mood induction procedures. Previous research has shown that that 
residualized change scores are reliable measures of psychophysiological reactivity across 
multiple experimental sessions and results in less error than difference scores when pre-test score 
variance is greater than posttest score variance (as reviewed by Llabre et al., 1991), which could 
have been the pattern of responding observed during this study. 
Data Analysis 
The following procedures were used to analyze demographic, cognitive, mood, and 
cardiovascular data. All data were assessed for homogeneity of variance using Levene’s test. 
Violation of homogeneity of variance (p < .05) indicates that the assumption underlying analyses 
is not met. If homogeneity of variance was violated for independent samples t tests, results for 
equal variances not assumed were reported. If homogeneity of variance was violated for one-
way, factorial, or repeated measures analysis of variance (ANOVA), additional analyses were 




of covariates. If homogeneity of variance was significant with covariates and not significant 
without covariates, calculating the residual of the residualized change scores to assess normality 
and transforming the residualized change scores to re-assess homogeneity of variance would not 
have the intended effect. Instead, the planned analyses were conducted with the α level decreased 
from .05 to .01. 
There are multiple possibilities to remedy the violation this assumption which includes 
using a non-parametric test, transforming the data to reduce skewness, or decreasing the α level 
to reduce the likelihood of type II error (S. W. Ell, personal communication, February 9, 2016). 
Multiple steps were explored in an attempt to remedy the violation of this assumption. First, 
residuals of differences scores were calculated, and Kolmogorov-Smirnov’s and Shapiro-Wilk’s 
tests of normality were conducted (Field, 2009). If Levene’s test for homogeneity of variance 
continued to be significant, this indicated that the assumption underlying ANOVA was still not 
met. Second, residualized change scores were transformed using the reciprocal transformation 
(1/XiR). Of note, residualized change scores were reversed before conducting this transformation 
to preserve order (XiR = XHIGHEST – Xi). This transformation method was selected as the 
cognitive, mood, and cardiovascular data contained negative values, which cannot be 
transformed using log and square root transformations (Field, 2009). If Levene’s test for 
homogeneity of variance continued to be significant, this indicated that the assumption 
underlying ANOVA was still not met. Given that there are not non-parametric tests for 
evaluating interactions (Grace-Martin, 2019a), the remaining option was to move forward with 
the planned analyses and decreased the α level from .05 to .01.  
Of note, this study drew from two distinct literature bases (i.e., cognitive and mood 




previously noted by researchers (e.g., Castro-Schilo & Grimm, 2018), there is not one correct 
data analysis technique that can be used to test a study’s hypotheses when experimental 
procedures (e.g., random assignment, use of experimental and control conditions) intended to 
distribute variability and error across conditions are employed. The calls for a consensus on data 
analysis techniques for reactivity and recovery have been left unanswered (Linden et al., 1997). 
To represent the conventions of each literature base, two different data analysis techniques were 
used: repeated measures ANOVAs, which are typically used in the cardiovascular literature, and 
factorial ANOVAs, which are typically used in the cognitive and mood literature. 
Demographic information. Descriptive statistics were used to summarize the sample. 
Measures of central tendency and variability were used for continuous variables (i.e., age and 
BMI) while frequency statistics were used for categorical variables (i.e., sex, race, ethnicity, 
marital status, education level, and current and past CBT and antidepressant use). A series of 
independent samples t-tests were used to assess significant group differences of continuous 
variables (i.e., age and BMI) collected during session 1 (Table 3). In addition, a series of chi-
square tests were used to assess significant group differences of categorical variables (i.e., sex, 
race, ethnicity, education level, marital status, and current and past CBT and antidepressant use) 
collected during session 1 (Table 3). These variables were considered as potential covariates in 
subsequent analyses. 
Self-report measures. A series of independent samples t-tests were used to assess 
significant group differences of current depressive (i.e., BDI-II) and anxiety (i.e., STAI-I & II) 
symptoms collected during session 1 (Table 3). These variables were considered as potential 




 Cognitive measures. A series of 2 (group: formerly depressed, healthy control) X 2 
(condition: sad, neutral) factorial ANOVAs and a 2 (group: formerly depressed, healthy control) 
X 2 (condition: sad, neutral) repeated measures ANOVA were conducted to examine changes in 
dysfunctional beliefs on the DAS pre- and post-mood induction. Analyses were conducted using 
difference scores (i.e., DASDS), residualized change scores (i.e., ZRESDAS), and pre- and post-
mood induction measures (i.e., DAS I and DAS II). These analyses were used to assess 
significant differences in cognitive reactivity based on depressive history and mood induction 
procedure. Planned comparisons were conducted using contrast analyses. It was expected that 
formerly depressed participants exposed to the sad mood induction would report significantly 
more dysfunctional beliefs compared to formerly depressed participants exposed to the neutral 
mood induction and healthy control participants exposed to the sad and neutral mood inductions. 
Mood measures. A series of one-way (condition: sad, neutral) ANOVAs and a one-way 
(condition: sad, neutral) repeated measures ANOVA were conducted to examine changes in 
sadness on the VAS pre- and post-mood induction. Analyses were conducted using difference 
scores (i.e., VASDS), residualized change scores (i.e., ZRESVAS), and pre- and post-mood 
induction measures (i.e., VASPRE and VASPOST). These analyses were used as a manipulation 
check for the mood induction procedures to ensure that a sad mood was induced. Significant 
differences between conditions was only expected post-mood induction. It was expected that 
formerly depressed and healthy control participants exposed to the sad mood induction would 
report significantly more dysphoric mood (> 10.00% change in mood state; Martin, 1990) after 
the mood induction compared to formerly depressed and healthy control participants exposed to 




 In addition, a series of one-way (condition: sad, neutral) ANOVAs and a one-way 
(condition: sad, neutral) repeated measures ANOVA were conducted to assess changes in 
multiple emotions on the negative and positive affect general dimension and fear, guilt, hostility, 
and sadness basic negative emotional scales of the PANAS-X pre- and post-mood induction.  
Analyses were conducted using difference scores (i.e., PANAS-X NDS, PANAS-X PDS, PANAS-
X FDS, PANAS-X GDS, PANAS-X HDS, and PANAS-X SDS), residualized change scores (i.e., 
ZRESPANAS-X N, ZRESPANAS-X P, ZRESPANAS-X F, ZRESPANAS-X G, ZRESPANAS-X H, 
and ZRESPANAS-X S), and pre- and post-mood induction measures (i.e., PANAS-X NPRE/POST, 
PANAS-X PPRE/POST, PANAS-X FPRE/POST, PANAS-X GPRE/POST, PANAS-X HPRE/POST, and 
PANAS-X SPRE/POST). These analyses were used as a manipulation check for the mood induction 
procedures to assess if emotions other than sadness were induced. Significant differences 
between conditions were only expected post-mood induction. It was expected that formerly 
depressed and healthy control participants exposed to the sad mood induction would report a 
significant increase in negative affect and a significant decrease in positive affect after the mood 
induction compared to formerly depressed and healthy control participants exposed to the neutral 
mood induction. 
A series of 2 (group: formerly depressed, healthy control) X 2 (condition: sad, neutral) 
factorial ANOVAs and a 2 (group: formerly depressed, healthy control) X 2 (condition: sad, 
neutral) repeated measures ANOVA were conducted to examine changes in dysphoric mood on 
the VAS pre- and post-mood induction. Analyses were conducted using difference scores (i.e., 
VASDS), residualized change scores (i.e., ZRESVAS), and pre- and post-mood induction measures 
(i.e., VASPRE and VASPOST). These analyses were used to assess significant differences in mood 




conducted using contrast analyses. It was expected that formerly depressed and healthy control 
participants exposed to the sad mood induction would report significantly more dysphoric mood 
compared to formerly depressed and healthy control participants exposed to the neutral mood 
induction. 
Cardiovascular measures. A series of one-way ANOVAs were used to assess 
significant group differences in cardiovascular functioning at baseline. Analyses were conducted 
using an average of the last two and five minutes of HP, RSA, CO, and PEP during baseline 
(e.g., HPBL2/BL5, RSABL2/BL5, COBL2/BL5, and PEPBL2/BL5). It was expected that formerly depressed 
and healthy control participants would exhibit similar cardiovascular functioning for HP, RSA, 
PEP, or CO during the baseline film. 
A series of 2 (group: formerly depressed, healthy control) X 2 (condition: sad, neutral) 
factorial ANOVAs and a 2 (group: formerly depressed, healthy control) X 2 (condition: sad, 
neutral) repeated measures ANOVAs were used to assess significant group differences in 
cardiovascular reactivity during the mood induction. Analyses were conducted using difference 
scores (i.e., HPDS2RA/DS5RA, RSADS2RA/DS5RA, CODS2RA/DS5RA, and PEPDS2RA/DS5RA), residualized 
change scores (i.e., ZRES2/RES5HPRA, ZRES2/RES5RSARA, ZRES2/RES5CORA, and ZRES2/RES5PEPRA), 
and baseline and mood induction measures (i.e., HPBL2/BL5/MI2/MI5, RSABL2/BL5/MI2/MI5, 
COBL2/BL5/MI2/MI5, and PEPBL2/BL5/MI2/MI5). Planned comparisons were conducted using contrast 
analyses. It was expected that formerly depressed participants exposed to the sad mood induction 
would exhibit decreased HP, RSA, and CO and increased PEP during the mood induction 
compared to formerly depressed participants exposed to the neutral mood induction and healthy 




A series of 2 (group: formerly depressed, healthy control) X 2 (condition: sad, neutral) 
factorial ANOVAs and a 2 (group: formerly depressed, healthy control) X 2 (condition: sad, 
neutral) repeated measures ANOVAs were used to assess significant group differences in 
cardiovascular recovery after the mood induction. Analyses were conducted using difference 
scores (i.e., HPDS2RC/DS5RC, RSADS2RC/DS5RC, CODS2RC/DS5RC, and PEPDS2RC/DS5RC), residualized 
change scores (i.e., ZRES2/RES5HPRC, ZRES2/RES5RSARC, ZRES2/RES5CORC, and ZRES2/RES5PEPRC), and 
baseline and recovery measures (i.e., HPBL2/BL5/RC2/RC5, RSABL2/BL5/RC2/RC5, COBL2/BL5/RC2/RC5, and 
PEPBL2/BL5/RC2/RC5). Planned comparisons were conducted using contrast analyses. It was 
expected that formerly depressed participants exposed to the sad mood induction would exhibit 
reduced cardiovascular recovery during the recovery film compared to formerly depressed 
participants exposed to the neutral mood induction and healthy control participants exposed to 
the sad and neutral mood induction. 
Hypothesis 1 
Formerly depressed participants exposed to the sad mood induction would report 
significantly higher levels of cognitive reactivity on the DAS post-mood induction than formerly 
depressed participants exposed to the neutral mood induction and healthy control participants 
exposed to the sad and neutral mood inductions. Cognitive reactivity was operationalized as 
difference scores (i.e., DASDS) and residualized change scores (i.e., ZRESDAS) for the DAS 
administered pre- and post-mood induction as well as pre- and post-mood induction measures 
(i.e., DAS-SF I and DAS II). A series of 2 (group: formerly depressed, healthy control) X 2 
(condition: sad, neutral) factorial ANOVAs using difference scores and residualized change 




measures ANOVA were used to assess the relationship between depression history, mood 
manipulation, and cognitive reactivity. 
Figure 7. Cognitive Reactivity Post-Mood Induction 
 
Note. Lower DAS scores indicate cognitive reactivity post-mood induction.   
Hypothesis 2 
Formerly depressed and healthy control participants exposed to the sad mood induction 
would report significantly higher levels of mood reactivity on the VAS post-mood induction than 
formerly depressed and healthy control participants exposed to the neutral mood induction. No 
significant differences in mood reactivity on the VAS post-mood induction were expected 
between formerly depressed and healthy control participants exposed to the sad mood induction. 
Mood reactivity was operationalized as difference scores (i.e., VASDS) and residualized change 
scores (i.e., ZRESVAS) for the VAS administered pre- and post-mood induction as well as pre- 
and post-mood induction measures (i.e., VASPRE and VASPOST). A series of 2 (group: formerly 
depressed, healthy control) X 2 (condition: sad, neutral) factorial ANOVAs using difference 
























(condition: sad, neutral) repeated measures ANOVA were used to assess the relationship 
between depression history, mood manipulation, and mood reactivity. 
Figure 8. Mood Reactivity Post-Mood Induction 
 
Note. Higher VAS scores indicate mood reactivity post-mood induction.  
Hypothesis 3 
Formerly depressed participants exposed to the sad mood induction would exhibit a 
maladaptive pattern of cardiovascular reactivity (i.e., decreased HP, RSA, and CO and increased 
PEP) during the mood induction compared to formerly depressed participants exposed to the 
neutral mood induction and healthy control participants exposed to the sad and neutral mood 
inductions. An average of the first five minutes of the mood induction was computed for HP, 
RSA, PEP, and CO (i.e., HPMI2/MI5, RSAMI2/MI5, COMI2/MI5, and PEPMI2/MI5) and serve as a mood 
induction measure. An average of the last five minutes of the mood induction was computed for 
HP, RSA, PEP, and CO (i.e., HPBL2/BL5, RSABL2/BL5, COBL2/BL5, and PEPBL2/BL5) and serve as a 
baseline measure. Cardiovascular reactivity was operationalized as the difference score for the 






















and PEPDDS2RA/DS5RA) and residualized change scores for the average of each cardiovascular 
measure (i.e., ZRES2/RES5HPRA, ZRES2/RES5RSARA, ZRES2/RES5CORA, and ZRES2/RES5PEPRA) assessed 
during baseline and the mood induction (i.e., HPBL2/BL5/MI2/MI5, RSABL2/BL5/MI2/MI5, 
COBL2/BL5/MI2/MI5, and PEPBL2/BL5/MI2/MI5). A series of 2 (group: formerly depressed, healthy 
control) X 2 (condition: sad, neutral) factorial ANOVAs using difference scores and residualized 
change scores and a 2 (group: formerly depressed, healthy control) X 2 (condition: sad, neutral) 
repeated measures ANOVA were used to assess the relationship between history of depression, 
mood manipulation, and cardiovascular reactivity. 
Figure 9. Cardiovascular Reactivity during Mood Induction 
Note. Higher HP, RSA, and CO and lower PEP is considered to represent more adaptive 
























































Formerly depressed participants exposed to the sad mood induction would exhibit 
reduced cardiovascular recovery (i.e., decreased HP, RSA, and CO and increased PEP compared 
to baseline) during the recovery film compared to formerly depressed participants exposed to the 
neutral mood induction and healthy control participants exposed to the sad and neutral mood 
inductions. An average of the last five minutes of recovery was computed for HP, RSA, PEP, 
and CO (e.g., HPRC2/RC5, RSARC2/RC5, CORC2/RC5, and PEPRC2/RC5) and serve as a recovery 
measure. An average of the last five minutes of the mood induction was computed for HP, RSA, 
PEP, and CO (i.e., HPBL2/BL5, RSABL2/BL5, COBL2/BL5, and PEPBL2/BL5) and serve as a baseline 
measure. Cardiovascular recovery was operationalized as the difference score for the average of 
each cardiovascular measure (i.e., HPDS2RC/DS5RC, RSADS2RC/DS5RC, CODS2RC/DS5RC, and 
PEPDS2RC/DS5RC) and residualized change scores for the average of each cardiovascular measure 
(i.e., ZRES2/RES5HPRC, ZRES2/RES5RSARC, ZRES2/RES5CORC, and ZRES2/RES5PEPRC) during the baseline 
and the recovery period (i.e., HPBL2/BL5/RC2/RC5, RSABL2/BL5/RC2/RC5, COBL2/BL5/RC2/RC5, and 
PEPBL2/BL5/RC2/RC5). A series of 2 (group: formerly depressed, healthy control) X 2 (condition: 
sad, neutral) factorial ANOVAs using difference scores and residualized change scores and a 2 
(group: formerly depressed, healthy control) X 2 (condition: sad, neutral) repeated measures 
ANOVA were used to assess the relationship between history of depression, mood manipulation, 








Figure 10. Cardiovascular Recovery during Recovery Film 
Note. A return to baseline cardiovascular functioning is considered to represent more adaptive 
cardiovascular recovery during the recovery period.  























































Table 3. Study Procedure and Hypotheses Chart 




Contact and demographic information 
Exclusion criteria 
GHS: language and visual abilities, current and past health conditions 
BDI-II: current depressive symptoms 
PHQ-9: past depressive symptoms 








BDI-II: current depressive symptoms 
STAI-I & II: current anxiety symptoms 
Physical measure BMI: calculated via height and weight 
Interview 
Treatment History: current and past CBT and antidepressant use 
SCID-IV-RV: psychiatric diagnoses Exclusion criteria 
Session 2 
Baseline 






DAS-SF I: dysfunctional beliefs at baseline Baseline cognitions 
VAS: dysphoric mood at baseline  Baseline mood, 
manipulation check PANAS-X: dysphoric mood at baseline 
Mood induction 
ECG and ICG recording while listening to 7:38 minute piece of sad or 





DAS-SF II: dysfunctional beliefs post MI (i.e., cognitive reactivity to MI) Post MI cognitions, H1 
VAS: dysphoric mood post MI (i.e., mood reactivity to MI) 
Post MI mood, 
manipulation check, H2 
PANAS-X: dysphoric mood post MI 
Post MI mood, 
manipulation check 
Recovery 








Note. GHS = General Health Screen; BDI-II = Beck Depression Inventory – Second Edition; PHQ-9 = Patient Health Questionnaire – 
9; BAI = Beck Anxiety Inventory; STAI-I & II = State-Trait Anxiety Inventory – I & II; CBT = cognitive-behavioral therapy; BMI = 
body mass index; SCID-IV-RV = Structured Clinical Interview for DSM-IV-TR – Research Version; ECG = electrocardiogram; ICG 
= impedance cardiography; H = hypothesis; DAS I = Dysfunctional Attitudes Scale – Short Form I; DAS II = Dysfunctional Attitudes 







 The purpose of this study was to characterize cognitive, mood, and cardiovascular 
reactivity to and recovery from a sad mood induction in individuals with a history of depression 
compared to healthy, never depressed individuals. A transient sad or neutral mood was 
experimentally induced using an empirically validated music and autobiographical recall mood 
induction. Self-report measures were used to test the study hypotheses regarding cognitive and 
mood reactivity to the transient mood (i.e., Hypotheses 1 and 2). Cardiovascular measures were 
used to test the study hypotheses regarding cardiovascular reactivity to and cardiovascular 
recovery from the transient mood (i.e., Hypotheses 3 and 4).  
Session 1 
Demographic Information 
Participants were recruited from the University of Maine psychology undergraduate 
participant pool and the surrounding community. The distribution of participants by recruitment 
source and group is presented in Table 4. While the majority of the final sample was drawn from 
the undergraduate participant pool (n = 87, 65.90%), over a third of the sample was recruited 
from the surrounding community (n = 45, 34.10%).  
Table 4. Recruitment Source by Group 
   Group 
  Total (N = 132) FD (n = 45) HC (n = 87) 
Recruitment source n % n % n % 
Participant pool 87 65.90 21 46.70 66 75.90 
Community 45 34.10 24 53.30 21 24.10 





Participants who met the eligibility criteria during screening were invited to participate in 
session 1. 282 participants completed session 1. At session 1, 109 participants (38.65%) were 
excluded, leaving 173 participants (61.35%) who were eligible to participate in session 2. Of 
these participants, 59 participants met the inclusion criteria for the formerly depressed group and 
114 participants met the inclusion criteria for the healthy control group. Between sessions 1 and 
2, 41 participants (23.70%) were lost to follow-up. 132 participants (76.30%) completed session 
2, with 45 participants in the formerly depressed group and 87 participants in the healthy control 
group. A flow chart of participant recruitment visually depicts this information (Figure 11). 
Figure 11. Flow Chart of Participant Recruitment 
 
Note. FD = formerly depressed; HC = healthy control. 
Following session 1, participants in the two groups were randomly assigned to the two 
experimental conditions. The distribution of participants in the two experimental conditions by 
group is presented in Table 5. Formerly depressed and healthy control participants were assigned 
to the sad (n = 65) and neutral (n = 67) mood inductions roughly evenly, with slight differences 




N = 132 nFD = 45 nHC = 87
Session 1 eligible for session 2




N = 109 excluded




Table 5. Condition by Group 
   Group 
  Total (N = 132) FD (n = 45) HC (n = 87) 
Condition n % n % n % 
SMI 65 49.20 21 46.70 44 50.60 
NMI 67 50.80 24 53.30 43 49.40 
Note. FD = formerly depressed; HC = healthy control; SMI = sad mood induction; NMI = neutral 
mood induction.  
Descriptive statistics. Participants demographic information that was considered as 
potential covariates. Descriptive statistics for demographic information for the entire sample are 
presented in Table 6 while means, standard deviations, p values, and effect sizes for 
demographic information by group are presented in Tables 6 and 7. Participants in this study (N 
= 132) were predominantly younger (M = 20.79, SD = 5.65), female (n = 81, 61.40%), Caucasian 
(n = 115, 87.10%), never married (n = 121, 91.67%) college students (n = 114, 86.40%). These 
results are consistent with the demographic make-up of the University of Maine and surrounding 
community as Orono, Maine is a university town. Of note, the racial and ethnic make-up of the 
study is consistent with the location as the state of Maine currently has the highest proportion of 
Caucasian residents in the country at 94.70% (United States Census Bureau, 2017). A subset of 
the sample included older (range = 18-60), college educated (n = 16, 12.90%) adults. 
Participants’ BMI was on average, in the overweight range (M = 25.16, SD = 5.65), which is 
consistent with recent estimates that 35.90% of Maine’s population falls within the overweight 
range (Centers for Disease Control and Prevention, 2017). A low proportion of participants 
reported current or previous mental health treatment (psychotherapy = 2.00-8.00%, psychotropic 
medication = 7.00-12.00%). 
 Independent samples t-tests. Means, standard deviations, p values, and effect sizes for 




used to examine differences between groups for continuous variables (i.e., age and BMI). 
Levene’s test for homogeneity of variance was significant for age (F(129) = 26.96, p < .001) but 
not BMI (F(128) = .97, p = .33), indicating that this assumption underlying t-test was met for 
BMI but not age. Consequently, results for equal variances not assumed are reported for age. 
Formerly depressed participants were significantly older (t(49.01) = 2.27, p = .03, CI = .34, 5.62, 
d = .47) than healthy control participants. There were no significant difference between groups 
for BMI (t(128) = -.18, p = .86, CI = -2.28, 1.90, d  = .03).  
Chi-square tests. Means, standard deviations, p values, and effect sizes for demographic 
information by group are presented in Table 7. Chi-square tests were used to examine differences 
between the two groups for categorical variables (i.e., sex, race, ethnicity, education level, 
marital status, and current and past CBT and antidepressant use). Unsurprisingly, formerly 
depressed participants reported significantly more past CBT use (χ2(1) = 6.72, p = .04, w = .23) 
and current (χ2(1) = 16.54, p < .001, w = .35) and past (χ2(1) = 21.78, p < .001, w = .41) 
antidepressant use than healthy control participants. There were no significant difference 
between groups for sex (χ2(1) = 3.33, p = .07, w = .16), race (χ2(3) = 2.44, p = .49, w = .14), 
Hispanic/Latino (χ2(1) = 3.18, p = .08, w = .16) or Franco-American (χ2(1) = .06, p = .80, w = 
.02) ethnicity, marital status (χ2(2) = 5.18, p = .08, w = .20), education level (χ2(5) = 5.67, p = 
.34, w = .21), and current CBT use (χ2(1) = 4.82, p = .09, w = .19). Treatment history data was 
not collected for 16 formerly depressed and 40 healthy control participants. Due to the large 







Table 6. Descriptive Statistics for Demographic Information 
Measure M SD Sample range 
Age, years 20.79 5.65 18-60 
BMI, kg/m2 25.16 5.65 16.14-47.76 
Note. BMI = body mass index. 
Table 7. Means, Standard Deviations, P Values, and Effect Sizes for Demographic Information 
by Group 
  Group   
 Total (N = 132) FD (n = 45) HC (n = 87)   
Variable M SD M SD M SD p d 
Age, years 20.79 5.65 22.77 8.43 19.79 3.11 .03 .47 
BMI, kg/m2 25.16 5.65 25.04 5.73 25.22 5.64 .86 .03 
Variable n % n % n %   p w 
Sex                                                                                                                        .07          .16  
   Male 50 37.90 12 26.70 38 43.70   
   Female 81 61.40 32 71.10 49 56.30   
Race                                                                                                                          .49            .14  
   Caucasian 115 87.10 41 91.10 74 85.10   
   African American 4 3.00 0 N/A 4 4.60   
   Asian American 4 3.00 1 2.20 3 3.40   
   Multiple races 7 5.30 2 4.40 5 5.70   
Ethnicity  
   Hispanic/Latino 6 4.50 0 N/A 6 6.90 .08           .16 
   Franco-American 10 7.60 3 6.70 7 8.00 .80           .02 
Marital status                                                                                                         .08          .20  
   Married 8 6.10 4 8.90 4 4.60   
   Never married 121 91.70 38 84.40 83 95.40   
   Divorced 2 1.50 2 4.40 0 N/A   
Education level                                                                                                      .34                     .21
   High school 57 43.20 15 33.30 42 48.30   
   1 year of college 30 22.70 9 20.00 21 24.10   
   2+ years of college 27 20.50 12 26.70 15 17.20   
   Associates degree 1 .80 0 N/A 1 1.10   
   Bachelor’s degree 9 6.80 5 11.10 4 4.60   
   Doctoral degree 7 5.30 3 6.70 4 4.60   
Treatment history         
   Past CBT 8 6.10 6 13.30 2 2.30 .04 .23 
   Current CBT 2 1.50 2 4.40 0 N/A .09 .19 
   Past RX 12 9.10 11 24.40 1 1.10 < .001 .41 





Note. FD = formerly depressed; HC = healthy control; BMI = body mass index; CBT = cognitive 
behavioral therapy; RX = antidepressant medication; One FD participant elected not to provide 
any demographic data and one HC participant elected not to provide race data. Treatment history 
data was not collected for 16 FD and 40 HC participants. Consequently, percentages for some 
category do not add up to 100.00%. 
Self-Report Measures 
During session 1, participants completed two self-report measures that were considered 
as potential covariates. The BDI-II (Beck et al., 1996a; Appendix C) was used to evaluate the 
severity of current depressive symptoms. Respondents rated the severity of depressive symptoms 
experienced over the past two weeks on a scale from 0 to 3, with 0 indicating the symptom is not 
present and 3 indicating that the symptom is present and severe. Total scores ranged from 0 to 
63, with higher scores indicating greater levels of depressive symptom severity. The STAI-I & II 
(Spielberger et al., 1983; Appendix I) was used to assesses cognitive, affective, and somatic 
symptoms of both state and trait anxiety. Respondents rated the severity of anxiety symptoms 
experienced at the moment for the state version and in general for the trait version from 1 to 4, 
with 1 indicating the symptom is almost never present and 4 indicating that the symptom is 
almost always present. Total scores for each version ranged from 20 to 80, with higher scores 
indicating greater levels of state or trait anxiety symptom severity. Outlier data for the STAI-II (n 
= 1) was winsorized to address extreme values. No outlier data was present for the BDI-II or 
STAI-I. 
Descriptive statistics. Descriptive statistics for session 1 self-report measures are 
presented in Table 8. The BDI-II demonstrated good internal consistency (α = .89) and the STAI-
I demonstrated acceptable internal consistency (α = .71) in this study sample (Tavakol & 
Dennick, 2011). Cronbach’s alpha indicated that the STAI-II was not a reliable measure of state 
anxiety symptoms (α = .40). Consequently, the measure was removed from further analyses 




Table 8. Descriptive Statistics for Session 1 Self-Report Measures 
Measure M SD Sample range Sample α 
BDI-II 5.50 6.28 0-35 .89 
STAI-I 45.35 5.67 32-64 .71 
STAI-II 44.90 4.08 36-55 .40 
Note. BDI-II = Beck Depression Inventory – Second Edition; STAI-I = State-Trait Anxiety 
Inventory – I; STAI-II = State-Trait Anxiety Inventory – II. 
 
Independent samples t-tests. Means, standard deviations, p values, and effect sizes for 
session 1 self-report measures by group are presented in Table 9. Independent samples t-tests 
were used to examine differences between groups for current depressive (i.e., BDI-II) and state 
anxiety (i.e., STAI-I) symptoms. Levene’s test for homogeneity of variance was significant for 
the BDI-II (F(125) = 24.92, p < .001) and STAI-I (F(121) = 5.05, p = .03), indicating that this 
assumption underlying t-test was not met. Consequently, results for equal variances not assumed 
are reported for the BDI-II and STAI-I. Formerly depressed participants reported significantly 
higher levels of current depressive symptoms on the BDI-II (t(49.77) = 5.08, p < .001, CI = 3.98, 
9.19, d = 1.06) than healthy control participants. There were no significant difference between 
groups for current state anxiety symptoms on the STAI-I (t(60.73) = -1.01, p = .32, CI = -3.63, 
1.19, d = .20). 
Table 9. Means, Standard Deviations, P Values, and Effect Sizes for Session 1 Self-Report 
Measures by Group 
  Group   
 Total (N = 127) FD (n = 42) HC (n = 85)   
Measure M SD M SD M SD p d 
BDI-II  5.50 6.28 9.91 7.99 3.32 3.68 < .001 1.06 
 Total (N = 123) FD (n = 40) HC (n = 83)   
Measure M SD M SD M SD p d 
STAI-I  45.35 5.67 44.53 6.77 45.74 5.06 .32 .20 
Note. FD = formerly depressed; HC = healthy control; BDI-II = Beck Depression Inventory – 






During session 2, participants completed two versions of one self-report measure that was 
used to assess cognitive reactivity to the mood induction (i.e., Hypothesis 1). The DAS-SF I & II 
(Beevers et al., 2007; Appendix L) was used to evaluate changes in dysfunctional beliefs about 
oneself before and after the mood induction. Respondents rated their beliefs experienced most of 
the time on a scale of 1 to 4, with 1 indicating that they totally agreed with the statement and 4 
indicating that they totally disagreed with the statement. Total scores ranged from 9 to 36, with 
lower scores indicating greater levels of the dysfunctional beliefs. Cognitive reactivity was 
operationalized as difference scores (i.e., DASDS) and residualized change scores (i.e., ZRESDAS) 
for the DAS administered pre- and post-mood induction as well as pre- and post-mood induction 
measures (i.e., DAS I and DAS II). No outlier data was present for the DAS-SF I, DAS-SF II, 
and DASDS. 
Descriptive statistics. Descriptive statistics for session 2 cognitive measures are 
presented in Table 10. The DAS-SF I & II demonstrated acceptable internal consistency (α = .79-
.80) in this study sample (Tavakol & Dennick, 2011). The difference (i.e., DS) and residualized 
change (i.e., ZRES/ZRES) scores are calculated measures. Consequently, Cronbach’s alpha could 
not be calculated. 
Table 10. Descriptive Statistics for Session 2 Cognitive Measures 
Measure M SD Sample range Sample α 
DAS-SF I 27.67 3.87 19-36 .80 
DAS-SF II 27.03 3.96 16-36 .79 
DASDS -.64 2.87 -8-8  
ZRESDAS .00 1.00 -2.51-2.95  
Note. DAS I = Dysfunctional Attitudes Scale – Short Form I; DAS II = Dysfunctional Attitudes 





A series of 2 (group: formerly depressed, healthy control) X 2 (condition: sad, neutral) 
factorial ANOVAs using difference scores and residualized change scores and a 2 (group: 
formerly depressed, healthy control) X 2 (condition: sad, neutral) repeated measures ANOVA 
were used to test the hypothesis that formerly depressed participants exposed to the sad mood 
induction would report significantly more dysfunctional beliefs on the DAS post-mood induction 
than formerly depressed participants exposed to the neutral mood induction and healthy control 
participants exposed to the sad and neutral mood inductions. Means, standard deviations, p 
values, and effect sizes for session 2 cognitive measures by group are presented in Table 11 
while means, standard deviations, p values, and effect sizes for session 2 cognitive measures by 
group and condition are presented in Table 12. Planned comparisons were conducted using 
contrast analyses. Means, standard deviations, and p values for session 2 cognitive measures for 
planned comparisons are presented in Table 13. 
DAS. Analyses conducted using the DAS are reviewed below. 
2 X 2 factorial ANOVA – difference score. None of the covariates that were under 
consideration were significantly associated with cognitive reactivity (all p’s > .05) and were 
dropped from the final model. Levene’s test for homogeneity of variance was not significant 
(F(3,122) = .43, p = .73), indicating that this assumption underlying ANOVA was met. Neither 
the main effects of group (F(1,122) = 1.27, p = .26, η2 = .01) or condition (F(1,122) = .23, p = 
.63, η2 = .002) nor the group by condition interaction (F(1,122) = 1.81, p = .18, η2 = .02) were 
significant, indicating that there was no significant difference in cognitive reactivity on the DAS 
post-mood induction between groups or conditions or the group by condition interaction when 




cognitive reactivity on the DAS post-mood induction (t(122) = -1.51, pL = .23, pQ = .18, pC = 
.94) when comparing formerly depressed participants exposed to the sad mood induction to 
formerly depressed participants exposed to the neutral mood induction and healthy control 
participants exposed to the sad and neutral mood inductions. 
2 X 2 factorial ANOVA – residualized change score. None of the covariates that were 
under consideration were significantly associated with cognitive reactivity (all p’s > .05) and 
were dropped from the final model. Levene’s test for homogeneity of variance was not 
significant (F(3,122) = .68, p = .57), indicating that this assumption underlying ANOVA was 
met. Formerly depressed participants reported significantly higher levels of dysfunctional beliefs 
on the DAS post-mood induction (F(1,122) = 5.11, p = .03, η2 = .04) than healthy control 
participants. Neither the main effect of condition (F(1,122) = .14, p = .71, η2 = .001) nor the 
group by condition interaction (F(1,122) = 1.02, p = .31, η2 = .008) were significant, indicating 
that there was no significant difference in cognitive reactivity on the DAS post-mood induction 
between mood induction conditions or the group by condition interaction when using 
residualized change scores. Using contrast analyses, formerly depressed participants exposed to 
the sad mood induction reported significantly higher levels of dysfunctional beliefs on the DAS 
post-mood induction (t(122) = -1.86, pL = .03, pQ = .31, pC = .49) compared to healthy control 
participants exposed to the sad mood induction and formerly depressed and healthy control 
participants exposed to the neutral mood induction. 
2 X 2 repeated measures ANOVA. Current depressive (p < .001) and state anxiety (p = 
.03) symptoms were significantly associated with cognitive reactivity and were included in the 
final model. The remaining covariates that were under consideration were not significantly 




Levene’s test for homogeneity of variance was not significant (DAS-SF I: F(3,111) = .14, p = 
.93; DAS-SF II: F(3,111) = .04, p = .99), indicating that this assumption underlying ANOVA 
was met. Neither the main effects of group (F(1,109) = .67, p = .42, η2 = .006) or condition 
(F(1,109) = .03, p = .87, η2 < .001) nor the group by condition interaction (F(1,109) = .79, p = 
.38, η2 = .007) were significant, indicating that there was no significant difference in cognitive 
reactivity on the DAS post-mood induction between groups or conditions or the group by 
condition interaction when using repeated measures. Contrast analyses revealed that there was no 
significant difference in cognitive reactivity on the DAS post-mood induction (F(1,111) = .01, p 
= .92) when comparing formerly depressed participants exposed to the sad mood induction to 
formerly depressed participants exposed to the neutral mood induction and healthy control 
participants exposed to the sad and neutral mood inductions.  
Post-hoc power analyses. Post-hoc power analyses were conducted using G*Power 
3.1.9.2 (Faul et al., 2007) to determine the power achieved by the DAS analyses. Results 
indicated that the current model had a power of .36 for the difference score, .17 for the 
residualized change score, and .13 for the repeated measures. Results suggested that given the 
current study’s sample size, α level, and observed effect size, there was a 13 to 36% chance of 
detecting an effect depending on which analytic technique was used. 
Sensitivity analyses. Sensitivity analyses were conducted using G*Power 3.1.9.2 (Faul et 
al., 2007) to determine the minimum effect size needed to obtain significant results for the DAS 
analyses. Results indicated that the required effect size was f = .25 for the factorial ANOVAs and 
f = .28 for the repeated measures ANOVA. Results suggested that given the current study’s 
sample size and α level, at least a medium effect size was required to obtain significant results if 




Table 11. Means, Standard Deviations, P Values, and Effect Sizes for Session 2 Cognitive 
Measures by Group 
  Group   
 Total (N = 126) FD (n = 43) HC (n = 83)   
Measure M SD M SD M SD p η2 
DAS-SF I 27.67 3.87 26.23 3.87 28.40 3.68   
DAS-SF II 27.03 3.96 25.27 3.59 27.95 3.84   
DASDS -.64 2.87 -1.02 2.94 -.45 2.83 .26 .01 
ZRESDAS .00 1.00 -.27 .97 .14 .99 .03 .04 
DASRM       .42 .006 
Note. FD = formerly depressed; HC = healthy control; DAS I = Dysfunctional Attitudes Scale – 
Short Form I; DAS II = Dysfunctional Attitudes Scale – Short Form II; DS = difference score; 




Table 12. Means, Standard Deviations, P Values, and Effect Sizes for Session 2 Cognitive Measures by Group and Condition 
  Group and Condition   
 Total (N = 126) FD/SMI (n = 20) FD/NMI (n = 23) HC/SMI (n = 42) HC/NMI (n = 41)   
Measure M SD M SD M SD M SD M SD p η2 
DAS-SF I 27.67 3.87 26.85 4.02 25.70 3.75 28.00 3.50 28.79 3.85   
DAS-SF II 27.03 3.96 25.30 3.50 25.25 3.75 27.95 3.81 27.95 3.92   
DASDS -.64 2.87 -1.55 2.54 -.57 3.23 -.21 2.78 -.68 2.89 .18 .02 
ZRESDAS .00 1.00 -.41 .82 -.15 1.10 .20 .98 .08 1.00 .31 .008 
DASRM           .38 .007 
Note. The difference between pre- and post-mood induction measures may not precisely equal the difference score as outlier data was 
addressed differently depending on the type of analyses conducted; FD = formerly depressed; HC = healthy control; SMI = sad mood 
induction; NMI = neutral mood induction; DAS I = Dysfunctional Attitudes Scale – Short Form I; DAS II = Dysfunctional Attitudes 
Scale – Short Form II; DS = difference score; ZRES = residualized change scores; RM = repeated measures. 
 
 
Table 13. Means, Standard Deviations, and P Values for Session 2 Cognitive Measures for Planned Comparisons 
  Group and Condition    
 Total (N = 126) FD/SMI (n = 20) FD/NMI, HC/SMI, 
HC/NMI (n = 106) 
   
Measure M SD M SD M SD pL pQ pC 
DAS-SF I 27.67 3.87 26.85 4.02 27.83 3.84    
DAS-SF II 27.03 3.96 25.30 3.50 27.35 3.97    
DASDS -.64 2.87 -1.55 2.54 -.47 2.90 .23 .18 .94 
ZRESDAS .00 1.00 -.41 .82 .08 1.01 .03 .31 .49 
DASRM       .92   
Note. FD = formerly depressed; HC = healthy control; SMI = sad mood induction; NMI = neutral mood induction; L 
= linear; Q = quadratic; C = cubic; DAS I = Dysfunctional Attitudes Scale – Short Form I; DAS II = Dysfunctional 





During session 2, participants completed one self-report measure twice that was used to 
assess mood reactivity to the mood induction (i.e., Hypothesis 2) and served as a manipulation 
check for the mood induction procedures to assess if feelings of sadness were induced. The VAS 
(Appendix L) was used to evaluate subjective changes in mood before and after the mood 
induction. Respondents rated their current level of sadness on a scale of 0 to 100, with 0 
indicating lower levels of sadness and 100 indicating higher levels of sadness. Total scores 
ranged from 0 to 100, with higher scores indicating greater levels of sadness. Mood reactivity 
was operationalized as difference scores (i.e., VASDS) and residualized change scores (i.e., 
ZRESVAS) for the VAS administered pre- and post-mood induction as well as pre- and post-
mood induction measures (i.e., VASPRE and VASPOST).  
In addition, participants completed one self-report measure twice that was used as a 
manipulation check for the mood induction procedures to assess if emotions other than sadness 
were induced. The PANAS-X (Watson & Clark, 1994; Appendix L) was used to evaluate 
changes in mood before and after the mood induction. Respondents rated the extent to which 
they were experiencing 60 affective adjectives on a Likert scale from 1 to 5, with 1 indicating 
that were not or very slightly experiencing the affective state and 3 indicating that they were 
experiencing the affective state extremely. Total scores for the general dimension scale (i.e., 
negative and positive affect) were calculated by summing the 10 affective adjectives that 
comprise each scale and ranged from 0 to 10, with higher scores indicating greater levels of the 
respective affect. Total scores for specific affective state scales (i.e., fear, guilt, hostility, and 




scale and ranged from 0 to 4, 5, 6, or 8, with higher scores indicating greater levels of the 
respective affect.  
Outlier data for the VASDS (n = 7), PANAS-X NDS (n = 1), PANAS-X PDS (n = 4), 
PANAS-X FDS (n = 1), PANAS-X GDS (n = 24), PANAS-X HDS (n = 6), and PANAS-X SDS (n = 
3) were winsorized to address extreme values. Outlier data for the VASPRE (n = 3), PANAS-X 
NPRE (n = 4), PANAS-X NPOST (n = 2), PANAS-X FPRE (n = 4), PANAS-X FPOST (n = 2), 
PANAS-X GPRE (n = 6), PANAS-X GPOST (n = 2), PANAS-X HPRE (n = 2), PANAS-X HPOST (n 
= 2), PANAS-X SPRE (n = 1) were winsorized to address extreme values. In addition, outlier data 
for the ZRESVAS (n = 5), ZRESPANAS-X N (n = 2), ZRESPANAS-X P (n = 4), ZRESPANAS-X F 
(n = 1), ZRESPANAS-X G (n = 27), ZRESPANAS-X H (n = 1), and ZRESPANAS-X P (n = 4) were 
winsorized to address extreme values. No outlier data was present for the VASPOST, PANAS-X 
PPRE, PANAS-X PPOST, or PANAS-X SPOST.  
Descriptive statistics. Descriptive statistics for session 2 mood measures are presented in 
Table 14. The pre- (i.e., PRE) and post- (i.e., POST) mood induction scores are single item 
measures. Consequently, Cronbach’s alpha could not be calculated. The difference (i.e., DS) and 
residualized change (i.e., ZRES) scores are calculated measures. Consequently, Cronbach’s alpha 
could not be calculated. All of the general dimension and basic negative emotion scales of the 









Table 14. Descriptive Statistics for Session 2 Mood Measures  
Measure M SD Sample range Sample α 
VASPRE 8.67 13.29 0-63  
VASPOST 24.99 26.22 0-93  
VASDS 15.61 24.33 -17-93  
ZRESVAS -.14 .89 -1.30-3.05  
PANAS-X NPRE 14.80 5.62 10-41 .90 
PANAS-X NPOST 15.35 5.58 10-42 .89 
PANAS-X NDS .47 2.33 -6-9  
ZRESPANAS-X N -.05 .75 -1.95-4.33  
PANAS-X PPRE 29.82 6.42 12-43 .85 
PANAS-X PPOST 27.66 7.55 10-46 .90 
PANAS-X PDS -2.14 3.36 -14-7  
ZRESPANAS-X P .14 .91 -4.18-4.76  
PANAS-X FPRE 8.96 3.81 6-26 .89 
PANAS-X FPOST 8.94 3.79 6-22 .90 
PANAS-X FDS -.06 1.58 -5-6  
ZRESPANAS-X F .02 .85 -2.81-3.83  
PANAS-X GPRE 7.91 3.32 6-23 .91 
PANAS-X GPOST 8.27 3.62 6-25 .93 
PANAS-X GDS .24 1.36 -3-8  
ZRESPANAS-X G                     -.15 .36 -1.98-4.70  
PANAS-X HPRE 8.46 3.19 6-27 .86 
PANAS-X HPOST 8.66 3.27 6-30 .84 
PANAS-X HDS .14 1.79 -4-8  
ZRESPANAS-X H                     -.12 .73 -1.59-6.98  
PANAS-X SPRE 7.80 3.39 5-25 .89 
PANAS-X SPOST 8.06 3.51 5-25 .90 
PANAS-X SDS .20 1.83 -4-9  
ZRESPANAS-X S -10 .80 -1.76-4.87  
Note. The difference between pre- and post-mood induction measures may not precisely equal 
the difference score as outlier data was addressed differently depending on the type of analyses 
conducted; VAS = Visual Analogue Scale; PRE = pre-mood induction; POST = post-mood 
induction; DS = difference score; ZRES = residualized change scores; PANAS-X = Positive and 
Negative Affect Scale – Expanded Form; N = negative affect general dimension scale; P = 
positive affect general dimension scale; F = fear basic negative emotional scale; H = hostility 
basic negative emotional scale; G = guilt basic negative emotional scale; S = sadness basic 








A series of one-way (condition: sad, neutral) ANOVAs using difference scores and 
residualized change scores and a one-way (condition: sad, neutral) repeated measures ANOVA 
were used as a manipulation check for the mood induction procedures to ensure that a sad mood 
was induced. The manipulation was conducted using both the VAS and the PANAS-X negative 
and positive affect general dimension and fear, guilt, hostility, and sadness basic negative 
emotional scales.  
Descriptive statistics. Descriptive statistics for session 2 measures used for the 
manipulation check are included in Table 14. Means, standard deviations, p values, and effect 
sizes for the VAS and PANAS-X negative and positive affect general dimension and fear, guilt, 
hostility, and sadness basic negative emotional scales by condition are presented in Table 15. 
VAS. Analyses conducted using the VAS are reviewed below. 
One-way ANOVA – difference score. Sex (p = .02) was significantly associated with the 
VAS and was included in the final model. The remaining covariates that were under 
consideration were not significantly associated with the VAS (all p’s > .05) and were dropped 
from the final model. Levene’s test for homogeneity of variance was significant (F(1,120) = 
47.46, p < .001), indicating that this assumption underlying ANOVA was not met. Of note, this 
did not appear to be driven by the inclusion of the covariate. Without the covariate, Levene’s test 
for homogeneity of variance was significant (F(1,121) = 55.62, p < .001).  
In line with the planned analyses, multiple steps were explored in an attempt to remedy 
the violation of this assumption. First, residuals of differences scores were calculated and 
Kolmogorov-Smirnov’s and Shapiro-Wilk’s tests of normality were conducted. Residuals of 




the sad mood induction condition (Kolmogorov-Smirnov: D(17) = .15, p = .20; Shapiro-Wilk: 
D(17) = .95, p = .38). However, residuals of difference scores were not normally distributed for 
the remaining groups and conditions (all p’s < .05). Second, difference scores were transformed 
using the reciprocal transformation. Levene’s test for homogeneity of variance continued to be 
significant (F(1,121) = 23.84, p < .001), indicating that this assumption underlying ANOVA was 
still not met. Consequently, the one-way ANOVA was conducted with the α level decreased 
from .05 to .01. Participants exposed to the sad mood induction reported significantly higher 
levels of sadness on the VAS post-mood induction (F(1,119) = 44.68, p < .001, η2 = .27) than 
participants exposed to the neutral mood induction when using difference scores. 
One-way ANOVA – residualized change score. Sex (p = .02) was significantly 
associated with the VAS and was included in the final model. The remaining covariates that were 
under consideration were not significantly associated with the VAS (all p’s > .05) and were 
dropped from the final model. Levene’s test for homogeneity of variance was significant 
(F(1,120) = 50.61, p < .001), indicating that this assumption underlying ANOVA was not met. 
Of note, this did not appear to be driven by the inclusion of the covariate. Without the covariate, 
Levene’s test for homogeneity of variance was significant (F(1,121) = 49.74, p < .001).  
In line with the planned analyses, multiple steps were explored in an attempt to remedy 
the violation of this assumption. First, residuals of residualized change scores were calculated 
and Kolmogorov-Smirnov’s and Shapiro-Wilk’s tests of normality were conducted. Residuals of 
residualized change scores were normally distributed for the formerly depressed participants 
exposed to the sad mood induction (Kolmogorov-Smirnov: D(17) = .15, p = .20; Shapiro-Wilk: 
D(17) = .95, p = .38). However, residuals of residualized change scores were not normally 




scores were transformed using the reciprocal transformation. Levene’s test for homogeneity of 
variance continued to be significant (F(1,121) = 24.68, p < .001), indicating that this assumption 
underlying ANOVA was still not met. Consequently, the one-way ANOVA was conducted with 
the α level decreased from .05 to .01. Participants exposed to the sad mood induction reported 
significantly higher levels of sadness on the VAS post-mood induction (F(1,119) = 48.36, p < 
.001, η2 = .29) than participants exposed to the neutral mood induction when using residualized 
change scores. 
One-way repeated measures ANOVA. Sex (p = .04) and current depressive symptoms (p 
= .008) were significantly associated with the VAS and were included in the final model. The 
remaining covariates that were under consideration were not significantly associated with the 
VAS (all p’s > .05) and were dropped from the final model. Levene’s test for homogeneity of 
variance was not significant for the pre-mood induction measure (VASPRE: F(1,116) = 2.92, p = 
.09) but was significant for the post-mood induction measure (VASPOST: F(1,116) = 47.84, p < 
.001), indicating that this assumption underlying ANOVA was not met. Of note, this did not 
appear to be driven by the inclusion of the covariates. Without the covariates, Levene’s test for 
homogeneity of variance was not significant for the pre-mood induction measure (VASPRE: 
F(1,121) = 1.54, p = .22) but was significant for the post-mood induction measure (VASPOST: 
F(1,121) = 38.95, p < .001).  
In line with the planned analyses, multiple steps were explored in an attempt to remedy 
the violation of this assumption. Residuals could not be calculated as there was only one measure 
for each calculation. The pre- and post-mood induction measures were transformed using the 
reciprocal transformation. Levene’s test for homogeneity of variance was not significant for the 




for the post-mood induction measure (VASPOST: F(1,121) = 4.34, p = .04), indicating that this 
assumption underlying ANOVA was still not met. Consequently, the one-way ANOVA was 
conducted with the α level decreased from .05 to .01. Participants exposed to the sad mood 
induction reported significantly higher levels of sadness on the VAS post-mood induction 
(F(1,114) = 25.80, p < .001, η2 = .19) than participants exposed to the neutral mood induction 
when using repeated measures. 
PANAS-X N. Analyses conducted using the PANAS-X negative affect general 
dimension scale are reviewed below. 
One-way ANOVA – difference score. None of the covariates that were under 
consideration were significantly associated with negative affect on the PANAS-X (all p’s > .05) 
and were dropped from the final model. Levene’s test for homogeneity of variance was not 
significant (F(1,118) = 3.07, p = .08), indicating that this assumption underlying ANOVA was 
met. The main effect of condition (F(1,118) = 2.37, p = .13, η2 = .02) was not significant, 
indicating that there was no significant difference in reporting of negative affect on the PANAS-
X between mood induction conditions when using difference scores. 
One-way ANOVA – residualized change score. Current depressive symptoms (p = .002) 
were significantly associated with negative affect on the PANAS-X and were included in the 
final model. The remaining covariates that were under consideration were not significantly 
associated with negative affect on the PANAS-X (all p’s > .05) and were dropped from the final 
model. Levene’s test for homogeneity of variance was significant (F(1,113) = 8.04, p = .005), 
indicating that this assumption underlying ANOVA was not met. Of note, this did not appear to 
be driven by the inclusion of the covariate. Without the covariate, Levene’s test for homogeneity 




In line with the planned analyses, multiple steps were explored in an attempt to remedy 
the violation of this assumption. First, residuals of differences scores were calculated and 
Kolmogorov-Smirnov’s and Shapiro-Wilk’s tests of normality were conducted. Residuals of 
difference scores were normally distributed for the formerly depressed participants exposed to 
the sad (Kolmogorov-Smirnov: D(23) = .15, p = .20; Shapiro-Wilk: D(23) = .93, p = .11) and 
neutral (Kolmogorov-Smirnov: D(17) = .20, p = .07; Shapiro-Wilk: D(17) = .91, p = .09) mood 
inductions. However, residuals of difference scores were not normally distributed for the 
remaining groups and conditions (p’s < .05). Second, difference scores were transformed using 
the reciprocal transformation. Levene’s test for homogeneity of variance continued to be 
significant (F(1,118) = 10.35, p = .002), indicating that this assumption underlying ANOVA was 
still not met. Consequently, the one-way ANOVA was conducted with the α level decreased 
from .05 to .01. With the adjusted p value, the main effect of condition (F(1,112) = 5.35, p = .02, 
η2 = .05) was not significant, indicating that there was no significant difference in reporting of 
negative affect on the PANAS-X between mood induction conditions when using residualized 
change scores.  
One-way repeated measures ANOVA. Current depressive symptoms (p < .001) were 
significantly associated with negative affect on the PANAS-X and were included in the final 
model. The remaining covariates that were under consideration were not significantly associated 
with negative affect on the PANAS-X (all p’s > .05) and were dropped from the final model. 
Levene’s test for homogeneity of variance was not significant (PANAS-X NPRE: F(1,113) = .52, 
p = .47; PANAS-X NPOST: F(1,113) = .06, p = .80), indicating that this assumption underlying 




significant, indicating that there was no significant difference in reporting of negative affect on 
the PANAS-X between mood induction conditions when using repeated measures. 
PANAS-X P. Analyses conducted using the PANAS-X positive affect general dimension 
scale are reviewed below. 
One-way ANOVA – difference score. BMI (p = .04) and current depressive symptoms (p 
= .004) were significantly associated with positive affect on the PANAS-X and were included in 
the final model. The remaining covariates that were under consideration were not significantly 
associated with positive affect on the PANAS-X (all p’s > .05) and were dropped from the final 
model. Levene’s test for homogeneity of variance was not significant (F(1,116) = 3.26, p = .07), 
indicating that this assumption underlying ANOVA was met. The main effect of condition 
(F(1,114) = 3.59, p = .06, η2 = .03) was not significant, indicating that there was no significant 
difference in reporting of positive affect on the PANAS-X between mood induction conditions 
when using difference scores. 
One-way ANOVA – residualized change score. BMI (p = .04) and current depressive 
symptoms (p = .0014) were significantly associated with positive affect on the PANAS-X and 
were included in the final model. The remaining covariates that were under consideration were 
not significantly associated with positive affect on the PANAS-X (all p’s > .05) and were 
dropped from the final model. Levene’s test for homogeneity of variance was significant 
(F(1,116) = 3.89, p = .05), indicating that this assumption underlying ANOVA was not met. Of 
note, this appeared to be driven by the inclusion of the covariates. Without the covariates, 
Levene’s test for homogeneity of variance was not significant (F(1,121) = 2.65, p = .11). 
Consequently, calculating the residual of the residualized change scores to assess normality and 




the intended effect. Instead, the one-way ANOVA was conducted with the α level decreased 
from .05 to .01. The main effect of condition (F(1,114) = 3.77, p = .06, η2 = .03) was not 
significant, indicating that there was no significant difference in reporting of positive affect on 
the PANAS-X between mood induction conditions when using residualized change scores. 
One-way repeated measures ANOVA. Current state anxiety symptoms (p < .001) were 
significantly associated with positive affect on the PANAS-X and were included in the final 
model. The remaining covariates that were under consideration were not significantly associated 
with positive affect on the PANAS-X (all p’s > .05) and were dropped from the final model. 
Levene’s test for homogeneity of variance was not significant (PANAS-X PPRE: F(1,113) = .44, 
p = .51; PANAS-X PPOST: F(1,113) = 1.85, p = .18), indicating that this assumption underlying 
ANOVA was met. The main effect of condition (F(1,112) = .78, p = .38, η2 = .007) was not 
significant, indicating that there was no significant difference in reporting of positive affect on 
the PANAS-X between mood induction conditions when using repeated measures. 
PANAS-X F. Analyses conducted using the PANAS-X fear negative basic emotional 
scale are reviewed below. 
One-way ANOVA – difference score. None of the covariates that were under 
consideration were significantly associated with fear on the PANAS-X (all p’s > .05) and were 
dropped from the final model. Levene’s test for homogeneity of variance was not significant 
(F(1,121) = .10, p = .76), indicating that this assumption underlying ANOVA was met. The main 
effect of condition (F(1,121) = .003, p = .96, η2 < .001) was not significant, indicating that there 
was no significant difference in reporting of fear on the PANAS-X between mood induction 




One-way ANOVA – residualized change score. None of the covariates that were under 
consideration were significantly associated with fear on the PANAS-X (all p’s > .05) and were 
dropped from the final model. Levene’s test for homogeneity of variance was not significant 
(F(1,121) = 1.08, p = .30), indicating that this assumption underlying ANOVA was met. The 
main effect of condition (F(1,121) = .02, p = .89, η2 < .001) was not significant, indicating that 
there was no significant difference in reporting of fear on the PANAS-X between mood 
induction conditions when using residualized change scores. 
One-way repeated measures ANOVA. Current depressive symptoms (p < .001) were 
significantly associated with fear on the PANAS-X and were included in the final model. The 
remaining covariates that were under consideration were not significantly associated with fear on 
the PANAS-X (all p’s > .05) and were dropped from the final model. Levene’s test for 
homogeneity of variance was not significant (PANAS-X FPRE: F(1,116) = 1.70, p = .20; 
PANAS-X FPOST: F(1,116) = .12, p = .73), indicating that this assumption underlying ANOVA 
was met. The main effect of condition (F(1,115) = .08, p = .78, η2 = .001) was not significant, 
indicating that there was no significant difference in reporting of fear on the PANAS-X between 
mood induction conditions when using repeated measures. 
PANAS-X G. Analyses conducted using the PANAS-X guilt negative basic emotional 
scale are reviewed below. 
One-way ANOVA – difference score. Current depressive symptoms (p < .001) were 
significantly associated with guilt on the PANAS-X and were included in the final model. The 
remaining covariates that were under consideration were not significantly associated with guilt 
on the PANAS-X (all p’s > .05) and were dropped from the final model. Levene’s test for 




assumption underlying ANOVA was met. Participants exposed to the sad mood induction 
reported significantly higher levels of guilt on the PANAS-X post-mood induction (F(1,115) = 
9.72, p = .002, η2 = .08) than participants exposed to the neutral mood induction when using 
difference scores. 
One-way ANOVA – residualized change score. Current depressive symptoms (p < .001) 
were significantly associated with guilt on the PANAS-X and were included in the final model. 
The remaining covariates that were under consideration were not significantly associated with 
guilt on the PANAS-X (all p’s > .05) and were dropped from the final model. Levene’s test for 
homogeneity of variance was not significant (F(1,116) = 1.23, p = .27), indicating that this 
assumption underlying ANOVA was met. Participants exposed to the sad mood induction 
reported significantly higher levels of guilt on the PANAS-X post-mood induction (F(1,115) = 
8.69, p = .004, η2 = .07) than participants exposed to the neutral mood induction when using 
residualized change scores. 
One-way repeated measures ANOVA. Current depressive symptoms (p < .001) were 
significantly associated with guilt on the PANAS-X and were included in the final model. The 
remaining covariates that were under consideration were not significantly associated with guilt 
on the PANAS-X (all p’s > .05) and were dropped from the final model. Levene’s test for 
homogeneity of variance was not significant (PANAS-X GPRE: F(1,116) = 1.32, p = .25; 
PANAS-X GPOST: F(1,116) = .02, p = .88), indicating that this assumption underlying ANOVA 
was met. The main effect of condition (F(1,115) = .02, p = .90, η2 < .001) was not significant, 
indicating that there was no significant difference in reporting of guilt on the PANAS-X between 




PANAS-X H. Analyses conducted using the PANAS-X hostility negative basic 
emotional scale are reviewed below. 
One-way ANOVA – difference score. Current state anxiety symptoms (p = .01) were 
significantly associated with hostility on the PANAS-X and were included in the final model. 
The remaining covariates that were under consideration were not significantly associated with 
hostility on the PANAS-X (all p’s > .05) and were dropped from the final model. Levene’s test 
for homogeneity of variance was significant (F(1,114) = 5.92, p = .02), indicating that this 
assumption underlying ANOVA was not met. Of note, this did not appear to be driven by the 
inclusion of the covariate. Without the covariate, Levene’s test for homogeneity of variance was 
significant (F(1,123) = 5.48, p = .02).  
In line with the planned analyses, multiple steps were explored in an attempt to remedy 
the violation of this assumption. First, residuals of differences scores were calculated and 
Kolmogorov-Smirnov’s and Shapiro-Wilk’s tests of normality were conducted. Residuals of 
difference scores were normally distributed for one measure of normality for the formerly 
depressed participants exposed to the neutral mood induction (Shapiro-Wilk: D(23) = .93, p = 
.12). However, residuals of difference scores were not normally distributed for the remaining 
groups and conditions (p’s < .05). Second, difference scores were transformed using the 
reciprocal transformation. Levene’s test for homogeneity of variance continued to be significant 
(F(1,122) = 5.31, p = .02), indicating that this assumption underlying ANOVA was still not met. 
Consequently, the one-way ANOVA was conducted with the α level decreased from .05 to .01. 
The main effect of condition (F(1,113) = 2.99, p = .09, η2 = .03) was not significant, indicating 
that there was no significant difference in reporting of hostility on the PANAS-X between mood 




One-way ANOVA – residualized change score. Current depression (p = .004) and state 
anxiety (p = .003) symptoms were significantly associated with hostility on the PANAS-X and 
were included in the final model. The remaining covariates that were under consideration were 
not significantly associated with hostility on the PANAS-X (all p’s > .05) and were dropped 
from the final model. Levene’s test for homogeneity of variance was significant (F(1,111) = 
3.85, p = .05), indicating that this assumption underlying ANOVA was not met. Of note, this did 
not appear to be driven by the inclusion of the covariates. Without the covariates, Levene’s test 
for homogeneity of variance was significant (F(1,123) = 3.80, p = .05).  
In line with the planned analyses, multiple steps were explored in an attempt to remedy 
the violation of this assumption. First, residuals of differences scores were calculated and 
Kolmogorov-Smirnov’s and Shapiro-Wilk’s tests of normality were conducted. Residuals of 
residualized change scores were normally distributed for one measure of normality for the 
formerly depressed participants exposed to the neutral mood induction (Shapiro-Wilk: D(23) = 
.93, p = .12). However, residuals of residualized change scores were not normally distributed for 
the remaining groups and conditions (p’s < .05). Second, residualized change scores were 
transformed using the reciprocal transformation. Levene’s test for homogeneity of variance 
continued to be significant (F(1,123) = 4.07, p = .05), indicating that this assumption underlying 
ANOVA was still not met. Consequently, the one-way ANOVA was conducted with the α level 
decreased from .05 to .01. The main effect of condition (F(1,109) = 2.32, p = .13, η2 = .02) was 
not significant, indicating that there was no significant difference in reporting of hostility on the 
PANAS-X between mood induction conditions when using residualized change scores. 
One-way repeated measures ANOVA. BMI (p =.05) and current depression symptoms (p 




final model. The remaining covariates that were under consideration were not significantly 
associated with hostility on the PANAS-X (all p’s > .05) and were dropped from the final model. 
Levene’s test for homogeneity of variance was not significant (PANAS-X HPRE: F(1,118) = 3.14, 
p = .08; PANAS-X HPOST: F(1,118) = 3.38, p = .07), indicating that this assumption underlying 
ANOVA was met. The main effect of condition (F(1,116) = 1.22, p = .27, η2 = .01) was not 
significant, indicating that there was no significant difference in reporting of hostility on the 
PANAS-X between mood induction conditions when using repeated measures. 
PANAS-X S. Analyses conducted using the PANAS-X sadness negative basic emotional 
scale are reviewed below. 
One-way ANOVA – difference score. Current depressive symptoms (p = .03) were 
significantly associated with sadness on the PANAS-X and were included in the final model. The 
remaining covariates that were under consideration were not significantly associated with 
sadness on the PANAS-X (all p’s > .05) and were dropped from the final model. Levene’s test 
for homogeneity of variance was significant (F(1,118) = 16.56, p < .001), indicating that this 
assumption underlying ANOVA was not met. Of note, this did not appear to be driven by the 
inclusion of the covariate. Without the covariate, Levene’s test for homogeneity of variance was 
significant (F(1,123) = 11.42, p = .001).  
In line with the planned analyses, multiple steps were explored in an attempt to remedy 
the violation of this assumption. First, residuals of differences scores were calculated and 
Kolmogorov-Smirnov’s and Shapiro-Wilk’s tests of normality were conducted. Residuals of 
difference scores were normally distributed for the formerly depressed participants exposed to 
the neutral mood induction (Kolmogorov-Smirnov: D(23) = .14, p = .20; Shapiro-Wilk: D(23) = 




the sad mood induction (Kolmogorov-Smirnov: D(19) = .20, p = .06). However, residuals of 
difference scores were not normally distributed for the remaining groups and conditions (all p’s 
< .05). Second, difference scores were transformed using the reciprocal transformation. Levene’s 
test for homogeneity of variance continued to be significant (F(1,123) = 14.33, p < .001), 
indicating that this assumption underlying ANOVA was still not met. Consequently, the one-way 
ANOVA was conducted with the α level decreased from .05 to .01. Participants exposed to the 
sad mood induction reported significantly higher levels of sadness on the PANAS-X post-mood 
induction (F(1,117) = 11.67, p = .001, η2 = .09) than participants exposed to the neutral mood 
induction when using difference scores.  
One-way ANOVA – residualized change score. Current depressive symptoms (p < .001) 
were significantly associated with sadness on the PANAS-X and were included in the final 
model. The remaining covariates that were under consideration were not significantly associated 
with sadness on the PANAS-X (all p’s > .05) and were dropped from the final model. Levene’s 
test for homogeneity of variance was significant (F(1,118) = 20.67, p < .001), indicating that this 
assumption underlying ANOVA was not met. Of note, this did not appear to be driven by the 
inclusion of the covariate. Without the covariate, Levene’s test for homogeneity of variance was 
significant (F(1,123) = 17.35, p < .001).  
In line with the planned analyses, multiple steps were explored in an attempt to remedy 
the violation of this assumption. First, residuals of differences scores were calculated and 
Kolmogorov-Smirnov’s and Shapiro-Wilk’s tests of normality were conducted. Residuals of 
difference scores were normally distributed for the formerly depressed participants exposed to 
the neutral mood induction (Kolmogorov-Smirnov: D(23) = .14, p = .20; Shapiro-Wilk: D(23) = 




the sad mood induction (Kolmogorov-Smirnov: D(19) = .20, p = .06). However, residuals of 
difference scores were not normally distributed for the remaining groups and conditions (all p’s 
< .05). Second, residualized change scores were transformed using the reciprocal transformation. 
Levene’s test for homogeneity of variance continued to be significant (F(1,123) = 11.89, p = 
.001), indicating that this assumption underlying ANOVA was still not met. Consequently, the 
one-way ANOVA was conducted with the α level decreased from .05 to .01. Participants 
exposed to the sad mood induction reported significantly higher levels of sadness on the 
PANAS-X post-mood induction (F(1,117) = 12.76,  p = .001, η2 = .10) than participants exposed 
to the neutral mood induction when using residualized change scores. 
One-way repeated measures ANOVA. Current depressive symptoms (p < .001) were 
significantly associated with sadness on the PANAS-X and were included in the final model. The 
remaining covariates that were under consideration were not significantly associated with 
sadness on the PANAS-X (all p’s > .05) and were dropped from the final model. Levene’s test 
for homogeneity of variance was not significant (PANAS-X SPRE: F(1,118) = .12, p = .74; 
PANAS-X SPOST: F(1,118) = .82, p = .37), indicating that this assumption underlying ANOVA 
was met. The main effect of condition (F(1,117) = .13, p = .72, η2 = .001) was not significant, 
indicating that there was no significant difference in reporting of sadness on the PANAS-X 









Table 15. Means, Standard Deviations, P Values, and Effect Sizes for Measures Used for the 
Manipulation Check by Condition 
  Condition   
 Total (N = 123) SMI (n = 60) NMI (n = 63)   
Measure M SD M SD M SD p η2 
VASPRE 8.67 13.29 9.05 14.90 8.30 11.64   
VASPOST 24.99 26.22 38.18 28.23 12.22 16.00   
VASDS 15.61 24.33 28.33 27.25 3.49 12.32 < .001 .27 
ZRESVAS -.14 .89 .52 1.09 -.52 .52 < .001 .29 
VASRM       < .001 .19 
 Total (N = 120) SMI (n = 61) NMI (n = 59)   
Measure M SD M SD M SD p η2 
PANAS-X NPRE 14.80 5.62 14.73 6.18 14.87 5.03   
PANAS-X NPOST 15.35 5.58 15.65 6.00 15.05 5.16   
PANAS-X NDS .47 2.33 .79 2.63 .14 1.93 .13 .02 
ZRESPANAS-X N -.05 .75 .14 1.13 -.19 .71 .02a .05 
PANAS-X NRM       .46 .005 
 Total (N = 123) SMI (n = 62) NMI (n = 61)   
Measure M SD M SD M SD p η2 
PANAS-X PPRE 29.82 6.42 29.52 6.46 30.11 6.42   
PANAS-X PPOST 27.66 7.55 26.84 7.93 28.48 7.12   
PANAS-X PDS -2.14 3.36 -2.71 3.76 -1.56 2.81 .06 .03 
ZRESPANAS-X P .14 .91 -.13 .95 .16 .68 .12 .02 
PANAS-X PRM       .38 .007 
 Total (N = 123) SMI (n = 61) NMI (n = 62)   
Measure M SD M SD M SD p η2 
PANAS-X FPRE 8.96 3.81 8.94 4.30 8.98 3.30   
PANAS-X FPOST 8.94 3.79 8.89 3.92 9.00 3.68   
PANAS-X FDS -.06 1.58 -.05 1.61 -.07 1.56 .96 < .001 
ZRESPANAS-X F .02 .85 -.02 .91 .003 1.02 .89 < .001 
PANAS-X FRM       .78 .001 
 Total (N = 123) SMI (n = 63) NMI (n = 60)   
Measure M SD M SD M SD p η2 
PANAS-X GPRE 7.91 3.32 7.73 3.25 8.08 3.40   
PANAS-X GPOST 8.27 3.62 8.37 3.97 8.18 3.24   
PANAS-X GDS .24 1.36 .55 1.65 -.09 .87 .002 .08 
ZRESPANAS-X G -.15 .36 .14 1.05 -.24 .51 .004 .07 
PANAS-X GRM       .90 < .001 
      
      
      
      
      




Table 15 Continued     
 Total (N = 125) SMI (n = 63) NMI (n = 62)   
Measure M SD M SD M SD p η2 
PANAS-X HPRE 8.46 3.19 8.49 3.59 8.42 2.77   
PANAS-X HPOST 8.66 3.27 8.97 3.82 8.34 2.57   
PANAS-X HDS .14 1.79 .43 2.15 -.15 1.29 .09 .03 
ZRESPANAS-X H             -.12 .73 .14 1.18 -.15 .73 .13 .02 
PANAS-X HRM       .27 .01 
 Total (N = 125) SMI (n = 63) NMI (n = 62)   
Measure M SD M SD M SD p η2 
PANAS-X SPRE 7.80 3.39 7.52 3.65 8.08 3.12   
PANAS-X SPOST 8.06 3.51 8.32 3.96 7.79 3.00   
PANAS-X SDS .20 1.83 .71 2.18 -.32 1.18 .001 .09 
ZRESPANAS-X S -10 .80 .24 1.16 -.28 .56 .001 .10 
PANAS-X SRM       .72 .001 
Note. SMI = sad mood induction; NMI = neutral mood induction; VAS = Visual Analogue 
Scale; DS = difference score; ZRES = residualized change scores; PANAS-X = Positive and 
Negative Affect Scale – Expanded Form; N = negative affect general dimension scale; a = not 
significant due to adjusted p value; P = positive affect general dimension scale; F = fear basic 
negative emotional scale; H = hostility basic negative emotional scale; G = guilt basic negative 
emotional scale; S = sadness basic negative emotional scale; RM = repeated measures. 
Hypothesis 2 
A series of 2 (group: formerly depressed, healthy control) X 2 (condition: sad, neutral) 
factorial ANOVAs using difference scores and residualized change scores and a 2 (group: 
formerly depressed, healthy control) X 2 (condition: sad, neutral) repeated measures ANOVA 
were used to test the hypothesis that formerly depressed and healthy control participants exposed 
to the sad mood induction would report significantly more dysphoric mood on the VAS post-
mood induction than formerly depressed and healthy control participants exposed to the neutral 
mood inductions. Means, standard deviations, p values, and effect sizes for session 2 mood 
measures by group are presented in Table 16 while means, standard deviations, p values, and 
effect sizes for session 2 mood measures by group and condition are presented in Table 17. 
Planned comparisons were conducted using contrast analyses. Means, standard deviations, and p 




VAS. Analyses conducted using the VAS are reviewed below. 
2 X 2 factorial ANOVA – difference score. None of the covariates that were under 
consideration were significantly associated with mood reactivity (all p’s > .05) and were dropped 
from the final model. Levene’s test for homogeneity of variance was significant (F(3,119) = 
17.15, p < .001), indicating that this assumption underlying ANOVA was not met.  
In line with the planned analyses, multiple steps were explored in an attempt to remedy 
the violation of this assumption. First, residuals of differences scores were calculated and 
Kolmogorov-Smirnov’s and Shapiro-Wilk’s tests of normality were conducted. Residuals of 
difference scores were normally distributed for the formerly depressed participants exposed to 
the sad mood induction (Kolmogorov-Smirnov: D(17) = .15, p = .20; Shapiro-Wilk: D(17) = .95, 
p = .38). However, residuals of difference scores were not normally distributed for the remaining 
groups and conditions (all p’s < .05). Second, difference scores were transformed using the 
reciprocal transformation. Levene’s test for homogeneity of variance continued to be significant 
(F(3,119) = 14.60, p < .001), indicating that this assumption was still not met. Consequently, the 
one-way ANOVA was conducted with the α level decreased from .05 to .01. 
Formerly depressed participants reported significantly higher levels of sadness on the 
VAS post-mood induction (F(1,119) = 7.49, p = .007, η2 = .06) than healthy control participants. 
In addition, participants exposed to the sad mood induction reported significantly higher levels of 
sadness on the VAS post-mood induction (F(1,119) = 51.17, p < .001, η2 = .30) than participants 
exposed to the neutral mood induction. The group by condition interaction was not significant 
(F(1,119) = 3.20, p = .08, η2 = .03) when using difference scores. It is possible that this is due to 
lack of power rather than lack of effect. Using contrast analyses that did not assume equal 




induction reported significantly higher levels of sadness on the VAS post-mood induction 
(t(37.12) = 6.23, pL < .001, pQ = .08, pC < .001) compared to formerly depressed and healthy 
control participants exposed to the neutral mood induction. In addition, formerly depressed 
participants exposed to the sad mood induction reported significantly higher levels of sadness on 
the VAS post-mood induction (t(18.16) = 4.14, pL < .001, pQ = .08, pC < .001) compared to 
healthy control participants exposed to the sad mood induction and formerly depressed and 
healthy control participants exposed to the neutral mood induction. 
2 X 2 factorial ANOVA – residualized change score. None of the covariates that were 
under consideration were significantly associated with mood reactivity (all p’s > .05) and were 
dropped from the final model. Levene’s test for homogeneity of variance was significant 
(F(3,119) = 15.94, p < .001), indicating that this assumption underlying ANOVA was not met.  
In line with the planned analyses, multiple steps were explored in an attempt to remedy 
the violation of this assumption. First, residuals of residualized change scores were calculated 
and Kolmogorov-Smirnov’s and Shapiro-Wilk’s tests of normality were conducted. Residuals of 
residualized change scores were normally distributed for the formerly depressed participants 
exposed to the sad mood induction (Kolmogorov-Smirnov: D(17) = .15, p = .20; Shapiro-Wilk: 
D(17) = .95, p = .38). However, residuals of residualized change scores were not normally 
distributed for the remaining groups and conditions (all p’s < .05). Second, residualized change 
scores were transformed using the reciprocal transformation. Levene’s test for homogeneity of 
variance continued to be significant (F(3,119) = 14.98, p < .001), indicating that this assumption 
was still not met. Consequently, the factorial ANOVA was conducted with the α level decreased 




Formerly depressed participants reported significantly higher levels of sadness on the 
VAS post-mood induction (F(1,119) = 10.16, p = .002, η2 = .08) than healthy control 
participants. In addition, participants exposed to the sad mood induction reported significantly 
higher levels of sadness on the VAS post-mood induction (F(1,119) = 53.94, p < .001, η2 = .31) 
than participants exposed to the neutral mood induction. The group by condition interaction was 
not significant (F(1,119) = 2.18, p = .14, η2 = .02) when using residualized change scores. It is 
possible that this is due to lack of power rather than lack of effect. Using contrast analyses that 
did not assume equal variances, formerly depressed and healthy control participants exposed to 
the sad mood induction reported significantly higher levels of sadness on the VAS post-mood 
induction (t(38.07) = 6.54, pL < .001, pQ = .14, pC < .001) compared to formerly depressed and 
healthy control participants exposed to the neutral mood induction. In addition, formerly 
depressed participants exposed to the sad mood induction reported significantly higher levels of 
sadness on the VAS post-mood induction (t(18.22) = 4.37, pL < .001, pQ = .14, pC < .001) 
compared to healthy control participants exposed to the sad mood induction and formerly 
depressed and healthy control participants exposed to the neutral mood induction. 
2 X 2 repeated measures ANOVA. None of the covariates that were under consideration 
were significantly associated with mood reactivity (all p’s > .05) and were dropped from the final 
model. Levene’s test for homogeneity of variance was not significant for the pre-mood induction 
measure (VASPRE: F(3,119) = 2.48, p = .06) but was significant for the post-mood induction 
measure (VASPOST: F(3,119) = 12.07, p < .001), indicating that this assumption underlying 
ANOVA was not met.  
In line with the planned analyses, multiple steps were explored in an attempt to remedy 




for each calculation. The pre- and post-mood induction measures were transformed using the 
reciprocal transformation. Levene’s test for homogeneity of variance continued to be significant 
(VASPRE: F(3,119) = 2.97, p = .04; VASPOST: F(3,119) = 9.71, p < .001), indicating that this 
assumption underlying ANOVA was still not met. Consequently, the factorial ANOVA was 
conducted with the α level decreased from .05 to .01.  
Formerly depressed participants reported significantly higher levels of sadness on the 
VAS post-mood induction (F(1,119) = 11.95, p = .001, η2 = .09) than healthy control 
participants. In addition, participants exposed to the sad mood induction reported significantly 
higher levels of sadness on the VAS post-mood induction (F(1,119) = 23.60, p < .001, η2 = .17) 
than participants exposed to the neutral mood induction. The group by condition interaction was 
not significant (F(1,119) = .02, p = .90, η2 < .001) when using repeated measures. Using contrast 
analyses that did not assume equal variances, formerly depressed and healthy control participants 
exposed to the sad mood induction reported significantly higher levels of sadness on the VAS 
post-mood induction (F(1,121) = 22.79, p < .001) compared to formerly depressed and healthy 
control participants exposed to the neutral mood induction. In addition, formerly depressed 
participants exposed to the sad mood induction reported significantly higher levels of sadness on 
the VAS post-mood induction (F(1,121) = 14.58, p < .001) compared to healthy control 
participants exposed to the sad mood induction and formerly depressed and healthy control 
participants exposed to the neutral mood induction. 
Post-hoc power analyses. Post-hoc power analyses were conducted using G*Power 
3.1.9.2 (Faul et al., 2007) to determine the power achieved by the VAS analyses. Results 
indicated that the current model had a power of .26 for the difference score, .16 for the 




current study’s sample size, α level, and observed effect size, there was a 1 to 26% chance of 
detecting an effect depending on which analytic technique was used. 
Sensitivity analyses. Sensitivity analyses were conducted using G*Power 3.1.9.2 (Faul et 
al., 2007) to determine the minimum effect size needed to obtain significant results for the VAS 
analyses. Results indicated that the required effect size was f = .31 for the factorial ANOVAs and 
f = .30 for the repeated measures ANOVA. Results suggested that given the current study’s 
sample size and α level, at least a medium effect size was required to obtain significant results if 
a power of .80 was achieved. 
Table 16. Means, Standard Deviations, P Values, and Effect Sizes for Session 2 Mood Measures 
by Group 
  Group   
 Total (N = 123) FD (n = 40) HC (n = 83)   
Measure M SD M SD M SD p η2 
VASPRE 8.67 13.29 11.78 15.02 7.17 12.19   
VASPOST 24.99 26.22 33.90 27.81 20.59 24.39   
VASDS 15.61 24.33 20.85 29.47 13.08 21.15 .007 .06 
ZRESVAS -.14 .89 .25 1.15 -.14 .89 .002 .08 
VASRM       .001 .09 
Note. The difference between pre- and post-mood induction measures may not precisely equal 
the difference score as outlier data was addressed differently depending on the type of analyses 
conducted; FD = formerly depressed; HC = healthy control; VAS = Visual Analogue Scale; PRE = 
pre-mood induction; POST = post-mood induction; DS = difference score; ZRES = residualized 




Table 17. Means, Standard Deviations, P Values, and Effect Sizes for Session 2 Mood Measures by Group and Condition 
  Group and Condition   
 Total (N = 123) FD/SMI (n = 17) FD/NMI (n = 23) HC/SMI (n = 43) HC/NMI (n = 40)   
Measure M SD M SD M SD M SD M SD p η2 
VASPRE 8.67 13.29 9.22 15.11 13.78 14.97 8.98 14.99 5.22 7.94   
VASPOST 24.99 26.22 51.83 27.38 19.87 18.93 32.47 26.87 7.83 12.28   
VASDS 15.61 24.33 41.12 29.60 5.87 18.71 23.28 24.85 2.13 6.19 .08 .03 
ZRESVAS -.14 .89 1.05 1.16 -.35 .71 .31 1.00 -.62 .34 .14 .02 
VASRM           .90 < .001 
Note. The difference between pre- and post-mood induction measures may not precisely equal the difference score as outlier data was 
addressed differently depending on the type of analyses conducted; FD = formerly depressed; HC = healthy control; SMI = sad mood 
induction; NMI = neutral mood induction; VAS = Visual Analogue Scale; PRE = pre-mood induction; POST = post-mood induction; DS = 














Table 18. Means, Standard Deviations, and P Values for Session 2 Mood Measures for Planned Comparisons 
  Group and Condition    
 Total (N = 123) FD+HC/SMI                      
(n = 60) 
FD+HC/NMI         
(n = 63) 
   
Measure M SD M SD M SD pL pQ pC 
VASPRE 8.67 13.29 9.05 14.90 8.30 11.64    
VASPOST 24.99 26.22 38.18 28.23 12.22 16.00    
VASDS 15.61 24.33 28.33 27.25 3.49 12.32 < .001 .08 < .001 
ZRESVAS -.14 .89 .52 1.09 -.52 .52 < .001 .14 < .001 
VASRM       < .001   
 Total (N = 123) FD/SMI (n = 17) FD/NMI, HC/SMI, 
HC/NMI (n = 106) 
   
Measure M SD M SD M SD pL pQ pC 
VASPRE 8.67 13.29 9.22 15.11 8.57 13.04    
VASPOST 24.99 26.22 51.83 27.38 20.43 23.23    
VASDS 15.61 24.33 41.12 29.60 11.52 20.78 < .001 .08 < .001 
ZRESVAS -.14 .89 1.05 1.16 -.18 .85 < .001 .14 < .001 
VASRM       < .001   
Note. The difference between pre- and post-mood induction measures may not precisely equal the difference score 
as outlier data was addressed differently depending on the type of analyses conducted; FD = formerly depressed; HC 
= healthy control; SMI = sad mood induction; NMI = neutral mood induction; L = linear; Q = quadratic; C = cubic; 
VAS = Visual Analogue Scale; PRE = pre-mood induction; POST = post-mood induction; DS = difference score; ZRES = 





During session 2, participants’ physiological responding was recorded to assess 
cardiovascular reactivity to the mood induction (i.e., Hypothesis 3) and recovery from the mood 
induction (i.e., Hypothesis 3). The physiological recordings of interest are cardiovascular 
measures derived from ECG and ICG. ECG was used to collect data that was used to calculate 
HP and RSA. MindWare Technologies Ltd. (2009) hardware and Biolab 3.1 analysis software 
set to collect ECG data falling within -5 and 5 volts with a sampling rate of 1,000 hertz were 
utilized in conjunction with the five GSC electrode sensors located on the participants’ right 
collarbone, bottom left rib, bottom right rib, jugular notch, and sternum. ICG was used to collect 
data that was used to calculate RSA, CO, and PEP. Of note, CO was dropped from analyses. 
Typical values for resting CO range from 4 to 12 liters per minute (J. Schmidt, personal 
communication, April 16, 209). Average CO values ranged from 1.62 to 365.73 during baseline, 
1.49 to 390.58 during the mood induction, and 1.69 to 175.80 during recovery, indicating that 
this cardiovascular measure was not accurate. It was determined that this issue was due to 
inaccurate SV values. SV is not used to calculate HP, RSA, or PEP and therefore, these 
cardiovascular measures were not affected. MindWare Technologies Ltd. (2009) hardware and 
Biolab 3.1 analysis software set to collect ICG data falling at a sampling rate of 1,000 Hertz and 
calibrated at .10 volts per one-ohm change for Z0 and 1.00 volts per ohms per second for dZ/dt 
were utilized in conjunction with the two GSC electrode sensors located on the participants’ mid-
back and upper-back parallel within 1.50 inches of the jugular notch and sternum sensors. 
Cardiovascular functioning at baseline was calculated for each cardiovascular measure 




RSABL2/BL5, COBL2/BL5, and PEPBL2/BL5). No outlier data was present for HPBL2, HPBL5, RSABL2, 
RSABL5, PEPBL2, and PEPBL5.  
Cardiovascular functioning for the mood induction was calculated for each 
cardiovascular measure using the average obtained during the first two and five minutes of the 
mood induction (i.e., HPMI2/5, RSAMI2/5, COMI2/5, and PEPMI2/5). No outlier data was present for 
HPMI2, HPMI5, RSAMI2, RSAMI5, PEPMI2, and PEPMI5. 
Cardiovascular functioning for recovery was calculated for each cardiovascular measure 
using the average obtained during the last two and five minutes of recovery (i.e., HPRC2/5, 
RSARC2/5, CORC2/5, and PEPRC2/5). Outlier data for the PEPRC2 (n = 1) were winsorized to address 
extreme values. No outlier data was present for HPRC2, HPRC5, RSARC2, RSARC5, and PEPRC5. 
Cardiovascular reactivity was operationalized as the difference score for the average of 
each cardiovascular measure (i.e., HPDS2RA/DS5RA, RSADS2RA/DS5RA, CODS2RA/DS5RA, and 
PEPDS2RA/DS5RA) and residualized change scores for the average of each cardiovascular measure 
(i.e., ZRES2/RES5HPRA, ZRES2/RES5RSARA, ZRES2/RES5CORA, and ZRES2/RES5PEPRA) assessed during 
baseline and the mood induction (i.e., HPBL2/BL5/MI2/MI5, RSABL2/BL5/MI2/MI5, COBL2/BL5/MI2/MI5, and 
PEPBL2/BL5/MI2/MI5). Outlier data for the RSADS2RA (n = 1), RSADS5RA (n = 1), PEPDS2RA (n = 2), 
and PEPDS5RA (n = 2) were winsorized to address extreme values. No outlier data was present for 
HPDS2RA and HPDS5RA. In addition, outlier data for the ZRES2RSARA (n = 1), ZRES5RSARA (n = 1), 
ZRES2PEPRA (n = 2), and ZRES5PEPRA (n = 2) were winsorized to address extreme values. 
Cardiovascular recovery was operationalized as the difference score for the average of 
each cardiovascular measure (i.e., HPDS2RC/DS5RC, RSADS2RC/DS5RC, CODS2RC/DS5RC, and 
PEPDS2RC/DS5RC) and residualized change scores for the average of each cardiovascular measure 




induction and the recovery period (i.e., HPBL2/BL5/RC2/RC5, RSABL2/BL5/RC2/RC5, COBL2/BL5/RC2/RC5, 
and PEPBL2/BL5/RC2/RC5). Outlier data for the RSADS5RC (n = 3), PEPDS2RC (n = 4), and PEPDS5RC (n 
= 2) were winsorized to address extreme values. No outlier data was present for HPDS2RA, and 
HPDS5RA, and RSADS2RC. In addition, outlier data for the ZRES2HPRC (n = 1), ZRES5HPRC (n = 1), 
and ZRES2PEPRC (n = 4) were winsorized to address extreme values 
Descriptive statistics. Descriptive statistics for session 2 cardiovascular measures are 
presented in Table 19. The baseline (i.e., BL2/BL5), mood induction (i.e., MI2/MI5), and recovery 
(i.e., RC2/RC5) scores are single item measures. Consequently, Cronbach’s alpha could not be 
calculated. The difference (i.e., DS) and residualized change (i.e., ZRES2/ZRES5) scores are 

















Table 19. Descriptive Statistics for Session 2 Cardiovascular Measures 
Measure M SD Sample range 
HPBL2 781.45 104.55 487.51-1,060.85 
HPBL5 785.51 105.88 538.41-1,045.88 
HPMI2 799.21 111.48 591.72-1,045.57 
HPMI5 788.89 108.15 600.29-1,049.48 
HPRC2 783.98 102.44 627.45-1,109.76 
HPRC5 787.42 103.62 633.77-1,109.32 
HPDS2RA 17.76 39.29 -79.84-159.61 
ZRES2HPRA .00 1.00 -2.48-3.64 
HPDS5RA 3.38 33.73 -91.22-126.04 
ZRES5HPRA .00 1.00 -2.67-3.48 
HPDS2RC 4.23 49.12 -97.39-236.03 
ZRES2HPRC .07 .78 -1.40-1.70 
HPDS5RC 3.70 37.99 -104.38-189.20 
ZRES5HPRC .03 .85 -2.69-1.29 
RSABL2 5.84 1.04 3.75-9.19 
RSABL5 5.83 1.01 3.65-9.37 
RSAMI2 6.03 1.15 1.81-9.49 
RSAMI5 5.89 1.13 1.36-9.44 
RSARC2 5.82 1.00 3.45-8.13 
RSARC5 5.79 .93 3.67-8.45 
RSADS2RA .24 .61 -1.22-1.97 
ZRES2RSARA .02 .73 -1.52-1.89 
RSADS5RA .11 .45 -.72-1.78 
ZRES5RSARA .03 .58 -1.02-1.38 
RSADS2RC -.02 .70 -1.82-1.99 
ZRES2RSARC .00 1.00 -2.99-2.65 
RSADS5RC -.05 .43 -1.37-.96 
ZRES5RSARC .00 1.00 -2.11-3.12 
PEPBL2 120.61 11.90 90-146.50 
PEPBL5 120.37 11.68 90-145.80 
PEPMI2 119.77 12.74 77.00-147.00 
PEPMI5 119.91 13.04 75.00-146.00 
PEPRC2 120.15 14.33 58.50-145.50 
PEPRC5 120.91 12.24 87.60-146.00 
PEPDS2RA -.48 4.19 -10.50-9.00 
ZRES2PEPRA -.01 .65 -1.33-1.06 
PEPDS5RA -.31 4.13 -18.80-10.40 
ZRES5PEPRA .04 .64 -1.26-1.47 
PEPDS2RC .68 5.06 -17.00-15.50 
ZRES2PEPRC .09 .53 -1.80-1.51 
PEPDS5RC .79 4.57 -16.00-11.00 




Note. The difference between baseline and mood induction or mood induction and recovery 
measures may not precisely equal the difference score as outlier data was addressed differently 
depending on the type of analyses conducted; HP = heart period at baseline; BL = baseline; MI = 
mood induction; RC = recovery; 2 = average obtained during a two-minute interval; 5 = average 
obtained during a five-minute interval; DS = difference score; RA = reactivity; ZRES = residualized 
change scores; RSA = respiratory sinus arrhythmia; PEP = pre-ejection period. 
Baseline Cardiovascular Functioning 
A series of one-way ANOVAs were used to assess significant group differences in 
cardiovascular functioning at baseline. It was expected that formerly depressed and healthy 
control participants would exhibit similar cardiovascular functioning for HP, RSA, PEP, or CO 
during baseline.  
HP – two-minutes. Analyses conducted for baseline cardiovascular functioning using 
two-minute averages of HP are reviewed below. 
One-way ANOVA. Age (p = .01) and BMI (p = .04) were significantly associated with 
baseline two-minute HP functioning and were included in the final model. The remaining 
covariates that were under consideration were not significantly associated with two-minute HP 
functioning (all p’s > .05) and were dropped from the final model. Levene’s test for homogeneity 
of variance was not significant (F(1,90) = .04, p = .84), indicating that this assumption 
underlying ANOVA was met. The main effect of group (F(1,88) = .80, p = .37, η2 = .009) was 
not significant, indicating that there was no significant difference in baseline two-minute HP 
functioning between groups when using univariate analysis. 
HP – five-minutes. Analyses conducted for baseline cardiovascular functioning using 
five-minute averages of HP are reviewed below. 
One-way ANOVA. Age (p = .008) and BMI (p = .04) were significantly associated with 
baseline five-minute HP functioning and were included in the final model. The remaining 




functioning (all p’s > .05) and were dropped from the final model. Levene’s test for homogeneity 
of variance was not significant (F(1,90) = .03, p = .86), indicating that this assumption 
underlying ANOVA was met. The main effect of group (F(1,88) = .80, p = .37, η2 = .009) was 
not significant, indicating that there was no significant difference in baseline five-minute HP 
functioning between groups when using univariate analysis. 
RSA – two-minutes. Analyses conducted for baseline cardiovascular functioning using 
two-minute averages of RSA are reviewed below. 
One-way ANOVA. None of the covariates that were under consideration were 
significantly associated with baseline two-minute RSA functioning (all p’s > .05) and were 
dropped from the final model. Levene’s test for homogeneity of variance was not significant 
(F(1,93) = .05, p = .82), indicating that this assumption underlying ANOVA was met. The main 
effect of group (F(1,93) = .47, p = .50, η2 = .005) was not significant, indicating that there was no 
significant difference in baseline two-minute RSA functioning between groups when using 
univariate analysis. 
RSA – five-minutes. Analyses conducted for baseline cardiovascular functioning using 
five-minute averages of RSA are reviewed below. 
One-way ANOVA. None of the covariates that were under consideration were 
significantly associated with baseline five-minute RSA functioning (all p’s > .05) and were 
dropped from the final model. Levene’s test for homogeneity of variance was not significant 
(F(1,93) = .26, p = .61), indicating that this assumption underlying ANOVA was met. The main 
effect of group (F(1,93) = .80, p = .38, η2 = .008) was not significant, indicating that there was no 





PEP – two-minutes. Analyses conducted for baseline cardiovascular functioning using 
two-minute averages of PEP are reviewed below. 
One-way ANOVA. Current state anxiety symptoms (p = .03) were significantly 
associated with baseline two-minute PEP functioning and were included in the final model. The 
remaining covariates that were under consideration were not significantly associated with two-
minute PEP functioning (all p’s > .05) and were dropped from the final model. Levene’s test for 
homogeneity of variance was not significant (F(1,84) = .19, p = .66), indicating that this 
assumption underlying ANOVA was met. The main effect of group (F(1,83) = 2.04, p = .16, η2 = 
.02) was not significant, indicating that there was no significant difference in baseline two-
minute PEP functioning between groups when using univariate analysis. 
PEP – five-minutes. Analyses conducted for baseline cardiovascular functioning using 
five-minute averages of PEP are reviewed below. 
One-way ANOVA. Current state anxiety symptoms (p = .01) were significantly 
associated with baseline five-minute PEP functioning and were included in the final model. The 
remaining covariates that were under consideration were not significantly associated with five-
minute PEP functioning (all p’s > .05) and were dropped from the final model. Levene’s test for 
homogeneity of variance was not significant (F(1,84) = .06, p = .80), indicating that this 
assumption underlying ANOVA was met. The main effect of group (F(1,83) = 1.60, p = .21, η2 = 
.02) was not significant, indicating that there was no significant difference in baseline five-
minute PEP functioning between groups when using univariate analysis. 
Hypothesis 3 
A series of 2 (group: formerly depressed, healthy control) X 2 (condition: sad, neutral) 




(group: formerly depressed, healthy control) X 2 (condition: sad, neutral) repeated measures 
ANOVAs were used to test the hypothesis that formerly depressed individuals exposed to the sad 
mood induction would exhibit a maladaptive pattern of cardiovascular reactivity (i.e., decreased 
HP, RSA, and CO and increased PEP) during the mood induction compared to formerly 
depressed participants exposed to the neutral mood induction and healthy control participants 
exposed to the sad and neutral mood inductions. Means, standard deviations, p values, and effect 
sizes for session 2 cardiovascular measures by group are presented in Table 20 while means, 
standard deviations, p values, and effect sizes for session 2 cardiovascular measures by group 
and condition are presented in Table 21. Planned comparisons were conducted using contrast 
analyses. Means, standard deviations, and p values for session 2 mood measures for planned 
comparisons are presented in Table 22. 
HP – two-minutes. Analyses conducted for cardiovascular reactivity using two-minute 
averages of HP are reviewed below. 
2 X 2 factorial ANOVA – difference score. None of the covariates that were under 
consideration were significantly associated with two-minute HP reactivity (all p’s > .05) and 
were dropped from the final model. Levene’s test for homogeneity of variance was not 
significant (F(3,92) = .94, p = .43), indicating that this assumption underlying ANOVA was met. 
Neither the main effects of group (F(1,92) = 2.52, p = .12, η2 = .03) or condition (F(1,92) = 1.15, 
p = .29, η2 = .01) nor the group by condition interaction (F(1,92) = .24, p = .62, η2 = .003) were 
significant, indicating that there was no significant difference in two-minute HP reactivity 
between groups or conditions or the group by condition interaction when using difference scores. 
Contrast analyses revealed that there was no significant difference in two-minute HP reactivity 




exposed to the sad mood induction to formerly depressed participants exposed to the neutral 
mood induction and healthy control participants exposed to the sad and neutral mood inductions. 
2 X 2 factorial ANOVA – residualized change score. None of the covariates that were 
under consideration were significantly associated with two-minute HP reactivity (all p’s > .05) 
and were dropped from the final model. Levene’s test for homogeneity of variance was not 
significant (F(3,92) = .95, p = .42), indicating that this assumption underlying ANOVA was met. 
Neither the main effects of group (F(1,92) = 2.51, p = .12, η2 = .03) or condition (F(1,92) = 1.14, 
p = .29, η2 = .01) nor the group by condition interaction (F(1,92) = .25, p = .62, η2 = .003) were 
significant, indicating that there was no significant difference in two-minute HP reactivity 
between mood induction conditions or the group by condition interaction when using 
residualized change scores. Contrast analyses revealed that there was no significant difference in 
two-minute HP reactivity (t(92) = 1.62, pL = .07, pQ = .62, pC = .80) when comparing formerly 
depressed participants exposed to the sad mood induction to formerly depressed participants 
exposed to the neutral mood induction and healthy control participants exposed to the sad and 
neutral mood inductions. 
2 X 2 repeated measures ANOVA. Age (p = .01) and BMI (p = .02) were significantly 
associated with two-minute HP reactivity and were included in the final model. The remaining 
covariates that were under consideration were not significantly associated with two-minute HP 
reactivity (all p’s > .05) and were dropped from the final model. Levene’s test for homogeneity 
of variance was not significant (HPBL2: F(3,88) = 1.54, p = .21; HPMI2: F(3,88) = 2.00, p = .12), 
indicating that this assumption underlying ANOVA was met. Neither the main effects of group 
(F(1,86) = .07, p = .79, η2 = .001) or condition (F(1,86) = 1.78, p = .19, η2 = .02) nor the group 




was no significant difference in two-minute HP reactivity between groups or conditions or the 
group by condition interaction when using repeated measures. Contrast analyses revealed that 
there was no significant difference in two-minute HP reactivity (F(1,88) = .54, p = .46) when 
comparing formerly depressed participants exposed to the sad mood induction to formerly 
depressed participants exposed to the neutral mood induction and healthy control participants 
exposed to the sad and neutral mood inductions. 
HP – five-minutes. Analyses conducted for cardiovascular reactivity using five-minute 
averages of HP are reviewed below. 
2 X 2 factorial ANOVA – difference score. Franco-American ethnicity (p = .002) was 
significantly associated with five-minute HP reactivity and was included in the final model. The 
remaining covariates that were under consideration were not significantly associated with five-
minute HP reactivity (all p’s > .05) and were dropped from the final model. Levene’s test for 
homogeneity of variance was not significant (F(3,91) = 1.60, p = .20), indicating that this 
assumption underlying ANOVA was met. Formerly depressed participants exhibited 
significantly higher levels of five-minute HP reactivity during the mood induction (F(1,90) = 
4.13, p = .05, η2 = .04) than healthy control participants. Neither the main effect of condition 
(F(1,90) = 2.10, p = .15, η2 = .02) nor the group by condition interaction (F(1,90) = 1.22, p = .27, 
η2 = .01) were significant, indicating that there was no significant difference in five-minute HP 
reactivity between mood induction conditions or the group by condition interaction when using 
difference scores. Using contrast analyses, formerly depressed participants exposed to the sad 
mood induction reported exhibited higher levels of five-minute HP reactivity during the mood 




mood induction and formerly depressed and healthy control participants exposed to the neutral 
mood induction. 
2 X 2 factorial ANOVA – residualized change score. Franco-American ethnicity (p = 
.002) was significantly associated with five-minute HP reactivity and was included in the final 
model. The remaining covariates that were under consideration were not significantly associated 
with five-minute HP reactivity (all p’s > .05) and were dropped from the final model. Levene’s 
test for homogeneity of variance was not significant (F(3,91) = 1.41, p = .25), indicating that this 
assumption underlying ANOVA was met. Formerly depressed participants exhibited 
significantly higher levels of five-minute HP reactivity during the mood induction (F(1,90) = 
4.49, p = .04, η2 = .05) than healthy control participants. Neither the main effect of condition 
(F(1,90) = 2.20, p = .14, η2 = .02) nor the group by condition interaction (F(1,90) = 1.21, p = .27, 
η2 = .01) were significant, indicating that there was no significant difference in five-minute HP 
reactivity between mood induction conditions or the group by condition interaction when using 
residualized change scores. Using contrast analyses, formerly depressed participants exposed to 
the sad mood induction reported exhibited higher levels of five-minute HP reactivity during the 
mood induction (F(3,90) = 2.32, p = .08) compared to healthy control participants exposed to the 
sad mood induction and formerly depressed and healthy control participants exposed to the 
neutral mood induction. 
2 X 2 repeated measures ANOVA. Age (p = .01) and BMI (p = .03) were significantly 
associated with five-minute HP reactivity and were included in the final model. The remaining 
covariates that were under consideration were not significantly associated with five-minute HP 
reactivity (all p’s > .05) and were dropped from the final model. Levene’s test for homogeneity 




indicating that this assumption underlying ANOVA was met. Neither the main effects of group 
(F(1,86) = .001, p = .97, η2 < .001) or condition (F(1,86) = 2.17, p = .14, η2 = .03) nor the group 
by condition interaction (F(1,86) = 1.38, p = .24, η2 = .02) were significant, indicating that there 
was no significant difference in five-minute HP reactivity between groups or conditions or the 
group by condition interaction when using repeated measures. Contrast analyses revealed that 
there was no significant difference in five-minute HP reactivity (F(1,88) = 1.29, p = .26) when 
comparing formerly depressed participants exposed to the sad mood induction to formerly 
depressed participants exposed to the neutral mood induction and healthy control participants 
exposed to the sad and neutral mood inductions. 
Post-hoc power analyses. Post-hoc power analyses were conducted using G*Power 
3.1.9.2 (Faul et al., 2007) to determine the power achieved by the HP reactivity analyses. Of 
note, analyses were only conducted using five-minute HP reactivity as this is a more stable 
measure than  of  HP reactivity. Results indicated that the current model had a power of .16 for 
the difference and residualized change scores and .19 for the repeated measures. Results 
suggested that given the current study’s sample size, α level, and observed effect size, there was 
a 16 to 19% chance of detecting an effect depending on which analytic technique was used. 
Sensitivity analyses. Sensitivity analyses were conducted using G*Power 3.1.9.2 (Faul et 
al., 2007) to determine the minimum effect size needed to obtain significant results for the HP 
reactivity analyses. Of note, analyses were only conducted using five-minute HP reactivity as 
this is a more stable measure than two-minute HP reactivity. Results indicated that the required 
effect size was f = .29 for the factorial ANOVAs and f = .34 for the repeated measures ANOVA. 
Results suggested that given the current study’s sample size and α level, at least a medium effect 




RSA – two-minutes. Analyses conducted for cardiovascular reactivity using two-minute 
averages of RSA are reviewed below. 
2 X 2 factorial ANOVA – difference score. Education level (p = .01) was significantly 
associated with two-minute RSA reactivity and was included in the final model. The remaining 
covariates that were under consideration were not significantly associated with two-minute RSA 
reactivity (all p’s > .05) and were dropped from the final model. Levene’s test for homogeneity 
of variance was not significant (F(3,90) = .50, p = .69), indicating that this assumption 
underlying ANOVA was met. Neither the main effects of group (F(1,89) = 2.49, p = .12, η2 = 
.03) or condition (F(1,89) = .04, p = .85, η2 < .001) nor the group by condition interaction 
(F(1,89) = .36, p = .55, η2 = .004) were significant, indicating that there was no significant 
difference in two-minute RSA reactivity between groups or conditions or the group by condition 
interaction when using difference scores. Contrast analyses revealed that there was no significant 
difference in two-minute RSA reactivity (F(3,89) = 1.00, p = .40) when comparing formerly 
depressed participants exposed to the sad mood induction to formerly depressed participants 
exposed to the neutral mood induction and healthy control participants exposed to the sad and 
neutral mood inductions. 
2 X 2 factorial ANOVA – residualized change score. Sex (p = .04) and education level 
(p = .01) were significantly associated with two-minute RSA reactivity and were included in the 
final model. The remaining covariates that were under consideration were not significantly 
associated with two-minute RSA reactivity (all p’s > .05) and were dropped from the final 
model. Levene’s test for homogeneity of variance was not significant (F(3,90) = .13, p = .94), 
indicating that this assumption underlying ANOVA was met. Neither the main effects of group 




by condition interaction (F(1,88) = .52, p = .47, η2 = .006) were significant, indicating that there 
was no significant difference in two-minute RSA reactivity between groups or conditions or the 
group by condition interaction when using residualized change scores. Contrast analyses 
revealed that there was no significant difference in two-minute RSA reactivity (F(3,88) = .53, p 
= .66) when comparing formerly depressed participants exposed to the sad mood induction to 
formerly depressed participants exposed to the neutral mood induction and healthy control 
participants exposed to the sad and neutral mood inductions. 
2 X 2 repeated measures ANOVA. None of the covariates that were under consideration 
were significantly associated with two-minute RSA reactivity (all p’s > .05) and were dropped 
from the final model. Levene’s test for homogeneity of variance was not significant (RSABL2: 
F(3,91) = .87, p = .46; RSAMI2: F(3,91) = .42, p = .74), indicating that this assumption 
underlying ANOVA was met. Neither the main effects of group (F(1,91) = .35, p = .56, η2 = 
.004) or condition (F(1,91) = .27, p = .61, η2 = .003) nor the group by condition interaction 
(F(1,91) = 2.48, p = .12, η2 = .03) were significant, indicating that there was no significant 
difference in two-minute RSA reactivity between groups or conditions or the group by condition 
interaction when using repeated measures. Contrast analyses revealed that there was no 
significant difference in two-minute RSA reactivity (F(1,93) = .73, p = .40) when comparing 
formerly depressed participants exposed to the sad mood induction to formerly depressed 
participants exposed to the neutral mood induction and healthy control participants exposed to 
the sad and neutral mood inductions. 
RSA – five-minutes. Analyses conducted for cardiovascular reactivity using five-minute 




2 X 2 factorial ANOVA – difference score. None of the covariates that were under 
consideration were significantly associated with five-minute RSA reactivity (all p’s > .05) and 
were dropped from the final model. Levene’s test for homogeneity of variance was not 
significant (F(3,91) = 1.38, p = .25), indicating that this assumption underlying ANOVA was 
met. Neither the main effects of group (F(1,91) = 1.43, p = .23, η2 = .02) or condition (F(1,91) = 
.83, p = .36, η2 = .009) nor the group by condition interaction (F(1,91) = .14, p = .71, η2 = .002) 
were significant, indicating that there was no significant difference in five-minute RSA reactivity 
between groups or conditions or the group by condition interaction when using difference scores. 
Contrast analyses revealed that there was no significant difference in five-minute RSA reactivity 
(t(91) = .89, pL = .15, pQ = .71, pC = .78) when comparing formerly depressed participants 
exposed to the sad mood induction to formerly depressed participants exposed to the neutral 
mood induction and healthy control participants exposed to the sad and neutral mood inductions. 
2 X 2 factorial ANOVA – residualized change score. None of the covariates that were 
under consideration were significantly associated with five-minute RSA reactivity (all p’s > .05) 
and were dropped from the final model. Levene’s test for homogeneity of variance was not 
significant (F(3,91) = 1.88, p = .14), indicating that this assumption underlying ANOVA was 
met. Neither the main effects of group (F(1,91) = .87, p = .35, η2 = .009) or condition (F(1,91) = 
1.19, p = .28, η2 = .01) nor the group by condition interaction (F(1,91) = .68, p = .41, η2 = .007) 
were significant, indicating that there was no significant difference in five-minute RSA reactivity 
between mood induction conditions or the group by condition interaction when using 
residualized change scores. Contrast analyses revealed that there was no significant difference in 
five-minute RSA reactivity (t(91) = .62 pL = .19, pQ = .41, pC = .58) when comparing formerly 




exposed to the neutral mood induction and healthy control participants exposed to the sad and 
neutral mood inductions. 
2 X 2 repeated measures ANOVA. None of the covariates that were under consideration 
were significantly associated with five-minute RSA reactivity (all p’s > .05) and were dropped 
from the final model. Levene’s test for homogeneity of variance was not significant (RSABL5: 
F(3,91) = 1.41, p = .24, RSAMI5: F(3,91) = .19, p = .90), indicating that this assumption 
underlying ANOVA was met. Neither the main effects of group (F(1,91) = .14, p = .71, η2 = 
.002) or condition (F(1,91) = .67, p = .41, η2 = .007) nor the group by condition interaction 
(F(1,91) = 2.12, p = .15, η2 = .02) were significant, indicating that there was no significant 
difference in five-minute RSA reactivity between groups or conditions or the group by condition 
interaction when using repeated measures. Contrast analyses revealed that there was no 
significant difference in five-minute RSA reactivity (F(1,93) = .28, p = .60) when comparing 
formerly depressed participants exposed to the sad mood induction to formerly depressed 
participants exposed to the neutral mood induction and healthy control participants exposed to 
the sad and neutral mood inductions. 
Post-hoc power analyses. Post-hoc power analyses were conducted using G*Power 
3.1.9.2 (Faul et al., 2007) to determine the power achieved by the RSA reactivity analyses. Of 
note, analyses were only conducted using five-minute RSA reactivity as this is a more stable 
measure than two-minute RSA reactivity. Results indicated that the current model had a power 
of .12 for the difference score, .13 for the residualized change score, and .20 for the repeated 
measures. Results suggested that given the current study’s sample size, α level, and observed 
effect size, there was a 12 to 20% chance of detecting an effect depending on which analytic 




Sensitivity analyses. Sensitivity analyses were conducted using G*Power 3.1.9.2 (Faul et 
al., 2007) to determine the minimum effect size needed to obtain significant results for the RSA 
reactivity analyses. Of note, analyses were only conducted using five-minute RSA reactivity as 
this is a more stable measure than two-minute RSA reactivity. Results indicated that the required 
effect size was f = .29 for the factorial ANOVAs and f = .32 for the repeated measures ANOVA. 
Results suggested that given the current study’s sample size and α level, at least a medium effect 
size was required to obtain significant results if a power of .80 was achieved. 
PEP – two-minutes. Analyses conducted for cardiovascular reactivity using two-minute 
averages of PEP are reviewed below. 
2 X 2 factorial ANOVA – difference score. Education level (p = .01) was significantly 
associated with two-minute PEP reactivity and was included in the final model. The remaining 
covariates that were under consideration were not significantly associated with cardiovascular 
reactivity (all p’s > .05) and were dropped from the final model. Levene’s test for homogeneity 
of variance was not significant (F(3,90) = 1.02, p = .39), indicating that this assumption 
underlying ANOVA was met. Neither the main effects of group (F(1,89) = .005, p = .94, η2 < 
.001) or condition (F(1,89) = .85, p = .36, η2 = .009) nor the group by condition interaction 
(F(1,89) = .003, p = .96, η2 < .001) were significant, indicating that there was no significant 
difference in two-minute PEP reactivity between groups or conditions or the group by condition 
interaction when using difference scores. Contrast analyses revealed that there was no significant 
difference in two-minute PEP reactivity (F(3,89) = .35, p = .79) when comparing formerly 
depressed participants exposed to the sad mood induction to formerly depressed participants 
exposed to the neutral mood induction and healthy control participants exposed to the sad and 




2 X 2 factorial ANOVA – residualized change score. Education level (p = .04) was 
significantly associated with two-minute PEP reactivity and was included in the final model. The 
remaining covariates that were under consideration were not significantly associated with two-
minute PEP reactivity (all p’s > .05) and were dropped from the final model. Levene’s test for 
homogeneity of variance was not significant (F(3,90) = .91, p = .44), indicating that this 
assumption underlying ANOVA was met. Neither the main effects of group (F(1,89) = .004, p = 
.95, η2 < .001) or condition (F(1,89) = .78, p = .38, η2 = .009) nor the group by condition 
interaction (F(1,89) = .02, p = .89, η2 < .001) were significant, indicating that there was no 
significant difference in two-minute PEP reactivity between mood induction conditions or the 
group by condition interaction when using residualized change scores. Contrast analyses 
revealed that there was no significant difference in two-minute PEP reactivity (F(3,89) = .35, p = 
.79) when comparing formerly depressed participants exposed to the sad mood induction to 
formerly depressed participants exposed to the neutral mood induction and healthy control 
participants exposed to the sad and neutral mood inductions. 
2 X 2 repeated measures ANOVA. Age (p = .05), race (p = .05), and current state anxiety 
symptoms (p = .02) were significantly associated with two-minute PEP reactivity and were 
included in the final model. The remaining covariates that were under consideration were not 
significantly associated with two-minute PEP reactivity (all p’s > .05) and were dropped from 
the final model. Levene’s test for homogeneity of variance was not significant (PEPBL2: F(3,80) 
= .71, p = .55; PEPMI2: F(3,80) = .63, p = .60), indicating that this assumption underlying 
ANOVA was met. Neither the main effects of group (F(1,77) = .21, p = .65, η2 = .003) or 
condition (F(1,77) = .81, p = .37, η2 = .01) nor the group by condition interaction (F(1,77) = .29, 




minute PEP reactivity between groups or conditions or the group by condition interaction when 
using repeated measures. Contrast analyses revealed that there was no significant difference in 
two-minute PEP reactivity (F(1,79) = .17, p = .68) when comparing formerly depressed 
participants exposed to the sad mood induction to formerly depressed participants exposed to the 
neutral mood induction and healthy control participants exposed to the sad and neutral mood 
inductions. 
PEP – five-minutes. Analyses conducted for cardiovascular reactivity using five-minute 
averages of PEP are reviewed below. 
2 X 2 factorial ANOVA – difference score. Race (p = .004) and education level (p = 
.004) were significantly associated with five-minute PEP reactivity and were included in the final 
model. The remaining covariates that were under consideration were not significantly associated 
with five-minute PEP reactivity (all p’s > .05) and were dropped from the final model. Levene’s 
test for homogeneity of variance was not significant (F(3,89) = .29, p = .83), indicating that this 
assumption underlying ANOVA was met. Neither the main effects of group (F(1,87) = .03, p = 
.86, η2 < .001) or condition (F(1,87) = .64, p = .43, η2 = .007) nor the group by condition 
interaction (F(1,87) = .69, p = .41, η2 = .008) were significant, indicating that there was no 
significant difference in five-minute PEP reactivity between groups or conditions or the group by 
condition interaction when using difference scores. Contrast analyses revealed that there was no 
significant difference in two-minute PEP reactivity (F(3,87) = .33, p = .80) when comparing 
formerly depressed participants exposed to the sad mood induction to formerly depressed 
participants exposed to the neutral mood induction and healthy control participants exposed to 




2 X 2 factorial ANOVA – residualized change score. Education level (p = .008) was 
significantly associated with five-minute PEP reactivity and was included in the final model. The 
remaining covariates that were under consideration were not significantly associated with five-
minute PEP reactivity (all p’s > .05) and were dropped from the final model. Levene’s test for 
homogeneity of variance was not significant (F(3,90) = .41, p = .75), indicating that this 
assumption underlying ANOVA was met. Neither the main effects of group (F(1,89) = .05, p = 
.82, η2 = .001) or condition (F(1,89) = .79, p = .38, η2 = .009) nor the group by condition 
interaction (F(1,89) = .30, p = .59, η2 = .003) were significant, indicating that there was no 
significant difference in five-minute PEP reactivity between mood induction conditions or the 
group by condition interaction when using residualized change scores. Contrast analyses 
revealed that there was no significant difference in five-minute PEP reactivity (F(3,89) = .30, p = 
.82) when comparing formerly depressed participants exposed to the sad mood induction to 
formerly depressed participants exposed to the neutral mood induction and healthy control 
participants exposed to the sad and neutral mood inductions. 
2 X 2 repeated measures ANOVA. Age (p = .04), race (p = .03), and current state anxiety 
symptoms (p = .02) were significantly associated with five-minute PEP reactivity and were 
included in the final model. The remaining covariates that were under consideration were not 
significantly associated with five-minute PEP reactivity (all p’s > .05) and were dropped from 
the final model. Levene’s test for homogeneity of variance was not significant (PEPBL5: F(3,80) 
= .68, p = .57; PEPMI5: F(3,80) = .49, p = .69), indicating that this assumption underlying 
ANOVA was met. Neither the main effects of group (F(1,77) = .18, p = .67, η2 = .002) or 
condition (F(1,77) = .54, p = .46, η2 = .007) nor the group by condition interaction (F(1,77) = 




five-minute PEP reactivity between groups or conditions or the group by condition interaction 
when using repeated measures. Contrast analyses revealed that there was no significant 
difference in two-minute PEP reactivity (F(1,80) = .05, p = .83) when comparing formerly 
depressed participants exposed to the sad mood induction to formerly depressed participants 
exposed to the neutral mood induction and healthy control participants exposed to the sad and 
neutral mood inductions. 
Post-hoc power analyses. Post-hoc power analyses were conducted using G*Power 
3.1.9.2 (Faul et al., 2007) to determine the power achieved by the PEP reactivity analyses. Of 
note, analyses were only conducted using five-minute PEP reactivity as this is a more stable 
measure than two-minute PEP reactivity. Results indicated that the current model had a power of 
.14 for the difference score, .08 for the residualized change score, and .07 for the repeated 
measures. Results suggested that given the current study’s sample size, α level, and observed 
effect size, there was a 7 to 14% chance of detecting an effect depending on which analytic 
technique was used. 
Sensitivity analyses. Sensitivity analyses were conducted using G*Power 3.1.9.2 (Faul et 
al., 2007) to determine the minimum effect size needed to obtain significant results for the PEP 
reactivity analyses. Of note, analyses were only conducted using five-minute PEP reactivity as 
this is a more stable measure than two-minute PEP reactivity. Results indicated that the required 
effect size was f = .29 for the factorial ANOVAs and f = .34 for the repeated measures ANOVA. 
Results suggested that given the current study’s sample size and α level, at least a medium effect 







A series of 2 (group: formerly depressed, healthy control) X 2 (condition: sad, neutral) 
factorial ANOVAs using difference scores and residualized change scores and a series of 2 
(group: formerly depressed, healthy control) X 2 (condition: sad, neutral) repeated measures 
ANOVAs were used to test the hypothesis that formerly depressed individuals exposed to the sad 
mood induction would exhibit reduced cardiovascular recovery (i.e., decreased HP, RSA, and 
CO and increased PEP compared to baseline) during the recovery film compared to formerly 
depressed participants exposed to the neutral mood induction and healthy control participants 
exposed to the sad and neutral mood inductions. Means, standard deviations, p values, and effect 
sizes for session 2 cardiovascular measures by group are presented in Table 20 while means, 
standard deviations, p values, and effect sizes for session 2 cardiovascular measures by group 
and condition are presented in Table 21. Planned comparisons were conducted using contrast 
analyses. Means, standard deviations, and p values for session 2 mood measures for planned 
comparisons are presented in Table 22. 
HP – two-minutes. Analyses conducted for cardiovascular recovery using two-minute 
averages of HP are reviewed below. 
2 X 2 factorial ANOVA – difference score. None of the covariates that were under 
consideration were significantly associated with two-minute HP recovery (all p’s > .05) and were 
dropped from the final model. Levene’s test for homogeneity of variance was significant 
(F(3,91) = 4.23, p = .008), indicating that this assumption underlying ANOVA was not met.  
In line with the planned analyses, multiple steps were explored in an attempt to remedy 
the violation of this assumption. First, residuals of difference scores were calculated and 




difference scores were normally distributed for the healthy control group (Kolmogorov-Smirnov: 
D(65) = .09, p = .20; Shapiro-Wilk: D(65) = .96, p = .06), formerly depressed participants 
exposed to the neutral mood induction (Kolmogorov-Smirnov: D(15) = .13, p = .20; Shapiro-
Wilk: D(15) = .95, p = .51), and healthy control participants exposed to the sad mood induction 
(Kolmogorov-Smirnov: D(34) = .08, p = .20; Shapiro-Wilk: D(34) = .97, p = .52) and for one 
measure of normality for the formerly depressed group (Kolmogorov-Smirnov: D(30) = .13, p = 
.18), sad mood induction condition (Kolmogorov-Smirnov: D(49) = .11, p = .17), and formerly 
depressed participants exposed to the sad mood induction (Kolmogorov-Smirnov: D(15) = .16, p 
= .20). However, residuals of difference scores were not normally distributed for the remaining 
groups and conditions (all p’s < .05). Second, difference scores were transformed using the 
reciprocal transformation. Levene’s test for homogeneity of variance continued to be significant 
(F(3,91) = 18.69, p < .001), indicating that this assumption underlying ANOVA was still not 
met. Consequently, the factorial ANOVA was conducted with the α level decreased from .05 to 
.01.  
With the adjusted p value, neither the main effects of group (F(1,91) = 4.96, p = .03, η2 = 
.05) or condition (F(1,91) = 4.09, p = .05, η2 = .04) nor the group by condition interaction 
(F(1,91) = 5.55, p = .02, η2 = .06) were significant, indicating that there was no significant 
difference in two-minute HP recovery between groups or conditions or the group by condition 
interaction when using difference scores. For the main effects and interaction, it is possible that 
this is due to lack of power rather than lack of effect. Using contrast analyses that did not assume 
equal variances, formerly depressed participants exposed to the sad mood induction reported 
exhibited higher levels of five-minute HP reactivity during the mood induction (t(15.26) = 1.31, 




induction and formerly depressed and healthy control participants exposed to the neutral mood 
induction. 
2 X 2 factorial ANOVA – residualized change score. None of the covariates that were 
under consideration were significantly associated with two-minute HP recovery (all p’s > .05) 
and were dropped from the final model. Levene’s test for homogeneity of variance was 
significant (F(3,91) = 7.08, p < .001), indicating that this assumption underlying ANOVA was 
not met.  
In line with the planned analyses, multiple steps were explored in an attempt to remedy 
the violation of this assumption. First, residuals of residualized change scores were calculated 
and Kolmogorov-Smirnov’s and Shapiro-Wilk’s tests of normality were conducted. Residuals of 
residualized change scores were normally distributed for the healthy control group 
(Kolmogorov-Smirnov: D(65) = .07, p = .20; Shapiro-Wilk: D(65) = .99, p = .92), neutral mood 
induction condition (Kolmogorov-Smirnov: D(46) = .12, p = .10; Shapiro-Wilk: D(46) = .97, p = 
.17), formerly depressed participants exposed to the neutral mood induction (Kolmogorov-
Smirnov: D(15) = .13, p = .20; Shapiro-Wilk: D(15) = .95, p = .51), and healthy control 
participants exposed to the sad mood induction (Kolmogorov-Smirnov: D(34) = .08, p = .20; 
Shapiro-Wilk: D(34) = .97, p = .52) and for one measure of normality for the formerly depressed 
group (Kolmogorov-Smirnov: D(30) = .13, p = .18), sad mood induction condition 
(Kolmogorov-Smirnov: D(49) = .11, p = .17), formerly depressed participants exposed to the sad 
mood induction (Kolmogorov-Smirnov: D(15) = .16, p = .20), and healthy control participants 
exposed to the neutral mood induction (Shapiro-Wilk: D(31) = .94, p = .06). However, residuals 
of difference scores were not normally distributed for the remaining groups and conditions (all 




transformation. Levene’s test for homogeneity of variance continued to be significant (F(1,91) = 
19.58, p < .001), indicating that this assumption underlying ANOVA was still not met. 
Consequently, the factorial ANOVA was conducted with the α level decreased from .05 to .01.  
With the adjusted p value, neither the main effects of group (F(1,91) = 4.12, p = .05, η2 = 
.04) or condition (F(1,91) = .16, p = .69, η2 = .002) nor the group by condition interaction 
(F(1,91) = 4.58, p = .04, η2 = .05) were significant, indicating that there was no significant 
difference in two-minute HP recovery between groups or conditions or the group by condition 
interaction when using residualized change scores. For the main effects and interaction, it is 
possible that this is due to lack of power rather than lack of effect. Using contrast analyses that 
did not assume equal variances, formerly depressed participants exposed to the sad mood 
induction reported exhibited higher levels of five-minute HP reactivity during the mood 
induction (t(15.24) = 1.44, pL = .05, pQ = .04, pC = .58) compared to healthy control participants 
exposed to the sad mood induction and formerly depressed and healthy control participants 
exposed to the neutral mood induction. 
2 X 2 repeated measures ANOVA. BMI (p = .05) was significantly associated with two-
minute HP recovery and was included in the final model. The remaining covariates that were 
under consideration were not significantly associated with two-minute HP recovery (all p’s > 
.05) and were dropped from the final model. Levene’s test for homogeneity of variance was not 
significant for the mood induction measure (HPBL2: F(3,88) = .90, p = .45) but was significant 
for the recovery measure (HPRC2: F(3,88) = 2.89, p = .04), indicating that this assumption 
underlying ANOVA was not met. Of note, this appeared to be driven by the inclusion of the 
covariate. Without the covariate, Levene’s test for homogeneity of variance was not significant 




residual of the mood induction and recovery measures to assess normality or transforming the 
mood induction and recovery measures to re-assess homogeneity of variance would not have the 
intended effect. Instead, the factorial ANOVA was conducted with the α level decreased from 
.05 to .01. Neither the main effects of group (F(1,87) = .05, p = .82, η2 = .001) or condition 
(F(1,87) = 1.20, p = .28, η2 = .01) nor the group by condition interaction (F(1,87) = .87,  p = .35, 
η2 = .01) were significant, indicating that there was no significant difference in two-minute HP 
recovery between groups or conditions or the group by condition interaction when using repeated 
measures. Contrast analyses that did not assume equal variances revealed that there was no 
significant difference in two-minute HP recovery (F(1,90) = .86, p = .36) when comparing 
formerly depressed participants exposed to the sad mood induction to formerly depressed 
participants exposed to the neutral mood induction and healthy control participants exposed to 
the sad and neutral mood inductions. 
HP – five-minutes. Analyses conducted for cardiovascular recovery using five-minute 
averages of HP are reviewed below. 
2 X 2 factorial ANOVA – difference score. None of the covariates that were under 
consideration were significantly associated with five-minute HP recovery (all p’s > .05) and were 
dropped from the final model. Levene’s test for homogeneity of variance was significant 
(F(3,91) = 3.08, p = .03), indicating that this assumption underlying ANOVA was not met.  
In line with the planned analyses, multiple steps were explored in an attempt to remedy 
the violation of this assumption. First, residuals of difference scores were calculated and 
Kolmogorov-Smirnov’s and Shapiro-Wilk’s tests of normality were conducted. Residuals of 
difference scores were normally distributed for the healthy control group (Kolmogorov-Smirnov: 




(Kolmogorov-Smirnov: D(46) = .10, p = .20; Shapiro-Wilk: D(46) = .95, p = .06), formerly 
depressed participants exposed to the sad (Kolmogorov-Smirnov: D(15) = .15, p = .20; Shapiro-
Wilk: D(15) = .90, p = .09) and neutral (Kolmogorov-Smirnov: D(15) = .11, p = .20; Shapiro-
Wilk: D(15) = .97, p = .91) mood inductions, and healthy control participants exposed to the sad 
mood induction (Kolmogorov-Smirnov: D(34) = .11, p = .20; Shapiro-Wilk: D(34) = .96, p = 
.22) and for one measure of normality for the formerly depressed group (Kolmogorov-Smirnov: 
D(30) = .12, p = .20), sad mood induction condition (Kolmogorov-Smirnov: D(49) = .11, p = 
.13), and healthy control participants exposed to the neutral mood induction (Kolmogorov-
Smirnov: D(31) = .12, p = .20). However, residuals of difference scores were not normally 
distributed for the remaining groups and conditions (all p’s < .05). Second, difference scores 
were transformed using the reciprocal transformation. Levene’s test for homogeneity of variance 
continued to be significant (F(3,91) = 7.19, p < .001), indicating that this assumption underlying 
ANOVA was still not met. Consequently, the factorial ANOVA was conducted with the α level 
decreased from .05 to .01.  
Neither the main effects of group (F(1,91) = 3.55, p = .06, η2 = .04) or condition (F(1,91) 
= .65, p = .42, η2 = .007) nor the group by condition interaction (F(1,91) = 3.66, p = .06, η2 = .04) 
were significant, indicating that there was no significant difference in five-minute HP recovery 
between groups or conditions or the group by condition interaction when using difference scores. 
For the main effects and interaction, it is possible that this is due to lack of power rather than 
lack of effect. Using contrast analyses that did not assume equal variances, formerly depressed 
participants exposed to the sad mood induction reported exhibited higher levels of five-minute 




to healthy control participants exposed to the sad mood induction and formerly depressed and 
healthy control participants exposed to the neutral mood induction. 
2 X 2 factorial ANOVA – residualized change score. None of the covariates that were 
under consideration were significantly associated with five-minute HP recovery (all p’s > .05) 
and were dropped from the final model. Levene’s test for homogeneity of variance was 
significant (F(3,91) = 6.92, p < .001), indicating that this assumption underlying ANOVA was 
not met.  
In line with the planned analyses, multiple steps were explored in an attempt to remedy 
the violation of this assumption. First, residuals of difference scores were calculated and 
Kolmogorov-Smirnov’s and Shapiro-Wilk’s tests of normality were conducted. Residuals of 
difference scores were normally distributed for the healthy control group (Kolmogorov-Smirnov: 
D(65) = .07, p = .20; Shapiro-Wilk: D(65) = .97, p = .15), neutral mood induction condition 
(Kolmogorov-Smirnov: D(46) = .09, p = .20; Shapiro-Wilk: D(46) = .98, p = .75), formerly 
depressed participants exposed to the sad (Kolmogorov-Smirnov: D(15) = .15, p = .20; Shapiro-
Wilk: D(15) = .90, p = .09) and neutral (Kolmogorov-Smirnov: D(15) = .11, p = .20; Shapiro-
Wilk: D(15) = .97, p = .91) mood inductions, and healthy control participants exposed to the sad 
(Kolmogorov-Smirnov: D(34) = .11, p = .20; Shapiro-Wilk: D(34) = .96, p = .22) and neutral 
(Kolmogorov-Smirnov: D(31) = .10, p = .20; Shapiro-Wilk: D(31) = .98, p = .75) mood 
induction and for one measure of normality for the formerly depressed group (Kolmogorov-
Smirnov: D(30) = .12, p = .20) and sad mood induction condition (Kolmogorov-Smirnov: D(49) 
= .11, p = .13). However, residuals of difference scores were not normally distributed for the 
remaining groups and conditions (all p’s < .05). Second, difference scores were transformed 




significant (F(3,91) = 13.14, p < .001), indicating that this assumption underlying ANOVA was 
still not met. Consequently, the factorial ANOVA was conducted with the α level decreased from 
.05 to .01.  
With the adjusted p value, neither the main effects of group (F(1,91) = 4.91,  p = .03, η2 = 
.05) or condition (F(1,91) = 1.24, p = .27, η2 = .01) nor the group by condition interaction 
(F(1,91) = 3.86, p = .05, η2 = .04) were significant, indicating that there was no significant 
difference in five-minute HP recovery between groups or conditions or the group by condition 
interaction when using residualized change scores. For the main effects and interaction, it is 
possible that this is due to lack of power rather than lack of effect. Using contrast analyses that 
did not assume equal variances, formerly depressed participants exposed to the sad mood 
induction reported exhibited higher levels of five-minute HP reactivity during the mood 
induction (t(15.88) = 1.79, pL = .02, pQ = .05, pC = 1.00) compared to healthy control participants 
exposed to the sad mood induction and formerly depressed and healthy control participants 
exposed to the neutral mood induction. 
2 X 2 repeated measures ANOVA. BMI (p = .05) was significantly associated with five-
minute HP recovery and was included in the final model. The remaining covariates that were 
under consideration were not significantly associated with five-minute HP recovery (all p’s > 
.05) and were dropped from the final model. Levene’s test for homogeneity of variance was not 
significant (HPBL5: F(3,88) = 1.22, p = .31; HPRC5: F(3,88) = 2.23, p = .09), indicating that this 
assumption underlying ANOVA was met. Neither the main effects of group (F(1,87) = .09, p = 
.77, η2 = .001) or condition (F(1,87) = 1.71, p = .19, η2 = .02) nor the group by condition 
interaction (F(1,87) = 1.27, p = .26, η2 = .01) were significant, indicating that there was no 




condition interaction when using repeated measures. Contrast analyses revealed that there was no 
significant difference in five-minute HP recovery (F(1,90) = 1.36, p = .25) when comparing 
formerly depressed participants exposed to the sad mood induction to formerly depressed 
participants exposed to the neutral mood induction and healthy control participants exposed to 
the sad and neutral mood inductions. 
Post-hoc power analyses. Post-hoc power analyses were conducted using G*Power 
3.1.9.2 (Faul et al., 2007) to determine the power achieved by the HP recovery analyses. Of note, 
analyses were only conducted using five-minute HP recovery as this is a more stable measure 
than two-minute HP recovery. Results indicated that the current model had a power of .27 for the 
difference and residualized change scores and .11 for the repeated measures. Results suggested 
that given the current study’s sample size, α level, and observed effect size, there was a 11 to 
27% chance of detecting an effect depending on which analytic technique was used. 
Sensitivity analyses. Sensitivity analyses were conducted using G*Power 3.1.9.2 (Faul et 
al., 2007) to determine the minimum effect size needed to obtain significant results for the HP 
recovery analyses. Of note, analyses were only conducted using five-minute HP recovery as this 
is a more stable measure than two-minute HP recovery. Results indicated that the required effect 
size was f = .36 for the factorial ANOVAs and f = .34 for the repeated measures ANOVA. 
Results suggested that given the current study’s sample size and α level, at least a medium effect 
size was required to obtain significant results if a power of .80 was achieved. 
RSA – two-minutes. Analyses conducted for cardiovascular recovery using two-minute 
averages of RSA are reviewed below. 
2 X 2 factorial ANOVA – difference score. None of the covariates that were under 




were dropped from the final model. Levene’s test for homogeneity of variance was not 
significant (F(3,90) = 1.39, p = .25), indicating that this assumption underlying ANOVA was 
met. Neither the main effects of group (F(1,90) = .02, p = .88, η2 < .001) or condition (F(1,90) = 
.85, p = .36, η2 = .009) nor the group by condition interaction (F(1,90) = 2.17, p = .14, η2 = .02) 
were significant, indicating that there was no significant difference in two-minute RSA recovery 
between groups or conditions or the group by condition interaction when using difference scores. 
Contrast analyses revealed that there was no significant difference in two-minute RSA recovery 
(t(90) = 1.32, pL = .59, pQ = .14, pC = .45) when comparing formerly depressed participants 
exposed to the sad mood induction to formerly depressed participants exposed to the neutral 
mood induction and healthy control participants exposed to the sad and neutral mood inductions. 
2 X 2 factorial ANOVA – residualized change score. None of the covariates that were 
under consideration were significantly associated with two-minute RSA recovery (all p’s > .05) 
and were dropped from the final model. Levene’s test for homogeneity of variance was not 
significant (F(3,90) = 1.93, p = .13), indicating that this assumption underlying ANOVA was 
met. Neither the main effects of group (F(1,90) = .06, p = .81, η2 = .001) or condition (F(1,90) = 
1.08, p = .30, η2 = .01) nor the group by condition interaction (F(1,90) = 1.05, p = .31, η2 = .01) 
were significant, indicating that there was no significant difference in two-minute RSA recovery 
between groups or conditions or the group by condition interaction when using residualized 
change scores. Contrast analyses revealed that there was no significant difference in two-minute 
RSA recovery (t(90) = .94, pL = .81, pQ = .31, pC = .30) when comparing formerly depressed 
participants exposed to the sad mood induction to formerly depressed participants exposed to the 





2 X 2 repeated measures ANOVA. None of the covariates that were under consideration 
were significantly associated with two-minute RSA recovery (all p’s > .05) and were dropped 
from the final model. Levene’s test for homogeneity of variance was not significant (RSABL2: 
F(3,90) = 1.09, p = .36; RSARC2: F(3,90) = 2.54, p = .06), indicating that this assumption 
underlying ANOVA was met. Neither the main effects of group (F(1,90) = .99, p = .32, η2 = .01) 
or condition (F(1,90) = .20, p = .66, η2 = .002) nor the group by condition interaction (F(1,90) = 
.90, p = .35, η2 = .01) were significant, indicating that there was no significant difference in two-
minute RSA recovery between groups or conditions or the group by condition interaction when 
using repeated measures. Contrast analyses revealed that there was no significant difference in 
two-minute RSA recovery (F(1,92) = .46, p = . 50) when comparing formerly depressed 
participants exposed to the sad mood induction to formerly depressed participants exposed to the 
neutral mood induction and healthy control participants exposed to the sad and neutral mood 
inductions. 
RSA – five-minutes. Analyses conducted for cardiovascular recovery using five-minute 
averages of RSA are reviewed below. 
2 X 2 factorial ANOVA – difference score. None of the covariates that were under 
consideration were significantly associated with five-minute RSA recovery (all p’s > .05) and 
were dropped from the final model. Levene’s test for homogeneity of variance was not 
significant (F(3,90) = 2.37, p = .08), indicating that this assumption underlying ANOVA was 
met. Neither the main effects of group (F(1,90) = .06, p = .81, η2 = .001) or condition (F(1,90) = 
.24, p = .63, η2 = .003) nor the group by condition interaction (F(1,90) = 1.86, p = .18, η2 = .02) 
were significant, indicating that there was no significant difference in five-minute RSA recovery 




Contrast analyses revealed that there was no significant difference in two-minute RSA recovery 
(t(90) = 1.08, pL = .67, pQ = .18, pC = .74) when comparing formerly depressed participants 
exposed to the sad mood induction to formerly depressed participants exposed to the neutral 
mood induction and healthy control participants exposed to the sad and neutral mood inductions. 
2 X 2 factorial ANOVA – residualized change score. None of the covariates that were 
under consideration were significantly associated with five-minute RSA recovery (all p’s > .05) 
and were dropped from the final model. Levene’s test for homogeneity of variance was not 
significant (F(3,90) = 1.67, p = .18), indicating that this assumption underlying ANOVA was 
met. Neither the main effects of group (F(1,90) = .001, p = .98, η2 < .001) or condition (F(1,90) = 
.51, p = .48, η2 = .006) nor the group by condition interaction (F(1,90) = .88, p = .35, η2 = .01) 
were significant, indicating that there was no significant difference in five-minute RSA recovery 
between mood induction conditions or the group by condition interaction when using 
residualized change scores. Contrast analyses revealed that there was no significant difference in 
two-minute RSA recovery (t(90) = .88, pL = .73, pQ = .35, pC = .53) when comparing formerly 
depressed participants exposed to the sad mood induction to formerly depressed participants 
exposed to the neutral mood induction and healthy control participants exposed to the sad and 
neutral mood inductions. 
2 X 2 repeated measures ANOVA. None of the covariates that were under consideration 
were significantly associated with five-minute RSA recovery (all p’s > .05) and were dropped 
from the final model. Levene’s test for homogeneity of variance was not significant (RSABL5: 
F(3,90) = 1.44, p = .24; RSARC5: F(3,90) = .73, p = .54), indicating that this assumption 
underlying ANOVA was met. Neither the main effects of group (F(1,90) = .45, p = .50, η2 = 




(F(1,90) = 1.05, p = .31, η2 = .01) were significant, indicating that there was no significant 
difference in five-minute RSA recovery between groups or conditions or the group by condition 
interaction when using repeated measures. Contrast analyses revealed that there was no 
significant difference in two-minute RSA recovery (F(1,92) = .49, p = .49) when comparing 
formerly depressed participants exposed to the sad mood induction to formerly depressed 
participants exposed to the neutral mood induction and healthy control participants exposed to 
the sad and neutral mood inductions. 
Post-hoc power analyses. Post-hoc power analyses were conducted using G*Power 
3.1.9.2 (Faul et al., 2007) to determine the power achieved by the RSA recovery analyses. Of 
note, analyses were only conducted using five-minute RSA recovery as this is a more stable 
measure than two-minute RSA recovery. Results indicated that the current model had a power of 
.28 for the difference score, .16 for the residualized change score, and .11 for the repeated 
measures. Results suggested that given the current study’s sample size, α level, and observed 
effect size, there was a 11 to 28% chance of detecting an effect depending on which analytic 
technique was used. 
Sensitivity analyses. Sensitivity analyses were conducted using G*Power 3.1.9.2 (Faul et 
al., 2007) to determine the minimum effect size needed to obtain significant results for the RSA 
recovery analyses. Of note, analyses were only conducted using five-minute RSA recovery as 
this is a more stable measure than two-minute RSA recovery. Results indicated that the required 
effect size was f = .29 for the factorial ANOVAs and f = .34 for the repeated measures ANOVA. 
Results suggested that given the current study’s sample size and α level, at least a medium effect 




PEP – Two-Minute. Analyses conducted for cardiovascular recovery using two-minute 
averages of PEP are reviewed below. 
2 X 2 factorial ANOVA – difference score. None of the covariates that were under 
consideration were significantly associated with two-minute PEP recovery (all p’s > .05) and 
were dropped from the final model. Levene’s test for homogeneity of variance was not 
significant (F(3,90) = 1.83, p = .15), indicating that this assumption underlying ANOVA was 
met. Neither the main effects of group (F(1,90) = .006, p = .94, η2 < .001) or condition (F(1,90) = 
.15, p = .70, η2 = .002) nor the group by condition interaction (F(1,90) = .11, p = .75, η2 = .001) 
were significant, indicating that there was no significant difference in two-minute PEP recovery 
between groups or conditions or the group by condition interaction when using difference scores. 
Contrast analyses revealed that there was no significant difference in two-minute PEP recovery 
(t(90) = -.01, pL = .92, pQ = .75, pC = .71) when comparing formerly depressed participants 
exposed to the sad mood induction to formerly depressed participants exposed to the neutral 
mood induction and healthy control participants exposed to the sad and neutral mood inductions. 
2 X 2 factorial ANOVA – residualized change score. None of the covariates that were 
under consideration were significantly associated with two-minute PEP recovery (all p’s > .05) 
and were dropped from the final model. Levene’s test for homogeneity of variance was not 
significant (F(3,90) = 2.46, p = .07), indicating that this assumption underlying ANOVA was 
met. Neither the main effects of group (F(1,90) = .03, p = .86, η2 < .001) or condition (F(1,90) = 
.17, p = .68, η2 = .002) nor the group by condition interaction (F(1,90) = .04, p = .85, η2 < .001) 
were significant, indicating that there was no significant difference in two-minute PEP recovery 
between groups or conditions or the group by condition interaction when using residualized 




PEP recovery (t(90) = .03, pL = .98, pQ = .85, pC = .65) when comparing formerly depressed 
participants exposed to the sad mood induction to formerly depressed participants exposed to the 
neutral mood induction and healthy control participants exposed to the sad and neutral mood 
inductions. 
2 X 2 repeated measures ANOVA. Current state anxiety symptoms (p = .01) were 
significantly associated with two-minute PEP recovery and were included in the final model. The 
remaining covariates that were under consideration were not significantly associated with two-
minute PEP recovery (all p’s > .05) and were dropped from the final model. Levene’s test for 
homogeneity of variance was not significant (PEPBL2: F(3,81) = .86, p = .47; PEPRC2: F(3,81) = 
1.57, p = .20), indicating that this assumption underlying ANOVA was met. Neither the main 
effects of group (F(1,80) = .08, p = .78, η2 = .001) or condition (F(1,80) = .43, p = .52, η2 = .005) 
nor the group by condition interaction (F(1,80) = .33,  p = .57, η2 = .004) were significant, 
indicating that there was no significant difference in two-minute PEP recovery between groups 
or conditions or the group by condition interaction when using repeated measures. Contrast 
analyses revealed that there was no significant difference in two-minute PEP recovery (F(1,82) = 
.03, p = .86) when comparing formerly depressed participants exposed to the sad mood induction 
to formerly depressed participants exposed to the neutral mood induction and healthy control 
participants exposed to the sad and neutral mood inductions. 
PEP – Five-Minute. Analyses conducted for cardiovascular recovery using five-minute 
averages of PEP are reviewed below. 
2 X 2 factorial ANOVA – difference score. Hispanic/Latino ethnicity (p = .03) was 
significantly associated with five-minute PEP recovery and was included in the final model. The 




minute PEP recovery (all p’s > .05) and were dropped from the final model. Levene’s test for 
homogeneity of variance was not significant (F(3,89) = 1.46, p = .23), indicating that this 
assumption underlying ANOVA was met. Neither the main effects of group (F(1,88) = .65, p = 
.42, η2 = .007) or condition (F(1,88) = .08, p = .78, η2 = .001) nor the group by condition 
interaction (F(1,88) = .24, p = .62, η2 = .003) were significant, indicating that there was no 
significant difference in five-minute PEP recovery between groups or conditions or the group by 
condition interaction when using difference scores. Contrast analyses revealed that there was no 
significant difference in two-minute PEP recovery (F(3,88) = .29, p = .83) when comparing 
formerly depressed participants exposed to the sad mood induction to formerly depressed 
participants exposed to the neutral mood induction and healthy control participants exposed to 
the sad and neutral mood inductions. 
2 X 2 factorial ANOVA – residualized change score. None of the covariates that were 
under consideration were significantly associated with five-minute PEP recovery (all p’s > .05) 
and were dropped from the final model. Levene’s test for homogeneity of variance was not 
significant (F(3,90) = 2.39, p = .07), indicating that this assumption underlying ANOVA was 
met. Neither the main effects of group (F(1,90) = .79, p = .38, η2 = .009) or condition (F(1,90) = 
.01, p = .94, η2 < .001) nor the group by condition interaction (F(1,90) = .22, p = .64, η2 = .002) 
were significant, indicating that there was no significant difference in five-minute PEP recovery 
between groups or conditions or the group by condition interaction when using residualized 
change scores. Contrast analyses revealed that there was no significant difference in two-minute 
PEP recovery (t(90) = -.26, pL = .41, pQ = .64, pC = .74) when comparing formerly depressed 




neutral mood induction and healthy control participants exposed to the sad and neutral mood 
inductions. 
2 X 2 repeated measures ANOVA. Current state anxiety symptoms (p = .02) were 
significantly associated with five-minute PEP recovery and were included in the final model. The 
remaining covariates that were under consideration were not significantly associated with five-
minute PEP recovery (all p’s > .05) and were dropped from the final model. Levene’s test for 
homogeneity of variance was not significant (PEPBL5: F(3,81) = .97, p = .41; PEPRC5: F(3,81) = 
.57, p = .64), indicating that this assumption underlying ANOVA was met. Neither the main 
effects of group (F(1,80) = .01, p = .91, η2 < .001) or condition (F(1,80) = .76, p = .39, η2 = .009) 
nor the group by condition interaction (F(1,80) = .14, p = .71, η2 = .002) were significant, 
indicating that there was no significant difference in five-minute PEP recovery between groups 
or conditions or the group by condition interaction when using repeated measures. Contrast 
analyses revealed that there was no significant difference in two-minute PEP recovery (F(1,82) = 
.07, p = .79) when comparing formerly depressed participants exposed to the sad mood induction 
to formerly depressed participants exposed to the neutral mood induction and healthy control 
participants exposed to the sad and neutral mood inductions. 
Post-hoc power analyses. Post-hoc power analyses were conducted using G*Power 
3.1.9.2 (Faul et al., 2007) to determine the power achieved by the PEP recovery analyses. Of 
note, analyses were only conducted using five-minute PEP recovery as this is a more stable 
measure than two-minute PEP recovery. Results indicated that the current model had a power of 
.08 for the difference score, .07 for the residualized change score, and .06 for the repeated 




effect size, there was a 6 to 8% chance of detecting an effect depending on which analytic 
technique was used. 
Sensitivity analyses. Sensitivity analyses were conducted using G*Power 3.1.9.2 (Faul et 
al., 2007) to determine the minimum effect size needed to obtain significant results for the PEP 
recovery analyses. Of note, analyses were only conducted using five-minute PEP recovery as this 
is a more stable measure than two-minute PEP recovery. Results indicated that the required 
effect size was f = .29 for the factorial ANOVAs and f = .34 for the repeated measures ANOVA. 
Results suggested that given the current study’s sample size and α level, at least a medium effect 

















Table 20. Means, Standard Deviations, P Values, and Effect Sizes for Session 2 Cardiovascular 
Measures by Group 
  Group   
 Total (N = 96) FD (n = 31) HC (n = 65)   
Measure M SD M SD M SD p η2 
HPBL2  781.45 104.55 788.61 115.45 778.03 99.71 .37 .009 
HPBL5  785.51 105.88 795.20 118.17 780.89 100.14 .37 .009 
HPMI2  799.21 111.48 815.35 120.99 791.51 106.77   
HPMI5  788.89 108.15 809.20 119.87 779.20 101.64   
 Total (N = 95) FD (n = 30) HC (n = 65)   
Measure M SD M SD M SD p η2 
HPRC2  783.98 102.44 800.54 119.94 776.33 93.30   
HPRC5  787.42 103.62 804.24 121.00 779.65 94.56   
 Total (N = 96) FD (n = 31) HC (n = 65)   
Measure M SD M SD M SD p η2 
HPDS2RA 17.76 39.29 26.74 42.78 13.48 37.10 .12 .03 
ZRES2HPRA .00 1.00 .24 1.09 -.10 .94 .12 .03 
HPDS5RA  3.38 33.73 14.00 39.80 -1.69 29.43 .05 .04 
ZRES5HPRA .00 1.00 .34 1.18 -.14 .88 .04 .05 
HPRARM2       .79 .001 
HPRARM5       .97 < .001 
 Total (N = 95) FD (n = 30) HC (n = 65)   
Measure M SD M SD M SD p η2 
HPDS2RC  4.23 49.12 17.09 62.74 -1.70 40.59 .03b .05 
ZRES2HPRC .07 .78 .29 1.32 -.14 .75 .05b .04 
HPDS5RC  3.70 37.99 14.41 48.55 -1.24 31.19 .06 .04 
ZRES5HPRC .03 .85 .31 1.32 -.16 .74 .03b .05 
HPRCRM2       .82 .001 
HPRCRM5       .77 .001 
 Total (N = 95) FD (n = 31) HC (n = 64)   
Measure M SD M SD M SD p η2 
RSABL2 5.84 1.04 5.68              1.13 5.91             .99 .50 .005 
RSABL5 5.83 1.01 5.71 1.11 5.89 .96 .38 .008 
RSAMI2 6.03 1.15 6.02 1.09 6.03 1.18   
RSAMI5 5.89 1.13 5.90 1.07 5.88 1.16   
 Total (N = 94) FD (n = 30) HC (n = 64)   
Measure M SD M SD M SD p η2 
RSARC2 5.82 1.00 5.69 1.11 5.89 .95   
RSARC5 5.79 .93 5.71 1.00 5.83 .90   
      
      
      
      




Table 20 Continued     
 Total (N = 95) FD (n = 31) HC (n = 64)   
Measure M SD M SD M SD p η2 
RSADS2RA .24 .61 .34 .65 .20 .59 .12 .03 
ZRES2RSARA .02 .73 .13 .74 .02 .73 .50 .005 
RSADS5RA .11 .45 .19 .52 .07 .41 .23 .02 
ZRES5RSARA .03 .58 .15 .66 .03 .58 .35 .009 
RSARARM2       .56 .004 
RSARARM5       .70 .002 
 Total (N = 94) FD (n = 30) HC (n = 64)   
Measure M SD M SD M SD p η2 
RSADS2RC -.02 .70 -.004 .79 -.03 .66 .88 < .001 
ZRES2RSARC .00 1.00 -.03 1.12 .03 .94 .81 .001 
RSADS5RC -.05 .43 -.04 .41 -.06 .44 .81 .001 
ZRES5RSARC .00 1.00 .005 .91 -.002 1.04 .98 < .001 
RSARCRM2       .32 .01 
RSARCRM5       .50 .005 
 Total (N = 95) FD (n = 31) HC (n = 64)   
Measure M SD M SD M SD p η2 
PEPBL2 120.61 11.90 121.05 11.10 120.40 12.34 .16 .02 
PEPBL5 120.37 11.68 120.70 11.13 120.21 12.02 .21 .02 
PEPMI2 119.77 12.74 120.73 11.01 119.31 13.56   
PEPMI5 119.91 13.04 121.15 11.41 119.31 13.81   
 Total (N = 94) FD (n = 30) HC (n = 64)   
Measure M SD M SD M SD p η2 
PEPRC2 120.15 14.33 119.43 15.34 120.48 13.95   
PEPRC5 120.91 12.24 120.51 10.72 121.09 12.96   
 Total (N = 95) FD (n = 31) HC (n = 64)   
Measure M SD M SD M SD p η2 
PEPDS2RA -.48 4.19 -.32 4.24 -.56 4.20 .94 < .001 
ZRES2PEPRA -.01 .65 .10 .76 .05 .76 .95 < .001 
PEPDS5RA -.31 4.13 .13 3.61 -.52 4.37 .86 < .001 
ZRES5PEPRA .04 .64 .11 .67 -.02 .81 .82 .001 
PEPRARM2       .65 .003 
PEPRARM5       .67 .002 
 Total (N = 94) FD (n = 30) HC (n = 64)   
Measure M SD M SD M SD p η2 
PEPDS2RC .68 5.06 .60 3.41 .71 5.70 .94 < .001 
ZRES2PEPRC .09 .53 .07 .39 .09 .59 .86 < .001 
PEPDS5RC .79 4.57 .12 3.94 1.10 4.84 .42 .007 
ZRES5PEPRC .00 1.00 -.11 .73 .05 .92 .38 .009 
PEPRCRM2       .78 .001 





Note. The difference between baseline and mood induction or mood induction and recovery 
measures may not precisely equal the difference score as outlier data was addressed differently 
depending on the type of analyses conducted; FD = formerly depressed; HC = healthy control; 
HP = heart period at baseline; BL = baseline; MI = mood induction; RC = recovery; 2 = average 
obtained during a two-minute interval; 5 = average obtained during a five-minute interval; DS = 
difference score; RA = reactivity; ZRES = residualized change scores; RSA = respiratory sinus 
arrhythmia; PEP = pre-ejection period; RM = repeated measures; b = only linear results are 






Table 21. Means, Standard Deviations, P Values, and Effect Sizes for Session 2 Cardiovascular Measures by Group and Condition 
  Group and Condition   
 Total (N = 96) FD/SMI (n = 15) FD/NMI (n = 16) HC/SMI (n = 34) HC/NMI (n = 31)   
Measure M SD M SD M SD M SD M SD   
HPBL2  781.45 104.55 787.33 131.66 789.82 102.36 784.73 87.35 770.69 112.74   
HPBL5  785.51 105.88 798.91 134.77 791.72 104.65 785.17 87.23 776.20 113.92   
HPMI2  799.21 111.48 820.97 129.38 810.08 116.58 800.55 98.33 781.59 116.15   
HPMI5  788.89 108.15 823.91 130.36 795.40 111.60 784.78 91.44 773.08 112.99   
 Total (N = 95) FD/SMI (n = 15) FD/NMI (n = 15) HC/SMI (n = 34) HC/NMI (n = 31)   
Measure M SD M SD M SD M SD M SD   
HPRC2  783.98 102.44 816.44 135.64 784.64 104.21 773.14 83.03 779.83 104.71   
HPRC5  787.42 103.62 824.47 133.33 784.01 108.06 779.60 85.45 779.71 105.08   
 Total (N = 96) FD/SMI (n = 15) FD/NMI (n = 16) HC/SMI (n = 34) HC/NMI (n = 31)   
Measure M SD M SD M SD M SD M SD p η2 
HPDS2RA 17.76 39.29 33.64 52.14 20.27 32.09 15.83 38.57 10.90 35.87 .62 .003 
ZRES2HPRA .00 1.00 .42 1.33 .08 .81 -.04 .98 -.16 .91 .62 .003 
HPDS5RA 3.38 33.73 25.00 44.83 3.69 32.53 -.39 30.55 -3.12 28.57 .27 .01 
ZRES5HPRA .00 1.00 .67 1.31 .03 .98 -.10 .91 -.19 .84 .27 .01 
HPRARM2           .44 .007 
HPRARM5           .24 .02 
 Total (N = 95) FD/SMI (n = 15) FD/NMI (n = 15) HC/SMI (n = 34) HC/NMI (n = 31)   
Measure M SD M SD M SD M SD M SD p η2 
HPDS2RC  4.23 49.12 29.11 81.49 5.07 34.67 -11.58 39.91 9.14 39.12 .02b .06 
ZRES2HPRC .07 .78 .56 1.68 .02 .79 -.32 .80 .05 .64 .04b .05 
HPDS5RC  3.70 37.99 25.56 58.82 3.26 34.00 -5.57 33.63 3.51 28.04 .06 .04 
ZRES5HPRC .03 .85 .63 1.56 -.01 .98 -.24 .89 -.07 .55 .05b .04 
HPRCRM2           .35 .01 
HPRCRM5           .26 .01 
        
        
        




Table 21 Continued        
 Total (N = 95) FD/SMI (n = 15) FD/NMI (n = 16) HC/SMI (n = 32) HC/NMI (n = 32)   
Measure M SD M SD M SD M SD M SD   
RSABL2 5.83 1.04 5.54 1.07 5.81 1.21 6.08 1.02 5.74 .94   
RSABL5 5.83 1.01 5.63 1.06 5.79 1.19 6.06 .97 5.71 .93   
RSAMI2 6.03 1.15 5.92 1.02 6.11 1.19 6.32 1.04 5.75 1.25   
RSAMI5 5.89 1.13 5.84 1.00 5.96 1.16 6.20 1.04 5.56 1.21   
 Total (N = 94) FD/SMI (n = 15) FD/NMI (n = 15) HC/SMI (n = 32) HC/NMI (n = 32)   
Measure M SD M SD M SD M SD M SD   
RSARC2 5.82 1.00 5.73 .86 5.65 1.34 6.01 .99 5.76 .91   
RSARC5 5.79 .93 5.70 .92 5.72 1.10 5.97 .94 5.70 .86   
 Total (N = 95) FD/SMI (n = 15) FD/NMI (n = 16) HC/SMI (n = 32) HC/NMI (n = 32)   
Measure M SD M SD M SD M SD M SD p η2 
RSADS2RA .24 .61 .37 .53 .30 .76 .24 .61 .16 .57 .55 .004 
ZRES2RSARA .02 .73 .14 .61 .13 .86 .13 .71 -.09 .74 .47 .006 
RSADS5RA .11 .45 .22 .37 .17 .64 .14 .40 .01 .42 .71 .002 
ZRES5RSARA .03 .58 .17 .47 .14 .81 .16 .57 -.10 .57 .41 .007 
RSARARM2           .12 .03 
RSARARM5           .15 .02 
 Total (N = 94) FD/SMI (n = 15) FD/NMI (n = 15) HC/SMI (n = 32) HC/NMI (n = 32)   
Measure M SD M SD M SD M SD M SD p η2 
RSADS2RC -.02 .70 .18 .74 -.19 .82 -.07 .78 .02 .53 .14 .02 
ZRES2RSARC .00 1.00 .20 .94 -.26 1.26 .03 1.10 .03 .78 .31 .01 
RSADS5RC -.05 .43 .05 .35 -.12 .46 -.10 .53 -.02 .34 .18 .02 
ZRES5RSARC .00 1.00 .19 .79 -.18 1.00 -.03 1.19 .02 .88 .35 .01 
RSARCRM2           .35 .01 
RSARCRM5           .31 .01 
 Total (N = 95) FD/SMI (n = 15) FD/NMI (n = 16) HC/SMI (n = 32) HC/NMI (n = 32)   
Measure M SD M SD M   
PEPBL2 120.61 11.90 118.97 11.36 123.00   
PEPBL5 120.37 11.68 118.99 11.06 122.30   
PEPMI2 119.77 12.74 118.73 10.52 122.59   




Table 21 Continued        
 Total (N = 94) FD/SMI (n = 15) FD/NMI (n = 15) HC/SMI (n = 32) HC/NMI (n = 32)   
Measure M SD M SD M SD M SD M SD   
PEPRC2 120.15 14.33 120.47 10.68 118.40 19.26 120.66 12.65 120.28 15.51   
PEPRC5 120.91 12.24 120.12 10.35 120.91 11.42 120.27 12.78 122.03 13.33   
 Total (N = 95) FD/SMI (n = 15) FD/NMI (n = 16) HC/SMI (n = 32) HC/NMI (n = 32)   
Measure M SD M SD M SD M SD M SD p η2 
PEPDS2RA -.48 4.19 -.23 4.69 -.41 3.92 -.04 4.21 -1.13 4.19 .96 < .001 
ZRES2PEPRA -.01 .65 .10 .83 .09 .71 .15 .74 -.06 .77 .89 < .001 
PEPDS5RA -.31 4.13 .31 3.73 -.04 3.62 -.31 4.95 -.77 3.67 .41 .008 
ZRES5PEPRA .04 .64 .15 .70 .07 .67 .03 .91 -.07 .70 .59 .003 
PEPRARM2           .59 .004 
PEPRARM5           .56 .004 
 Total (N = 94) FD/SMI (n = 15) FD/NMI (n = 15) HC/SMI (n = 32) HC/NMI (n = 32)   
Measure M SD M SD M SD M SD M SD p η2 
PEPDS2RC .68 5.06 .63 3.64 .57 3.29 1.09 4.54 .28 6.84 .75 .001 
ZRES2PEPRC .09 .53 .08 .37 .06 .42 .13 .43 .06 .74 .85 < .001 
PEPDS5RC .79 4.57 .35 2.95 -.11 4.84 .82 3.69 1.41 5.93 .62 .003 
ZRES5PEPRC .00 1.00 -.08 .54 -.15 .89 .003 .65 .11 1.16 .64 .002 
PEPRARM2           .57 .004 
PEPRARM5           .71 .002 
Note. The difference between baseline and mood induction or mood induction and recovery measures may not precisely equal 
the difference score as outlier data was addressed differently depending on the type of analyses conducted; FD = formerly 
depressed; HC = healthy control; SMI = sad mood induction; NMI = neutral mood induction; HP = heart period at baseline; BL 
= baseline; MI = mood induction; RC = recovery; 2 = average obtained during a two-minute interval; 5 = average obtained during 
a five-minute interval; DS = difference score; RA = reactivity; ZRES = residualized change scores; RSA = respiratory sinus 










Table 22. Means, Standard Deviations, and P Values for Session 2 Cardiovascular Measures for Planned 
Comparisons 
  Group and Condition    
 Total (N = 96) FD/SMI (n = 15) FD/NMI, HC/SMI, 
HC/NMI (n = 81) 
   
Measure M SD M SD M SD    
HPBL2  781.45 104.55 787.33 131.66 780.36 99.70    
HPBL5  785.51 105.88 798.91 134.77 783.03 100.47    
HPMI2  799.21 111.48 820.97 129.38 795.18 108.28    
HPMI5  788.89 108.15 823.91 130.36 782.40 103.16    
 Total (N = 95) FD/SMI (n = 15) FD/NMI, HC/SMI, 
HC/NMI (n = 80) 
   
Measure M SD M SD M SD    
HPRC2  783.98 102.44 816.44 135.64 777.89 94.80    
HPRC5  787.42 103.62 824.47 133.33 780.47 96.52    
 Total (N = 96) FD/SMI (n = 15) FD/NMI, HC/SMI, 
HC/NMI (n = 81) 
   
Measure M SD M SD M SD pL pQ pC 
HPDS2RA 17.76 39.29 33.64 52.14 14.82 36.08 .06 .62 .80 
ZRES2HPRA .00 1.00 .42 1.33 -.06 .92 .07 .62 .80 
HPDS5RA 3.38 33.73 25.00 44.83 -.63 29.93 .10b   
ZRES5HPRA .00 1.00 .67 1.31 -.11 .89 .08b   
HPRARM2       .46   
HPRARM5       .26   
       
       
       
       
       
       




Table 22 Continued       
 Total (N = 95) FD/SMI (n = 15) FD/NMI, HC/SMI, 
HC/NMI (n = 80) 
   
Measure M SD M SD M SD pL pQ pC 
HPDS2RC  4.23 49.12 29.11 81.49 -.43 39.43 .11 .04 .53 
ZRES2HPRC .07 .78 .56 1.68 -.11 .75 .05 .04 .58 
HPDS5RC  3.70 37.99 25.56 58.82 -.40 31.56 .05 .06 .90 
ZRES5HPRC .03 .85 .63 1.56 -.13 .79 .02 .05 1.00 
HPRCRM2       .36   
HPRCRM5       .25   
 Total (N = 95) FD/SMI (n = 15) FD/NMI, HC/SMI, 
HC/NMI (n = 80) 
   
Measure M SD M SD M SD    
RSABL2 5.84 1.04 5.54 1.07 5.89 1.03    
RSABL5 5.83 1.01 5.63 1.06 5.87 1.00    
RSAMI2 6.03 1.15 5.92 1.02 6.05 1.17    
RSAMI5 5.89 1.13 5.84 1.00 5.90 1.16    
 Total (N = 94) FD/SMI (n = 15) FD/NMI, HC/SMI, 
HC/NMI (n = 79) 
   
Measure M SD M SD M SD    
RSARC2 5.82 1.00 5.73 .86 5.84 1.03    
RSARC5 5.79 .93 5.69 .92 5.81 .94    
 Total (N = 95) FD/SMI (n = 15) FD/NMI, HC/SMI, 
HC/NMI (n = 80) 
   
Measure M SD M SD M SD pL pQ pC 
RSADS2RA .24 .61 .37 .53 .22 .62 .40b   
ZRES2RSARA .02 .73 .14 .61 .04 .75 .66b   
RSADS5RA .11 .45 .22 .37 .09 .46 .15 .71 .78 
ZRES5RSARA .03 .58 .17 .47 .05 .63 .19 .41 .58 
RSARARM2       .40   
RSARARM5       .60   
       




Table 22 Continued       
 Total (N = 94) FD/SMI (n = 15) FD/NMI, HC/SMI, 
HC/NMI (n = 79) 
   
Measure M SD M SD M SD pL pQ pC 
RSADS2RC -.02 .70 .18 .74 -.06 .69 .59 .14 .45 
ZRES2RSARC .00 1.00 .20 .94 -.03 1.01 .81 .31 .30 
RSADS5RC -.05 .43 .05 .35 -.07 .44 .67 .18 .74 
ZRES5RSARC .00 1.00 .19 .79 -.04 1.03 .73 .35 .53 
RSARCRM2       .50   
RSARCRM5       .49   
 Total (N = 95) FD/SMI (n = 15) FD/NMI, HC/SMI, 
HC/NMI (n = 80) 
   
Measure M SD M SD M SD    
PEPBL2 120.61 11.90 118.97 11.37 120.92 12.04    
PEPBL5 120.37 11.68 118.99 11.06 120.63 11.84    
PEPMI2 119.77 12.74 118.73 10.52 119.96 13.17    
PEPMI5 119.91 13.04 119.29 10.98 120.03 13.45    
 Total (N = 94) FD/SMI (n = 15) FD/NMI, HC/SMI, 
HC/NMI (n = 79) 
   
Measure M SD M SD M SD    
PEPRC2 120.15 14.33 120.47 10.68 120.09 14.98    
PEPRC5 120.91 12.24 120.12 10.35 121.06 12.62    
 Total (N = 95) FD/SMI (n = 15) FD/NMI, HC/SMI, 
HC/NMI (n = 80) 
   
Measure M SD M SD M SD pL pQ pC 
PEPDS2RA -.48 4.19 -.23 4.69 -.53 4.12 .79b   
ZRES2PEPRA -.01 .65 .10 .83 .06 .74 .79b   
PEPDS5RA -.31 4.13 .31 3.73 -.43 4.21 .80b   
ZRES5PEPRA .04 .64 .15 .70 .001 .78 .82b   
PEPRARM2       .68   
PEPRARM5       .83   
       




Table 22 Continued       
 Total (N = 94) FD/SMI (n = 15) FD/NMI, HC/SMI, 
HC/NMI (n = 79) 
   
Measure M SD M SD M SD pL pQ pC 
PEPDS2RC .68 5.06 .63 3.64 .68 5.31 .92 .75 .71 
ZRES2PEPRC .09 .53 .08 .37 .09 .56 .98 .85 .65 
PEPDS5RC .79 4.57 .35 2.95 .87 4.83 .83b   
ZRES5PEPRC .00 1.00 -.08 .54 .01 .91 .41 .64 .74 
PEPRCRM2       .86   
PEPRCRM5       .79   
Note. The difference between baseline and mood induction or mood induction and recovery measures may not 
precisely equal the difference score as outlier data was addressed differently depending on the type of analyses 
conducted; FD = formerly depressed; HC = healthy control; SMI = sad mood induction; NMI = neutral mood 
induction; L = linear; Q = quadratic; C = cubic; HP = heart period at baseline; BL = baseline; MI = mood induction; RC 
= recovery; 2 = average obtained during a two-minute interval; 5 = average obtained during a five-minute interval; DS 
= difference score; RA = reactivity; ZRES = residualized change scores; RSA = respiratory sinus arrhythmia; PEP = 






Bivariate Correlations. Bivariate correlations were used to examine correlations for 
cognitive, mood, and cardiovascular measures. Of note, only relevant variables were analyzed. 
Only five-minute averages for cardiovascular measures are presented as they are more a reliable 
measure of cardiovascular functioning than two-minute averages (S. K. McCoy, personal 
communication, June 14, 2019). A correlation matrix for cognitive, mood, and cardiovascular 
pre- and post-mood induction scores for the entire sample is presented in Table 23, correlation 
matrices for cognitive, mood, and cardiovascular pre- and post-mood induction scores by group 
are presented in Table 24, and correlation matrices for cognitive, mood, and cardiovascular pre- 
and post-mood induction scores by group and condition are presented in Table 25. Correlation 
matrices for cognitive, mood, and cardiovascular change scores for the entire sample are 
presented in Table 26, correlation matrices for cognitive, mood, and cardiovascular change 
scores by group are presented in Table 27, and correlation matrices for cognitive, mood, and 
cardiovascular change scores by group and condition are presented in Table 28.  
Cognitive and mood measures. Bivariate correlations were used to investigate the 
relationship between cognitive and mood measures pre- and post-mood induction. Correlations 
between pre- and post-mood induction scores for the entire sample were examined. Pre- and 
post-mood induction measures were positively correlated for the DAS-SF I & II, VASPRE and 
VASPOST, PANAS-X NPRE and PANAS-X NPOST, PANAS-X PPRE and PANAS-X PPOST, 
PANAS-X GPRE and PANAS-X GPOST, and PANAS-X SPRE and PANAS-X SPOST (r = .36-.91, p 
< .001 for all). These results suggest that pre- and post-mood induction scores for cognitive and 
mood measures all correlate with one another as expected. 
Correlations between pre- and post-mood induction, difference, and residualized change 




with the VASPRE, PANAS-X NPRE, PANAS-X NPOST, PANAS-X GPRE, PANAS-X GPOST, 
PANAS-X SPRE, and PANAS-X SPOST (r = -.31--.47, p < .001 for all). The DAS II was positively 
correlated with the PANAS-X PPOST (r = .27, p < .01) and negatively correlated with the 
VASPRE, VASPOST, PANAS-X NPRE, PANAS-X NPOST, PANAS-X GPRE, PANAS-X GPOST, 
PANAS-X SPRE, and PANAS-X SPOST (r = -.24--.46, p < .01-.001). Some of these correlations 
were also obtained when using difference and residualized change scores. The DASDS and 
ZRESDAS was positively correlated with the PANAS-X PDS and ZRESPANAS-X P (r = .26-.29, p 
< .01-.001) and negatively correlated with the VASDS and ZRESVAS (r = -.20--.23, p < .05 for 
all). Of note, the valences of these correlations are in the expected direction as lower scores on 
the DAS are indicative of increased dysfunctional beliefs. Therefore, these results suggest that 
increased dysfunctional thoughts pre- and post-mood induction were associated with increased 
dysphoric mood, negative affect, guilt, and sadness pre- and post-mood induction while 
increased dysfunctional thoughts post-mood induction were also associated with decreased 
positive affect post-mood induction. In addition, these results indicate that increased 
dysfunctional thoughts during the experimental paradigm was associated with increased 
dysphoric mood and decreased positive affect post-mood induction. 
The VASPRE was positively correlated with the PANAS-X NPRE, PANAS-X NPOST, 
PANAS-X GPRE, PANAS-X GPOST, PANAS-X SPRE, and PANAS-X SPOST (r = .33-.41, p < .001 
for all). The VASPOST was positively correlated with the PANAS-X NPOST and PANAS-X SPOST 
(r = .22-.39, p < .05-.001) and negatively correlated with the PANAS-X PPOST (r = -.27, p < .01). 
Correlations were also obtained between the VAS and PANAS-X subscales when using 
difference and residualized change scores. The VASDS and ZRESVAS was positively correlated 




and negatively correlated with the PANAS-X PDS and ZRESPANAS-X P (r = -.36--.38, p < .001 
for all). These results suggest that increased dysphoric mood pre-mood induction was associated 
with increased negative affect, guilt, and sadness pre- and post-mood induction while increased 
dysphoric mood post-mood induction was associated with increased negative affect and sadness 
and decreased positive affect post-mood induction. In addition, these results indicate that 
increased dysphoric mood during the experimental paradigm was associated with increased 
negative affect, guilt, and sadness and decreased positive affect post-mood induction. 
The PANAS-X NPRE was positively correlated with the PANAS-X GPRE, PANAS-X 
GPOST, PANAS-X SPRE, and PANAS-X SPOST (r =.67-.87, p < .001 for all). The PANAS-X NPOST 
was positively correlated with the PANAS-X GPRE, PANAS-X GPOST, PANAS-X SPRE, and 
PANAS-X SPOST (r =.73-.84, p < .001 for all). These correlations were also obtained when using 
difference and residualized change scores. The PANAS-X NDS and ZRESPANAS-X N was 
positively correlated with the PANAS-X GDS, ZRESPANAS-X G, PANAS-X SDS, and 
ZRESPANAS-X S (r = .46-.64, p < .001 for all). These results suggest that increased negative 
affect pre- and post-mood induction was associated with increased guilt and sadness pre- and 
post-mood induction. In addition, these results indicate that increased negative affect during the 
experimental paradigm was associated with increased guilt and sadness post-mood induction. 
While the PANAS-X PPRE and PANAS-X PPOST were not associated with other pre- and 
post-mood induction PANAS-X measures, significant correlations were present when using 
difference and residualized change scores. The PANAS-X PDS was negatively correlated with the 
PANAS-X SDS (r = -.38, p < .001) while the ZRESPANAS-X P was negatively correlated with the 




affect during the experimental paradigm was associated with decreased guilt and sadness post-
mood induction. 
The PANAS-X GPRE and PANAS-X GPOST was positively correlated with the PANAS-X 
SPRE and PANAS-X SPOST (r =.60-.70, p < .001 for all). These correlations were also obtained 
when using difference and residualized change scores. The PANAS-X GDS and ZRESPANAS-X 
G was positively correlated with the PANAS-X SDS and ZRESPANAS-X S (r = .48-.52, p < .001 
for all). These results suggest that increased guilt pre- and post-mood induction was associated 
with increased sadness pre- and post-mood induction. In addition, these results indicate that 
increased guilt during the experimental paradigm was associated with increased sadness post-
mood induction. 
Correlations between cognitive and mood pre- and post-mood induction, difference, and 
residualized change scores were evaluated between groups. For formerly depressed participants, 
most of the pre- and post-mood induction measures were positively correlated, including the 
DAS-SF I & II, PANAS-X NPRE and PANAS-X NPOST, PANAS-X PPRE and PANAS-X PPOST, 
PANAS-X GPRE and PANAS-X GPOST, and PANAS-X SPRE and PANAS-X SPOST (r = .69-.90, p 
< .001 for all). However, the VASPRE and VASPOST (r = .14, p > .05) were not significantly 
correlated, suggesting that there was a significant difference in dysphoric mood pre- and post-
mood induction for formerly depressed participants. The DASDS and ZRESDAS were not 
correlated with any of the mood or affect measures. The VASDS and ZRESVAS were positively 
correlated with the PANAS-X NDS, GDS, and SDS and ZRESPANAS-X N, G, and S (r = .40-.56, p 
< .05-.001) and negatively correlated with the PANAS-X PDS and ZRESPANAS-X P (r = -.52, p < 
.001 for all). The PANAS-X NDS and ZRESPANAS-X N were positively correlated with the 




for all). The PANAS-X PDS and ZRESPANAS-X P were negatively correlated with the PANAS-X 
SDS and ZRESPANAS-X G (r = -.49--.56, p < .001 for all). Finally, the PANAS-X GDS and 
ZRESPANAS-X G were positively correlated with the PANAS-X SDS and ZRESPANAS-X S (r = 
.60-.65, p < .001 for all). Overall, these correlations show a similar pattern to those previously 
reported for the entire sample. 
For healthy control participants, all pre- and post-mood induction measures were 
positively correlated, including the DAS-SF I & II, VASPRE and VASPOST, PANAS-X NPRE and 
PANAS-X NPOST, PANAS-X PPRE and PANAS-X PPOST, PANAS-X GPRE and PANAS-X GPOST, 
and PANAS-X SPRE and PANAS-X SPOST (r = .46-.91, p < .001 for all). Importantly, these results 
suggest that there was no difference in dysphoric mood pre- and post-mood induction for healthy 
control participants. The DASDS and ZRESDAS was positively correlated with the PANAS-X PDS 
and ZRESPANAS-X P (r = .25-.28, p < .05 for all). The VASDS and ZRESVAS were positively 
correlated with the PANAS-X SDS and ZRESPANAS-X G (r = .41-.50, p < .001 for all) and 
negatively correlated with the PANAS-X PDS and ZRESPANAS-X P (r = -.29-.32, p < .01 for all). 
The PANAS-X NDS and ZRESPANAS-X N were positively correlated with the PANAS-X GDS, 
ZRESPANAS-X G, PANAS-X SDS, and ZRESPANAS-X S (r = .36-.48, p < .001 for all). The 
PANAS-X PDS and ZRESPANAS-X P were negatively correlated with the PANAS-X SDS and 
ZRESPANAS-X G (r = -.34--.37, p < .01-.001). Finally, the PANAS-X GDS and ZRESPANAS-X G 
were positively correlated with the PANAS-X SDS and ZRESPANAS-X S (r = .29-.30, p < .01 for 
all). Overall, these correlations show a similar pattern to those previously reported for the entire 
sample. 
Correlations between cognitive and mood pre- and post-mood induction, difference, and 




depressed participants exposed to the sad mood induction, most of the pre- and post-mood 
induction measures were positively correlated, including the DAS-SF I & II, PANAS-X NPRE and 
PANAS-X NPOST, PANAS-X PPRE and PANAS-X PPOST, PANAS-X GPRE and PANAS-X GPOST, 
and PANAS-X SPRE and PANAS-X SPOST (r = .77-.87, p < .001 for all). However, the VASPRE 
and VASPOST (r = .16, p > .05) were not significantly correlated, suggesting that there was a 
significant difference in dysphoric mood pre- and post-mood induction for formerly depressed 
participants exposed to the sad mood induction. The DASDS was negatively correlated with the 
VASDS (r = -.58, p < .05) while the ZRESDAS was not correlated with any of the mood or affect 
measures. The VASDS and ZRESVAS were positively correlated with the PANAS-X NDS, 
PANAS-X SDS, ZRESPANAS-X N, and ZRESPANAS-X G (r = .49-.57, p < .05 for all). The 
PANAS-X NDS and ZRESPANAS-X N were positively correlated with the PANAS-X GDS, 
ZRESPANAS-X G, PANAS-X SDS, and ZRESPANAS-X S (r = .52-.78, p < .05-.001). The 
PANAS-X PDS and ZRESPANAS-X P were negatively correlated with the PANAS-X SDS and 
ZRESPANAS-X G (r = -.57--.65, p < .01-.001). Finally, the PANAS-X GDS and ZRESPANAS-X G 
were positively correlated with the PANAS-X SDS and ZRESPANAS-X S (r = .59-.65, p < .01 for 
all). Overall, these correlations show a similar pattern to those previously reported for the entire 
sample. 
For formerly depressed participants exposed to the neutral mood induction, most of the 
pre- and post-mood induction measures were positively correlated, including the DAS-SF I & II, 
PANAS-X NPRE and PANAS-X NPOST, PANAS-X PPRE and PANAS-X PPOST, PANAS-X GPRE 
and PANAS-X GPOST, and PANAS-X SPRE and PANAS-X SPOST (r = .63-.95, p < .001 for all). 
However, the VASPRE and VASPOST (r = .37, p > .05) were not significantly correlated, 




induction for formerly depressed participants exposed to the neutral mood induction. Of note, 
this correlation was stronger than the correlation for formerly depressed participants exposed to 
the sad mood induction (r = .16, p > .05). The DASDS, ZRESDAS, VASDS, ZRESVAS, PANAS-X 
PDS, ZRESPANAS-X P, PANAS-X GDS, and ZRESPANAS-X G were not correlated with any of 
the mood or affect measures. The PANAS-X NDS and ZRESPANAS-X N were positively 
correlated with the PANAS-X GDS, ZRESPANAS-X G, PANAS-X SDS, and ZRESPANAS-X S (r = 
.62-.72, p < .01-.001). Overall, these correlations show a similar pattern to those previously 
reported for the entire sample with the exception of some of the mood and affective measures. 
For healthy control participants exposed to the sad mood induction, all pre- and post-
mood induction measures were positively correlated, including the DAS-SF I & II, VASPRE and 
VASPOST, PANAS-X NPRE and PANAS-X NPOST, PANAS-X PPRE and PANAS-X PPOST, 
PANAS-X GPRE and PANAS-X GPOST, and PANAS-X SPRE and PANAS-X SPOST (r = .41-.92, p 
< .01-.001). Importantly, these results suggest that there was no difference in dysphoric mood 
pre- and post-mood induction for healthy control participants exposed to the sad mood induction. 
The DASDS and ZRESDAS were not correlated with any of the mood or affect measures. The 
VASDS and ZRESVAS were positively correlated with the PANAS-X SDS and ZRESPANAS-X G (r 
= .40-.51, p < .01-.001). The PANAS-X NDS and ZRESPANAS-X N were positively correlated 
with the PANAS-X GDS, ZRESPANAS-X G, PANAS-X SDS, and ZRESPANAS-X S (r = .42-.53, p 
< .01-.001). The PANAS-X PDS and ZRESPANAS-X P were negatively correlated with the 
PANAS-X SDS and ZRESPANAS-X G (r = -.40--.41, p < .01 for all). Finally, the PANAS-X GDS 
and ZRESPANAS-X G were positively correlated with the PANAS-X SDS and ZRESPANAS-X S 
(r = .34, p < .01 for all). Overall, these correlations show a similar pattern to those previously 




For healthy control participants exposed to the neutral mood induction, all pre- and post-
mood induction measures were positively correlated, including the DAS-SF I & II, VASPRE and 
VASPOST, PANAS-X NPRE and PANAS-X NPOST, PANAS-X PPRE and PANAS-X PPOST, 
PANAS-X GPRE and PANAS-X GPOST, and PANAS-X SPRE and PANAS-X SPOST (r = .64-.94, p 
< .001 for all). Importantly, these results suggest that there was no difference in dysphoric mood 
pre- and post-mood induction for healthy control participants exposed to the neutral mood 
induction. The ZRESDAS was positively correlated with ZRESPANAS-X P (r = .36, p < .05). The 
ZRESPANAS-X N was positively correlated with the, ZRESPANAS-X G and ZRESPANAS-X S (r 
= .39-.40, p < .05 for all). The DASDS, VASDS, ZRESVAS, PANAS-X NDS, PANAS-X PDS, 
ZRESPANAS-X P, PANAS-X GDS, and ZRESPANAS-X G were not correlated with any of the 
mood or affect measures. Overall, these correlations show a similar pattern to those previously 
reported for the entire sample with the exception of some of the mood and affective measures. 
Cardiovascular measures. Bivariate correlations were used to investigate the relationship 
between cardiovascular measures pre- and post-mood induction. Correlations between pre- and 
post-mood induction, difference, and residualized change scores for the entire sample were 
examined. Five-minute HP during baseline, mood induction, and recovery were positively 
correlated when using pre- and post-mood induction (r = .94-.96, p < .001 for all). Five-minute 
HP reactivity and recovery were positively correlated when using difference and residualized 
change scores (r = .59, p < .001 for all). Five-minute RSA during baseline, mood induction, and 
recovery were positively correlated when using pre- and post-mood induction (r = .75-.90, p < 
.001 for all). Five-minute RSA reactivity and recovery were positively correlated when using 
difference and residualized change scores (r = .46-.47, p < .001 for all). Five-minute PEP during 




mood induction (r = .89-.91, p < .001 for all). Finally, five-minute PEP reactivity and recovery 
were positively correlated when using difference and residualized change scores (r = .37-.45, p < 
.001 for all). These results suggest that pre- and post-mood induction scores for cardiovascular 
measures all correlate with one another as expected. 
Correlations between cardiovascular pre- and post-mood induction, difference, and 
residualized change scores were evaluated between groups. For formerly depressed participants, 
five-minute HP during baseline, mood induction, and recovery were positively correlated when 
using pre- and post-mood induction (r = .95-.97, p < .001 for all). Five-minute HP reactivity and 
recovery were positively correlated when using difference and residualized change scores (r = 
.54-.55, p < .05 for all). Five-minute RSA during baseline, mood induction, and recovery were 
positively correlated when using pre- and post-mood induction (r = .89-.93, p < .001 for all). 
Five-minute RSA reactivity and recovery were positively correlated when using difference and 
residualized change scores (r = .48-.53, p < .01 for all). Five-minute PEP during baseline, mood 
induction, and recovery were positively correlated when using pre- and post-mood induction (r = 
.92-.96, p < .001 for all). Five-minute PEP reactivity and recovery were positively correlated 
when using difference and residualized change scores (r = .59-.60, p < .05 for all). Overall, these 
correlations show a similar pattern to those previously reported for the entire sample. 
For healthy control participants, five-minute HP during baseline, mood induction, and 
recovery were positively correlated when using pre- and post-mood induction (r = .94-.97, p < 
.001 for all). Five-minute HP reactivity and recovery were positively correlated when using 
difference and residualized change scores (r = .45-.48, p < .05 for all). Five-minute RSA during 
baseline, mood induction, and recovery were positively correlated when using pre- and post-




positively correlated when using difference and residualized change scores (r = .46, p < .001 for 
all). Five-minute PEP during baseline, mood induction, and recovery were positively correlated 
when using pre- and post-mood induction (r = .96-.97, p < .001 for all). Five-minute PEP 
reactivity and recovery were positively correlated when using difference and residualized change 
scores (r = .39-.46, p < .05 for all). Overall, these correlations show a similar pattern to those 
previously reported for the entire sample. 
Correlations between cardiovascular pre- and post-mood induction, difference, and 
residualized change scores were evaluated between groups and conditions. For formerly 
depressed participants exposed to the sad mood induction, five-minute HP during baseline, mood 
induction, and recovery were positively correlated when using pre- and post-mood induction (r = 
.94-.98, p < .001 for all). Five-minute HP reactivity and recovery were not correlated when using 
difference and residualized change scores. Five-minute RSA during baseline, mood induction, 
and recovery were positively correlated when using pre- and post-mood induction (r = .94-.96, p 
< .001 for all). Five-minute RSA reactivity and recovery were positively correlated when using 
difference and residualized change scores (r = .65-.67, p < .01 for all). Five-minute PEP during 
baseline, mood induction, and recovery were positively correlated when using pre- and post-
mood induction (r = .93-.95, p < .001 for all). Five-minute PEP reactivity and recovery were not 
correlated when using difference and residualized change scores. Overall, these correlations 
show a similar pattern to those previously reported for the entire sample with the exception of 
some cardiovascular measures. 
For formerly depressed participants exposed to the neutral mood induction, five-minute 
HP during baseline, mood induction, and recovery were positively correlated when using pre- 




were positively correlated when using difference and residualized change scores (r = .88-.89, p < 
.05 for all). Five-minute RSA during baseline, mood induction, and recovery were positively 
correlated when using pre- and post-mood induction (r = .85-.93, p < .001 for all). Five-minute 
RSA reactivity and recovery were not correlated when using difference and residualized change 
scores. Five-minute PEP during baseline, mood induction, and recovery were positively 
correlated when using pre- and post-mood induction (r = .91-.98, p < .001 for all). Five-minute 
PEP reactivity and recovery were not correlated when using difference and residualized change 
scores. Overall, these correlations show a similar pattern to those previously reported for the 
entire sample with the exception of some cardiovascular measures. 
For healthy control participants exposed to the sad mood induction, five-minute HP 
during baseline, mood induction, and recovery were positively correlated when using pre- and 
post-mood induction (r = .92-.97, p < .001 for all). Five-minute HP reactivity and recovery were 
positively correlated when using residualized change, but not difference, scores (r = .59, p < .01). 
Five-minute RSA during baseline, mood induction, and recovery were positively correlated 
when using pre- and post-mood induction (r = .85-.92, p < .001 for all). Five-minute RSA 
reactivity and recovery were positively correlated when using difference and residualized change 
scores (r = .49-.50, p < .01 for all). Five-minute PEP during baseline, mood induction, and 
recovery were positively correlated when using pre- and post-mood induction (r = .96-.98, p < 
.001 for all). Five-minute PEP reactivity and recovery were positively correlated when using 
difference, but not residualized change, scores (r = .63, p < .05). Overall, these correlations show 





For healthy control participants exposed to the neutral mood induction, five-minute HP 
during baseline, mood induction, and recovery were positively correlated when using pre- and 
post-mood induction (r = .95-.97, p < .001 for all). Five-minute HP reactivity and recovery were 
not correlated when using difference and residualized change scores. Five-minute RSA during 
baseline, mood induction, and recovery were positively correlated when using pre- and post-
mood induction (r = .47-.90, p < .01-.001). Five-minute RSA reactivity and recovery were 
positively correlated when using difference and residualized change scores (r = .47-.48, p < .01 
for all). Five-minute PEP during baseline, mood induction, and recovery were positively 
correlated when using pre- and post-mood induction (r = .92-.97, p < .001 for all). Five-minute 
PEP reactivity and recovery were not correlated when using difference and residualized change 
scores. Overall, these correlations show a similar pattern to those previously reported for the 
entire sample with the exception of some cardiovascular measures. 
Cognitive, mood, and cardiovascular measures. Bivariate correlations were used to 
investigate the relationship between cognitive, mood, and cardiovascular measures pre- and post-
mood induction. Correlations between pre- and post-mood induction, difference, and 
residualized change scores for the entire sample were examined. The majority of the self-report 
measures (with the exception of the PANAS-X PPRE, PANAS-X PPOST, and ZRESVAS) were not 
significantly correlated with HP, RSA, or PEP.  
Correlations between pre- and post-mood induction, difference, and residualized change 
scores were evaluated between groups. For formerly depressed participants, the majority of the 
self-report measures (with the exception of the VASPOST and PANAS-X NDS) were not 
significantly correlated with HP, RSA, or PEP. For healthy control participants, the majority of 




PANAS-X GDS, PANAS-X SDS, ZRESDAS, ZRESVAS, ZRESPANAS-X G, and ZRESPANAS-X S) 
were not significantly correlated with HP, RSA, or PEP. Overall, these correlations show a 
similar pattern to those previously reported for the entire sample with the exception of some 
measures. However, one notable association was observed. The post-mood induction VAS was 
negatively correlated with five-minute HP during baseline, mood induction, and recovery (r = -
.56--.57, p < .05 for all), suggesting that formerly depressed participants who experience an 
increase in sadness post-mood induction exhibit decreased HP during baseline, mood induction, 
and recovery. These correlations run counter to the trends found for Hypotheses 2, 3, and 4. 
Consequently, additional analyses were conducted for the group and condition interaction, which 
revealed that the relationship between the VASPOST and HP during baseline, mood induction, and 
recovery was more robust in formerly depressed participants exposed to the neutral mood 
induction (r = -.51--.62, p > .19 for all) than those exposed to the sad mood induction (r = -.31--
.46, p > .19 for all).  
Correlations between pre- and post-mood induction, difference, and residualized change 
scores were evaluated between groups and conditions. For formerly depressed participants 
exposed to the sad mood induction, the majority of the self-report measures (with the exception 
of the ZRESDAS and ZRESRSARC) were not significantly correlated with HP, RSA, or PEP. For 
formerly depressed participants exposed to the neutral mood induction, the majority of the self-
report measures (with the exception of the PANAS-X NPOST and PEPBL5, PANAS-X GPRE, 
PANAS-X GPOST, and PEPRC5 and VASDS, ZRESVAS, RSADS5RA, and ZRESRSARA) were not 
significantly correlated with HP, RSA, or PEP. For healthy control participants exposed to the 
sad mood induction, the majority of the self-report measures (with the exception of the 




HPDS5RA, PANAS-X SDS and HPDS5RC, ZRESPANAS-X P and ZRESHPRA, and ZRESPANAS-X G 
and ZRESHPRC) were not significantly correlated with HP, RSA, or PEP. For healthy control 
participants exposed to the neutral mood induction, the majority of the self-report measures (with 
the exception of the PANAS-X NPOST, PANAS-X PPRE, and PEPBL5, PANAS-X PPRE and 
PEPRC5, VASDS and HPDS5RA, PANAS-X SDS and PEPDS5RC, ZRESDAS and ZRESHPRC, 
ZRESPANAS-X N,  ZRESPANAS-X G, and ZRESPEPRC) were not significantly correlated with 
HP, RSA, or PEP. Overall, these correlations show a similar pattern to those previously reported 




Table 23. Correlation Matrix for Cognitive, Mood, and Cardiovascular Pre- and Post-Mood Induction Scores for the Entire Sample 
Measure 1. 2. 3. 4. 5. 6. 7. 8. 9. 10. 11. 12. 13. 14. 15. 16. 17. 18. 19. 20. 
1. DAS I                     
2. DAS II .73e                    
3. VASPRE -.31e -.24d                   
4. VASPOST -.17 -.26d .36e                  
5. PANAS-X NPRE -.47e -.43e .37e .08                 
6. PANAS-X NPOST -.45e -.40e .41e .22c .91e                
7. PANAS-X PPRE .21c .12 -.06 -.07 .08 .06               
8. PANAS-X PPOST .22c .27d -.13 -.27d .08 .02 .85e              
9. PANAS-X GPRE -.47e -.44e .34e .08 .87e .79e -.07 -.07             
10. PANAS-X GPOST -.43e -.46e .33e .17 .80e .84e -.04 -.11 .90e            
11. PANAS-X SPRE -.44e -.42e .35e .14 .78e .73e -.08 -.07 .70e .67e           
12 PANAS-X SPOST -.45e -.43e .37e .39e .67e .75e -.05 -.17 .60e .70e .84e          
13. HPBL5 -.03 -.02 .11 -.18 .06 .00 .02 .09 .04 -.05 -.12 -.03         
14. HPMI5 -.04 .004 .12 -.21 .13 .03 .10 .16 .03 -.09 -.07 -.01 .95e        
15. HPRC5 -.12 -.13 .11 -.21 .10 .04 .09 .14 .01 -.04 -.06 .02 .94e .96e       
16. RSABL5 .02 -.01 .07 .07 .09 .01 .09 .08 .10 .04 .08 .06 -.02 .04 -.03      
17. RSAMI5 -.01 .003 .14 .17 .02 -.01 .15 .11 .05 -.003 -.01 -.01 .13 .14 .08 .75e     
18. RSARC5 -.03 -.03 .11 .08 .13 .06 .16 .14 .14 .09 .10 .06 .02 .07 .02 .90e .80e    
19. PEPBL5 .06 .06 -.16 -.29 -.13 -.17 .25 .34c -.13 -.07 -.27 -.27 .23c .22c .20c -.19 -.13 -.07   
20. PEPMI5 -.04 -.03 -.09 -.21 -.04 -.10 .27 .33c -.07 -.04 -.16 -.16 .23c .23c .21c -.20 -.14 -.07 .91e  
21. PEPRC5 .07 .03 -.15 -.26 -.03 -.09 .38c .44d -.11 -.06 -.18 -.15 .23c .25c .25c -.06 -.06 .03 .89e .91e 
Note. DAS I = Dysfunctional Attitudes Scale – Short Form I; DAS II = Dysfunctional Attitudes Scale – Short Form II; VAS = Visual 
Analogue Scale; PRE = pre mood induction; POST = post mood induction; PANAS-X = Positive and Negative Affect Scale – Expanded 
Form; N = negative affect general dimension scale; P = positive affect general dimension scale; G = guilt basic negative emotional 
scale; S = sadness basic negative emotional scale; HP = heart period at baseline; BL = baseline; 5 = average obtained during a five-
minute interval; MI = mood induction; RC = recovery; RSA = respiratory sinus arrhythmia; PEP = pre-ejection period; c = p < .05; d = p 














Table 24. Correlation Matrices for Cognitive, Mood, and Cardiovascular Pre- and Post-Mood Induction Scores by Group 
FD  
Measure 1. 2. 3. 4. 5. 6. 7. 8. 9. 10. 11. 12. 13. 14. 15. 16. 17. 18. 19. 20. 
1. DAS I                     
2. DAS II .69e                    
3. VASPRE -.03 .13                   
4. VASPOST .21 .04 .14                  
5. PANAS-X NPRE -.55e -.50e .22 -.12                 
6. PANAS-X NPOST -.49e -.46d .16 .11 .90e                
7. PANAS-X PPRE .03 -.02 -.10 .07 .15 .15               
8. PANAS-X PPOST -.05 -.01 -.04 -.23 .28 .17 .83e              
9. PANAS-X GPRE -.53e -.54e .19 -.13 .87e .78e -.02 .13             
10. PANAS-X GPOST -.49e -.58e .15 .02 .80e .88e .03 .07 .86e            
11. PANAS-X SPRE -.48e -.35c .29 -.05 .76e .72e -.13 .02 .70e .69e           
12 PANAS-X SPOST -.44d -.31c .15 .19 .66e .76e .10 .03 .53e .70e .84e          
13. HPBL5 .28 .28 -.06 -.56c .06 -.08 .06 .10 .07 -.06 -.35 -.38         
14. HPMI5 .18 .21 .03 -.57c .19 .01 .09 .09 .12 -.05 -.23 -.26 .97e        
15. HPRC5 .14 .07 -.001 -.57c .12 .02 .08 .04 .08 -.001 -.23 -.20 .95e .96e       
16. RSABL5 -.12 -.21 .13 -.02 .23 .11 .08 .16 .19 .13 .27 .16 -.45 -.35 -.40      
17. RSAMI5 -.08 -.14 .11 .08 .16 .07 .10 .20 .12 .04 .16 .06 -.36 -.29 -.30 .89e     
18. RSARC5 -.06 -.11 .08 -.02 .28 .18 .11 .24 .23 .17 .31 .18 -.33 -.28 -.34 .93e .91e    
19. PEPBL5 -.04 .03 -.26 -.24 -.24 -.09 .01 .09 -.22 -.05 -.47 -.36 .12 .02 -.02 -.67d -.65d -.57c   
20. PEPMI5 -.07 .06 -.21 -.21 -.14 -.04 .04 .11 -.12 -.03 -.33 -.25 .12 .03 -.08 -.64c -.66d -.56c .96e  
21. PEPRC5 .04 -.05 -.22 -.15 -.12 .04 .20 .17 -.13 .03 -.26 -.13 .06 .004 .08 -.57c -.57c -.52 .92e .94e 
HC  
Measure 1. 2. 3. 4. 5. 6. 7. 8. 9. 10. 11. 12. 13. 14. 15. 16. 17. 18. 19. 20. 
1. DAS I                     
2. DAS II .72e                    
3. VASPRE -.44e -.39e                   
4. VASPOST -.28c -.31d .46e                  
5. PANAS-X NPRE -.33d -.29c .48e .14                 
6. PANAS-X NPOST -.34d -.25c .58e .20 .91e                
7. PANAS-X PPRE .20 .06 .02 -.06 .19 .16               
8. PANAS-X PPOST .21 .24c -.10 -.22c .19 .14 .85e              
9. PANAS-X GPRE -.33d -.27c .46e .14 .82e .76e .04 -.01             
10. PANAS-X GPOST -.29d -.27c .46e .15 .72e .75e .08 -.01 .91e            
11. PANAS-X SPRE -.33d -.40e .35e .19 .74e .67e .08 .04 .62e .56e           
12 PANAS-X SPOST -.38e -.42e .52e .48e .62e .68e -.01 -.14 .61e .62e .80e          
13. HPBL5 -.28 -.21 .30 .09 .02 .08 -.01 .10 .01 -.02 .12 .31         
14. HPMI5 -.24 -.16 .28 .11 .11 .13 .04 .15 .01 -.03 .17 .30 .97e        
15. HPRC5 -.34 -.29 .28 .07 .12 .14 .04 .15 -.01 .01 .18 .28 .94e .95e       
16. RSABL5 .07 .05 .05 .14 -.001 -.02 .07 .01 .06 .03 -.03 .03 .24 .24 .16      
17. RSAMI5 .03 .06 .15 .21 -.09 -.07 .18 .09 -.001 -.05 -.14 -.06 .37 .33 .24 .69e     




Table 24 Continued 
19. PEPBL5 .12 .05 -.02 -.30 -.002 -.19 .36 .45c .40 -.02 -.06 -.17 .27 .36 .29 .02 .07 .16   
20. PEPMI5 -.03 -.12 .08 -.17 .08 -.10 .40c .46c .09 .04 .08 -.02 .35 .43c .38 .03 .08 .19 .97e  
21. PEPRC5 .05 -.004 -.01 -.24 .11 -.08 .42c .51d .09 .06 .02 -.04 .35 .44c .38 .12 .10 .24 .96e .96e 
Note. FD = formerly depressed; HC = healthy control; DAS I = Dysfunctional Attitudes Scale – Short Form I; DAS II = Dysfunctional 
Attitudes Scale – Short Form II; VAS = Visual Analogue Scale; PRE = pre mood induction; POST = post mood induction; PANAS-X = 
Positive and Negative Affect Scale – Expanded Form; N = negative affect general dimension scale; P = positive affect general 
dimension scale; G = guilt basic negative emotional scale; S = sadness basic negative emotional scale; HP = heart period at baseline; 
BL = baseline; 5 = average obtained during a five-minute interval; MI = mood induction; RC = recovery; RSA = respiratory sinus 





























Table 25. Correlation Matrices for Cognitive, Mood, and Cardiovascular Pre- and Post-Mood Induction Scores by Group and Condition 
FD/SMI  
Measure 1. 2. 3. 4. 5. 6. 7. 8. 9. 10. 11. 12. 13. 14. 15. 16. 17. 18. 19. 20. 
1. DAS I                     
2. DAS II .78e                    
3. VASPRE -.17 .01                   
4. VASPOST .42 .28 .16                  
5. PANAS-X NPRE -.85e -.63d .20 -.46                 
6. PANAS-X NPOST -.76e -.60d .09 -.23 .87e                
7. PANAS-X PPRE .17 .06 -.05 .06 .10 .04               
8. PANAS-X PPOST .07 -.03 -.07 -.31 .35 .12 .77e              
9. PANAS-X GPRE -.79e -.68e .03 -.49c .90e .77e -.10 .13             
10. PANAS-X GPOST -.78e -.71e -.01 -.35 .80e .89e -.08 .01 .87e            
11. PANAS-X SPRE -.77e -.54c .09 -.40 .88e .82e -.21 .01 .82e .79e           
12 PANAS-X SPOST -.67d -.51c -.03 -.12 .72e .84e .04 -.07 .60d .79e .81e          
13. HPBL5 .29 .15 -.47 -.36 .002 -.18 .50 .42 -.04 -.14 -.31 -.19         
14. HPMI5 .22 .06 -.42 -.31 .12 -.12 .56 .45 -.01 -.12 -.20 -.03 .98e        
15. HPRC5 .16 -.003 -.35 -.46 .002 -.11 .45 .36 -.07 -.06 -.29 -.07 .95e .94e       
16 RSABL5 -.18 -.15 .50 .19 .32 .27 .23 .26 .13 .17 .34 .33 -.76c -.67c -.74c      
17. RSAMI5 -.09 .02 .49 .13 .26 .21 .32 .39 -.02 .02 .25 .24 -.70c -.64 -.67c .94e     
18. RSARC5 -.17 -.02 .34 .07 .41 .37 .27 .36 .15 .20 .42 .39 -.74c -.67c -.74c .94e .96e    
19. PEPBL5 -.03 -.14 -.08 -.14 .06 .33 .03 .12 .12 .39 -.25 -.17 .08 -.01 .12 -.51 -.52 -.46   
20. PEPMI5 -.09 -.16 -.21 -.06 .22 .37 .06 .11 .22 .38 -.11 -.06 .09 .04 .07 -.49 -.55 -.46 .95e  
21. PEPRC5 .06 -.07 -.18 -.18 .16 .26 .22 .25 .07 .25 -.20 -.10 .25 .20 .27 -.51 -.53 -.48 .93e .95e 
FD/NMI  
Measure 1. 2. 3. 4. 5. 6. 7. 8. 9. 10. 11. 12. 13. 14. 15. 16. 17. 18. 19. 20. 
1. DAS I                     
2. DAS II .63e                    
3. VASPRE .15 .14                   
4. VASPOST -.17 -.07 .37                  
5. PANAS-X NPRE -.24 -.41c .29 .21                 
6. PANAS-X NPOST -.26 -.35 .30 .31 .95e                
7. PANAS-X PPRE -.17 -.10 -.10 -.05 .21 .25               
8. PANAS-X PPOST -.15 -.01 -.03 -.11 .24 .26 .93e              
9. PANAS-X GPRE -.27 -.44c .32 .27 .88e .84e .08 .12             
10. PANAS-X GPOST -.21 -.46c .38 .32 .81e .87e .14 .18 .91e            
11. PANAS-X SPRE -.14 -.17 .52d .36 .58d .58d -.05 .04 .57d .53d           
12 PANAS-X SPOST -.25 -.13 .47c .43c .55d .63e .14 .20 .49c .52d .94e          
13. HPBL5 .36 .20 -.49 -.62 -.15 -.23 -.62 -.41 -.01 .05 -.67 -.79         
14. HPMI5 .25 .01 -.52 -.58 -.07 -.16 -.58 -.47 .002 .04 -.64 -.74 .97e        
15. HPRC5 .12 -.16 -.44 -.51 -.08 -.16 -.55 -.55 -.01 .03 -.62 -.69 .93e .97e       
16. RSABL5 -.08 -.31 .000 -.20 .16 -.02 -.05 .06 .28 .15 .22 .01 -.21 -.15 -.13      




Table 25 Continued 
18. RSARC5 .04 -.20 .02 -.12 .16  -.01 -.04 .12 .32 .19 .20 -.06 .08 .11 .08 .93e .87e    
19. PEPBL5 -.07 .43 -.48 -.73 .72 -.81c -.05 .03 -.80 -.79 -.79 -.69 .33 .23 .23 -.89c -.83c -.73   
20. PEPMI5 -.01 .53 -.39 -.65 -.70 -.77 -.01 .12 -.74 -.73 -.70 -.61 .24 .09 -.09 -.85c -.89c -.70 .98e  
21. PEPRC5 -.06 .26 -.54 -.54 -.80 -.83 -.03 -.39 -.98d -.98e -.53 -.30 -.31 -.26 -.18 -.91c -.95c -.95c .91e .96e 
HC/SMI 
Measure 1. 2. 3. 4. 5. 6. 7. 8. 9. 10. 11. 12. 13. 14. 15. 16. 17. 18. 19. 20. 
1. DAS I                     
2. DAS II .71e                    
3. VASPRE -.55e -.46d                   
4. VASPOST -.35c -.38c .41d                  
5. PANAS-X NPRE -.30c -.26 .54e .13                 
6. PANAS-X NPOST -.30c -.25 .69e .24 .92e                
7. PANAS-X PPRE .04 .01 .06 .01 .36c .33c               
8. PANAS-X PPOST .02 .17 -.05 -.13 .33c .31c .82e              
9. PANAS-X GPRE -.34c -.35c .56e .19 .73e .67e .18 .05             
10. PANAS-X GPOST -.31c -.34c .56e .18 .63e .68e .23 .08 .89e            
11. PANAS-X SPRE -.31c -.45d .42d .33c .74e .71e .25 .17 .51e .43d           
12 PANAS-X SPOST -.38c -.47e .59e .65e .48e .58e .08 -.11 .45d .47e .74e          
13. HPBL5 -.24 -.16 .26 .16 .11 .08 -.05 .07 .10 .01 .32 .45         
14. HPMI5 -.22 -.11 .23 .09 .19 .14 -.02 .16 .08 -.02 .34 .38 .97e        
15. HPRC5 -.36 -.25 .22 .09 .22 .15 .01 .16 .04 .02 .36 .36 .92e .95e       
16. RSABL5 .13 .03 -.08 .10 -.05 -.11 .14 .002 .01 -.05 .01 .02 .45 .36 .25      
17. RSAMI5 .04 -.01 -.01 .16 -.03 -.09 .15 .03 .12 -.02 .05 .04 .47 .37 .27 .92e     
18. RSARC5 -.07 -.05 .07 .14 .01 -.03 .24 .11 .19 .08 .03 -.01 .34 .28 .25 .85e .89e    
19. PEPBL5 -.08 .09 .27 -.13 .24 .12 .14 .38 .31 .20 .09 -.04 .55c .60c .61c .38 .46 .58c   
20. PEPMI5 -.30 -.13 .38 .07 .37 .24 .29 .45 .40 .29 .30 .16 .58c .62c .65c .30 .40 .54 .96e  
21. PEPRC5 -.13 .02 .26 -.03 .31 .16 .21 .43 .33 .18 .20 .06 .55c .61c .61c .37 .44 .55 .98e .98e 
HC/NMI  
Measure 1. 2. 3. 4. 5. 6. 7. 8. 9. 10. 11. 12. 13. 14. 15. 16. 17. 18. 19. 20. 
1. DAS I                     
2. DAS II .73e                    
3. VASPRE -.30 -.33c                   
4. VASPOST -.22 -.42d .64e                  
5. PANAS-X NPRE -.37c -.32 .45d .33c                 
6. PANAS-X NPOST -.38c -.25 .43d .20 .90e                
7. PANAS-X PPRE .35c .13 -.01 .03 -.02 -.05               
8. PANAS-X PPOST .42d .35c -.15 -.21 -.02 -.08 .88e              
9. PANAS-X GPRE -.33c -.20 .41d .23 .91e .86e -.10 -.09             
10. PANAS-X GPOST -.28 -.20 .34c .22 .84e .84e -.10 -.15 .94e            
11. PANAS-X SPRE -.37c -.36c .38c .34c .76e .68e -.15 -.19 .73e .70e           
12 PANAS-X SPOST -.38c -.37c .39c .28 .82e .80e -.13 -.19 .81e .83e .92e          
13. HPBL5 -.33 -.32 .53 .16 -.20 .11 .03 .11 -.16 -.07 .29 .06         




Table 25 Continued 
15. HPRC5 -.33 -.42 .48 .16 -.11 .13 .08 .15 -.13 -.01 -.17 .16 .96e .95e       
16. RSABL5 .02 .09 .17 -.11 .07 .05 .04 .10 .01 .08 -.05 -.01 .11 .15 .14      
17. RSAMI5 .04 .16 .27 -.15 -.16 -.09 .28 .27 -.11 -.12 -.27 -.22 .52 .47 .37 .47d     
18. RSARC5 .02 .04 .20 -.07 .06 .04 .12 .14 -.004 .05 -.06 -.01 .19 .23 .21 .90e .63e    
19. PEPBL5 .50 .22 -.35 -.21 -.41 -.56c .59c .45 -.35 -.32 -.25 -.28 -.17 -.02 -.17 -.11 .15 -.06   
20. PEPMI5 .44 .12 -.29 -.17 -.45 -.53 .53 .39 -.40 -.33 -.22 -.22 -.02 .14 -.02 -.01 .19 .03 .97e  
21. PEPRC5 .42 .18 -.34 -.24 -.27 -.33 .66d .54 -.27 -.08 -.25 -.07 .02 .18 .03 .12 .20 .15 .92e .92e 
Note. FD = formerly depressed; HC = healthy control; SMI = sad mood induction; NMI = neutral mood induction; DAS I = 
Dysfunctional Attitudes Scale – Short Form I; DAS II = Dysfunctional Attitudes Scale – Short Form II; VAS = Visual Analogue 
Scale; PRE = pre mood induction; POST = post mood induction; PANAS-X = Positive and Negative Affect Scale – Expanded Form; N = 
negative affect general dimension scale; P = positive affect general dimension scale; G = guilt basic negative emotional scale; S = 
sadness basic negative emotional scale; HP = heart period at baseline; BL = baseline; 5 = average obtained during a five-minute 
interval; MI = mood induction; RC = recovery; RSA = respiratory sinus arrhythmia; PEP = pre-ejection period; c = p < .05; d = p < .01; e 





Table 26. Correlation Matrices for Cognitive, Mood, and Cardiovascular Change Scores for 
Entire Sample 
Measure 1. 2. 3. 4. 5. 6. 7. 8. 9. 10. 11. 
1. DASDS            
2. VASDS -.20c           
3. PANAS-X NDS .04 .24d          
4. PANAS-X PDS .26d -.36e -.05         
5. PANAS-X GDS -.15 .28d .58e -.17        
6. PANAS-X SDS -.02 .48e .46e -.38e .48e       
7. HPDS5RA .18 -.11 -.24 .08 -.24 -.18      
8. HPDS5RC .06 -.18 .01 .05 .15 -.08 .59e     
9. RSADS5RA .05 .15 .12 -.08 .05 .03 -.23 -.02    
10. RSADS5RC .10 -.10 .05 .04 .10 -.08 -.15 .19 .47e   
11. PEPDS5RA .01 .17 -.21 -.14 -.28 -.02 .13 .08 -.12 .04  
12. PEPDS5RC .07 -.06 -.31 .04 -.27 .15 .15 .06 -.28 -.16 .37e 
Measure 1. 2. 3. 4. 5. 6. 7. 8. 9. 10. 11. 
1. ZRESDAS            
2. ZRESVAS -.23c           
3. ZRESPANAS-X N -.01 .29d          
4. ZRESPANAS-X P .29e -.38e -.06         
5. ZRESPANAS-X G -.07 .52e .53e -.40e        
6. ZRESPANAS-X S -.17 .28d .64e -.15 .52e       
7. ZRES5HPRA .18 -.12 -.22 .11 -.13 -.27      
8. ZRES5HPRC -.03 -.28 .05 .11 -.002 .12 .59e     
9. ZRES5RSARA .04 .20c .05 -.08 .004 .01 -.09 -.16    
10. ZRES5RSARC .07 -.04 .01 .04 -.09 .08 -.06 .04 .46e   
11. ZRES5PEPRA -.12 .22 -.14 -.16 .08 -.28 .12 .08 -.12 .16  
12. ZRES5PEPRC .05 -.08 -.24 .09 .18 -.24 .21c .17 -.15 -.04 .45e 
Note. DAS = Dysfunctional Attitudes Scale; DS = difference score; VAS = Visual Analogue 
Scale; PANAS-X = Positive and Negative Affect Scale – Expanded Form; N = negative affect 
general dimension scale; P = positive affect general dimension scale; G = guilt basic negative 
emotional scale; S = sadness basic negative emotional scale; HP = heart period at baseline; 5 = 
average obtained during a five-minute interval; RSA = respiratory sinus arrhythmia; PEP = pre-



















Table 27. Correlation Matrices for Cognitive, Mood, and Cardiovascular Change Scores by 
Group 
FD 
Measure 1. 2. 3. 4. 5. 6. 7. 8. 9. 10. 11. 
1. DASDS            
2. VASDS -.31           
3. PANAS-X NDS -.09 .47d          
4. PANAS-X PDS .24 -.52e -.18         
5. PANAS-X GDS -.20 .40c .71e -.26        
6. PANAS-X SDS -.06 .56e .56e -.56e .60e       
7. HPDS5RA .22 -.18 -.34 -.36 -.31 -.01      
8. HPDS5RC .40 -.36 .09 -.15 .16 .29 .54c     
9. RSADS5RA .15 .22 .16 .06 .03 .11 -.38 .18    
10. RSADS5RC .12 -.05 .07 .18 .14 .01 -.72d -.41 .53d   
11. PEPDS5RA .35 -.06 -.39 -.02 -.42 -.13 .02 -.41 -.41 -.06  
12. PEPDS5RC .02 -.25 -.54c -.23 -.30 -.01 .23 -.003 -.06 -.17 .60c 
Measure 1. 2. 3. 4. 5. 6. 7. 8. 9. 10. 11. 
1. ZRESDAS            
2. ZRESVAS -.25           
3. ZRESPANAS-X N -.07 .48d          
4. ZRESPANAS-X P .22 -.52e -.17         
5. ZRESPANAS-X G -.02 .53e .61e -.49e        
6. ZRESPANAS-X S -.22 .40c .74e -.23 .65e       
7. ZRES5HPRA .07 -.19 -.31 -.35 .10 -.33      
8. ZRES5HPRC .11 -.43 .05 -.16 .33 .10 .55c     
9. ZRES5RSARA .14 .25 .05 .14 -.03 -.003 -.13 .12    
10. ZRES5RSARC .19 -.04 -.03 .32 -.09 .12 -.50 -.50 .48d   
11. ZRES5PEPRA .35 -.04 -.39 -.02 -.07 -.43 .05 -.43 -.44 -.15  
12. ZRES5PEPRC .07 -.22 -.47 -.21 .07 -.24 .21 .06 -.11 -.19 .59c 
HC 
Measure 1. 2. 3. 4. 5. 6. 7. 8. 9. 10. 11. 
1. DASDS            
2. VASDS -.11           
3. PANAS-X NDS .13 .03          
4. PANAS-X PDS .25c -.29d -.02         
5. PANAS-X GDS -.12 -.01 .44e -.14        
6. PANAS-X SDS .02 .41e .36e -.34d .30d       
7. HPDS5RA .07 .09 -.19 .10 -.01 -.38      
8. HPDS5RC -.15 -.03 -.10 .09 .45c -.44c .48c     
9. RSADS5RA .03 .08 .10 -.11 .003 -.04 -.08 -.10    
10. RSADS5RC .10 -.13 .04 .01 .08 -.14 .08 .36 .46e   
11. PEPDS5RA -.26 .42c .11 -.22 .04 .13 -.15 .10 .05 .10  
12. PEPDS5RC .03 .27 .09 .10 -.03 .39c .06 .08 -.43c -.18 .46c 
Measure 1. 2. 3. 4. 5. 6. 7. 8. 9. 10. 11. 
1. ZRESDAS            
2. ZRESVAS -.16           
3. ZRESPANAS-X N .06 .10          
4. ZRESPANAS-X P .28c -.32d .004         
5. ZRESPANAS-X G -.07 .50e .43e -.37e        
6. ZRESPANAS-X S -.08 .01 .48e -.09 .29d       
7. ZRES5HPRA .12 .09 -.08 .14 .30 -.06      
8. ZRES5HPRC -.14 -.16 .07 .21 -.35 .51d .45c     
9. ZRES5RSARA .03 .16 .06 -.13 .02 -.05 -.07 -.29    
10. ZRES5RSARC .04 -.04 .04 -.03 -.10 .08 .06 .20 .46e   
11. ZRES5PEPRA -.43c .48c .20 -.25 .26 .04 -.15 .16 .05 .09  





Note. FD = formerly depressed; HC = healthy control; DAS = Dysfunctional Attitudes Scale; DS 
= difference score; VAS = Visual Analogue Scale; PANAS-X = Positive and Negative Affect 
Scale – Expanded Form; N = negative affect general dimension scale; P = positive affect general 
dimension scale; G = guilt basic negative emotional scale; S = sadness basic negative emotional 
scale; HP = heart period at baseline; 5 = average obtained during a five-minute interval; RSA = 
respiratory sinus arrhythmia; PEP = pre-ejection period; ZRES = standardized residualized change 




Table 28. Correlation Matrices for Cognitive, Mood, and Cardiovascular Change Scores by 
Group and Condition 
FD/SMI 
Measure 1. 2. 3. 4. 5. 6. 7. 8. 9. 10. 11. 
1. DASDS            
2. VASDS -.58c           
3. PANAS-X NDS -.20 .57c          
4. PANAS-X PDS .20 -.46 -.15         
5. PANAS-X GDS -.03 .22 .73e -.15        
6. PANAS-X SDS -.21 .57c .52c -.65d .59d       
7. HPDS5RA -.04 .39 -.33 -.47 .01 .24      
8. HPDS5RC -.09 -.41 .30 -.10 .61 .45 .16     
9. RSADS5RA .25 -.21 .11 .24 -.10 .06 -.56 .32    
10. RSADS5RC .38 -.38 .09 .34 -.01 -.11 -.87d -.21 .67d   
11. PEPDS5RA .29 .28 -.48 -.28 -.44 -.09 .28 -.50 -.42 -.05  
12. PEPDS5RC -.25 -.10 -.62 -.40 -.19 .13 .13 -.10 .08 .16 .58 
Measure 1. 2. 3. 4. 5. 6. 7. 8. 9. 10. 11. 
1. ZRESDAS            
2. ZRESVAS -.43           
3. ZRESPANAS-X N -.10 .52c          
4. ZRESPANAS-X P .13 -.49 -.11         
5. ZRESPANAS-X G -.10 .49c .56c -.57c        
6. ZRESPANAS-X S -.11 .19 .78e -.11 .65d       
7. ZRES5HPRA -.35 .37 -.34 -.53 .40 -.01      
8. ZRES5HPRC -.40 -.45 .24 -.17 .50 .57 .10     
9. ZRES5RSARA .44 -.08 .01 .32 -.002 -.07 -.24 .26    
10. ZRES5RSARC .58c -.29 .06 .46 -.004 .04 -.54 -.44 .65d   
11. ZRES5PEPRA .21 .25 -.46 -.30 -.02 -.46 .32 -.49 -.53 -.21  
12. ZRES5PEPRC -.17 -.13 -.56 -.35 .15 -.14 .16 .04 -.09 -.05 .56 
FD/NMI 
Measure 1. 2. 3. 4. 5. 6. 7. 8. 9. 10. 11. 
1. DASDS            
2. VASDS .14           
3. PANAS-X NDS .18 .32          
4. PANAS-X PD5 .19 -.30 -.11         
5. PANAS-X GDS -.29 .10 .72e -.07        
6. PANAS-X SDS .39 .29 .62e -.26 .39       
7. HPDS5RA -.13 .79 -.20 -.78 -.54 .07      
8. HPDS5RC .85 .05 -.06 -.38 -.55 .60 .89c     
9. RSADS5RA .11 .57c .24 -.01 .21 .16 -.17 .16    
10. RSADS5RC -.02 -.12 -.05 .21 .19 .003 -.63 -.46 .47   
11. PEPDS5RA .38 -.49 .32 .51 .15 -.09 -.70 -.46 -.35 .03  
12. PEPDS5RC .35 .16 -.06 .19 -.45 -.44 -.03 -.06 -.38 -.63 .77 
Measure 1. 2. 3. 4. 5. 6. 7. 8. 9. 10. 11. 
1. ZRESDAS            
2. ZRESVAS .07           
3. ZRESPANAS-X N .06 .35          
4. ZRESPANAS-X P .22 -.28 -.09         
5. ZRESPANAS-X G .36 .29 .69e -.17        
6. ZRESPANAS-X S -.26 .14 .62d -.07 .34       
7. ZRES5HPRA -.47 .69 -.13 -.77 .29 -.51      
8. ZRES5HPRC .37 .15 -.25 -.36 .71 -.56 .88c     
9. ZRES5RSARA -.01 .58c .09 .07 -.10 .12 .08 .10    
10. ZRES5RSARC -.02 -.15 -.28 .37 -.44 .05 -.41 -.34 .41   
11. ZRES5PEPRA .55 -.19 .36 .52 -.06 .15 -.74 -.64 -.30 -.05  






Table 28 Continued 
HC/SMI 
Measure 1. 2. 3. 4. 5. 6. 7. 8. 9. 10. 11. 
1. DASDS            
2. VASDS -.19           
3. PANAS-X NDS -.01 .03          
4. PANAS-X PDS .26 -.26 -.01         
5. PANAS-X GDS -.10 -.09 .53e -.09        
6. PANAS-X SDS -.01 .40d .42d -.40d .34c       
7. HPDS5RA .26 -.22 -.25 .55c -.16 -.65c      
8. HPDS5RC -.03 -.15 -.23 .18 .44 -.68d .53     
9. RSADS5RA .14 .08 .01 .07 -.004 -.05 -.33 -.22    
10. RSADS5RC .30 -.13 .12 .12 .18 -.16 .15 .46 .50d   
11. PEPDS5RA -.48 .53 -.05 -.27 .10 .05 -.14 .08 .23 .24  
12. PEPDS5RC -.31 .56c -.49 .13 -.50 -.12 .27 .04 -.08 -.09 .63c 
Measure 1. 2. 3. 4. 5. 6. 7. 8. 9. 10. 11. 
1. ZRESDAS            
2. ZRESVAS -.22           
3. ZRESPANAS-X N -.06 .10          
4. ZRESPANAS-X P .27 -.28 .02         
5. ZRESPANAS-X G -.12 .51e .42d -.41d        
6. ZRESPANAS-X S -.08 -.04 .52e -.07 .34c       
7. ZRES5HPRA .21 -.21 -.13 .55c -.54 -.16      
8. ZRES5HPRC .04 -.29 -.05 .32 -.65c .52 .59d     
9. ZRES5RSARA .04 .17 -.05 -.01 -.02 -.07 -.31 -.50    
10. ZRES5RSARC .16 -.02 .09 .06 -.14 .16 .08 .28 .49d   
11. ZRES5PEPRA -.64c .60c .08 -.29 .25 .10 -.16 .10 -.05 .11  
12. ZRES5PEPRC -.28 .47 -.40 .27 -.02 -.53 .38 .04 .10 .06 .51 
HC/NMI 
Measure 1. 2. 3. 4. 5. 6. 7. 8. 9. 10. 11. 
1. DASDS            
2. VASDS -.20           
3. PANAS-X NDS .27 -.30          
4. PANAS-X PDS .29 -.30 .01         
5. PANAS-X GDS -.16 .13 .32 -.23        
6. PANAS-X SDS .03 -.16 .25 -.12 .15       
7. HPDS5RA -.32 .58c -.51 -.25 .16 -.18      
8. HPDS5RC -.50 .18 .06 .04 .49 -.08 .34     
9. RSADS5RA -.07 -.34 .17 -.27 -.04 -.14 -.20 -.15    
10. RSADS5RC -.23 .07 -.04 -.28 -.13 -.02 -.06 .09 .48d   
11. PEPDS5RA .02 .06 .29 -.06 -.13 .21 -.29 .09 -.22 -.21  
12. PEPDS5RC .22 -.08 .52 .17 .36 .72d -.13 .12 -.66c -.32 .39 
Measure 1. 2. 3. 4. 5. 6. 7. 8. 9. 10. 11. 
1. ZRESDAS            
2. ZRESVAS -.27           
3. ZRESPANAS-X N .20 -.31          
4. ZRESPANAS-X P .36c -.27 .04         
5. ZRESPANAS-X G -.04 -.002 .39c -.17        
6. ZRESPANAS-X S -.10 .20 .40c -.16 .13       
7. ZRES5HPRA -.28 .38 -.41 -.21 -.12 .18      
8. ZRES5HPRC -.59c .07 .27 .11 .16 .49 .18     
9. ZRES5RSARA .03 -.30 .10 -.21 -.12 -.09 -.26 -.22    
10. ZRES5RSARC -.14 -.06 -.05 -.21 .01 -.13 -.12 .03 .47d   
11. ZRES5PEPRA -.13 .15 .29 -.07 .21 -.14 -.28 .27 -.08 -.06  









Note. FD = formerly depressed; HC = healthy control; SMI = sad mood induction; NMI = neutral 
mood induction; DAS = Dysfunctional Attitudes Scale; DS = difference score; VAS = Visual 
Analogue Scale; PANAS-X = Positive and Negative Affect Scale – Expanded Form; N = 
negative affect general dimension scale; P = positive affect general dimension scale; G = guilt 
basic negative emotional scale; S = sadness basic negative emotional scale; HP = heart period at 
baseline; 5 = average obtained during a five-minute interval; RSA = respiratory sinus arrhythmia; 
PEP = pre-ejection period; ZRES = standardized residualized change scores; c = p < .05; d = p < 








Vulnerability to depressive relapse and recurrence is difficult to delineate as it likely 
reflects a complex interaction of biological, psychological, and environmental factors. The 
majority of research on vulnerability to depressive relapse and recurrence has identified stable, 
unchangeable traits that are not amenable to modification (Burcusa & Iacono, 2007). 
Consequently, it is currently challenging for medical and mental healthcare providers to prevent 
or intervene during the depressogenic cycle. More research is needed to identify malleable 
vulnerability factors that can be specifically targeted during treatment or following treatment for 
relapse prevention to reduce the occurrence of future episodes of depression.  
Four such factors that have been proposed as potential pathways of vulnerability to 
relapse and recurrence for formerly depressed individuals include cognitive, mood, and 
cardiovascular reactivity to and recovery from sadness. There is still disagreement in the 
cognitive and mood reactivity literature whether dysfunctional thinking patterns or dysphoric 
mood states characterize remitted MDD. While the literature has examined cardiovascular 
functioning in formerly depressed individuals, there are significant concerns about the quality 
and generalizability of studies focused on cardiovascular reactivity in response to sadness in 
remitted MDD due to multiple methodological issues. There have been no studies conducted to 
date that have focused on cardiovascular recovery from sadness in remitted MDD. The present 
study aimed to characterize cognitive, mood, and cardiovascular reactivity to and recovery from 
a sad mood induction in individuals with a history of depression compared to healthy, never 




The first aim of this study was to examine cognitive reactivity in response to an 
experimentally-induced sad mood in remitted MDD. Theories of depression have proposed that 
dysfunctional patterns of thinking represent a cognitive vulnerability that contributes to the 
etiology, maintenance, and reoccurrence of depression (Beck, 1967; Lau, Segal, & Williams, 
2004; Scher, Ingram, & Segal, 2005). While these dysfunctional patterns of thinking have been 
observed in currently, but not formerly, depressed individuals (as reviewed by Teasdale, 1999), 
formerly depressed individuals continue to be at increased risk for depressive relapse and 
recurrence. Theoretical models, including the differential activation hypothesis by Teasdale 
(1988) and mood state dependent hypothesis by Miranda and Persons (1988), have proposed that 
cognitive vulnerabilities remain latent in formerly depressed individuals, are activated by 
dysphoric mood, and perpetuate depressed mood. Cognitive reactivity has been proposed as a 
predictor of relapse and recurrence.  
A large body of literature has investigated cognitive reactivity in remitted MDD. Cross-
sectional studies have generally shown that formerly depressed individuals exhibit cognitive 
reactivity in response to sadness compared to individuals without a history of depression (Gemar 
et al., 2001; Lau et al., 2012; Miranda et al., 1990, 1998; Roberts & Kassel, 1996; Van der Does, 
2002). In addition, longitudinal studies have shown that formerly depressed individuals who 
exhibit cognitive reactivity while euthymic or dysphoric have higher rates of relapse and 
recurrence over time (Jarrett et al., 2012; Kuyken et al., 2010; Segal et al., 1999, 2006). 
However, there are inconsistencies in this literature base. More specifically, some studies have 
failed to find cross-sectional differences in cognitive reactivity in response to sadness between 
formerly depressed and never depressed participants (Brosse et al., 1999; Dykman, 1999; Fresco 




that cognitive reactivity was predictive of relapse longitudinally (Lethbridge & Allen, 2008). The 
current study sought to contribute to this investigation and clarify prior inconsistent results. It 
was hypothesized that formerly depressed participants exposed to the sad mood induction would 
report significantly higher levels of dysfunctional beliefs on the DAS-SF II post-mood induction 
than formerly depressed participants exposed to the neutral mood induction and healthy control 
participants exposed to the sad and neutral mood inductions. 
The second aim of this study was to examine mood reactivity in response to an 
experimentally-induced sad mood in remitted MDD. Theories of depression have proposed that 
differential affective responding to emotionally-valenced stimuli represent an affective 
vulnerability that contributes to the etiology and reoccurrence of depression (Rottenberg & 
Gotlib, 2004). While depression is typically conceptualized as a condition marked by sad, low 
mood, there do appear to be differences in the expression of both positive and negative emotions 
among currently depressed individuals (Rottenberg et al., 2005b). Theoretical models, including 
the positive attenuation hypothesis, the negative potentiation hypothesis, and the emotional 
context insensitivity hypothesis by Rottenberg and Gotlib (2004), have proposed that depression 
is marked by differential affective responding to emotionally-valenced stimuli that perpetuates 
depressive symptoms or leads to recurrence of depression. Much like cognitive vulnerabilities, it 
has been proposed that differential affective responding to emotionally-valenced stimuli may 
remain latent in formerly depressed individuals, be activated by dysphoric mood, and perpetuate 
depressed mood (Rottenberg et al., 2005b). Mood reactivity has been proposed as a predictor of 
relapse and recurrence.  
A smaller body of literature has investigated mood reactivity in remitted MDD. Cross-




mood reactivity among formerly depressed and never depressed participants (Brosse et al., 1999; 
Dykman, 1997; Fresco et al., 2006; Gemar et al., 2001; Lau et al., 2012; Miranda & Persons, 
1988; Miranda et al., 1998; Solomon et al., 1998; Van der Does, 2002, 2005). Longitudinal 
studies have generally shown that formerly depressed individuals who exhibit blunted (i.e., 
decrease happiness in response to a sad mood induction; Lethbridge & Allen, 2008) or 
exaggerated (i.e., increased sadness in response to a sad mood induction; van Rijsbergen et al., 
2013) mood reactivity are more likely to experience another depressive episode. However, this is 
a limited literature base that requires additional inquiry. More specifically, some studies have 
failed to find cross-sectional differences in mood reactivity in response to sadness between 
formerly depressed and never depressed participants (Brosse et al., 1999; Dykman, 1997; Fresco 
et al., 2006; Gemar et al., 2001; Lau et al., 2012; Miranda & Persons, 1988; Miranda et al., 1998; 
Solomon et al., 1998; Van der Does, 2002, 2005). In addition, only two longitudinal studies 
evaluating whether mood reactivity is predictive of relapse and recurrence have been conducted. 
While there is currently disagreement in the literature about whether cognitive or mood 
reactivity are markers of vulnerability for relapse in remitted MDD, there is clear support for the 
notion that such vulnerabilities are mood state dependent in remitted depression. The current 
study sought to contribute to this investigation and clarify prior inconsistent results. It was 
hypothesized that formerly depressed and healthy control participants exposed to a sad mood 
induction would report significantly higher levels of dysphoric mood on the VAS post-mood 
induction than formerly depressed and healthy control participants exposed to the neutral mood 
inductions, with no significant differences in formerly depressed and healthy control participants 




Psychological research has attempted to identify biological and physiological correlates 
of psychological conditions, rather than relying solely on subjective self-report measures. 
Individual differences in cardiovascular functioning have been observed in a variety of different 
psychological conditions, including current MDD (Chang et al., 2012; Ehrenthal et al., 2010; Jin 
et al., 2015; Kemp et al., 2010, 2012; Kikuchi et al., 2009; Liang et al., 2015; Nugent et al. 2011; 
Panaite et al., 2016; Rottenberg, 2007b; Rottenberg et al., 2003, 2005a, 2007a; Salomon et al., 
2009; with the exception of Rottenberg et al., 2005b; Tsai et al., 2003). Theoretical models, 
including the polyvagal theory by Porges (1995), biopsychosocial model of challenge and threat 
by Blascovich and Tomaka (1996), and hawk-dove model by Smith (1982), have proposed that 
there is an association between behavioral, psychological, and physiological responding. These 
theories have been explored in currently depressed individuals but have not yet been adequately 
assessed in formerly depressed individuals. While it appears that the cardiovascular functioning 
of formerly depressed participants generally resembles that of healthy control participants at rest 
or in response to stress (Ahrens et al., 2008; Bylsma et al., 2014; Chang et al., 2013; Salomon et 
al., 2013; Vaccarino et al., 2008), it is plausible that the differences in cardiovascular functioning 
observed in currently depressed individuals may be mood state dependent in formerly depressed 
individuals. 
The third aim of this study was to explore cardiovascular reactivity in response to an 
experimentally-induced sad mood in remitted MDD. A small body of literature has investigated 
cardiovascular reactivity in remitted MDD. While some cross-sectional studies have shown that 
formerly depressed individuals exhibited an abnormal pattern of cardiovascular reactivity in 
response to sadness compared to individuals without a history of depression (Yaroslavsky et al., 




depressed and never depressed participants (Bylsma et al., 2015; Rottenberg et al., 2005b). As 
previously reviewed, there are significant concerns about the quality and generalizability of these 
due to multiple methodological issues (e.g., mixed sample of current and remitted depression, 
lack of assessment of CVD, limited range of cardiovascular measures assessed, lack of control 
group, limited investigation of adult-onset depression). The current study sought to advance this 
area of inquiry and address these methodological issues. It was hypothesized that formerly 
depressed individuals exposed to the sad mood induction would exhibit a maladaptive pattern of 
cardiovascular reactivity (i.e., decreased HP and RSA and increased PEP) during the mood 
induction compared to formerly depressed participants exposed to the neutral mood induction 
and healthy control participants exposed to the sad and neutral mood inductions.  
The fourth aim of this study was to explore cardiovascular recovery in response to an 
experimentally-induced sad mood in remitted MDD. Cardiovascular recovery provides an 
estimate of how long the physiological changes attributable to an emotionally-valenced stimulus 
persist after the stimulus has been removed. Research has suggested that cardiovascular recovery 
can result in the identification factors that contribute to the development of psychopathology and 
physiological abnormalities (Linden, Earle, Gerin, & Christenfeld, 1997; Haynes, Gannon, 
Orimoto, O’Brien, & Brandt, 1991). Unfortunately, none of the research on cardiovascular 
reactivity in remitted MDD has assessed cardiovascular recovery (Bylsma et al., 2015; 
Rottenberg et al., 2005b; Yaroslavsky et al., 2013, 2014 Study 2). The current study sought to 
establish this area of inquiry in remitted MDD. It was hypothesized that formerly depressed 
individuals exposed to the sad mood induction would exhibit reduced cardiovascular recovery 




film compared to formerly depressed participants exposed to the neutral mood induction and 
healthy control participants exposed to the sad and neutral mood inductions.  
Self-Report Measures  
Formerly depressed participants reported significantly higher levels of current depressive 
symptoms on the BDI-II than healthy control participants. Formerly depressed participants 
reported a mean score of 9.91 out of 63 on the BDI-II, which suggests the presence of mild 
depressive symptoms. Healthy control participants reported a mean score of 3.32 out of 63 on the 
BDI-II, which suggests the presence of minimal depressive symptoms. Despite the presence of 
some residual depressive symptoms, none of the formerly depressed participants met diagnostic 
criteria for a major depressive episode within the last month while none of the healthy control 
participants met diagnostic criteria for a major depressive episode within their lifetime. 
 Formerly depressed and healthy control participants reported similar levels of state 
anxiety symptoms on the STAI-I. Formerly depressed participants reported a mean score of 
44.53 out of 80 on the STAI-I while healthy control participants obtained a mean score of 45.74 
out of 80 on the STAI-I. The scores reported by this sample are slightly above the proposed cut 
scores of 39 to 40 for clinically significant symptoms of state anxiety on the STAI-I (Addolorato 
et al., 1999; Knight, Waal-Manning, & Spears, 1983). While no formal predictions were set, the 
lack of significant difference between groups was surprising given the fact that state anxiety 
symptoms have been shown to highly correlate with measures of depression (Julian, 2011). 
Consequently, it would be reasonable to foresee that formerly depressed participants would have 
reported greater state anxiety symptoms on the STAI-I than healthy control participants given the 





Cognitive and Mood Measures  
As expected, measures of cognition and mood assessed at different time points during the 
experimental paradigm were significantly correlated. More specifically, the DAS-SF I & II, 
VAS, and PANAS-X N, P, G, and S were significantly and positively correlated respectively 
when using pre- and post-mood induction measures. These findings suggested that while change 
in dysfunctional thoughts, dysphoric mood, and affective states were observed across the 
experimental paradigm for some measures, measures of cognition and mood continued to 
correlate throughout the experimental paradigm.  
In addition, measures of cognition and mood were significantly correlated when using 
difference and residualized change scores. The DAS was positively correlated with the PANAS-
X P and negatively correlated with the VAS. Of note, the valences of these correlations are in the 
expected direction as lower scores on the DAS are indicative of increased dysfunctional beliefs. 
The VAS was positively correlated with the PANAS-X N, G, and S and negatively correlated 
with the PANAS-X P. The PANAS-X N was positively correlated with the PANAS-X G and S 
while the PANAS-X P was negatively correlated with some measures of the PANAS-X G and S. 
Finally, the PANAS-X G was positively correlated with the PANAS-X S. These findings 
indicated an association between dysfunctional thoughts, dysphoric mood, and affective states 
across the experimental paradigm.  
Correlations observed in the formerly depressed and healthy control groups were similar 
to those observed in the entire sample with one important exception; the pre- and post-mood 
induction VAS measures were not significantly correlated in the formerly depressed group, 
suggesting that there was a significant difference in dysphoric mood pre- and post-mood 




participants exposed to both the sad and neutral mood induction, the correlation for pre- and 
post-mood induction VAS measures was stronger for formerly depressed participants exposed to 
the neutral mood induction (r = .37, p > .05) compared to formerly depressed participants 
exposed to the sad mood induction (r = .16, p > .05). These findings indicated that all formerly 
depressed participants report a change in dysphoric mood pre- and post-mood induction, with a 
greater change reported by formerly depressed participants exposed to the sad mood induction. 
Cognitive Reactivity 
 Contrary to expectations, there were no significant differences in cognitive reactivity on 
the DAS post-mood induction in formerly depressed participants exposed to the sad mood 
induction when using difference scores, residualized change scores, and repeated measures (see 
Figures 12 to 14). Post-hoc analyses revealed that the current study had a relatively low chance 
(13-36%) of detecting an effect due to insufficient power while sensitivity analyses indicated that 
at least a medium effect size was necessary to detect an effect if sufficient power had been 
obtained.  
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Figure 13. Cognitive Reactivity – Residualized Change Score Post-Mood Induction 
 
Figure 14. Cognitive Reactivity – Repeated Measures Pre- and Post-Mood Induction 
 
 However, there was one significant difference in cognitive reactivity that was identified 
using multiple comparisons. Formerly depressed participants reported significantly higher levels 
of dysfunctional beliefs on the DAS post-mood induction than healthy control participants when 
using residualized change scores. Of note, this measure can be counterintuitive to interpret as 












■Formerly Depressed/Sad Mood Induction ■Formerly Depressed/Neutral Mood Induction













■Formerly Depressed/Sad Mood Induction ■Formerly Depressed/Neutral Mood Induction




is in line with the majority of the cognitive reactivity literature, which has found that formerly 
depressed participants report higher levels of dysfunctional beliefs in response to a transient sad 
mood compared to healthy controls (Gemar et al., 2001; Lau et al., 2012; Miranda et al., 1990, 
1998; Roberts & Kassel, 1996; Van der Does, 2002). Notably, much of this research has elected 
to use residualized change scores rather than difference scores. In the current study, significant 
differences in cognitive reactivity may have been found between groups when using residualized 
change scores, but not difference scores, due to increased power with the former analysis. 
Analyses conducted with residualized change scores have more power due to smaller standard 
error and are therefore more likely to detect an effect (Castro-Schilo et al., 2018). In addition, 
research has shown that results can differ when analyses are conducted using difference scores 
and residualized change scores due to Lord’s paradox, which postulates that this difference 
occurs when the pattern or lack of pattern of change differs between groups and when baseline 
differences on the predictor are stable, change equally, or change unequally (as reviewed by 
Castro-Schilo et al., 2018).  
Contrast analyses indicated that formerly depressed participants exposed to the sad mood 
induction reported significantly higher levels of dysfunctional beliefs on the DAS post-mood 
induction compared to healthy control participants exposed to the sad mood induction and 
formerly depressed and healthy control participants exposed to the neutral mood induction when 
using residualized change scores. As previously mentioned, analyses conducted with residualized 
change scores have more power due to smaller standard error (Castro-Schilo et al., 2018) and the 
planned contrasts have the most power of all analyses as they only assess a circumscribed set of 
comparisons (Field, 2009). Therefore, it is questionable if the significant planned contrast results 




reflection of inflated type I error. The lack of consistent finding was unexpected as a significant 
proportion of the available research has found that formerly depressed individuals exhibit 
cognitive reactivity in response to sadness compared to healthy controls (Gemar et al., 2001; Lau 
et al., 2012; Miranda et al., 1990, 1998; Roberts & Kassel, 1996; Van der Does, 2002). However, 
there has been disagreement in the literature, with a subset of studies failing to find differences in 
cognitive reactivity in response to sadness based on depressive history (Brosse et al., 1999; 
Dykman, 1999; Fresco et al., 2006; Pfeiffer et al., 2015; Van der Does, 2005).  
One potential reason for the current study’s finding may be the measure that was 
employed. The DAS-SF I & II, an abbreviated version of the original DAS, was used to measure 
cognitive reactivity. The DAS-SF I & II was chosen over the DAS because it is significantly 
shorter (9-items versus 40-items) and the two measures have been shown to have similar 
psychometric properties. As previously noted, Beevers and colleagues (2007) found that there 
were no significant differences in residualized change scores for the DAS-A, DAS I, and DAS II 
(p = .79-.93, d = .00-.01) and the residualized change scores for the DAS-A, DAS I, and DAS II 
were very strongly correlated (r = .84-.91), suggesting that the long and short forms of the DAS 
perform similarly. The current study had the unique challenge of obtaining multiple self-report 
measures while participants were connected to psychophysiological equipment. The DAS-SF I & 
II was selected to minimize the amount of attentional demands, time, and movement needed to 
answer self-report measures as all of these factors can adversely impact psychophysiological 
recording. While none of the studies investigating cognitive reactivity have used the DAS-SF I & 
II, this is not because the measure is viewed unfavorably by depression researchers but rather, 
due to the fact that only four of these studies were conducted after the creation of the DAS in 




study as there may have been more variability with the 40-item measure. Additional research is 
needed to explore whether or not the DAS-SF I & II performs similarly to the DAS when 
assessing cognitive reactivity in a sample of formerly depressed participants. 
Manipulation Check 
As expected, participants exposed to the sad mood induction reported significantly higher 
levels of sadness on the VAS post-mood induction than participants exposed to the neutral mood 
induction when using difference scores, residualized change scores, and repeated measures. This 
change in pre- and post-mood induction measures (28.33%, increase of 28.33 points of 100-point 
scale) far exceeded the requirement of greater than 10.00% change in mood state that has been 
commonly used in the literature to indicate that a mood induction procedure has induced its 
intended mood state (Martin, 1990). In addition, participants exposed to the neutral mood 
induction did not exhibit a significant change in sadness (3.39%, increase of 3.39 points of 100-
point scale) when assessing pre- and post-mood induction measures. Overall, these results 
suggest that the mood induction procedure successfully induced a transient sad mood in 
participants exposed to the sad mood induction and did not induce a transient sad mood in 
participants exposed to the neutral mood induction. 
As expected, participants exposed to the sad mood induction reported significantly higher 
levels of sadness on the PANAS-X post-mood induction than participants exposed to the neutral 
mood induction when using difference scores and residualized change scores. While there were 
no significant differences between conditions when using repeated measures, it is possible that 
this is due to lower power in the between-subjects portion of this analysis (Guo, Logan, Glueck, 
& Muller, 2013). This change in pre- and post-mood induction measures aligns with the 




induction procedures successfully induced a transient sad mood in participants exposed to the 
sad mood induction and did not induce a transient sad mood in participants exposed to the 
neutral mood induction. 
As expected, there were no significant differences in reporting of positive affect, fear, and 
hostility on the PANAS-X between conditions when using difference scores, residualized change 
scores, and using repeated measures. While not significant due to the adjusted p value used due 
to violations of homogeneity of variance, participants exposed to the sad mood induction 
reported significantly higher levels of negative affect on the PANAS-X post-mood induction 
than participants exposed to the neutral mood induction when using residualized change scores 
but not difference scores or repeated measures. The PANAS-X negative affect general dimension 
scale contains the following affective states: afraid, scared, nervous, jittery, irritable, hostile, 
guilty, ashamed, upset, and distressed. It is possible that this finding was due to the fact that 
participants exposed to the sad mood induction reported elevations on the PANAS-X negative 
affect general dimension scale and PANAS-X guilt basic negative emotions scale, which both 
include some of the same affective states (i.e., guilty, ashamed). Overall, these results generally 
suggest that the mood induction procedure did not induce unintended general or specific 
affective status in participants exposed to both the sad and neutral mood inductions.  
Contrary to expectations, participants exposed to the sad mood induction reported 
significantly higher levels of guilt on the PANAS-X post-mood induction than participants 
exposed to the neutral mood induction when using difference scores and residualized change 
scores. While there were no significant differences between conditions when using repeated 
measures, it is possible that this is due to lower power in the between-subjects portion of this 




pattern of responding was observed in formerly depressed participants exposed to the sad mood 
induction rather than healthy control participants exposed to the sad mood induction (F(1,119) = 
14.92, p < .001, η2 = .11). While it was not anticipated that emotions other than sadness would be 
reported, the presence of guilt makes intuitive sense given its association with the construct of 
depression. According to schema theory, which significantly influenced cognitive 
conceptualizations of depression, the depressogenic schema is associated with “themes of 
personal deficiency, worthlessness, self-blame, guilt, deprivation, and rejection” (Martin, 1990, 
p. 687). Excessive or inappropriate guilt is commonly experienced during a major depressive 
episode, insomuch as guilt is a symptom in the diagnostic criteria for MDD (APAA, 2013) and 
included as a question in multiple clinician rating scales (e.g., Hamilton Rating Scale for 
Depression (HAM-D)) and self-report measures (e.g., BDI-II, PHQ-9, Center for Epidemiologic 
Studies of Depression Scale (CES-D), and Geriatric Depression Scale (GDS)) of depression. 
Research has consistently found that the constructs of depression and guilt are associated 
with each other (as reviewed by Orth, Berking, & Burkhardt, 2006). A study by Ghatavi, 
Nicolson, MacDonald, Osher, and Levitt (2002) investigated whether guilt is state and/or trait 
dependent in depression. Participants included individuals with current MDD (n = 34), remitted 
MDD (n = 22), chronic cardiac illness (n = 20), and healthy control participants without a history 
of Axis I disorders (n = 59). Of note, individuals with chronic cardiac illness were recruited as a 
comparison group free from psychiatric conditions with “similar global functioning” (Ghatavi et 
al., p. 308). Results indicated that participants with current MDD reported significantly higher 
levels of state guilt than all other participants while participants with remitted MDD reported 
significantly higher levels of state guilt than cardiac and healthy controls. In addition, 




significantly higher than cardiac and healthy controls. This study suggested that formerly 
depressed individuals experience elevated levels of state guilt compared to individuals without a 
history of depression as well as levels of trait guilt that are comparable to currently depressed 
individuals. In line with the differential activation and mood state dependent hypotheses, it is 
possible that elevations in state guilt observed in currently depressed individuals may remain 
latent in formerly depressed individuals until activated by a dysphoric mood. Additional research 
is needed to investigate whether or not guilt is mood state dependent in remitted MDD. 
Mood Reactivity 
 As expected, participants exposed to the sad mood induction reported significantly higher 
levels of dysphoric mood on the VAS post-mood induction than participants exposed to the 
neutral mood induction when using difference scores, residualized change scores, and repeated 
measures. This finding was in line with the literature that used a combination of music and 
autobiographical recall and observed mood reactivity in all participants who were subjected to 
the sad mood induction condition (Fresco et al., 2006; Gemar et al., 2001; Jarrett et al., 2012; 
Kuyken et al., 2010; Lau et al., 2012; Pfeiffer et al., 2015; Segal et al., 1999, 2006; Van der 
Does, 2002, 2005). Additionally, this finding makes intuitive sense; engaging in an emotionally-
valenced auditory and cognitive task induced the intended affective response. 
Contrary to expectations, formerly depressed participants reported significantly higher 
levels of dysphoric mood on the VAS post-mood induction than healthy control participants 
when using difference scores, residualized change scores, and repeated measures. While the 
interaction between group and condition was not significant (see Figures 15-17), it is possible 
that this is due to lack of power rather than lack of effect. Examination of the means and standard 




residualized change scores do suggest that there are significant discrepancies in the levels of 
dysphoric mood reported by the different groups and conditions, with formerly depressed 
participants exposed to the sad mood induction reporting elevated post-mood induction scores on 
the VAS compared to all other groups. Examination of the p values (p = .08-.14) for difference 
scores and residualized change scores indicate that these analyses were approaching significance 
and may have been significant if sufficient power had been obtained. In addition, examination of 
the effect sizes (η2 = .02-.03) for difference scores and residualized change scores indicate that 
they were in the small to medium range. While this was not true when using repeated measures, 
it is possible that this is due to lower power in the between-subjects portion of this analysis (Guo, 
Logan, Glueck, & Muller, 2013). Post-hoc analyses revealed that the current study had a 
relatively low chance (1-26%) of detecting an effect due to insufficient power while sensitivity 
analyses indicated that at least a medium effect size was necessary to detect an effect if sufficient 
power had been obtained. 
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Figure 16. Mood Reactivity – Residualized Change Score Post-Mood Induction 
 
Figure 17. Mood Reactivity – Repeated Measures Pre- and Post-Mood Induction 
 
Contrast analyses indicated that formerly depressed participants exposed to the sad mood 
induction reported significantly higher levels of dysphoric mood on the VAS post-mood 
induction compared to healthy control participants exposed to the sad mood induction and 
formerly depressed and healthy control participants exposed to the neutral mood induction when 
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planned contrasts have the most power as they only assess a circumscribed set of comparisons 
(Field, 2009). Unfortunately, these findings are challenging to clearly interpret as they are 
obfuscated by differing results obtained when disparate analytic techniques are employed and 
marginally insignificant results that are likely attributable to insufficient power.  
Taken together, results generally appear to suggest that formerly depressed participants 
exposed to the sad mood induction exhibited elevated mood reactivity in response to sadness 
compared to healthy control participants exposed to the sad mood induction and formerly 
depressed and healthy control participants exposed to the neutral mood induction. This finding 
runs contrary to all of the cross-sectional studies that have failed to find any group differences in 
mood reactivity between formerly depressed and never depressed participants (Brosse et al., 
1999; Dykman, 1997; Fresco et al., 2006; Gemar et al., 2001; Lau et al., 2012; Miranda & 
Persons, 1988; Miranda et al., 1998; Segal et al., 2006; Solomon et al., 1998; Van der Does, 
2002, 2005).  
There are a few potential reasons for the discrepant findings when comparing the current 
study to the literature base. First, a subset of the studies employed a different measure to evaluate 
mood reactivity (Multiple Affect Adjective Check List (MAACL); Dykman, 1997; Fresco et al., 
2006; Miranda & Persons, 1988; Solomon et al., 1998). Second, the studies that employed the 
VAS or a similar Likert-scale mood rating measure (e.g., “not at all” for 0 to “extremely” for 10 
rating of sadness without a visual representation of this rating system) have used a restricted 
range of potential scores (Gemar et al., 2001; Lau et al., 2012; Miranda et al., 1998; Segal et al., 
2006; Van der Does, 2002, 2005). Only one study (Brosse et al., 1999) used the same version of 
the VAS employed in the current study, which obtained a rating of participants’ current mood 




that this version of the VAS captured a greater level of variability in participants’ mood state and 
therefore, was more likely to identify differences than the other mood rating measures. 
Cardiovascular Functioning 
 As expected, measures of cardiovascular functioning assessed at different time points 
during the experimental paradigm were significantly correlated. More specifically, five-minute 
HP, RSA, and PEP during baseline, mood induction, and recovery were significantly and 
positively correlated when using pre- and post-mood induction measures while five-minute HP, 
RSA, and PEP reactivity and recovery were significantly and positively correlated when using 
difference and residualized change scores. These findings suggested that while change in 
cardiovascular functioning was observed across the experimental paradigm for some measures, 
measures of cardiovascular functioning continued to correlate throughout the experimental 
paradigm. 
Baseline Cardiovascular Functioning 
As expected, there were no significant differences in baseline cardiovascular functioning 
for HP, RSA, or PEP assessed with both two- and five-minute averages between groups when 
using univariate analysis. The lack of significant differences in baseline cardiovascular 
functioning between groups is consistent with previous studies that have failed to find significant 
differences in cardiovascular functioning at rest among individuals with remitted MDD (Bylsma 
et al., 2014, 2015; Chang et al., 2013; Rottenberg et al., 2005b; Salomon et al., 2013; Vaccarino 
et al., 2008). In addition, this finding is in line with the differential activation and mood state 
dependent hypotheses, which suggests that vulnerabilities to depression remain latent in formerly 





Contrary to expectations, the hypothesized pattern of cardiovascular reactivity (i.e., 
decreased HP and RSA and increased PEP) was not observed in formerly depressed participants 
exposed to the sad mood induction when using difference scores, residualized change scores, and 
repeated measures. The hypothesized pattern of cardiovascular reactivity was based on a 
combination of theoretical models and previous empirical findings examining differences in 
cardiovascular reactivity in the response to sadness in formerly depressed individuals. In the 
current study sample, a different pattern of cardiovascular reactivity (i.e., increased HP and RSA 
and blunted PEP) in response to the sad mood induction emerged among formerly depressed 
participants, albeit without significant differences for the group by condition interaction. 
Examination of the effect size values indicated that effect sizes ranged from non-existent (η2 = < 
.001) to in the small to medium range (η2 = .03). Post-hoc analyses revealed that the current 
study had a relatively low chance (7-20%) of detecting an effect due to insufficient power while 
sensitivity analyses indicated that at least a medium effect size was necessary to detect an effect 
if sufficient power had been obtained. Clearly, the current study was under powered to detect 
such an effect across the different cardiovascular measures.  
However, some significant differences in cardiovascular reactivity were identified using 
multiple comparisons. These differences were mainly found in HP, which is defined as the 
amount of time between heart beats measured in millisecond. HP was used in lieu of HR, which 
is defined as the number of beats produced by the heart per minute. While HP and HR are 
reciprocal measurements of cardiovascular functioning, they are not linearly related and can 
generate discrepant results when there are significant differences across participants or changes 




cardiovascular functioning would be attributable to autonomic effects and cardiovascular 
differences were ascribed to the experimental task (condition: sad, neutral) and group 
membership (group: formerly depressed, healthy control; Berntson et al., 2007). 
 Results revealed that formerly depressed participants exhibited significantly higher 
levels of five-minute HP reactivity during the mood induction than healthy control participants 
when using difference scores and residualized change scores (see Figures 21-23). Of note, 
differences between groups were not observed when using two-minute HP reactivity (see Figures 
18-20). While this was not true when using repeated measures for both two- and five-minute HP 
reactivity, it is possible that this is due to lower power in the between-subjects portion of this 
analysis (Guo, Logan, Glueck, & Muller, 2013). 
Examination of the means and standard deviations for the two- and five-minute HP 
baseline and mood induction measures suggest that this is due to differences in resulting 
averages when using the two approaches to calculate reactivity. Both groups showed similar 
cardiovascular functioning at baseline. In addition, both groups showed a cardiovascular reaction 
in response to the mood induction. For the two-minute HP averages, formerly depressed 
participants exhibited an increase in HP of 26.74 milliseconds compared to baseline 
cardiovascular functioning during the mood induction while healthy control participants 
exhibited an increase in HP of 13.48 milliseconds during the mood induction compared to 
baseline cardiovascular functioning. For the five-minute HP averages, formerly depressed 
participants exhibited an increase in HP of 14.00 milliseconds during the mood induction 
compared to baseline cardiovascular functioning while healthy control participants exhibited a 
decrease in HP of 1.69 milliseconds during the mood induction compared to baseline 




reactivity differed when using two-minute HP averages and the extent to which cardiovascular 
reactivity attenuated over time differed when using five-minute HP averages.  
Figure 18. Two-Minute Heart Period – Difference Score during Mood Induction 
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Figure 20. Two-Minute Heart Period – Repeated Measures Pre- and during Mood Induction 
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Figure 22. Five-Minute Heart Period – Residualized Change Score during Mood Induction 
 
Figure 23. Five-Minute Heart Period – Repeated Measures Pre- and during Mood Induction 
 
Multiple comparisons and contrast analyses were not significant for HP, RSA, or PEP. 
While not statistically significant, examination of the p values (p = .06-.08) for the contrast 
analyses for two-minute HP difference scores and residualized change scores and five-minute HP 
residualized change scores indicate that these analyses were approaching significance and may 
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repeated measures for both two- and five-minute HP reactivity contrast analyses, it is possible 
that this is due to lower power in the between-subjects portion of this analysis (Guo, Logan, 
Glueck, & Muller, 2013). Both of these findings are meaningful. The difference in magnitude of 
cardiovascular reactivity for two-minute HP suggests that when observed over a short period of 
time, formerly depressed individuals exposed to a sad mood induction may exhibit more 
pronounced HP reaction compared to healthy control individuals exposed to a sad mood 
induction as well as formerly depressed and healthy control individuals exposed to a neutral 
mood induction (see Figure 24). The extent to which cardiovascular reactivity attenuated over 
time significantly differed for five-minute HP, which suggests that when observed over a more 
extended period of time, formerly depressed individuals exposed to a sad mood induction may 
exhibit an elevated HP in response to an emotionally-valenced stimulus compared to healthy 
control individuals exposed to a sad mood induction as well as formerly depressed and healthy 
control individuals exposed to a neutral mood induction (see Figure 24). The latter finding points 
to importance of the remitted MDD literature moving beyond its persistent focus on 












Figure 24. Minute by Minute Heart Period during Mood Induction 
 
Cardiovascular Recovery 
Contrary to expectations, the expected maladaptive patterns of cardiovascular recovery 
(i.e., decreased HP and RSA and increased PEP compared to baseline) was not observed during 
the recovery film in formerly depressed participants exposed to the sad mood induction when 
using difference scores, residualized change scores, and repeated measures. The hypothesized 
pattern of cardiovascular recovery was also based on a combination of theoretical models and 
previous empirical findings examining differences in cardiovascular recovery in response to 
stress among formerly depressed individuals given the lack of investigation of cardiovascular 
recovery in the response to sadness in formerly depressed individuals. In the current study 
sample, a different pattern of cardiovascular recovery (i.e., increased HP and RSA and blunted 
PEP) during the recovery film emerged among formerly depressed participants, albeit without 
significant differences the group by condition interaction for RSA and PEP. Examination of the 
effect size values indicated that effect sizes ranged from non-existent (η2 = < .001) to small to 
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(6-28%) of detecting an effect due to insufficient power while sensitivity analyses indicated that 
at least a medium effect size was necessary to detect an effect if sufficient power had been 
obtained. The current study was under powered to detect such an effect in some of the 
cardiovascular measures. 
However, some significant differences in cardiovascular recovery were identified using 
multiple comparisons. While not significant due to the adjusted p value used due to violations of 
homogeneity of variance, formerly depressed participants exhibited significantly higher levels of 
two-minute HP during the recovery film when using difference and residualized change scores as 
well as five-minute HP during the recovery film when using residualized change scores than 
healthy control participants. The difference in magnitude of cardiovascular recovery was not 
large enough to reach statistical significance for five-minute HP recovery using difference 
scores. Examination of the means and standard deviations for the baseline and recovery measures 
and difference score do suggest that there are discrepancies in HP recovery exhibited by the 
different groups. Examination of the p values (p = .02-.05) indicate that this analysis was 
approaching significance and may have been significant if sufficient power had been obtained. In 
addition, examination of the effect sizes (η2 = .04-.06) for the two-minute HP difference scores 
and residualized change scores and five-minute HP residualized change scores indicate that they 
were in the small to medium and medium range. 
While not significant due to the adjusted p value used due to violations of homogeneity 
of variance, formerly depressed participants exposed to the sad mood induction exhibited 
significantly higher levels of two-minute HP during the recovery film when using difference and 
residualized change scores than formerly depressed participants exposed to the neutral mood 




Figures 25-27). In addition, formerly depressed participants exposed to the sad mood induction 
exhibited significantly higher levels of five-minute HP during the recovery film when using 
residualized change scores than formerly depressed participants exposed to the neutral mood 
induction and healthy control participants exposed to the sad and neutral mood inductions (see 
Figures 28-30). While five-minute HP recovery using difference scores did not meet statistical 
significance, examination of the p values (p = .06) indicated that these analyses were 
approaching significance and may have been significant if sufficient power had been obtained. In 
addition, examination of the effect size (η2 = .04) for the five-minute HP difference score 
indicate that they were in the small to medium range. While there were no significant differences 
between groups and conditions when using repeated measures, it is possible that this is due to 
lower power in the between-subjects portion of this analysis (Guo, Logan, Glueck, & Muller, 
2013). 
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Figure 26. Two-Minute Heart Period – Residualized Change Score during Recovery Film 
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Figure 28. Five-Minute Heart Period during Recovery Film 
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Figure 30. Five-Minute Heart Period – Repeated Measures Pre- and during Recovery Film 
 
Contrast analyses were not significant for RSA and PEP but were for some HP measures. 
Contrast analyses indicated that formerly depressed participants exposed to the sad mood 
induction exhibited significantly higher levels of two-minute HP when using residualized change 
scores and five-minute HP when using difference scores and residualized change scores during 
the recovery film compared to healthy control participants exposed to the sad mood induction 
and formerly depressed and healthy control participants exposed to the neutral mood induction. 
While this was not true when using repeated measures for both two- and five-minute HP 
recovery, it is possible that this is due to lower power in the between-subjects portion of this 
analysis (Guo, Logan, Glueck, & Muller, 2013). 
Examination of the means and standard deviations for the two- and five-minute HP 
baseline and recovery measures suggest that the two approaches to calculating recovery resulted 
in slightly different findings. Both groups showed similar cardiovascular functioning at baseline. 
However, there was a stark difference in cardiovascular recovery obtained during the recovery 
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induction exhibited an increase in HP of 29.11 milliseconds during the recovery film compared 
to baseline cardiovascular functioning. While formerly depressed and healthy control 
participants exposed to the neutral mood induction did not return to baseline cardiovascular 
functioning levels, their HP during the recovery film was significantly lower than formerly 
depressed participants exposed to the sad mood induction. Interestingly, healthy control 
participants exposed to the sad mood induction actually exhibited HP levels that were lower than 
their baseline cardiovascular functioning levels during the recovery film.  
For the five-minute HP averages, formerly depressed participants exposed to the sad 
mood induction exhibited an increase in HP of 25.00 milliseconds during the recovery film 
compared to baseline cardiovascular functioning. Formerly depressed and healthy control 
participants exposed to the neutral mood induction showed a decrease of HP compared to their 
two-minute HP averages that was closer to their baseline cardiovascular functioning levels. 
Healthy control participants exposed to the sad mood induction continued to exhibit HP levels 
that were lower than their baseline cardiovascular functioning levels during the recovery film, 
albeit to a lesser degree. Together, this suggests that the magnitude of cardiovascular recovery 
differed when comparing two- and five-minute HP averages and the extent to which 
cardiovascular recovery attenuated over time differed across groups and conditions when using 
two- and five-minute HP averages. 
Both of these findings are meaningful. The difference in attenuation of cardiovascular 
recovery for two-minute HP suggests that when observed over a short period of time, formerly 
depressed individuals exposed to a sad mood induction may exhibit less reduction in HP during 
recovery compared to healthy control individuals exposed to a sad mood induction as well as 




Figure 31). The difference in attenuation of cardiovascular recovery for five-minute HP suggests 
that when observed over an extended period of time, formerly depressed individuals exposed to a 
sad mood induction may continue to exhibit elevated HP during recovery compared to healthy 
control individuals exposed to a sad mood induction as well as formerly depressed and healthy 
control individuals exposed to a neutral mood induction (see Figure 31). Together, these findings 
suggest that cardiovascular recovery following a transient sad mood is impaired among formerly 
depressed individuals when examined using both two- and five-minute HP averages. 
Figure 31. Minute by Minute Heart Period during Recovery Film 
 
Implications 
 Several important implications can be drawn from the current study. The finding that 
generally, formerly depressed individual exposed to the sad mood induction experienced 
elevated levels of mood, rather than cognitive, reactivity provides a meaningful data point in the 
inconsistent literature base. Empirical evidence has found that compared to healthy control 
participants, those with remitted MDD report significant increases in dysfunctional beliefs (i.e., 
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reactivity; van Rijsbergen et al., 2013) in response to an experimentally-induced sad mood and 
prospectively predict relapse of depression over time. There has been disagreement in the 
literature whether dysfunctional thinking patterns or dysphoric mood states characterize remitted 
MDD, with recent research advancing the idea that mood reactivity may be an important 
construct of interest. While the current study sought to add clarity to the literature, results raise 
questions about what may be driving the different findings between studies. Additional research 
is needed to advance our understanding of these potentially malleable vulnerability factors 
associated with a history of depression, whether it be identification of mediators, moderators, or 
predictors of cognitive and mood reactivity. 
 In terms of treatment, the finding that formerly depressed individual exposed to the sad 
mood induction experienced elevated levels of mood reactivity may have important implications 
for psychotherapy. The evidence-based treatments for depression that are currently recognized 
by Division 12 of the American Psychological Association (APAB, 2016a) include the following 
13 treatment modalities: acceptance and commitment therapy (ACT), behavioral activation, 
cognitive behavioral analysis system of psychotherapy, CBT, CT, emotion focused therapy, 
interpersonal psychotherapy, problem-solving therapy, rational emotive behavioral therapy 
(REBT), reminiscence/life review therapy, self-management/self-control therapy, self-system 
therapy, and short-term psychodynamic therapy. Of note, the majority of the second and third 
wave therapies listed above are theorized to impact emotions indirectly. More specifically, the 
cognitive model that second wave psychotherapies (i.e., CBT, CT, REBT) are based on theorize 
that an individual’s perception of an event results in automatic thoughts that spurs a cascade of 
behavioral, emotion, and physiological responses (Beck, 1964). Consequently, the cognitive 




beliefs further along during the course of therapy, changes behavioral and emotional reactions 
(Beck, 2011). In other words, traditional cognitive-behavioral approaches to psychotherapy 
result in alterations of emotional responses through indirect techniques. 
 Third wave psychotherapies (e.g., ACT, dialectical behavior therapy (DBT), 
mindfulness-based cognitive therapy (MBCT)) are more closely connected by the techniques 
utilized rather than theoretical underpinning. Third wave therapies typically employ mindfulness 
strategies to increase awareness and acceptance of internal experiences including thoughts, 
feelings, and physiological sensations (Brown, Gaudiano, & Miller, 2013). In addition, some of 
these psychotherapies employ emotion-focused techniques. For example, DBT, an empirically-
supported treatment for borderline personality disorder (BPD; Division 12 of the APAB, 2016b) 
that traditionally consists of individual psychotherapy, group-based skills training, phone 
consultation, and team consultation (Linehan, 1993), focuses on building emotion regulation, 
distress tolerance, mindfulness, and interpersonal effectiveness skills. The emotion regulation 
module includes skills such as understanding and identifying emotions, changing undesirable 
emotions, reducing vulnerability to emotions, and managing intense emotions. The distress 
tolerance module includes skills such as crisis survival and radical acceptance of emotional 
reactions (Linehan, 2015). 
 While individuals with MDD and BPD exhibit different deficits in emotion regulation, it 
is possible that the emotion regulation and distress tolerance skills that are integral to DBT may 
be beneficial to formerly depressed individuals. Theoretical and empirical evidence suggests that 
vulnerability associated with depression remain latent in individuals who have recovered from a 
depressive episode until activated by dysphoric mood. This dysphoric mood is hypothesized to 




possible that providing individuals with remitted MDD emotion regulation and distress tolerance 
skills at the final phase of treatment initially targeting current MDD or during booster sessions 
for relapse prevention may increase their ability to recognize when a dysphoric mood occurs and 
select the appropriate strategies (e.g., mindfulness, problem solving, opposite action, cognitive 
restructuring; Linehan, 2005) to manage these emotions effectively and prevent the onset of a 
prolonged depressed mood. Research is needed to empirically test whether or not teaching these 
skills to at-risk remitted MDD populations could result in reductions in depressive relapse and 
recurrence over time. 
 While there were no significant differences in cardiovascular reactivity when examining 
the group by condition interaction, formerly depressed individuals generally exhibited a trend of 
elevated levels of HP and reduced attenuation of HP during the sad mood induction when using 
planned comparisons. As previously noted, HP has been used in the literature as an index of 
arousal, task involvement, and mental load and effort (Jorna, 1992). This finding suggests that 
formerly depressed individuals may experience elevated arousal during a sad mood and be more 
engaged in and devote more cognitive resources to the mood induction task. While not examined 
in the current investigation, one potential mechanism of action that may be explored to explain 
increased task involvement and mental load and effort in formerly depressed individuals during a 
sad mood induction is rumination given its prevalence in this population (Olatunji, Naragon-
Gainey, & Wolitzky-Taylor, 2013). Importantly, this finding points to potential differences in 
cardiovascular recovery in this population. The current study makes an important contribution to 
the literature as it was the first to investigate cardiovascular recovery following a sad mood 




The finding that generally, formerly depressed individual exposed to the sad mood 
induction exhibited elevated levels of HP during the recovery film greatly extends the current 
literature. A review of the remitted MDD literature indicates that only two studies have assessed 
cardiovascular reactivity in formerly depressed individuals, albeit in response to stress rather 
than sadness. Both of these studies suggested that formerly depressed individuals exhibited 
cardiovascular recovery following a speech stress test that resembled healthy control, rather than 
currently depressed, individuals (Bylsma et al., 2014; Salomon et al., 2009). Thus, this was the 
first study to investigate multiple measures of cardiovascular recovery from a transient sad mood 
in formerly depressed individuals. Using planned comparisons, the current study found that 
individuals with a history of depression take significantly longer to return to baseline levels of 
HP following a sad mood induction when using both two- and five-minute averages compared to 
healthy, never depressed individuals. This finding is striking as the study’s sample consisted of 
younger (M = 20.79, SD = 5.65), healthy individuals free from a variety of physical and mental 
health conditions that could have confounded the results. It is possible that formerly depressed 
individuals who are older, have experienced more depressive episodes over the course of their 
lifetime, and have comorbid physical and mental health conditions would exhibit a more 
pronounced cardiovascular response to a transient sad mood or experience more negative 
repercussions due to impaired HP recovery. 
Results suggest that formerly depressed individuals exposed to a sad mood induction  
experience elevated arousal during recovery and have more difficulty disengaging from a task. 
While not examined in the current investigation, one potential mechanism of action to explain 




rumination during the recovery period. Future research could investigate this possibility by 
asking participants to complete a state measure of rumination following the recovery period.  
The lasting impact of a transient sad mood on formerly depressed individuals may 
explain the susceptibility to CVD in this population. Higher HP during experimental tasks that 
involve attention is believed to be adaptive, as it is thought to represent arousal, task 
involvement, and mental load and effort. However, elevated HP during recovery may not be 
adaptive, especially if this persists for extended periods of time or occurs with regular frequency. 
The closest clinical variable that could serve as a proxy for elevated HP during recovery is 
resting HR, or the number of beats produced by the heart per minute while completely at rest. 
Research has indicated that elevated resting HR is associated with an increased risk of negative 
health outcomes, including cardiovascular events, CVD, and mortality, in individuals with and 
without pre-existing cardiovascular problems (Ho et al., 2014). A recent meta-analysis by Zhang, 
Shen, and Qi (2015) investigated the relationship between resting heart rate and all-cause and 
cardiovascular mortality. 46 prospective cohort studies met the inclusion and exclusion criteria, 
resulting in data from over 1,000,000 participants drawn from the general, rather than medically 
compromised, population. Results indicated that with every incremental increase of 10 beats per 
minute resting HR, there was an increase in the relative risk of all-cause (RR = 1.09, CI = 1.07-
1.12) and cardiovascular mortality (RR = 1.08, CI = 1.06-1.12) when cardiovascular risk factors 
were controlled for. Subgroup analyses were conducted to examine group differences in 
mortality risk. Using 45 beats per minute resting HR as a reference group, the risk of all-cause 
mortality increased linearly with resting HR while the risk of cardiovascular mortality 
significantly increased at 90 beats per minute resting HR. This meta-analysis, along with a large 




general population (Zhang et al., 2015, p. E60). Therefore, elevated HP in response to a transient 
sad mood and impaired HP recovery is likely maladaptive. 
It is possible that the impaired HP recovery observed in formerly depressed individuals 
exposed to the sad mood induction in the current study may increase vulnerability to depression 
and contribute to the development of psychopathology and physiological abnormalities (Linden 
et al., 1997; Haynes, Gannon, Orimoto, O’Brien, & Brandt, 1991). It is important to note that 
two characterizations of cardiovascular functioning were not captured by the experimental 
paradigm: the typical length of impaired HP recovery and occurrence of HP reactivity and 
recovery. First, impaired HP recovery may extend longer than was captured by the current study, 
which observed cardiovascular recovery over a 10-minute period. Given that HP continued to be 
elevated in formerly depressed individuals exposed to the sad mood induction at the 10-minute 
mark (see Figure 31), it is not currently known how long the elevation in HP would typically 
persist. Second, HP reactivity and impaired HP recovery in response to a transient sad mood 
likely occurs more often than was modeled in the experimental paradigm. Moreover, fluctuations 
in mood are common during daily life; a dysphoric mood may arise when an individual is 
reminded of a sad memory, reflects on a past failure, experiences a social slight, or engages in an 
interpersonal conflict. Therefore, elevations in HP and the resulting impaired HP recovery likely 
occurs at multiple times during the day and may last for extended amounts of time. There is a 
distinct possibility that formerly depressed individuals may regularly exhibit a pattern of 
repeated HP reactivity and impaired HP recovery in response to a transient sad mood, which 
impacts their cardiovascular health and functioning in a clinically significant manner. Further 
study of the duration of impaired HP recovery and incident of HP reactivity and recovery is 




In addition, it is plausible that impaired HP recovery following a transient sad mood in 
formerly depressed individuals are implicated in the well-established relationship between 
depression and CVD (Haigh & Bogucki, 2017; Haigh et al., 2018b). If formerly depressed 
individuals exhibit a pattern of repeated HP reactivity and impaired HP recovery in response to a 
transient sad mood, cardiovascular abnormalities may arise. While the current study did not 
directly explore this connection, it is an important first step for investigating this hypothesis. 
More research is needed to replicate these findings, extend these findings using longitudinal 
methods and if longitudinal results identify an association between cardiovascular recovery and 
physiological abnormalities, investigate biological mechanisms to determine the 
pathophysiological process at play and the efficacy of interventions (e.g., respiratory feedback, 
biofeedback, emotion regulation strategies) designed to facilitate cardiovascular recovery 
(Sharpley, 2002). 
Finally, the variable results obtained using different timing for (i.e., two- versus five-
minutes) and approaches (i.e., difference versus residualized change score) to calculate 
cardiovascular reactivity and recovery illustrate the challenge of conducting psychophysiological 
research. Unfortunately, there is little consistency across the literature as to how many minutes 
should be averaged to calculate reactivity and recovery or which time segments of reactivity or 
recovery should be selected. More research is needed to establish more formal guidelines as to 
the appropriate amount of time and timing of segments that researchers should select depending 
on their research question, experimental task, and population of interest, among other factors 
(Linden et al., 1997). This knowledge may be helpful for moving psychophysiological research 




analyses and increase standardization across studies, increasing the ease of cross-study 
comparisons. 
Strengths 
 The current study has several strengths, which meaningfully extend the findings of 
previous research. First, the current study addressed the multiple methodological issues present 
in previous research. Prior literature has relied upon a mixed sample of participants who were 
currently or formerly depressed (Bylsma et al., 2015; Yaroslavsky et al., 2013, 2014 Studies 1 
and 2; with the exception of Rottenberg et al., 2005b) and examined a very limited range of 
cardiovascular measures (i.e., HR or RSA only; Rottenberg et al., 2005b; Yaroslavsky et al., 
2013, 2014 Studies 1 and 2; with the exception of Bylsma et al., 2015). A large portion of the 
literature has failed to compare cardiovascular reactivity in response to both sad and neutral 
mood inductions (Yaroslavsky et al., 2013, 2014 Studies 1 and 2; with the exceptions of Bylsma 
et al., 2015 and Rottenberg et al., 2005b) and was conducted in formerly depressed adolescents 
(Bylsma et al., 2015; Yaroslavsky et al., 2014 Study 2; with the exceptions of Rottenberg et al., 
2005b and Yaroslavsky et al., 2013, 2014 Study 1) rather than adults. Finally, none of the 
literature explicitly assessed for the presence of CVD or investigated cardiovascular recovery 
(Bylsma et al., 2015; Rottenberg et al., 2005b; Yaroslavsky et al., 2013, 2014 Studies 1 and 2).  
Accordingly, this is the first study to examine a broad range of cardiovascular measures 
to assess cardiovascular reactivity to and recovery from sadness in an exclusively remitted MDD 
adult sample free from CVD. The current study employed a quasi-experimental design, which 
compared two groups (i.e., formerly depressed, healthy control) randomly assigned to two 




design, stringent inclusion and exclusion criteria, and control of potential confounding variables 
allowed for competing explanations to be ruled out. 
Second, the current study determined eligibility and group assignment using a structured 
clinical interview, the SCID-IV-RV, that had been adapted in accordance with the DSM-5. The 
SCID was developed in an effort to increase diagnostic reliability for DSM diagnoses through 
the use of standardized questions that aligned with diagnostic criteria and consistent language to 
enhance interrater agreement (Bergman & Fors, 2005). To be accurately determined, clinical 
diagnoses must be evaluated using a structured or semi-structured clinical interview rather than 
self-report measures due to the biases associated with these instruments (Paulhus & Vazire, 
2007). The use of the SCID-IV-RV in the current study allowed for diagnostic accuracy across 
the different experimenters evaluating whether or not participants met the inclusion and 
exclusion criteria. 
 Third, the current study employed multiple reliable and standardized methods that are in 
line with the recommendations of RDoC. Under the negative valence system, there are multiple 
constructs including acute threat (“fear”), potential harm (“anxiety”), sustained threat, frustrative 
non-reward, and loss. MDD aligns most closely with the construct of loss in the negative valence 
system (National Institute of Mental Health, 2011). RDoC recommends the use of multiple levels 
of analysis to assess a construct in an effort to obtain a more comprehensive understanding of the 
pathological mechanisms underlying current diagnostic categories and eventually, create a 
dimensional diagnostic system (Cuthbert, 2014). The RDoC negative valence systems 
workgroup has identified multiple behavioral assessment methods for studying the construct of 
loss including rumination, withdrawal, worry, crying, sadness, loss-relevant recall bias, 




retardation, anhedonia, increased self-focus, deficits in executive functioning, loss of drive, 
decreased libido, shame, amotivation, memory impairments, and intrusive thoughts (National 
Institute of Mental Health, 2011). In this study, cognitive reactivity aligns most closely with 
intrusive thoughts while mood reactivity aligns most closely with sadness. In addition, the RDoC 
negative valence system has identified multiple physiological assessment methods for studying 
the construct of loss including ANS, HPA, and neuroimmune dysregulation and prolonged 
psychophysiological reactivity (National Institute of Mental Health, 2011). In this study, 
cardiovascular reactivity aligns most closely with prolonged psychophysiological reactivity, and 
could also be subsumed under cardiovascular recovery. While the current study did assign group 
membership according to DSM diagnostic criteria, it did adopt a more dimensional approach in 
line with the recommendations of RDoC. 
Limitations and Future Directions 
The current study has several limitations, which can be addressed by future research. 
First, the study sample was recruited from the University of Maine psychology undergraduate 
participant pool and the surrounding community. The study sample was predominantly younger, 
female, Caucasian, never married college students despite significant efforts to recruit a more 
diverse sample. Consequently, the study sample is not representative of the U.S. population. 
While the reported rate of depression is higher women (Eaton et al., 2007; Grant et al., 2009; 
Hasin et al., 2005; Kessler et al., 2003; Kuehner, 2003, Seedat et al., 2009), younger to middle-
aged adults (Eaton et al., 2007; Grant et al., 2009; Haigh et al., 2018a; Kessler et al., 2003, 2005, 
2010), and Caucasian individuals (Alegría et al., 2008; Williams et al., 2007), more research is 
needed on risk for recurrence of depression across the population. Future research should attempt 




Second, the sample size recruited for the current study was relatively small. Significant 
efforts were made to recruit a sample size that was large enough to detect an effect should it be 
present. Power analysis using G*Power 3.1.9.2 (Faul et al., 2007) indicated that a sample of 128 
participants would result in an 80.00% chance of detecting a medium effect between two groups 
(i.e., formerly depressed and healthy control participants) exposed to two versions of the 
experimental paradigm (i.e., sad or neutral mood induction). While the recruitment target was 
met (N = 132), even slightly exceeded, distribution of participants was uneven between groups 
(nFD = 45, nHC = 87) and conditions (nSMI = 65, nNMI = 67). The main issue with unequal sample 
sizes when conducting ANOVA analyses is that it can impact homogeneity of variance. ANOVA 
is robust statistical test that can handle “moderate departures” from homogeneity of variance 
(Grace-Martin, 2019b). In the current study, multiple steps were explored in an attempt to 
remedy the violation of homogeneity of variance, including transforming the data to reduce 
skewness, or decreasing the α level to reduce the likelihood of type II error (S. W. Ell, personal 
communication, February 9, 2016). 
There were a variety of reasons for uneven distribution between groups and conditions in 
the current study. In regard to groups, it was challenging to recruit formerly depressed 
participants that met the inclusion and exclusion criteria. This is likely multifactorial and may be 
due to stigma associated with mental illness, elevated rates of comorbid medical and mental 
health conditions in depressed populations, and the chronic, recurrent nature of depression that 
may have resulted in eligible participants identified at screening who were subsequently 
excluded when assessed using the SCID-IV-RV at a later timepoint. Contrariwise, it was 
significantly easier to recruit healthy control participants. In regard to conditions, participants 




to between-session attrition from sessions 1 and 2. Finally, the power analysis conducted a priori 
may not have been precise as it was it was challenging to determine the anticipated effect size. 
First, the current study drew from two distinct literature bases (i.e., cognitive and mood literature 
and cardiovascular literature) that had different conventions and effect sizes of findings. Second, 
the cardiovascular literature for remitted depression was limited and often neglected to report 
effect sizes for findings. Future research that aims to replicate these findings should ensure that 
an adequate sample size is recruited to detect small to medium effects. Both researchers and 
editors should ensure that effect sizes are reported to allow for accurate power analyses when 
replicating results. In addition, future research that obtains an adequate sample size could 
consider dividing formerly depressed individuals into subgroups of variables that may mediate or 
moderate the relationship between depression and cognitive, mood, and cardiovascular reactivity 
and recovery in an effort to better predict recurrence of depression and advance precision 
medicine (Monroe et al., in press). 
 Third, the inclusion and exclusion criteria used in the current study were stringent. The 
inclusion and criteria omitted potential confounding variables that could have impacted 
psychophysiological measures. All participants were excluded from the study if they did not 
speak and read English fluently, were color blind, had been diagnosed with a learning disability 
that interferes with their ability to read or process visual information, had experienced certain 
physical conditions known to impact the recording of physiological responses, or underwent 
brain or neural surgery or brain radiation treatment. In addition, the inclusion and criteria omitted 
participants who met diagnostic criteria for certain psychiatric disorders. Formerly depressed 
participants were excluded if they met diagnostic criteria for current MDD within the past 




bipolar disorder, psychotic disorder, acute suicidal ideation, or mood episodes secondary to 
general medical conditions while healthy control participants were excluded if they met 
diagnostic criteria for any current or past psychological disorder. Consequently, the entire sample 
was exceptionally healthy, both physically and mentally. The rigor of the inclusion and exclusion 
criteria may have had the unintended consequence of selecting for a sample that may not be 
representative of depressed individuals seeking treatment in the community, which should be 
considered to avoid inappropriately extrapolating results to community-samples. Future research 
may consider using more lenient criteria, when possible, to obtain a more realistic sample of 
treatment seeking patients. More specifically, formerly depressed participants with diverse 
psychiatric presentations and healthy control participants with a history of non-depressive 
disorders may be included or considered as a separate comparison group.  
Fourth, CO, which was originally proposed as a cardiovascular measure, was dropped 
from analyses due to concerns its accuracy. Typical values for resting CO range from 4 to 12 
liters per minute (J. Schmidt, personal communication, April 16, 209). Average CO values 
ranged from 1.62 to 365.73 during baseline, 1.49 to 390.58 during the mood induction, and 1.69 
to 175.80 during recovery, indicating that this cardiovascular measure was not accurate. It was 
determined that this issue was due to inaccurate SV values. SV is not used to calculate HP, RSA, 
or PEP and therefore, these cardiovascular measures were not affected. Future research should 
include CO as a cardiovascular measure to evaluate the efficiency of the heart in response to a 
transient sad mood (Berntson et al, 2007). In addition, future research should expand beyond 
cardiovascular measures to also include neuroendocrine and immunological measures in an 
effort to understand their relationship and the pathopsychophysiological cascades that contribute 




Fifth, treatment history (i.e., current and past CBT and antidepressant use), which was 
originally proposed as a potential covariate, was not adequately captured in the study sample. 
Treatment history data was not collected for 16 formerly depressed and 40 healthy control 
participants. Due to the large amount of missing data, treatment history was removed from 
further analyses. CBT use was originally proposed as a potential covariate because previous 
research has suggested that engagement in CBT is associated with lower levels of cognitive 
reactivity (Jarrett et al., 2012; Kuyken et al., 2010; Segal et al., 1999). None of the 
cardiovascular studies conducted in remitted MDD participants reported participants’ 
engagement in CBT interventions or psychotherapy more broadly (Ahrens et al., 2008; Bylsma 
et al., 2014, 2015; Chang et al., 2012; Rottenberg et al., 2005b; Salomon et al., 2013; Wilson et 
al., 2016; Yaroslavsky et al., 2013, 2014a, 2014b). Antidepressant use was originally proposed as 
a potential covariate because previous research has found an association between antidepressant 
use and certain measures of cardiovascular functioning (e.g., RSA; Licht et al., 2008). While the 
majority of the cardiovascular studies conducted in remitted MDD participants did not exclude 
for the use of antidepressant medications (Ahrens et al., 2008; Bylsma et al., 2014, 2015; 
Rottenberg et al., 2005; Salomon et al., 2013; Wilson et al., 2016; Yaroslavsky et al., 2013, 
2014a, 2014b, with the exception of Chang et al., 2012), only a subset of these studies 
considered antidepressant medication as a potential covariate (i.e., Rottenberg et al., 2005b; 
Salomon et al., 2013; Vaccarino et al., 2008; Yaroslavsky et al., 2013, 2014a, 2014b). Of those 
studies, there were no significant differences based on medication status. Future research may 
consider including both CBT and antidepressant use as potential covariates to further expand 




Sixth, potential mediators and moderators of cardiovascular reactivity and recovery were 
not adequately captured in the current sample. As previously mentioned, one potential 
mechanism of action that may be explored to explain elevated cardiovascular reactivity and 
impaired cardiovascular recovery is rumination. This could be investigated by asking participants 
to record the thoughts that they were having during the mood induction and recovery period. Of 
note, it would be interesting to compare differences in cardiovascular recovery and rumination 
among formerly depressed individuals using different recovery tasks: a film that consists of 
potentially distracting visual and auditory stimuli, a piece of music that consists of potentially 
distracting auditory stimuli, a meditative exercise that consists of potentially distracting spoken 
words, and a silent recovery period without any distractions. Another potential mechanism of 
action that may be explored to explain impaired cardiovascular recovery is impaired mood 
recovery. This could be investigated by asking participants to complete the VAS after the 
recovery period. Future research may consider including these and other potential mediators and 
moderators to further expand upon the research base. 
Conclusions 
Increasing our understanding of vulnerability to depressive relapse and recurrence of 
depression is necessary to reduce the burden of this often-debilitating disorder, with an exigency 
to identify potentially malleable factors that can be targeted during treatment or following 
treatment for relapse prevention. Four potentially malleable factors that may be implicated in 
depressive relapse and recurrence include cognitive, mood, and cardiovascular reactivity to and 
recovery from sadness. Results from the current study suggest that mood, rather than cognitive, 
reactivity in response to a transient sad mood is observed in formerly depressed individuals. In 




measures of cardiovascular recovery or cardiovascular reactivity, following the induction of a 
transient sad mood is observed in formerly depressed individuals. Additional research is needed 
to replicate previous results indicating that mood reactivity is predictive of depressive relapse 
and recurrence as well as assess if the differences in cardiovascular responding observed in 
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Appendix A. Recruitment Flyers 
 
 
 HAVE YOU NEVER      
  BEEN DEPRESSED? 
 
 
Help the Maine Mood Disorders lab at UMaine in Orono learn more 
about how changes in mood impact risk for depression by 
participating in a paid research study. 
 
Take our survey if you: 
 Have no history of depression, anxiety, or any other emotional 
disorder	
 Do not suffer from alcohol abuse or dependence	
 Are between 18 and 60 years of age	
 
If you qualify: 
● Session 1 (Interview for about 1.5 hours in our lab; $20 
compensation)	
● Session 2 (Physiological recording while you complete a 
computer task in the lab for about 1 hour; $15 compensation) 	
● Session 3 (Online questionnaires that will take about 30 
minutes; entered in drawing with 1 in 10 chance to win a $25 
VISA Card) 	
 
TAKE OUR ONLINE SURVEY  
TO SEE IF YOU ARE ELIGIBLE! 
 
 
Scan this QR code  
or Visit: tinyurl.com/k3s2mrp  
or Text: 207-518-8089 













Appendix B. Screening Consent Forms 
Welcome to the University of Maine Psychology Department Pre-screening Questionnaires! 
  
You have chosen to participate in research studies to meet your research experience requirement. 
One option to partially complete this requirement is to complete the prescreening questionnaires. 
The purpose of this screening is to find individuals who score in certain ranges on questionnaires 
for several different research projects. Dr. Fayeza Ahmed, Dr. Emily Haigh, Dr. Jordan LaBouff, 
Dr. Rebecca Macaulay, Dr. Shannon McCoy, Dr. Doug Nangle, and Dr. Rebecca Schwartz-
Mette, professors in the Psychology Department, are conducting this screening. Based on your 
responses, you may be contacted to participate in one or more studies or you may not be 
contacted at all. 
 
What Will You Be Asked to Do?  
  
If you decide to participate, you will be asked to complete a series of questions about yourself, 




You may be asked questions like the following: Have you ever had a panic attack; have you ever 
been depressed; how do you feel about your political party; do you experience any of the 
following premenstrual symptoms (e.g., difficulty concentrating, depressed mood, breast 
tenderness); do you think fat people tend to be fat pretty much through their own fault; would 
you be upset if you learned that your son was gay; if I was hanging out with a homosexual 
person, I would worry that other people would think I was a homosexual too; do you consider 
yourself a Christian; have you lost interest in sex completely; are you feeling down, depressed, 
or hopeless; do you think that you may be dirty or contaminated; do you think Male 
homosexuality is a perversion; etc.  You may become uncomfortable answering some of the 
questions. If you have any concerns, please contact Melissa Jankowski (Graduate Student 
Coordinator of the Psychology Subject Pool) on First Class.  If any of the questions or content 
raises concerns that you wish to discuss and debrief with a professional, you should contact the 
University of Maine’s Counseling Services at Cutler Health Center (207-581-1392). 
  
Compensation:   
  
You will receive 1 hour of research credit for participating in this study.  You must reach the 




We need your name if you wish to be contacted for participation in one of the research projects. 
This information will not be shared with anyone other than the individuals' research teams 
named above, and identifying information will be kept separate in a different file (i.e., you will 
be identified by an arbitrary number).  The data file without identifying information will be kept 




name with your arbitrary identifier will be stored separately on a password protected drive in a 
locked laboratory or office, using software that provides additional security.  The prescreening 




Participation is voluntary.  While skipping an occasional answer is acceptable, in order for the 
data to be useful, most questions must be answered.  You must reach the finishing page of the 
survey to receive credit. If you decide at any point that you would rather not continue with the 
prescreener, you can do the article reviews OR participate in those studies that do not involve the 




If you have questions about this screening, please contact Dr. Jordan LaBouff (207-581-2826), 
352 Little Hall, or e-mail: sona.admin@umit.maine.edu). If you have questions about your rights 
as a research participant, please contact Gayle Jones, Assistant to the University of Maine’s 
Protection of Human Subjects Review Board, at 207-581-1498 (or e-mail 
gayle.jones@umit.maine.edu). 
 
By clicking "yes" below, I consent to participate in this study. 
 
Yes – I consent to participate and I am over 18 years old 
 
 
No – I do not consent 
 
 























Attention and Elaboration Study: Prescreen 
The University of Maine at Orono  
Prescreening Informed Consent Document (Community Participants) 
  
You are invited to participate in a research project being conducted by Dr. Emily Haigh, in the 
Department of Psychology at the University of Maine.  The purpose of the research is to learn 
about the emotional and physiological responses related to sad mood.  You must be at least 18 
years of age to participate.   
  
What Will You Be Asked to Do? 
  
Complete a set of online questionnaires to determine if you are eligible for the study.  
  
As part of the online survey you will answer questions about how you’re feeling (e.g. “After I 
overeat, occasionally I feel guilt or self-hate,” “I feel guilty all the time,” or “I am disgusted with 
myself.”) and different types of thoughts that people sometimes have (e.g., “I worry about 
making mistakes” or “I do not need the approval of other people in order to be happy”).  This 
portion of the study will take about 15-20-minutes total.   
  
If you are eligible for the study, you will receive an email inviting you to sign up to complete 
Session 1 in the lab.  During Session 1, participants will complete questionnaires and an 
interview, where they will be asked about their mood (e.g., “In the past month, have you been 
feeling depressed or down?”) and different symptoms (e.g., “In the past month, have you had 
trouble sleeping?”).  After the interview, a graduate student will measure your height and weight. 
Session 1 will take about 1.50 hours.  
  
Based on information gathered during Session 1, some participants will be asked to take part in 
Session 2.  If you are eligible and decide to participate in the second part, you will be scheduled 
for another session that will take place on a different day.  For Session 2, you will be asked to 
participate in physiological recording (sensors to detect electrical impulses will be attached to 
your chest and back) while you complete the following: self-report questionnaires, a 
computerized attention task, and listen to either a sad or neutral piece of music designed to 
induce a short-lasting sad mood or no change in mood.   
  
Participants that complete the second portion of the study will be invited to complete a third and 
final portion of the study.  For this part of the study, you will receive an email with a link to 
some questions about your mood and whether you have experienced any recent stressful events.   
  
Risks   
  
It is possible that you may feel uncomfortable when answering questions about yourself.  At any 
point during the study, you have the right to skip questions you do not wish to answer, or stop 
the session and choose not to participate in the remainder of the study.  You will not need to 
provide a reason for stopping the session.  You will receive a list of referrals for counseling 
services at the end of this questionnaire that can be downloaded.  If you indicate that you wish to 




Benefits   
  
While this study will have no direct benefit to you, this research will help us learn more about 




While there is no direct compensation for filling out this prescreen, by answering these questions 
you may qualify for Session 1 and Session 2 in our laboratory.  These sessions include monetary 




We need your name if you wish to be contacted for participation in this research project.   This 
information is not shared with anyone outside of the lab.  Identifying information will be kept 
separate in a different file.  A code number will be used to protect your identity.  The data file 
without identifying information will be kept on a password protected computer in a locked 
laboratory indefinitely.  The keyed file linking your name and code number will be stored 
separately on a password protected computer in the investigator’s locked office and will only be 
accessible by Dr. Emily Haigh, Maine Mood Disorders Lab graduate students, and research 
assistants who have been trained to deal with sensitive material.  Your name or other identifying 
information will not be reported in any publications.  The key linking your name to the data will 
be destroyed two years after data analysis is complete, which we anticipate will be in December, 
2018.  The key and the data files will be stored on separate computers.  All data will be kept 
indefinitely by the investigators.  You may decide that you do not want your data used in this 
research.  If you would like your data removed from the study and permanently deleted, please 




Participation is voluntary.  If you choose to take part in this study, you may stop at any 




If you have any questions about this study, please contact Emily Haigh at 
Emily.a.haigh@maine.edu.  If you have any questions about your rights as a research participant, 
please contact Gayle Jones, Assistant to the University of Maine’s Protection of Human Subjects 
Review Board, at 581-1498 or via e-mail gayle.jones@umit.maine.edu.    
 
Future Studies 
Would you be interested in being contacted for future studies conducted in the lab for 
monetary compensation? 
 






By clicking “Yes” below, you indicate that you have read and understand the above 
information and agree to participate. 
 















































Appendix C. Screening Self-Report Measures 
Contact Information 
 
Thank you for your interest in our study! Please provide your contact information below so we 
can contact you if you are eligible. 
 
Please provide your full name: _____ 
 
Please provide your email address: _____ 
 








































To start with, we would like to get some background information from you. 
 
1. What is your age? _____ 
 
2. What is your date of birth (MM/DD/YYYY)? _____ 
 




4. What is your marital situation (please check one)? 
○ Married 
○ Separated 
○ Never married/single 




5. Do you consider yourself to be Hispanic or Latino (i.e., a person of Mexican, Puerto 









7. What is your race? 
○ Native American or Alaska Native (i.e. a person having origins in any of the original  
     peoples of North, Central, or South America) 
○ Asian (i.e. a person having origins in any of the original peoples of the Far East,  
   Southeast Asia, or the Indian subcontinent including, for example, Cambodia, China,  
   India, Japan, Korea, Malaysia, Pakistan, the Philippine Islands, Thailand, and Vietnam) 
○ Black or African American (i.e. a person having origins in any of the black racial  
   groups of Africa) 
○ Native Hawaiian or Other Pacific Islander (i.e. a person having origins in any of the ..   
   original peoples of Hawaii, Guam, Samoa, or other Pacific Islands) 
○ White (i.e. a person having origins in any of the peoples of Europe, the Middle East, or  
   North Africa) 
○ Multiple races 






8. What is the highest grade in school you have completed (please check one)? 
○ Less than High School 
○ High School 
○ 1 year of college or technical school 
○ 2 or more years of college but did not graduate 
○ 4 years of college with degree 
○ Postgraduate, M.D., Ph.D. 










































General Health Screen (GHS) 
 
Please answer yes or no to the following questions: 
 




2. Are you color-blind?  
○ Yes 
○ No 
      
3. Have you ever been diagnosed with any learning disabilities that interfere with your 
ability to read or process visual information?   
○ Yes 
○ No 
            




5.   Have you ever been diagnosed with any neurological disorder, such as Alzheimer’s 

















9.   Have you ever been diagnosed with cardiovascular disease? Heart disease? 









Beck Depression Inventory – Second Edition (BDI-II) 
 
This questionnaire consists of 21 groups of statements. Please read each group of statements 
carefully, and then pick out the ONE STATEMENT in each group that best describes the way 
you have been feeling during the PAST TWO WEEKS, INCLUDING TODAY. Bubble in the 
number beside the statement you have picked. If several statements in the group seem to apply 
equally well, bubble in the highest number for that group. Be sure that you do not choose more 
than one statement for any group, including Item 16 (Changes in Sleeping Pattern) or Item 18 
(Changes in Appetite). 
 
1. Sadness 
    I do not feel sad. 
    I feel sad much of the time. 
    I am sad all the time. 
    I am so sad or unhappy that I can't stand it. 
 
2. Pessimism  
    I am not discouraged about my future. 
    I feel more discouraged about my future than I used to be. 
    I do not expect things to work out for me. 
    I feel my future is hopeless and will only get worse. 
 
3. Past Failure 
    I do not feel like a failure. 
    I have failed more than I should have. 
    As I look back, I see a lot of failures. 
    I feel I am a total failure as a person. 
 
4. Loss of Pleasure  
    I get as much pleasure as I ever did from the things I enjoy. 
    I don't enjoy things as much as I used to. 
    I get very little pleasure from the things I used to enjoy. 
    I can’t get any pleasure from the things I used to enjoy. 
 
5. Guilty Feelings 
    I don't feel particularly guilty. 
    I feel guilty over many things I have done or should have done. 
    I feel quite guilty most of the time. 
    I feel guilty all of the time. 
 
6. Punishment Feelings 
    I don't feel I am being punished. 
    I feel I may be punished. 
    I expect to be punished. 






    I feel the same about myself as ever. 
    I have lost confidence in myself. 
    I am disappointed with myself. 
    I dislike myself. 
 
8. Self-Criticalness 
    I don't criticize or blame myself more than usual. 
    I am more critical of myself than I used to be. 
    I criticize myself for all of my faults. 
    I blame myself for everything bad that happens. 
 
9. Suicidal Thoughts or Wishes  
    I don't have any thoughts of killing myself. 
    I have thoughts of killing myself, but I would not carry them out. 
    I would like to kill myself. 
    I would kill myself if I had the chance. 
 
10. Crying 
    I don't cry any more than I used to. 
    I cry more than I used to. 
    I cry over every little thing. 
    I feel like crying, but I can’t. 
 
11. Agitation  
    I am no more restless or wound up than usual. 
    I feel more restless or wound up than usual. 
    I am so restless or agitated that it’s hard to stay still. 
    I am so restless or agitated that I have to keep moving or doing something. 
 
12. Loss of Interest 
    I have not lost interest in other people or activities. 
    I am less interested in other people or things than before. 
    I have lost most of my interest in other people or things. 
    It’s hard to get interested in anything. 
 
13. Indecisiveness  
    I make decisions about as well as ever. 
    I find it more difficult to make decisions than usual. 
    I have much greater difficulty in making decisions than I used to. 









    I do not feel I am worthless. 
    I don’t consider myself as worthwhile and useful as I used to. 
    I feel more worthless as compared to other people. 
    I feel utterly worthless. 
 
15. Loss of Energy  
    I have as much energy as ever. 
    I have less energy than I used to have. 
    I don’t have enough energy to do very much. 
    I don’t have enough energy to do anything. 
 
16. Changes in Sleeping Pattern  
    I have not experienced any change in my sleeping pattern. 
    I sleep somewhat more than usual. 
    I sleep somewhat less than usual. 
    I sleep a lot more than usual. 
    I sleep a lot less than usual. 
    I sleep most of the day. 
    I wake up 1-2 hours early and can't get back to sleep. 
 
17. Irritability  
    I am no more irritable than usual. 
    I am more irritable than usual. 
    I am much more irritable than usual. 
    I am irritable all the time. 
 
18. Changes in Appetite   
    I have not experienced any change in my sleeping appetite. 
    My appetite is somewhat less than usual. 
    My appetite is somewhat more than usual. 
    My appetite is much less than usual. 
    My appetite is much greater than usual. 
    I have no appetite at all. 
    I crave food all the time. 
 
19. Concentration Difficulty  
    I can concentrate as well as ever. 
    I can't concentrate as well as usual. 
    It's hard to keep my mind on anything for very long. 








20. Tiredness or Fatigue  
    I am no more tired or fatigued than usual. 
    I get tired or fatigued more easily than usual. 
    I am too tired or fatigued to do a lot of the things I used to do. 
    I am too tired or fatigued to do most of the things I used to do. 
 
21. Loss of Interest in Sex  
    I have not noticed any recent change in my interest in sex. 
    I am less interested in sex than I used to be. 
    I am much less interested in sex now. 







































Patient Health Questionnaire – 9 (PHQ-9) 
 
For the two weeks in your life when you felt the most blue, sad, or depressed, how often were 
you bothered by any of the following problems? 
 
   
Rarely/ 








1. Little pleasure or interest in doing things 0 1 2 3 
2.  Feeling down, depressed or hopeless 0 1 2 3 
3. 
Trouble falling or staying asleep or 
sleeping too much 
0 1 2 3 
4. Feeling tired or having little energy 0 1 2 3 
5. Poor appetite or overeating 0 1 2 3 
6. 
Feeling bad about yourself – or that you 
are a failure or you have let yourself or 
your family down 
0 1 2 3 
7. 
Trouble concentrating on things, such as 
reading the newspaper or watching 
television 




Moving or speaking slowly so that other 
people could have noticed. Or the opposite 
– being so fidgety or restless that you have 
been moving around a lot more than usual 
0 1 2 3 
 
   Not at all Somewhat Very Extremely 
9. 
How difficult did these problems make it 
for you to do your work, take care of 

























Beck Anxiety Inventory (BAI) 
 
Below is a list of common symptoms of anxiety. Please carefully read each item in the list.  
Indicate how much you have been bothered by that symptom during the past month, including 
today, by circling the number in the corresponding space in the column next to each symptom. 
 
   
 
Not at all 
Mildly, but it 
didn’t bother me 
much 
Moderately – it 
wasn’t pleasant 
at times 
Severely – it 
bothered me a 
lot 
1. Numbness or tingling 0 1 2 3 
2.  Feeling hot 0 1 2 3 
3. Wobbliness in legs 0 1 2 3 
4. Unable to relax 0 1 2 3 
5. Fear of worst happening 0 1 2 3 
6. Dizzy or lightheaded 0 1 2 3 
7. Heart pounding/racing 0 1 2 3 
8. Unsteady 0 1 2 3 
9. Terrified or afraid 0 1 2 3 
10. Nervous 0 1 2 3 
11. Feeling of choking 0 1 2 3 
12. Hands trembling 0 1 2 3 
13. Shaky/unsteady 0 1 2 3 
14. Fear of losing control 0 1 2 3 
15. Difficulty breathing 0 1 2 3 
16. Fear of dying 0 1 2 3 
17. Scared 0 1 2 3 
18. Indigestion 0 1 2 3 
19. Faint/lightheaded 0 1 2 3 
20. Face flushed 0 1 2 3 


















Appendix D. Counseling Resources 
If you feel upset after having completed the study or find that some questions or aspects of the 
study triggered distress, talking with a qualified clinician may help. The following represents a 
list of resources that you may contact. These resources are options and in no way do they reflect 
an endorsement by the University of Maine.  
 
Counseling Services 
ON-CAMPUS RESOURCES Available for UMaine Faculty, Staff, and Students 
Counseling Center 
Cutler Health Building 
(Gannet Hall side) 








4:30 pm  
After business hours, 
call UMaine Police, 
581-4040 or 911 Psychological Services Center 
330 Corbett Hall 





 Weekdays 8:00 am- 
 4:30 pm 
COMMUNITY RESOURCES Available to Anyone 
Community Health & 
Counseling Services 
42 Cedar Street 
Bangor, ME  04401 









 Weekdays 8:00 am- 
 5:00 pm 
 
Maine Warm Line 







 7 days/week 5:00 pm-  
 8:00 am 
Maine Suicide and Crisis 
Hotline 







 7 days/week 24 hours 
Psychological Services Center 
330 Corbett Hall 




 Weekdays 8:00 am- 
 4:30 pm 
Contact Your Primary Care 
Provider 






  Mental Health Services Locator http://store.samhsa.gov/mhlocator 
   National Suicide Prevention Lifeline, Toll-Free, 24-hour Hotline, 1-800-273-TALK  





Appendix E. Recruitment Email 
Hello, 
 
Thank you very much for your interest in the research we are conducting at the Maine Mood 
Disorders Lab. We appreciate you taking the time to contact us and complete the online survey. 
 
Your responses to the survey indicate you qualify for the next step of our study, an in-person 
interview in our lab. This will take approximately two hours. This session will involve the 
completion of several online questionnaires about how you are feeling and different types of 
thoughts people sometimes have. You will then participate in an interview that will ask you 
about your mood and different symptoms related to disorders like depression and anxiety (e.g., 
In the past month, have you had trouble sleeping?). More details will be provided once you are 
scheduled. 
 
Using your name and email address, we created you a Sona Systems account. Sona is an online 
resource we use for scheduling.  
 
Please visit Sona here to schedule a time that works for you to come to the lab for approximately 





You are only eligible to participate in “Attention and Elaboration Session 1.” Please click 
on this study and enter the following password: blackbear.  
 





The Maine Mood Disorders Lab 
MMDL Website 















Appendix F. Research Participation Credit Schedule 
Credit will be awarded based on the amount of time that it takes for a participant to complete the 
session. Allow participants who are distressed to end participation in the study (discuss this with 
a graduate student) without loss of payment based on hours spent in the laboratory to the nearest 
half hour, as indicated below. 
 
Session 1: 
Up to ½ hour .50 research participation credit 
½ hour to 1 hour 1 research participation credit 
1 hour to 1 ½ hours 1.50 research participation credits 
1 ½ hours to 2 hours (or session completion) 2 research participation credits 
 
Session 2: 
Up to ½ hour .50 research participation credit 


































Appendix G. Payment Schedule 
Regardless of time spent in lab, pay full amount if participant completes the session. Allow 
participants who are distressed to end participation in the study (discuss this with a graduate 
student) without loss of payment based on hours spent in the laboratory to the nearest half hour, 
as indicated below. 
 
Session 1: 
Up to ½ hour $5.00 
½ hour to 1 hour $10.00 
1 hour to 1 ½ hours $15.00 
1 ½ hours to 2 hours (or session completion) $20.00 
 
Session 2: 
Up to ½ hour $8.00 


































Appendix H. Session 1 Consent Forms 
Attention and Elaboration Study: Session 1 
The University of Maine at Orono 
Informed Consent Document (PSY 100, 212) 
 
You are invited to participate in a research project being conducted by Dr. Emily Haigh, in the 
Department of Psychology at the University of Maine.  The purpose of the research is to learn 
about the emotional and physiological responses related to sad mood. You must be at least 18 
years of age to participate.   
 
What Will You Be Asked to Do? 
 
If you decide to participate, you will complete an online survey and an interview in the lab. As 
part of the online survey you will answer questions about how you’re feeling (e.g. “After I 
overeat, occasionally I feel guilt or self-hate.”) and different types of thoughts that people 
sometimes have (e.g., “I worry about making mistakes” or “I do not need the approval of other 
people in order to be happy”). This portion of the study will take about 30-minutes total.  
 
Next, you will participate in an interview. During the interview, you will be asked about your 
mood (e.g., “In the past month, have you been feeling depressed or down?”) and different 
symptoms that are related to disorders like depression and anxiety (e.g., “In the past month, have 
you had trouble sleeping?”) The interview will take about 1.50 hours. With your consent, we 
will audio-record the interview. The audio-record will be used to confirm that the interview was 
conducted properly by the researcher. Even if you agree to be audio-recorded, you may ask us to 
stop or destroy the audio file at any time during or after the study is completed.  After the 
interview, a graduate student will measure your height and weight. 
 
Based on information gathered during the interview and questionnaires, some participants will be 
asked to take part in a second part of the study. If you are eligible and decide to participate in the 
second part, you will be scheduled for another session that will take place on a different day.  
 
During the second part of the study, you will be given a description of the study and asked to 
give consent for the procedures involved. Briefly, you will be asked to participate in 
physiological recording (sensors to detect electrical impulses will be attached to your chest and 
back) while you complete the following: self-report questionnaires, a computerized attention task 
and listen to either a sad or neutral piece of music designed to induce a short-lasting sad mood or 
no change in mood.  
 
Participants that complete the second portion of the study will be invited to complete a third and 
final portion of the study. For this part of the study, you will receive an email with a link to some 










It is possible that you may feel uncomfortable when answering questions about yourself. At any 
point during the study, you have the right to skip questions you do not wish to answer, or stop 
the session and choose not to participate in the remainder of the study. You will not need to 
provide a reason for stopping the session. You will receive a list of referrals for counseling 




While this study will have no direct benefit to you, this research will help us learn more about 




You will receive 1 research credit for each hour of participation. Since the interview is expected 
to take 1.50 hours and the survey is expected to take 30-minutes, it is likely that you will earn 2 




Your name will not appear on any of the documents. A code number will be used to protect your 
identity. This code is stored on a file with software designed to provide added security. Data will 
be kept in the investigator’s locked office and will only be accessible by Dr. Emily Haigh, Maine 
Mood Disorders Lab graduate students, and research assistants who have been trained to deal 
with sensitive material. Your name or other identifying information will not be reported in any 
publications. The key linking your name to the data will be destroyed two years after data 
analysis is complete, which we anticipate will be in 2018.  All data, including audio recordings, 





Participation is voluntary. If you choose to take part in this study, you may stop at any time. You 
may also skip any questions you do not wish to answer. You will earn 1 credit for each hour of 




If you have any questions about this study, please contact Emily Haigh at 
Emily.a.haigh@maine.edu. If you have any questions about your rights as a research participant, 
please contact Gayle Jones, Assistant to the University of Maine’s Protection of Human Subjects 








I agree to audio recording the interview. 
   
Yes No  
 
Future Studies 
Would you be interested in being contacted for future studies conducted in the lab for 
monetary compensation? 
 
 Yes No 
 
 
Your signature below indicates that you have read and understand the above information 




____________________________________  ________________ 

































Attention and Elaboration Study: Session 1 
The University of Maine at Orono 
Informed Consent Document (Community Participants) 
 
You are invited to participate in a research project being conducted by Dr. Emily Haigh, in the 
Department of Psychology at the University of Maine.  The purpose of the research is to learn 
about the emotional and physiological responses related to sad mood. You must be at least 18 
years of age to participate.   
 
What Will You Be Asked to Do? 
 
If you decide to participate, you will complete an online survey and an interview in the lab. As 
part of the online survey you will answer questions about how you’re feeling (e.g. “After I 
overeat, occasionally I feel guilt or self-hate.”) and different types of thoughts that people 
sometimes have (e.g., “I worry about making mistakes” or “I do not need the approval of other 
people in order to be happy”). This portion of the study will take about 30-minutes total.  
 
Next, you will participate in an interview. During the interview, you will be asked about your 
mood (e.g., “In the past month, have you been feeling depressed or down?”) and different 
symptoms that are related to disorders like depression and anxiety (e.g., “In the past month, have 
you had trouble sleeping?”). The interview will take about 1.50 to 2 hours. With your consent, 
we will audio-record the interview. The audio-record will be used to confirm that the interview 
was conducted properly by the researcher. Even if you agree to be audio-recorded, you may ask 
us to stop or destroy the audio file at any time during or after the study is completed.  After the 
interview, a graduate student will measure your height and weight. 
 
Based on information gathered during the interview and questionnaires, some participants will be 
asked to take part in a second part of the study. If you are eligible and decide to participate in the 
second part, you will be scheduled for another session that will take place on a different day.  
 
During the second part of the study, you will be given a description of the study and asked to 
give consent for the procedures involved. Briefly, you will be asked to participate in 
physiological recording (sensors to detect electrical impulses will be attached to your chest and 
back) while you complete the following: self-report questionnaires, a computerized attention task 
and listen to either a sad or neutral piece of music designed to induce a short-lasting sad mood or 
no change in mood.  
 
Participants that complete the second portion of the study will be invited to complete a third and 
final portion of the study. For this part of the study, you will receive an email with a link to some 




It is possible that you may feel uncomfortable when answering questions about yourself. At any 
point during the study, you have the right to skip questions you do not wish to answer, or stop 




provide a reason for stopping the session. You will receive a list of referrals for counseling 




While this study will have no direct benefit to you, this research will help us learn more about 




You will receive $20 for participating in this research session to compensate you for your time 
and travel expenses. If you do not complete the session you will receive compensation pro-rated 




Your name will not appear on any of the documents. A code number will be used to protect your 
identity. This code is stored on a file with software designed to provide added security. Data will 
be kept in the investigator’s locked office and will only be accessible by Dr. Emily Haigh, Maine 
Mood Disorders Lab graduate students and research assistants who have been trained to deal 
with sensitive material. Your name or other identifying information will not be reported in any 
publications. The key linking your name to the data will be destroyed in about two years after 
data analysis is complete, which we anticipate will be in 2018. All data, including audio 
recordings, will be kept indefinitely by the investigators. The key and the data files will be stored 




Participation is voluntary. If you choose to take part in this study, you may stop at any time. You 




If you have any questions about this study, please contact Emily Haigh at 
Emily.a.haigh@maine.edu. If you have any questions about your rights as a research participant, 
please contact Gayle Jones, Assistant to the University of Maine’s Protection of Human Subjects 
Review Board, at 581-1498 or via e-mail at gayle.jones@umit.maine.edu.   
 
Audiotaping 
I agree to audio recording the interview. 
    










Would you be interested in being contacted for future studies conducted in the lab for 
monetary compensation? 
 
 Yes No 
 
 
Your signature below indicates that you have read and understand the above information 




____________________________________  ________________ 





































Appendix I. Session 1 Self-Report Measures 
Demographic Information 
 
To start with, we would like to get some background information from you. 
 
1. What is your age? _____ 
 
2. What is your gender? _____ 
 
3. What is your date of birth (MM/DD/YYYY)? _____ 
 
4. What is your marital situation (please check one)? 
○ Married 
○ Separated 
○ Never married/single 




5. Do you consider yourself to be Hispanic or Latino (i.e., a person of Mexican, Puerto 









7. What is your race? 
○ Native American or Alaska Native (i.e. a person having origins in any of the original  
     peoples of North, Central, or South America) 
○ Asian (i.e. a person having origins in any of the original peoples of the Far East,  
   Southeast Asia, or the Indian subcontinent including, for example, Cambodia, China,  
   India, Japan, Korea, Malaysia, Pakistan, the Philippine Islands, Thailand, and Vietnam) 
○ Black or African American (i.e. a person having origins in any of the black racial  
   groups of Africa) 
○ Native Hawaiian or Other Pacific Islander (i.e. a person having origins in any of the ..   
   original peoples of Hawaii, Guam, Samoa, or other Pacific Islands) 
○ White (i.e. a person having origins in any of the peoples of Europe, the Middle East, or  
   North Africa) 
○ Multiple races 






8. What is the highest grade in school you have completed (please check one)? 
○ Less than High School 
○ High School 
○ 1 year of college or technical school 
○ 2 or more years of college but did not graduate 
○ 4 years of college with degree 
○ Postgraduate, M.D., Ph.D. 










































Beck Depression Inventory – Second Edition (BDI-II) 
 
This questionnaire consists of 21 groups of statements. Please read each group of statements 
carefully, and then pick out the ONE STATEMENT in each group that best describes the way 
you have been feeling during the PAST TWO WEEKS, INCLUDING TODAY. Bubble in the 
number beside the statement you have picked. If several statements in the group seem to apply 
equally well, bubble in the highest number for that group. Be sure that you do not choose more 
than one statement for any group, including Item 16 (Changes in Sleeping Pattern) or Item 18 
(Changes in Appetite). 
 
1. Sadness 
    I do not feel sad. 
    I feel sad much of the time. 
    I am sad all the time. 
    I am so sad or unhappy that I can't stand it. 
 
2. Pessimism  
    I am not discouraged about my future. 
    I feel more discouraged about my future than I used to be. 
    I do not expect things to work out for me. 
    I feel my future is hopeless and will only get worse. 
 
3. Past Failure 
    I do not feel like a failure. 
    I have failed more than I should have. 
    As I look back, I see a lot of failures. 
    I feel I am a total failure as a person. 
 
4. Loss of Pleasure  
    I get as much pleasure as I ever did from the things I enjoy. 
    I don't enjoy things as much as I used to. 
    I get very little pleasure from the things I used to enjoy. 
    I can’t get any pleasure from the things I used to enjoy. 
 
5. Guilty Feelings 
    I don't feel particularly guilty. 
    I feel guilty over many things I have done or should have done. 
    I feel quite guilty most of the time. 
    I feel guilty all of the time. 
 
6. Punishment Feelings 
    I don't feel I am being punished. 
    I feel I may be punished. 
    I expect to be punished. 






    I feel the same about myself as ever. 
    I have lost confidence in myself. 
    I am disappointed with myself. 
    I dislike myself. 
 
8. Self-Criticalness 
    I don't criticize or blame myself more than usual. 
    I am more critical of myself than I used to be. 
    I criticize myself for all of my faults. 
    I blame myself for everything bad that happens. 
 
9. Suicidal Thoughts or Wishes  
    I don't have any thoughts of killing myself. 
    I have thoughts of killing myself, but I would not carry them out. 
    I would like to kill myself. 
    I would kill myself if I had the chance. 
 
10. Crying 
    I don't cry any more than I used to. 
    I cry more than I used to. 
    I cry over every little thing. 
    I feel like crying, but I can’t. 
 
11. Agitation  
    I am no more restless or wound up than usual. 
    I feel more restless or wound up than usual. 
    I am so restless or agitated that it’s hard to stay still. 
    I am so restless or agitated that I have to keep moving or doing something. 
 
12. Loss of Interest 
    I have not lost interest in other people or activities. 
    I am less interested in other people or things than before. 
    I have lost most of my interest in other people or things. 
    It’s hard to get interested in anything. 
 
13. Indecisiveness  
    I make decisions about as well as ever. 
    I find it more difficult to make decisions than usual. 
    I have much greater difficulty in making decisions than I used to. 









    I do not feel I am worthless. 
    I don’t consider myself as worthwhile and useful as I used to. 
    I feel more worthless as compared to other people. 
    I feel utterly worthless. 
 
15. Loss of Energy  
    I have as much energy as ever. 
    I have less energy than I used to have. 
    I don’t have enough energy to do very much. 
    I don’t have enough energy to do anything. 
 
16. Changes in Sleeping Pattern  
    I have not experienced any change in my sleeping pattern. 
    I sleep somewhat more than usual. 
    I sleep somewhat less than usual. 
    I sleep a lot more than usual. 
    I sleep a lot less than usual. 
    I sleep most of the day. 
    I wake up 1-2 hours early and can't get back to sleep. 
 
17. Irritability  
    I am no more irritable than usual. 
    I am more irritable than usual. 
    I am much more irritable than usual. 
    I am irritable all the time. 
 
18. Changes in Appetite   
    I have not experienced any change in my sleeping appetite. 
    My appetite is somewhat less than usual. 
    My appetite is somewhat more than usual. 
    My appetite is much less than usual. 
    My appetite is much greater than usual. 
    I have no appetite at all. 
    I crave food all the time. 
 
19. Concentration Difficulty  
    I can concentrate as well as ever. 
    I can't concentrate as well as usual. 
    It's hard to keep my mind on anything for very long. 








20. Tiredness or Fatigue  
    I am no more tired or fatigued than usual. 
    I get tired or fatigued more easily than usual. 
    I am too tired or fatigued to do a lot of the things I used to do. 
    I am too tired or fatigued to do most of the things I used to do. 
 
21. Loss of Interest in Sex  
    I have not noticed any recent change in my interest in sex. 
    I am less interested in sex than I used to be. 
    I am much less interested in sex now. 







































State-Trait Anxiety Inventory – I (STAI-I) 
 
A number of statements which people have used to describe themselves are given below. Read 
each statement and then circle the appropriate number to the right of the statement to indicate 
how you feel right now, that is, at this moment. There are no right or wrong answers. Do not 
spend too much time on any one statement but give the answer which seems to describe your 





1.  I feel calm  1 2 3 4 
2.  I feel secure    1 2 3 4 
3. I am tense    l 2 3 4 
4.  I feel strained  1 2 3 4 
5. I feel at ease 1 2 3 4 
6. I feel upset     1 2 3 4 
7. I am presently worrying over possible misfortune  1 2 3 4 
8. I feel satisfied  1 2 3 4 
9. I feel frightened    1 2 3 4 
10. I feel comfortable   1 2 3 4 
11. I feel self-confident   1 2 3 4 
12. I feel nervous    1 2 3 4 
13. I am jittery     1 2 3 4 
14. I feel indecisive  1 2 3 4 
15. I am relaxed   1 2 3 4 
16. I feel content 1 2 3 4 
17. I am worried      1 2 3 4 
18. I feel confused   1 2 3 4 
19. I feel steady  1 2 3 4 



























State-Trait Anxiety Inventory – II (STAI-II) 
 
A number of statements which people have used to describe themselves are given below.  Read 
each statement and then circle the appropriate number to the right of the statement to indicate 
how you generally feel.  
21.   I feel pleasant     1 2 3 4 
22. I feel nervous and restless  1 2 3 4 
23.  I feel satisfied with myself  1 2 3 4 
24. I wish I could be as happy as others seem to be  1 2 3 4 
25. I feel like a failure  1 2 3 4 
26.  I feel rested   1 2 3 4 
27.  I am "calm, cool, and collected"  1 2 3 4 
28. l feel that d difficulties are piling up so that I cannot overcome them  1 2 3 4 
29. l worry too much over something that really doesn't matter  1 2 3 4 
30. l am happy  l 2 3 4 
31.  I have disturbing thoughts   1 2 3 4 
32. I lack self-confidence   1 2 3 4 
33. I feel secure    1 2 3 4 
34. l make decisions easily  1 2 3 4 
35.  l feel inadequate  1 2 3 4 
36.  I am content   1 2 3 4 
37.  Some unimportant thought runs through my mind and bothers me  1 2 3 4 
38. l take disappointments so keenly that l can 't put them out of my mind  1 2 3 4 
39. I am a steady person   1 2 3 4 
40. I get in a state of tension or turmoil as I think over my recent concerns and 
interests  


































Are you currently seeing a therapist for emotional or behavioral problems?     
 
What type of therapy do you participate in (e.g., counseling, CBT, MBT, family, couples, group, 
or interpersonal therapy)? 
 
 
Are you currently being prescribed medication for emotional or behavioral problems?     
 
What type of medication are you prescribed (i.e., name of and purpose of medication and 





Have you ever see a therapist for emotional or behavioral problems?     
 
What type of therapy did you participate in (e.g., counseling, CBT, MBT, family, couples, group, 




Have you ever been prescribed medication for emotional or behavioral problems?     
What type of medication were you prescribed (i.e., name of and purpose of medication and 


















Appendix J. Session 1 Suicide Risk Assessment 
Questions to ask if you think someone may be at risk for suicide: 
 
Suicidal Ideation: 
Are you currently suicidal? 
 
Intent: 




Have you considered ways of killing yourself? 
 
Plan/Preparations: 
Do you have a suicide plan or have you made preparations for committing suicide? 
 
Means: 
Do you have means to kill yourself? 
 
Suicide Attempt: 
Have you ever attempted suicide? 
 
IF YES, THEN 
When was your last suicide attempt? 
 
When Students will need to speak with a clinician: 
 
If intent + suicide plan / intent + means / suicide plan + means / suicide attempt within last 
2 weeks + suicide ideation = Student NEEDS to speak with a clinician. 
 
*Use your judgment. If there is any question about whether a student (who has endorsed one or 
more of the above items) should speak with a clinician, consult with the clinician. For example, 
if a student endorses active suicidal ideation, but does not endorse intent or plan, you may still 
want to touch base with a clinician.  
 
*If Dr. Haigh is unavailable, contact Dr. O’Grady or Dr. Schwartz-Mette. (Contact information 
on next page). 
 
*If they are unavailable, walk student to the counseling center. 
 
Checking in with students who endorse some of the questions, but DON’T NEED to speak 







“I noticed that you endorsed (say what they endorsed). There are some very effective ways to 
help with some of the concerns we spoke about during the interview today. I have a list of 
referrals you may consider. I would strongly recommend these services to help with the way you 
have been feeling.” 
 





Emily Haigh:  
207-581-2025 (office); 215-317-0133 (cell) 
 
April O’Grady: 
207-945-3935 (home); 207-478-9742 (cell) 
 
Rebecca Schwartz-Mette:  
207-581-2048 (office); 573-239-2202 (cell) 
 
Counseling Services at UMaine: 
207-581-1392 
5721 Cutler Health Center, Room 125  



























Appendix K. Session 2 Consent Forms 
Attention and Elaboration Study: Session 2 
The University of Maine at Orono 
Informed Consent Document (PSY 100, 212) 
 
You are invited to participate in a research project being conducted by Dr. Emily Haigh in the 
Department of Psychology at the University of Maine.  The purpose of the research is to learn 
about the emotional and physiological responses related to sad mood.  You must be at least 18 
years of age to participate.   
 
What Will You Be Asked to Do? 
 
A trained female research assistant will place sensors on your body in order to record electrical 
activity of the heart, skin, and facial muscle groups. Once the sensors are placed on your body, 
you will be asked to sit comfortably in front of a computer in a small room. You will then be 
asked to complete the following tasks: watch a short video about Alaska’s Denali Mountain, 
answer some questions about how you’re feeling (e.g. check a box to indicate whether you are 
interested, upset, nervous), complete a short computer task and listen to either a sad or neutral 
piece of music designed to induce a short-lasting sad mood or no change in mood. This portion 




It is possible that you may feel uncomfortable when answering questions about yourself. At any 
point during the study, you have the right to skip questions you do not wish to answer, or stop 
the session and choose not to participate in the remainder of the study. You will not need to 
provide a reason for stopping the session. You will receive a list of referrals for counseling 




This study will have no direct benefit to you, though it will help to better understand how 




Students will earn 1 credit for their participation, unless they no longer require research points 
for course credit (e.g., have already earned 5 research credits as required by PSY 100).  In this 
case, students will receive $15 for their participation.  Monetary compensation is only available 




The code number you have been assigned during session 1 will again be used to protect your 




data will be kept in the investigator’s locked office and will only be accessible by Dr. Emily 
Haigh and Maine Mood Disorders Lab graduate students and research assistants who have 
completed training in order to deal with sensitive material. Your name or other identifying 
information will not be reported in any publications. As previously described, the key linking 
your name to the data will be destroyed in approximately two years after data analysis is 
complete, which we anticipate will be in December, 2018. All data will be kept indefinitely by 
the investigators. The key and the data files will be stored on separate computers. You may 
decide that you do not want you data used in this research.  If you would like you data removed 
from the study and permanently deleted, please email your request to the Principal Investigator, 




Participation is voluntary. If you choose to take part in this study, you may stop at any time. You 
may also skip any questions you do not wish to answer. If you are participating for monetary 
compensation, you will receive $15 for participating in this research session to compensate you 
for your time and travel expenses. If you do not complete the session, you will receive 




If you have any questions about this study, please contact Emily Haigh at 
Emily.a.haigh@maine.edu. If you have any questions about your rights as a research participant, 
please contact Gayle Jones, Assistant to the University of Maine’s Protection of Human Subjects 
Review Board, at 581-1498 (or e-mail gayle.jones@umit.maine.edu).   
  
Your signature below indicates that you have read and understand the above information 






















Attention and Elaboration Study: Session 2 
The University of Maine at Orono 
Informed Consent Document (Community Participants) 
 
You are invited to participate in a research project being conducted by Dr. Emily Haigh in the 
Department of Psychology at the University of Maine.  The purpose of the research is to learn 
about the emotional and physiological responses related to sad mood.  You must be at least 18 
years of age to participate.   
 
What Will You Be Asked to Do? 
 
A trained female research assistant will place sensors on your body in order to record electrical 
activity of the heart, skin, and facial muscle groups. Once the sensors are placed on your body, 
you will be asked to sit comfortably in front of a computer in a small room. You will then be 
asked to complete the following tasks: watch a short video about Alaska’s Denali Mountain, 
answer some questions about how you’re feeling (e.g. check a box to indicate whether you are 
interested, upset, nervous), complete a short computer task and listen to either a sad or neutral 
piece of music designed to induce a short-lasting sad mood or no change in mood. This portion 




It is possible that you may feel uncomfortable when answering questions about yourself. At any 
point during the study, you have the right to skip questions you do not wish to answer, or stop 
the session and choose not to participate in the remainder of the study. You will not need to 
provide a reason for stopping the session. You will receive a list of referrals for counseling 




This study will have no direct benefit to you, though it will help to better understand how 








The code number you have been assigned during session 1 will again be used to protect your 
identity. This code is stored on a file with software designed to provide additional security. All 
data will be kept in the investigator’s locked office and will only be accessible by Dr. Emily 
Haigh and Maine Mood Disorders Lab graduate students and research assistants who have 
completed training in order to deal with sensitive material. Your name or other identifying 
information will not be reported in any publications. As previously described, the key linking 




complete, which we anticipate will be in 2018. All data will be kept indefinitely by the 




Participation is voluntary. If you choose to take part in this study, you may stop at any time. You 
may also skip any questions you do not wish to answer. You will receive $15 for participating in 
this research session to compensate you for your time and travel expenses. If you do not 




If you have any questions about this study, please contact Emily Haigh at 
Emily.a.haigh@maine.edu. If you have any questions about your rights as a research participant, 
please contact Gayle Jones, Assistant to the University of Maine’s Protection of Human Subjects 
Review Board, at 581-1498 (or e-mail gayle.jones@umit.maine.edu).   
  
Your signature below indicates that you have read and understand the above information 































Appendix L. Session 2 Self-Report Measures 
Dysfunctional Attitudes Scale – Short Form (DAS-SF I) 
 
The sentences below describe people’s attitudes. Circle the number which best describes 
how much each sentence describes your attitude. Your answer should describe the way you 
think most of the time. 
 







If I don’t set the highest standards for 
myself, I am likely to end up a second-rate 
person. 
1 2 3 4 
2.  
My value as a person depends greatly on 
what others think of me. 
1 2 3 4 
 
3. 
People will probably think less of me if I 
make a mistake. 
1 2 3 4 
4. 
I am nothing if a person I love doesn’t 
love me. 
1 2 3 4 
5. 
If other people know what you are really 
like, they will think less of you. 
1 2 3 4 
6. 
If I fail at my work, then I am a failure as a 
person. 
1 2 3 4 
7. 
My happiness depends more on other 
people than it does me. 
1 2 3 4 
 
8. 
I cannot be happy unless other people 
admire me. 
1 2 3 4 
 
9. 
It is best to give up your own interests in 
order to pleasure other people. 



















Dysfunctional Attitudes Scale – Short Form (DAS-SF II) 
 
The sentences below describe people’s attitudes. Circle the number which best describes 
how much each sentence describes your attitude. Your answer should describe the way you 
think most of the time. 
 







If I am to be a worthwhile person, I must 
be truly outstanding in at least one major 
respect. 
1 2 3 4 
2.  
If you don’t have other people to lean on, 
you are bound to be sad. 
1 2 3 4 
 
3. 
I do not need the approval of other people 
in order to be happy. 
1 2 3 4 
4. 
If you cannot do something well, there is 
little point in doing it at all. 
1 2 3 4 
5. 
If I do not do well all the time, people will 
not respect me. 
1 2 3 4 
6. If others dislike you, you cannot be happy. 1 2 3 4 
7. 
People who have good ideas are more 
worthy than those who do not. 
1 2 3 4 
 
8. 
If I do not do as well as other people, it 
means I am an inferior human being. 
1 2 3 4 
 
9. 
If I fail partly, it is as bad as being a 
complete failure. 






















Visual Analogue Scale (VAS) 
 
We are interested in knowing about your current mood. Please mark an ‘X’ on the line below to 


























This scale consists of a number of words and phrases that describe different feelings and 
emotions. Read each item and then mark the appropriate answer in the space next to that word.  
Indicate to what extent you feel this way. Use the following scale to record your answers: 
 
1 2 3 4 5 
Very Slightly 
or not at all 
A Little Moderately Quite of Bit Extremely 
 
______ cheerful  ______ sad  ______ active      ______ angry at self 
______ disgusted  ______ calm   ______ guilty      ______ enthusiastic 
______ attentive  ______ afraid   ______ joyful      ______ downhearted 
______ bashful  ______ tired  ______ nervous   ______ sheepish 
______ sluggish  ______ amazed ______ lonely     ______ distressed 
______ daring ______ shaky   ______ sleepy     ______ blameworthy 
______ surprised  ______ happy  ______ excited    ______ determined 
______ strong ______ timid ______ hostile     ______ frightened 
______ scornful  ______ alone    ______ proud      ______ astonished 
______ relaxed  ______ alert   ______ jittery      ______ interested 
______ irritable  ______ upset   ______ lively       ______ loathing 
______ delighted  ______ angry  ______ ashamed  ______ confident 
______ inspired  ______ bold   ______ at ease     ______ energetic 
______ fearless  ______ blue   ______ scared      ______ concentrating 
______ disgusted  ______ shy   ______ drowsy    ______ dissatisfied 
























Appendix M. Debriefing Form 
Debriefing Form for Participation in a Research Study 
University of Maine 
 
Thank you for your participation in our study.  Your participation is greatly appreciated.  
 
Purpose of the Study: 
 
The purpose of this study is to examine how the way you think and the way your body 
physiologically responds (e.g. heart rate) to emotional stimuli relates to depression.  This study is 
important because it may help us understand how short periods of sad mood lead some 
individuals to develop lasting depressed mood.   
 
In this study you completed an interview and several questionnaires about how you think and 
feel. You also completed an attention task (e.g. computer task) and using sensors to detect 
electrical impulses we measured physiological arousal (e.g. heart rate) as you listened to music 
designed to either make you feel sad or no change in your mood. 
We expect to find that participants with a history of depression who completed an attention task 
with negative words and listened to the sad music will report more sad mood and have a stronger 
physiological response than individuals without a history of depression. Previous research has 
shown that individuals with depression have difficulty turning their attention away from negative 
stimuli and have negative repetitive thoughts in response to sad mood; however, little research 
has examined how these factors relate to physiological functioning.  
 
Do you have any questions about the study? When you were doing the study what did you think 
the study was about? Was there any part of the study that was difficult? How is your mood now? 
 
We realize that some of the questions asked may have provoked an emotional reaction.  As 
researchers, we do not provide mental health services and we will not be following up with you 
after the study.  However, we want to provide every participant in this study with a 
comprehensive and accurate list of clinical resources that are available, should you decide you 





You may decide that you do not want your data used in this research.  If you would like your 
data removed from the study and permanently deleted please email your request to Principal 
Investigator, Dr. Emily Haigh @ Emily.a.haigh@maine.edu.  
Whether you agree or do not agree to have your data used for this study, you will still receive 










If you would like to learn about the results of the study, let the researcher know and we will 




If you would like to learn more about cognitive vulnerability to depression please see the 
following references: 
 
Farb, N. A. S., Irving, J. A., Anderson, A. K., & Segal, Z. V. (2015). A two-factor model of 
relapse/recurrence vulnerability in unipolar depression. Journal of Abnormal Psychology, 124(1), 
38–53. http://doi.org/10.1037/abn0000031 
 
Key, B. L., Campbell, T. S., Bacon, S. L., & Gerin, W. (2008). The influence of trait and state 
rumination on cardiovascular recovery from a negative emotional stressor. Journal of Behavioral 
Medicine, 31(3), 237–248. http://doi.org/10.1007/s10865-008-9152-9 
 
Lethbridge, R., & Allen, N. B. (2008). Mood induced cognitive and emotional reactivity, life 
stress, and the prediction of depressive relapse. Behaviour Research and Therapy, 46(10), 1142–
1150. http://doi.org/10.1016/j.brat.2008.06.011 
 
Useful Contact Information: 
 
If you have any questions or concerns regarding this study, its purpose or procedures, or if you 
have a research-related problem, please feel free to contact the Principal Investigator, Dr. Emily 
Haigh at 207-581-2053. If you have other concerns about this study or would like to speak with 
someone not directly involved in the research study, you may contact the Chair of the 
Department of Psychology (Dr. Michael Robbins, Michael_Robbins@umit.maine.edu) 
 
If you have any questions concerning your rights as a research subject, you may contact Gayle 
Jones at the University of Maine Institutional Review Board for the Protection of Human 
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